 
Official Title:  A PHASE III, MULTICENTER, RANDOMIZED,  
OPEN -LABEL STUDY EVALUATING THE EFFICACY 
AND SAFETY OF ATEZOLIZUMAB (MPDL3280A,  
ANTI -PD-L1 ANTIBODY) IN COMBINATION WITH  
CARBOPLATIN + NAB-PACLITAXEL FOR  
CHEMOTHERAPY -NAIVE PATIENTS WITH STAGE IV  
NON- SQUAMOUS NON- SMALL CELL LUNG CANCER  
Study ID: [REMOVED]  
Document  Dates: Protocol  Amendment  Version 7: 24 October 2018  
SAP Version 4: 4 May 2018 
 
 
 
PROTOCOL AMENDMENT APPROVA L
CONFIDENTIA L
This clinical study is being sponsored globally by F. Hoffmann -La [COMPANY_002] Ltd of Basel, 
Switzerland. However, it may be implemented in individual countries by [CONTACT_26702]’s local affiliates, 
including Genentech, Inc. in the [LOCATION_002].  The information contain ed in this document, especially 
any unpublished data, is the property of F.Hoffmann -La [COMPANY_002] Ltd (or u nder its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
[CONTACT_10825], your staff , and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information will not be disclosed to others without written authorization from [COMPANY_002] except to the 
extent necessary to obtain informed consent from persons to w hom the drug may  be administered.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
Protocol GO29537 , Version 7PROTOCOL
TITLE: A PHA SE III, MULTICE NTER, RA NDOMIZED, 
OPEN -LABEL STUDY EVA LUATING THE EFFICA CY 
AND SAFETY OF ATEZOL IZUMA B (MPDL3280A , 
ANTIPD-L1 A NTIBODY) IN COM BINA TION WITH 
CARBOPLA TINNAB-PACLITA XEL FOR 
CHEMOTHERA PY-NAIVE P ATIENTS WITH STA GEIV 
NON- SQUA MOUS NON SMA LLCELL LUNG CA NCER
PROTOCOL NUMBER: GO29537/[STUDY_ID_REMOVED]
VERSION NUMBER: [ADDRESS_742972] NUMBER: 2014 -003206 -32
IND NUMBER: [ADDRESS_742973]: Atezolizumab (MPDL3280A, RO5541267) 
MEDICA L MONITOR: , M.D.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
DATE FINA L: 21 November 2014
DATES AMENDED: Version 2:  29 March 2015
Version 3:  [ADDRESS_742974] 2015
Version 4:  11 November 2015
Version 5:  15 June 2016
Version 6:  1 March 2017
Version 7:  See electronic date stamp below .
24-Oct-2018 09:26:56
Title
Approver's Name
[CONTACT_26862] (UTC)

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
2/Protocol GO29537 , Version 7PROTOCOL A MENDMENT, VERSION 7:
RATIONA LE
Protocol GO29537 has been amended to reflect a change in the definition for the end of 
study .  Changes to the protocol, along with a rationale for each change, are summarized 
below:
The end of study definition has been corrected.  This correction ensures that the 
study continues until last patient, last visit or until the Sponsor terminates the st udy 
(Section 3.2).
The inclusion criterion that addresses female contraception has been modified to 
specify when women must refrain from donating eggs (Section 4.1.1).
Instructions about patient withdrawal from the [COMPANY_002] Clinical Repository after site 
closure have been modified to indicate that the investigator must inform the Sponsor 
of patient withdrawal by [CONTACT_109790]_rcr -[EMAIL_1377] (Section 4.5.1 1.6).
The Medical Monitor has been chang ed, and the contact [CONTACT_565742] (Section 5.4.1).
Language has been revised to account for the fact that some sites may not allow 
follow -up on partner pregnancies (Section [IP_ADDRESS]) .
Language has been updated to indicate that therapeutic or elective abortions are 
not considered adverse events unless performed because of an underlying maternal 
or embryofetal toxicity.  In such cases, the underlying toxicity should be reported as 
a serious adverse event.  Language has also been adde d to clarify that all abortions 
are to be reported on the paper Clinical Trial Pregnancy Reporting Form
(Section [IP_ADDRESS]).
Language has been added for consistency with [COMPANY_002]'s current data retention 
policy and to accommodate more stringent local requiremen ts (if applicable)
(Section 7.6) .
Additional minor changes have been made to improve clarity and consistency.  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
3/Protocol GO29537 , Version 7TABLE OF CONTENTS
PROTOCOL AMENDMENT A CCEPTANCE FORM .......................................... [ADDRESS_742975]-Line Treatment for Advanced NSCLC 
without an EGFR Mutation or ALK 
Rearrangement ...................................................................... 32
1.1.3 nab-Paclitaxel Carboplatin for First -Line 
NSCLC .................................................................................. 33
1.1.4 AVASTIN and Vascular Endothelial Growth 
Factor .................................................................................... 36
[IP_ADDRESS] Clinical Studies of Bevacizumab and 
Platinum -Based Treatment in NSCLC ................................... 37
1.1.5 Targeted Therapy for NSCLC ................................................ 38
1.1.6 Erlotinib or Pemetrexed Maintenance Therapy for 
NSCLC .................................................................................. 38
1.2 Background on Atezolizumab ................................................ 39
1.2.1 Summary of Nonclinical Studies ............................................ 40
1.3 Clinical Experience with Atezolizumab .................................. 40
1.3.1 Ongoing Clinical Studies ........................................................ 40
1.3.2 Clinical Safety ........................................................................ 41
[IP_ADDRESS] Single -Agent Clinical Safety in Patients with 
NSCLC in Study PCD4989g .................................................. 41
[IP_ADDRESS] Single -Agent Clinical Safety in Patients with 
NSCLC in Study GO28753 (POPLAR) .................................. 43
[IP_ADDRESS] Single -Agent Clinical Safety in Patients with 
NSCLC in Study GO28915 (OAK) ......................................... 44
[IP_ADDRESS] Clinical Safety in Combination with Bevacizumab 
or Platinum -Based Doublet Chemotherapy ........................... 45
1.3.3 Clinical Activity ....................................................................... 47
[IP_ADDRESS] Single -Agent Clinical Activity in Patients with 
NSCLC in Study PCD4989g .................................................. 47
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
4/Protocol GO29537 , Version [IP_ADDRESS] Single -Agent Clinical Activity in Patients with 
NSCLC in Study GO28753 (POPLAR) .................................. 48
[IP_ADDRESS] Single -Agent Clinical Activity in Patients with 
NSCLC in Study GO28915 (OAK) ......................................... 50
[IP_ADDRESS] Clinical Efficacy in Combination with Platinum -
Based Doublet Chemotherapy in Patients with 
NSCLC .................................................................................. 51
1.3.4 Clinical Pharmacokinetics and Immunogenicity ..................... 51
1.3.5 Rationale for Atezolizumab Dosage ...................................... 51
1.4 Study Rationale and Benefit –Risk Assessment ..................... 52
1.4.1 Rationale for Testing Atezolizumab in 
Combination with Carboplatin/nab -Paclitaxel ........................ 53
2. OBJECTIVES .............................................................................................. 55
2.1 Efficacy Objectives ................................................................ 55
2.1.1 Co-Primary Efficacy Objectives ............................................. 55
2.1.2 Secondary Efficacy Objectives .............................................. 56
2.2 Safety Objectives ................................................................... 56
2.3 Pharmacokinetic Objectives .................................................. 57
2.4 Exploratory Objectives ........................................................... 57
3. STUDY DESIGN ......................................................................................... 57
3.1 Description of the Study ......................................................... 57
3.1.1 Independent Data Monitoring Committee .............................. 60
3.2 End of Study .......................................................................... 61
3.3 Rationale for Study Design .................................................... 61
3.3.1 Rationale for Testing Atezolizumab in Patients 
with  PD -L1–Unselected NSCLC ........................................... 61
3.3.2 Rationa le for Control Arm ...................................................... 62
3.3.3 Rationale for Open -Label Study ............................................ 62
3.3.4 Rationale for Progression -Free Survival and 
Overall Survival as Co -Primary Endpoints ............................. 63
3.3.5 Rationale for Allowing Patients to Continue 
Atezolizumab Treatment un til Loss of 
Clinical Benefit ....................................................................... 64
3.3.6 Rationale for Patient -Reported Outcome 
Assessments ......................................................................... 64
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
5/Protocol GO29537 , Version 73.3.7 Rationale for Collection of Archival and/or Fresh 
Tumor Specimens and Evaluation of PD- L1 and 
T-Effector Gene Signature ..................................................... 65
3.3.8 Rationale for Blood Sampling for Biomarkers ........................ 65
3.3.9 Rationale for the Collection of Mandatory Tumor 
Specimens at Radiographic Progression ............................... 66
3.4 Outcome Measures ............................................................... 66
3.4.1 Efficacy Outcome Measur es.................................................. 66
[IP_ADDRESS] Co-Primary Efficacy Outcome Measures ............................... 66
[IP_ADDRESS] Secondary Efficacy Outcome Measures ................................ 66
3.4.2 Safety Outcome Measures .................................................... 67
3.4.3 Pharmacokinetic Outcome Measures .................................... 67
3.4.4 Exploratory Outcome Measures ............................................ 68
4. MATERIALS AND MET HODS .................................................................... 68
4.1 Patients.................................................................................. 68
4.1.1 Inclusion Criteria .................................................................... 68
4.1.2 Exclusion Criteria ................................................................... 71
[IP_ADDRESS] Cancer -Specific Exclusions ................................................... 71
[IP_ADDRESS] General Medical Exclusions .................................................. 72
[IP_ADDRESS] Exclusion Criteria Related to Medications ............................. 74
[IP_ADDRESS] Exclusions Related to Chemotherapy .................................... 75
4.2 Method of Treatment Assignment and Blinding ..................... 75
4.3 Study Treat ment .................................................................... 76
4.3.1 Formulation, Packaging, and Handling .................................. 76
[IP_ADDRESS] Atezolizumab (MPDL3280A) ................................................. 76
[IP_ADDRESS] Carboplatin and nab -Paclitaxel .............................................. 76
[IP_ADDRESS] Erlotinib and Pemetrexed ...................................................... 76
4.3.2 Dosage, Administration, and Compliance .............................. 77
[IP_ADDRESS] Atezolizumab ......................................................................... 78
[IP_ADDRESS] Carboplatin and nab -Paclitaxel .............................................. 80
[IP_ADDRESS] Erlotinib and Pemetrexed ...................................................... 81
[IP_ADDRESS] Additional Required Medication ............................................. [ADDRESS_742976]- Study Access to Atezolizumab ...................................... 82
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
6/Protocol GO29537 , Version 74.4 Concomitant Therapy ............................................................ 82
4.4.1 Permitted Therapy ................................................................ .82
4.4.2 Cautionary Therapy for Atezolizumab -Treated 
Patients.................................................................................. 83
4.4.3 Prohibited Therapy ................................................................ 84
4.5 Study Assessments ............................................................... 84
4.5.1 Informed Consent Forms and Screening Log ........................ 85
4.5.2 Medical History and Demographic Dat a................................ 85
4.5.3 Physical Examinations ........................................................... 86
4.5.4 Vital Signs .............................................................................. 86
4.5.5 Tumor and Response Evaluations ......................................... 87
4.5.6 Laboratory Assessments and Biomarker 
Samples ................................................................................. 89
4.5.7 Tumor Tissue Samples .......................................................... 91
[IP_ADDRESS] Archival and Freshly Collected Tumor Tissue 
Samples for Screening .......................................................... 91
[IP_ADDRESS] Tumor Samples at the Time of Radiographic 
Progression ........................................................................... 92
[IP_ADDRESS] Tumor Samples at Other Timepoints ..................................... 92
[IP_ADDRESS] Use and Storage of Remaining Samples from  
Study -Relate dProcedures ..................................................... 93
4.5.8 Anti-Therapeutic Antibody Testing ......................................... 93
4.5.9 Electrocardiograms ................................................................ 93
4.5.10 Patient -Reported Outcomes .................................................. 94
4.5.11 Samples for [COMPANY_002] Clinical Repository .................................. 96
[IP_ADDRESS] Overview of the [COMPANY_002] Clinical Repository ............................ 96
[IP_ADDRESS] Approval by [CONTACT_565743] .................................................................. 96
[IP_ADDRESS] Sample Collection .................................................................. 96
[IP_ADDRESS] Confidentiality ........................................................................ 97
[IP_ADDRESS] Consent to Participate in the [COMPANY_002] Clinical 
Repository ............................................................................. 98
[IP_ADDRESS] Withdrawal from the [COMPANY_002] Clinical Repository ..................... 98
[IP_ADDRESS] Monitoring and Oversight ....................................................... 98
4.5.12 Timing of Assessments .......................................................... 99
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
7/Protocol GO29537 , Version [IP_ADDRESS] Screening and Baseline Assessments .................................. 99
[IP_ADDRESS] Assessments during Treatment ............................................. 99
[IP_ADDRESS] Assessments for Treatment- Crossover Patients ................. 100
[IP_ADDRESS] Assessments at Study Drug Discontinuation Visit ............... 100
[IP_ADDRESS] Follow -Up Assessments ...................................................... 101
[IP_ADDRESS] Assessments at Unplanned Visits ....................................... 102
4.6 Patient, Treatment, Study, and 
SiteDiscontinuation ............................................................. 102
4.6.1 Patient Discontinuation ........................................................ 102
4.6.2 Study Treatment Discontinuation ......................................... 103
4.6.3 Study and Site Discontinuation ............................................ 104
5. ASSESSMENT OF SAF ETY..................................................................... 105
5.1 Safety Plan .......................................................................... 105
5.1.1 Risks Associated with Atezolizumab ................................... 106
5.1.2 Risks Associated with Carboplatin ....................................... 106
5.1.3 Risks Associated with nab -Paclitaxel .................................. 106
5.1.4 Risks Associated with Erlotinib ............................................ 107
5.1.5 Risks Associated with Pemetrexed ...................................... 107
5.1.6 General Plan to Manage Safety Concerns .......................... 107
[IP_ADDRESS] Monitoring ............................................................................ 107
5.1.7 Dose Modification ................................................................ 108
[IP_ADDRESS] General Notes Regarding Dose Modification ....................... 108
[IP_ADDRESS] Atezolizumab Dose Modification .......................................... 108
5.1.8 Management of Atezolizumab -Specific Adverse 
Events.................................................................................. 109
5.1.9 Carboplatin and nab -Paclitaxel Dose Modification 
and Management of Specific Adverse Events ..................... 110
[IP_ADDRESS] Hematologic Toxicity ........................................................... 110
[IP_ADDRESS] Gastrointestinal Toxicity ....................................................... 111
[IP_ADDRESS] Neurological Toxicity ........................................................... 112
[IP_ADDRESS] Hepatic Toxicity (nab- Paclitaxel Only) ................................ .112
[IP_ADDRESS] Pulmonary Events and Pneumonitis:  
Atezolizumab and nab -Paclitaxel, or 
nab-Paclitaxel without Atezolizumab ................................... 113
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
8/Protocol GO29537 , Version [IP_ADDRESS] Other Toxicities .................................................................... 115
5.1.10 Erlotinib and Pemetrexed Dose Modification and 
Management of Specific Adverse Events ............................ 116
5.1.11 Potential Overlappi[INVESTIGATOR_70034] .......................................... 116
5.2 Safety Parameters and Definitions ...................................... 117
5.2.1 Adverse Events ................................................................... 117
5.2.2 Serious Adverse Events (Immediately Reportable 
totheSponsor) .................................................................... [ADDRESS_742977] (Immediately 
Reportable to the Sponsor) .................................................. 118
5.3 Methods and Timing for Capturing and 
Assessing Safety Parameters .............................................. 119
5.3.1 Adverse Event Reporting Period ......................................... 119
5.3.2 Eliciting Adverse Event Information ..................................... 120
5.3.3 Assessment of Severity of Adverse Events ......................... 120
5.3.4 Assessment of Causality of Adverse Events ....................... 121
5.3.5 Procedures for Recording Adverse Events .......................... 121
[IP_ADDRESS] Diagnosis versus Signs and Symptoms ............................... 121
[IP_ADDRESS] Adverse Events That Are Secondary to Other 
Events.................................................................................. 122
[IP_ADDRESS] Persistent or Recurrent Adv erse Events .............................. 122
[IP_ADDRESS] Abnormal Laboratory Values ............................................... 122
[IP_ADDRESS] Abnorma l Vital Sign Values ................................................. 123
[IP_ADDRESS] Abnormal Liver Function Tests ............................................ 124
[IP_ADDRESS] Deaths ................................................................................. 124
[IP_ADDRESS] Preexisting Medical Conditions ............................................ 125
[IP_ADDRESS] Worsening of NSCLC .......................................................... 125
[IP_ADDRESS] Hospi[INVESTIGATOR_26589] ........................ 125
[IP_ADDRESS] Adverse Events Associated with an Overdose or 
Error in Drug Administration ................................................ 126
[IP_ADDRESS] Patient -Reported Outcome Data ......................................... 126
5.4 Immediate Reporting Requirements from 
Investigator to Sponsor ........................................................ 126
5.4.1 Emergency Medical Contacts .............................................. 127
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
9/Protocol GO29537 , Version 75.4.[ADDRESS_742978] ................... 127
[IP_ADDRESS] Events That Occur prior to Study Drug Initiation .................. 127
[IP_ADDRESS] Events That Occur after Study Drug Initiation ...................... 127
5.4.3 Reporting Requirements for Pregnancies ............................ 128
[IP_ADDRESS] Pregnancies in Female Patients .......................................... 128
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients ............... 128
[IP_ADDRESS] Abortions ............................................................................. 129
[IP_ADDRESS] Congenital Anomalies/Birth Defects .................................... [ADDRESS_742979] of Study .......................................... 133
6.3 Summaries of Treatment Group Comparability ................... 133
6.4 Efficacy Analyses ................................................................ 134
6.4.1 Co-Primary Efficacy Endpoints ............................................ 134
6.4.2 Secondary Efficacy Endpoints ............................................. 135
[IP_ADDRESS] Progression- Free Survival and Overall Survival in 
Secondary Populations ........................................................ 135
[IP_ADDRESS] Objective Response Rate .................................................... 136
[IP_ADDRESS] Duration of Response .......................................................... 136
[IP_ADDRESS] Overall Survival Rate at Landmark Timepoints .................... 136
[IP_ADDRESS] Patient -Reported Outcomes ................................................ 137
6.4.3 Handling of Missing Data ..................................................... 137
6.5 Safety Analyses ................................................................... 138
6.5.1 Treatment Phase ................................................................ .138
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
10/Protocol GO29537 , Version 76.5.2 Crossover Phase (For Patients W ho Entered  
Study GO29537 under Protocol Versions 1 –4).................... 138
6.6 Pharmacokinetic Analyses ................................................... 139
6.7 Exploratory Analyses ........................................................... 139
6.7.1 Exploratory Analyses of Progression -Free 
Survival ................................................................................ 139
[IP_ADDRESS] Progression-Free Survival Rate at Landmark 
Timepoints ........................................................................... 139
[IP_ADDRESS] Non–Proto col-Specified Anti -Cancer Therapy ..................... 139
[IP_ADDRESS] Subgroup Analysis ............................................................... 139
[IP_ADDRESS] Sensitivity Analyses ............................................................. 140
6.7.2 Exploratory Analyses of Overall Survival ............................. 140
[IP_ADDRESS] Loss to Follow -Up................................................................ 140
[IP_ADDRESS] Subgroup Analysis ............................................................... 140
[IP_ADDRESS] Overall Survival Rate at Three -Year Landmark ................... 140
[IP_ADDRESS] Milestone Overall Survival Analysis ..................................... [ADDRESS_742980] or Ethics Committee .................. 147
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
11/Protocol GO29537 , Version 78.4 Confidentiality ...................................................................... 147
8.5 Financial Disclosure ............................................................ 147
9. STUDY DOCUMENTATI ON, MONITORING, 
AND ADMINISTRATION ........................................................................... 148
9.1 Study Documentation .......................................................... 148
9.2 Protocol Deviations .............................................................. 148
9.3 Site Inspections ................................................................... 148
9.4 Administrative Structure ....................................................... 148
9.5 Publication of Data and Protection of 
Trade Secrets ...................................................................... 149
9.6 Protocol Amendments ......................................................... 149
10. REFERENCES ......................................................................................... 150
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
12/Protocol GO29537 , Version 7LIST OF TA BLES
Table 1 Randomized Phase III Trials in Patients with Previously 
Untreated NSCLC ....................................................................... 35
Table 2 Study PCD4989g:  Adverse Events with Frequency 10% of 
Patients for All Grades ................................................................ 42
Table 3 Study GO28753 (POPLAR):  Adverse Events Reported in at 
Least 10% of Patients ................................................................ .44
Table 4 Adverse Events in Study GO28915 (OAK) wit h a Between -
Arm Difference in Frequency of at Least 5 Percentage Points ....45
Table 5 Study GP28328:  All Reported Adverse Events .......................... 46
Table 6 Patients with NSCLC in Study PCD4989g:  Investigator-
Assessed Confirmed Objective Response Rate by [CONTACT_70083]-L1 Expression, Duration of Response, and Six -Month 
Progression- Free Survival Ra tes (according to RECIST v1.1) ....48
Table 7 Efficacy Results in Study GO28753 (POPLAR):  
Intent -to-Treat Population ........................................................... 49
Table 8 Study GO28753 (POPLAR) Efficacy Results by [CONTACT_109791]-L1 Diagnostic Subgroups with Complementary 
Comparison Subgroupi[INVESTIGATOR_14839]:  Intent -to-Treat Population .............. [ADDRESS_742981] and Subsequent Infusio ns 
ofAtezolizumab .......................................................................... 79
Table 11 Vital Sign Measurements at Cycle 1 and All 
Subsequent Cycles ..................................................................... 87
Table 12 nab-Paclitaxel and Carboplatin Permanent Dose Reductions 
Based on Nadir ANC and Platelets ........................................... 111
Table 13 Carboplatin and nab-Paclitaxel Dose Modification Based on 
Gastrointestinal Toxicities in the Preceding Cycle .................... 111
Table 14 nab-Paclitaxel and Carboplatin Permanent Dose Reductions
for Neurological Toxicity ............................................................ 112
Table 15 Management Guidelines for Pneumonitis:  Atezolizumab and 
nab-Paclitaxel, or nab -Paclitaxel with or without 
Atezolizumab ............................................................................ 115
Table 16 nab-Paclitaxel and Carboplatin Permanent Dose Reductions 
for Non -Hematologic, Non -Gastrointestinal, Non -Neurologic, 
and Non -Hepatic Toxicity .......................................................... 116
Table 17 Adverse Event Severity Grading Scale for Events Not 
Specifically Listed in NCI CTCAE ............................................. 120
Table 18 Analysis Timing and Stoppi[INVESTIGATOR_565725]-WT Population ............................... 142
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
13/Protocol GO29537 , Version 7LIST OF FIGURES
Figure 1 Study Schema ............................................................................. 60
Figure 2 Conditions for Continuing Atezolizumab in Presence of 
Increased Radiographic Tumor Size (Applicable to Arm A 
and Arm B Crossover Patients Consented un der Study 
GO29537 Protocol Versions 1 4)............................................. [ADDRESS_742982] OF A PPENDICES
Appendix 1 Schedule of Assessments ......................................................... 158
Appendix 2 Schedule of Pharmacokinetic, Biomarker, and 
Anti-Therapeutic Antibody Assessments .................................. 164
Appendix 3 Schedule of Pharmacokinetic, Biomarker, and 
Anti-Therapeutic Antibody Assessments for Arm B Patients 
Who Cross Over to Receive Atezolizumab as Allowed under 
Protocol Versions 1 4............................................................... 167
Appendi x 4 American Joint Committee on Cancer Non Small Cell Lung 
Cancer Staging, 7th Edition ...................................................... 168
Appendix 5 Response Evaluation Criteria in Solid Tumors:  
Modified Exce rptfrom Original Publication ............................... 170
Appendix 6 Modified Response Evaluation Criteria in Solid Tumors ........... 182
Appendix 7 AntiPD-L1 Immunohistochemistry ........................................... 189
Appendix 8 EORTC QLQ -C30..................................................................... 190
Appendix 9 EORTC QLQ -LC13 ................................................................... 192
Appendix 10 EQ-5D-3L.................................................................................. 193
Appendix 11 Eastern Cooperative Oncology Group Performance 
Status Scale .............................................................................. 196
Appendix 12 Anaphylaxis Precautions ........................................................... 197
Appendix 13 Preexisting Autoimmune Diseases ........................................... 198
Appendix 14 Symptoms in Lung Cancer ........................................................ 199
Appendix 15 Patient Global Impression of Severity ....................................... 202
Appendix 16 Additional Guidance on Chemotherapy Administration ............. 203
Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
14/Protocol GO29537 , Version 7PROTOCOL A MENDMENT A CCEPTA NCE FORM
TITLE: A PHA SE III, MULTICE NTER, RA NDOMIZED, 
OPEN -LABEL STUDY EVA LUATING THE 
EFFICA CY AND S AFETY OF A TEZOLIZUMA B 
(MPDL3280A, ANTI PD-L1 A NTIBODY) IN 
COMBINA TION WITH 
CARBOPLA TINNAB-PACLITA XEL FOR 
CHEMOTHERA PY-NAIVE P ATIENTS WITH 
STAGEIV NON -SQUAMOUS NON SMA LLCELL 
LUNG CA NCER
PROTOCOL NUMBER: GO29537
VERSION NUMBER: [ADDRESS_742983] NUMBER: 2014 -003206 -32
IND NUMBER: [ADDRESS_742984]: Atezolizumab (MPD3280A, RO5541267)
MEDICA L MONITOR: , M.D.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
I agree to conduct the study  in accordance with the current protocol.
Principal Investigator’s Name  (print)
Principal Investigator’s Signature [CONTACT_33505].  Please return a copy to 
the Sponsor or their designee.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
15/Protocol GO29537 , Version 7PROTOCOL SYNOPSIS
TITLE: A PHA SE III, MULTICE NTER, R ANDOMIZED, OP EN-LABEL 
STUDY EVA LUATING THE EFFIC ACY  AND SA FETY OF 
ATEZOLIZUM AB (MPDL32 80A, ANTIPD-L1 A NTIBODY) IN 
COM BINA TION WITH CARBOPL ATINNAB-PACLITA XEL FOR 
CHEMOTHERA PY-NAIVE P ATIENTS WITH ST AGEIV 
NON -SQU AMOUS NON SMALL CELL LUNG CA NCER
PROTOCOL NUMBER: GO29537
VERSION NUMBER: [ADDRESS_742985] NUMBER: 2014- 003206 -32
IND NUMBER: [ADDRESS_742986]: Atezolizumab (MPDL3280A, RO5541267)
PHASE: III
INDIC ATION: Non-squamous non small cell lung cancer
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
Objectives
The term "wild type" (W T) refers to randomized patients who do not have a sensitizing EGFR 
mutation or ALK translocation.
The term " tumor gene expression" (tGE) refers to randomized patients with a defined level of 
expression of a PD- L1 and T -effector gene signature [CONTACT_109861], as analyzed through use 
of a centrally performed RNA -based assay.
Some efficacy endpoints will be analyz ed in a population of randomized patients with a defined 
level of PD -L1 expression on tumor cells (TCs) and tumor -infiltrating immune cells (ICs), as 
analyzed through use of a centrally performed immunohistochemistry  (IHC) test.
Efficacy Objectives
The co-primary objectives of this study are the following:
To evaluate the efficacy  of atezolizumab carboplatin nab-paclitaxel compared with 
carboplatin nab-paclitaxel as measured by [CONTACT_1697] -assessed progression -free survival 
(PFS) according to Response Evaluation Criteria in Solid Tumors ,Version 1.1 
(RECIST v1.1)in the tGE -WT population and the intent -to-treat wild type ( ITT-WT)
population
To evaluate the efficacy  of atezolizumab carboplatin nab-paclitaxel compared with 
carboplatin nab-p aclitaxel as measured by [CONTACT_70085] (OS) in the ITT -WT population
The secondary efficacy  objectives for this study are the following:
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_255853] -WT population
To evaluate the efficacy  of ate zolizumab as measured by [CONTACT_1697] -assessed PFS 
according to RECIST v1.1 and OS in the TC2/3 or IC2/3 WT population and the TC1/2/3 or 
IC1/2/3 W T population
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assessed PFS 
according to R ECIST v1.1 and OS in the tGE population and the ITT population 
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assessed objective 
response rate according to RECIST v1.1 for both the tGE -WT population and the ITT -WT 
population
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
16/Protocol GO29537 , Version 7To evalu ate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assessed duration of 
response according to RECIST v1.1 for both the tGE-WT population and the ITT -WT 
population
To evaluate the OS rate at 1 and 2 years in each treatment arm in the tGE -WT popula tion 
and the ITT -WT population
To determine the impact of atezolizumab as measured by [CONTACT_70113] (TTD) in 
patient -reported lung cancer sy mptoms of cough, dy spnea (single -item and multi -item 
subscales), chest pain, or arm/shoulder pain, using the European Organisation for the 
Research and Treatment of Cancer (EORTC) Quality -of-Life Questionnaire Core 30 
(QLQ -C30) and the supplemental lung cancer module (QLQ -LC13) in the tGE -WT 
population and the ITT -WT population
To determine the impact of atezoli zumabas measured by [CONTACT_109793] 
(i.e., improvement or deterioration based upon presenting s ymptomatology) in 
patient -reported lung cancer sy mptom (chest pain, dyspnea, and cough) score using the 
Symptoms in Lung Cancer (SILC) scale sy mptom severity score in the tGE -WT population 
and the ITT -WT population
Safety Objectives
The safety  objectives for this study are the fol lowing:
To evaluate the safety and tolerability of atezolizumab carboplatin nab-paclitaxel 
compared with carboplatin nab-paclitaxel
To evaluate the incidence and titers of anti -therapeutic antibodies (ATAs) against 
atezolizumab and to explore the pot ential relationship of the immunogenicity response with 
pharmacokinetics, safety, and efficacy
Pharmacokinetic Objectives
The pharmacokinetic (PK) objectives for this study are the following:
To characterize the pharmacokinetics of atezolizumab when given in combination with 
carboplatin and nab -paclitaxel
To characterize the pharmacokinetics of carboplatin when given in combination with 
nab-paclitaxel with and without atezolizumab
To characterize the pharmacokinetics of nab -paclitaxel when given in combination with 
carboplatin with and without atezolizumab
Exploratory Objectives
The exploratory objectives for this study are the following:
To evaluate PFS at 6 months and at 1 year in each treatment arm
To evaluate the OS rate at 3 years in each treatme nt arm
To assess predictive, prognostic, and pharmacodynamic exploratory biomarkers in archival 
and/or fresh tumor tissue and blood and their association with disease status, mechanisms 
of resistance, and/or response to study treatment
To evaluate the ut ility of biopsy at the time of apparent disease progression to distinguish 
apparent increases in tumor volume related to the immunomodulatory activity of 
atezolizumab (i.e., pseudoprogression/tumor immune infiltration) from true disease 
progression
To eval uate and compare patient’s health status as assessed by [CONTACT_70090] 
5Dimensions 3 -Level (EQ -5D-3L) questionnaire to generate utility scores for use in 
economic models for reimbursement
To determine the impact of atezolizumab as measured by [CONTACT_565744] -reported outcomes of health -related quality of life, lung cancer related s ymptoms, 
and functioning as assessed by [CONTACT_20368] -C30 and QLQ -LC13
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
17/Protocol GO29537 , Version 7Study Design
Description of Study
This is a randomized, Phase III, multicenter, open -label study (IMpower130) designed to 
evaluate the safety and efficacy of atezolizumab in combination with carboplatin nab-paclitaxel 
compared with treatment with carboplatin nab-paclitaxel in approxima tely 
715chemotherapy -naive patients with Stage IV non -squamous non small cell lung cancer
(NSCLC).
Tumor specimens will be prospectively tested for PD -L1 expression by a central laborator y. 
Eligible patients will be stratified by [CONTACT_4321] (male vs. female), p resence of liver metastases at 
baseline (yes vs. no), and by [CONTACT_4002] -L1 tumor expression by [CONTACT_4658] (TC3 and any IC vs. TC0/1/2 and 
IC2/3 vs. TC0/1/2 and IC0/1) and randomized in a 2:1 ratio to receive one of the following 
treatment regimens.
Treatment Arm A:  Atez olizumab carboplatin nab-paclitaxel (Induction: four or six 21- day 
cycles); atezolizumab (Maintenance: 21 -day cycles)
Treatment Arm B:  Carboplatin nab-paclitaxel (Induction: four or six 21 -day cycles); best 
supportive care or pemetrexed (Maintenance: 21 -day cycles)
The number of cy cles of induction treatment (four or six) will be at the discretion of the 
investigator and will be determined and documented prior to randomization. Induction treatment 
will be administered on a 21 -day c ycle until the following occurs (whichever occurs first):  
1) adm inistration of four or six cycles or 2) disease progression (Arm B) or loss of clinical benefit 
(Arm A) is documented.  
Following the induction phase, patients who are randomized to atezolizumab (Arm A) may  
continue treatment with atezolizumab beyond radiographic disease progression according to 
RECIST v1.1 , provided they are experiencing clinical benefit as assesse d by [CONTACT_093] 
(i.e., in the absence of unacceptable toxicity or sy mptomatic deterioration attributed to disease 
progression as determined by [CONTACT_255857], biopsy results [if available], and clinical status).  Patients randomized to 
carboplatin nab-paclitaxel (Arm B) will b e offered best support ive care provided they have 
non-progressive disease.  Switch maintenance to pemetrexed is also permitted for patients 
randomized to Arm B.  Switch maintenance must be administered within [ADDRESS_742987] induction cycle .
Patients who entered Study GO29537 under Protocol Versions 1 4and are randomized to 
carboplatin nab paclitaxel will be given the option to cross over to receive atezolizumab as 
monotherapy upon progressive disease per RECIST v1.1, provided they continue to meet 
eligibility criteria.  Safety data for patients who crossed over from Arm B to receive atezolizumab 
as allowed under Protocol Versions 1 4will be summarized for explorator y purposes.
For A tezolizumab -Treated Patients O nly
During treatment (induction or maintenance), patients receiving atezolizumab (including patients 
in Arm B who entered Study GO29537 under Protocol Versions 1 [ADDRESS_742988] v1.1)who show evidence 
of clinical benefit will be permitted to continue atezolizumab after the criteria per RECIST v1.1 
for progressive disease are met if they meet all of the following criteria:
Evidence of clinical benefit as assessed by [CONTACT_093]
Absence of sy mptoms and signs (including worsening of laboratory values, e.g., new or 
worsening hypercalcemia) indicating unequivocal progression of disease
No decline in Eastern Cooperative Oncology Group (ECOG) performance status that can 
be attributed t o disease progression
Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal disease) that 
cannot be managed by [CONTACT_990] -allowed medical interventions
Patients must provide written consent to acknowledge deferring other treatment o ptions in 
favor of continuing atezolizumab at the time of initial progression
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
18/Protocol GO29537 , Version 7Treatment with induction chemotherapy (Arms A and B) and pemetrexed (Arm B )as switch 
maintenance mu st be discontinued in all patients who exhibit evidence of progressive diseas e
according to RECIST v1.[ADDRESS_742989] v1.1 (or loss of clinical benefit for atezolizumab -treated 
patients who had continued treatment with atezolizumab after radiographic disease progression 
according to RECIS T v1.1), withdrawal of consent, study termination by [CONTACT_2728], or death, 
whichever occurs first.  Patients who discontinue treatment for reasons other than radiographic 
disease progression according to RECIST v1.1 (e.g., toxicity , symptomatic deterioration )will 
continue scheduled tumor assessments until radiographic disease progression according to 
RECIST v1.1 (or loss of clinical benefit for atezolizumab -treated patients who had continued 
treatment with atezolizumab after radiographic disease progression a ccording to RECIST v1.1), 
withdrawal of consent, study termination by [CONTACT_2728], or death, whichever occurs first, 
regardless of whether patients start a new anti -cancer therapy.
All primary imaging data used for tumor assessment will be collected by [CONTACT_565745], independent review of response endpoint s.  The independent reviews of the stored 
scans will be performed when requested.
Patients in all treatment arms will undergo a mandatory tumor biops y sam ple collection, unless 
not clinical ly feasible as assessed and documented by [CONTACT_431], at the first evidence of 
radiographic disease progression.  These data will be used to explore whether radiographic 
findings are consistent with the presence of tumor.  Additionally, these data will be analyzed to 
evaluate the association between changes in tumor tissue and clinical outcome and to 
understand further the potential mechanisms of progression and resistance to atezolizumab as 
compared with such mechanisms after treatment with chemotherapy alone.  This explorator y 
biom arker evaluation will not be used for any treatment -related decisions.  Patients in Arm A 
and patients in Arm B ( who entered Study GO29537 under Protocol Versions 1 4)who are 
unable to undergo biopsy sample collection but who otherwise meet the criteria listed above 
may continue/crossover to recei ve atezolizumab.
Number of Patients
Approximately [ADDRESS_742990] meet all of the following criteria to be eligible for study entry:
Signed Informed Consent Form
Male or female, 18 yearsof age or older
ECOG perform ance status of 0 or 1
Histologically or cytologically confirmed, Stage IV non -squamous NSCLC (per the Union 
Internationale contre le Cancer/American Joint Committee on Cancer staging s ystem, 7th 
edition)
Patients with tumors of mixed histology (i.e., squam ous and non -squamous) are eligible 
if the major histological component appears to be non -squamous.
No prior treatment for Stage IV non -squamous NSCLC
Patients with a sensitizing mutation in the EGFR gene must have experienced disease 
progression (during or after treatment) or intolerance to treatment with one or more 
EGFR tyrosine kinase inhibitors ( TKIs), such as erlotinib, gefitinib, or another EGFR TKI 
appropriate for the treatment of EGFR -mutant NSCLC.
Patients known to have an ALK fusion oncogene must have experienced disease 
progression (during or after treatment) or intolerance to treatment with one or more ALK 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
19/Protocol GO29537 , Version 7inhibitors (e.g., crizotinib) appropriate for the treatment of NSCLC in patients hav ing an 
ALK fusion oncogene.  
Patients with unknown EGFR and ALK status require test results at screening.  ALK 
and/or EGFR may be assessed locally or at a central laboratory.
Patients who have received prior neo- adjuvant, adjuvant chemotherapy, radiothera py, 
or chemoradiotherapy with curative intent for non -metastatic disease must have 
experienced a treatment -free interval of at least [ADDRESS_742991] chemotherapy, radiotherapy, or chemoradiotherapy c ycle.
Patients with a histor y of treated asy mptomatic central nervous system ( CNS )metastases 
are eligible, provided they meet all of the following criteria:
Only supratentorial and cerebellar metastases allowed (i.e., no metastases to midbrain, 
pons, medulla or spi[INVESTIGATOR_1831])
No ongoing requirement for corticosteroids as therapy for CNS disease
No stereotactic radiation within [ADDRESS_742992] 
receive radiation therapy and/or surgery for CNS metastases.  Following treatment, these 
patients may then be eligible without the need for an additional brain scan prior to 
randomization, if all other criteria are met.
Known PD- L1 tumor status as determined by [CONTACT_109794] a central 
laborator y on previously obtained archival tumor tissue or tissue obtained from a biops y at 
screening
A representative formalin -fixed paraffin -embedded (FFPE) tumor specimen in paraffin 
block (preferred) or 15 or more unstained, freshly cut, serial sections on slides from an 
FFPE tumor specimen is required for participation in this study.  If fewer than 15 slides 
are available at baseline (but no fewer than 10), the patient may  still be eligible, upon 
discussion with the Medical Monitor.  This specimen must be accompanied by [CONTACT_109795].
Fine- needle aspi[INVESTIGATOR_1516] (defined as samples that do no t preserve tissue architecture and 
yield cell suspension and/or cell smears), brushing, cell pellet specimens (e.g., from 
pleural effusion, and lavage samples) are not acceptable .  
Tumor tissue from bone metastases that is subject to decalcification is no t acceptable.   
For core -needle biopsy specimens, preferably at least three cores embedded in a single 
paraffin block, should be submitted for evaluation. 
Measurable disease, as defined by [CONTACT_393] v1.1
Previously irradiated lesions can only be considered a s measurable disease if disease 
progression has been unequivocally documented at that site since radiation and the 
previously irradiated lesion is not the only site of disease. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
20/Protocol GO29537 , Version 7Adequate hematologic and end organ function, defined by [CONTACT_565746] 14 days prior to randomization:
ANC  1500 cells/ L without granuloc yte colony -stimulating factor support
Lymphocyte count 500/L
Platelet count 100,000/ L without transfusion 
Hemoglobin  9.0 g/dL
Patients may be transfused to meet this criterion.
INR or aPTT 1.5upper limit of normal ( ULN)
This applies only to patients who are not receiving therapeutic anticoagulation; 
patients receiving therapeutic anticoagulation should be on a stable dose.
AST, ALT, and alkaline phos phatase  2.5ULN, with the following exceptions:
Patients with documented liver metastases:  AST and/or ALT 5ULN
Patients with documented liver or bone metastases:  alkaline phosphatase 5ULN.
Serum bilirubin 1.25ULN
Patients with known Gi lbert disease who have serum bilirubin level 3ULN m ay be 
enrolled .
Serum creatinine 1.5ULN
For female patients of childbearing potential agreement (by [CONTACT_109796]/or partner) to use a 
highly effective form(s) of contraception that results in a low failure rate [ 1% per year] 
when used consistently and correctly, and to continue its use for [ADDRESS_742993] refrain from donating eggs during this same period.  For male patients with 
female partners of childbearing potential, agreement (by [CONTACT_109796]/or partner) to use a 
highly effective form(s) of contraception that results in a low failure rate [ 1% per year] 
when used consistently and correctly, and to continue its use for [ADDRESS_742994] 
dose of nab -paclitaxel and/or carboplatin, whichever is later.  Such methods include:  
combined (estrogen and progestogen containing) hormonal contraception, progestogen -
only hormonal contr aception associated with inhibition of ovulation together with another 
additional barrier method always containing a spermicide, intrauterine device, intrauterine 
hormone -releasing system, bilateral tubal occlusion or vasectomized partner (on the 
understan ding that this is the only one partner during the whole study duration), and sexual 
abstinence.  Male patients should not donate sperm during this study and for at least 
6months after the last dose of nab -paclitaxel and/or carboplatin, whichever is later.
Oral contraception should alway s be combined with an additional contraceptive method 
because of a potential interaction with the study drug.  The same rules are valid for male 
patients involved in this clinical study if they have a partner of childbirth p otential.  Male 
patients must always use a condom.
Women who are not postmenopausal ( 12months of non therapy -induced amenorrhea) or 
surgically sterile must have a negative serum pregnancy test result within 14 days prior to 
initiation of study drug.
Exclusion Criteria
Patients who meet any of the criteria below will be excluded from study  entry:
Cancer -Specific Exclusions
Active or untreated CNS metastases as determined by [CONTACT_565747]
Spi[INVESTIGATOR_33373]/or radiation or previously 
diagnosed and treated spi[INVESTIGATOR_70036]  2 weeks prior to rando mization
Leptomeningeal disease
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
21/Protocol GO29537 , Version 7Uncontrolled tumor -related pain
Patients requiring pain medication must be on a stable regimen at study entr y.
Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or 
metastases causing nerve impi[INVESTIGATOR_20804]) should be treated prior to randomization.  
Patients should be recovered from the effects of radiation.  There is no required 
minimum recovery period.
Asymptomatic metastatic lesions whose further growth would likely cause functional 
deficits o r intractable pain (e.g., epi[INVESTIGATOR_33375]) should be considered for locoregional therapy, if appropriate, 
prior to randomization.
 Uncontrolled pleural effusion, pericardial effusion, or asci tes requiring recurrent drainage 
procedures (once monthly or more frequently)
Patients with indwelling catheters (e.g., PleurX®) are allowed.
Uncontrolled or s ymptomatic hypercalcemia ( 1.5 mmol/L ionized calcium or Ca 12 mg/dL 
or corrected serum calcium ULN) 
Patients who are receiving denosumab prior to randomization must be willing and 
eligible to receive a bisphosphonate instead while in the study.
Malignancies other than NSCLC within 5 years prior to randomization , with the exception of 
those with a negligible risk of metastasis or death (e.g., expected 5 -year OS 90%) treated 
with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, 
basal or squamous cell skin cancer, localized prostate cancer treated surgically with 
curative intent, ductal carcinoma in situ treated surgically with curative intent)
Known tumor PD -L1 expression status as determined by [CONTACT_70095] (e.g., patients whose PD -L1 expression status was determined during screen ing for 
entry into a study with anti PD-1 or anti PD-L1 antibodies but were not eligible are 
excluded)
General Medical Exclusions
Women who are pregnant, lactating, or intending to become pregnant during the study
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or 
humanized antibodies or fusion proteins
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovar y 
cells or any component of the atezolizumab formulation
History of autoimmune disease, including, but not limited to, m yasthenia gravis, myositis,
autoimmune hepatitis, sy stemic lupus erythematosus, rheumatoid arthritis, inflammatory  
bowel disease, vascular thrombosis associated with antiphospholipid syndrome, W egener’s 
granulomatosis, Sjögren’s syndrome, Guillain -Barré syndrome, multiple sclerosis, vasculitis, 
or glomerulonephritis 
Patients with a histor y of autoimmune -related hypothy roidism on a stable dose of 
thyroid replacement hormone are eligible for this study.
Patients with controlled T ype 1 diabetes mellitus on a stable dose of insulin regimen are 
eligible for this study .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
22/Protocol GO29537 , Version 7Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic 
manifestations only (e.g., patients with psoriatic arth ritis would be excluded) are 
permitted provided that they meet the following conditions: 
Rash must cover less than 10% of body surface area.
Disease is well controlled at baseline and only requiring low -potency topi[INVESTIGATOR_28709].
No acute exacerbations of underlying condition within the previous 12 months (not 
requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, 
biologic agents, oral calcineurin inhibitors, high -potency  or oral steroids)
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis 
obliterans), drug -induced pneumonitis, idiopathic pneumonitis, or evidence of active 
pneum onitis on screening chest CT scan
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
Positive test for HIV
All patients will be tested for HIV prior to inclusion into the study; patients who test 
positive for HIV will be excluded from the clinical study.
Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B 
surface antigen [HBsAg] test at screening )or hepatitis C
Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined 
as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are 
eligible only if they are negativ e for HBV DN A.
Patients who are positive for hepatitis C virus (HCV) antibody are eligible only if PCR is 
negative for HCV RNA.
Active tuberculosis
Severe infections within 4 weeks prior to randomization, including but not limited to 
hospi[INVESTIGATOR_33377], bacteremia, or severe pneumonia
Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to 
randomization
Patients receiving prophylactic antibiotics (e.g., for prevention of a urinar y tract 
infection or to prevent chronic obstructive pulmonary disease exacerbation) are 
eligible.
Significant cardiovascular disease, such as [LOCATION_001] Heart Association cardiac disease 
(Class II or greater), m yocardial infarction, or cerebrovascular accident within the 3 months 
prior to randomization, unstable arrhythmias, or unstable angina
Patients with known coronary arter y disease, congestive heart failure not meeting the
above criteria, or left ventricular ejection fraction 50% must be on a stable medical 
regimen that is o ptimiz ed in the opi[INVESTIGATOR_021], in consultation with a 
cardiologist if appropriate.
Major surgical procedure other than for diagnosis within 28 day s prior to randomization or 
anticipation of need for a major surgical procedure during the course of the study
Prior allogeneic bone marrow transplantation or solid organ transplant
Administration of a live, attenuated vaccine within [ADDRESS_742995] udy
Any other diseases, metabolic dysfunction, physical examination finding, or clinical 
laborator y finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that contraindicates 
the use of an investigational drug or that may affect the interpretation of the results or 
renders the patient at high risk from treatment complications
Illness or condition that interferes with the patient’s capacity to understand, follow and/or 
comply with study procedures
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
23/Protocol GO29537 , Version 7Exclusion Criteria Related to Medications
Any approv ed anti -cancer therapy, including hormonal therapy within 21 day s prior to 
initiation of study treatment; the following exceptions are allowed:
TKIs approved for treatment of NSCLC discontinued 7days prior to randomization.  
The baseline scan must be ob tained after discontinuation of prior TKIs.
Treatment with any other investigational agent with therapeutic intent within 28 days prior to 
randomization
Prior treatment with CD137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], anti PD-1, 
and anti PD-L1 therapeutic antibodies
Patients who have had prior antiCTLA -4 treatment may be enrolled, provided the 
following requirements are met:
Last dose of antiCTLA -[ADDRESS_742996] 6 weeks prior to randomization
No history of severe immune -mediated adverse effects fro m antiCTLA -4 
(National Cancer Institute Common Terminology Criteria for Adverse Events 
[NCI CTCAE] Grades 3 and 4)
Treatment with s ystemic immunostimulatory agents (including but not limited to IFNs, IL- 2) 
within 4 weeks or five half -lives of the drug, wh ichever is longer, prior to randomization
Prior treatment with cancer vaccines is allowed.
Treatment with s ystemic immunosuppressive medications (including, but not limited to, 
corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti tumor 
necrosis factor [anti -TNF] agents) within [ADDRESS_742997] received acute, low -dose ( 10mg oral prednisone or equivalent) , 
systemic immunosuppressant medications may  be enrolled in the study.
The use of corticosteroids ( 10mg oral prednisone or equivalent) for chronic 
obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients 
with orthostatic hypotension, and low -dose supplemental corticosteroids for 
adrenocortical insufficiency is allowed.
Exclusions Related to Chemotherapy
Known history of severe allergic reactions to platinum -containing compounds or mannitol
Known sensitivity to any component of nab-paclitaxel
Grade 2 peripheral neuropathy as defined by [CONTACT_4652] v4.0
Known history of severe hypersensitivity reactions to products containing Cremophor®EL 
(e.g., cyclo sporin for injection concentrate and teniposide for injection concentrate)
Length of Study
The final PFS analy sis will be conducted when all of the following criteria have been met:  
approximately [ADDRESS_742998] been enrolled into an extension study.  The Sponsor may decide to terminate the 
study at any time.  If the Sponsor decides to end the study, patients who are still receiving 
study treatment or are in survival follow -up may be offer ed enrollment in an extension study 
or a non -interventional study.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
24/Protocol GO29537 , Version 7Outcome Measures
Efficacy Outcome Measures
The co -primary efficacy  outcome measures for this study are as follows:
PFS, defined as the time from randomization to the first occurrence of disease progression 
as determined by [CONTACT_3143] v1.[ADDRESS_742999] in the tGE -WT population and the ITT -WT population
OS, def ined as the time from randomization to death from any  cause , in the ITT -WT 
population
The secondary efficacy  outcome measures for this study are the following:
OS in the tGE -WT population
PFS, as determined by [CONTACT_3143] v1.1, and OS in the TC2/3 or 
IC2/3 W T population and the TC1/2/3 or IC1/2/3 W T population
PFS, as determined by [CONTACT_3143] v1.1, and OS in the tGE 
population and the ITT population
Objective response, defined as a partial response or a com plete response as determined by 
[CONTACT_3143] v1.1 for the tGE -WT population and the ITT -WT 
population
DOR, defined as the time interval from first occurrence of a documented objective response 
to the time of disease progression as d etermined by [CONTACT_26309] v1.[ADDRESS_743000] for the tGE -WT population and the ITT -WT 
population
OS rates at 1 and 2 years for the tGE -WT population and the ITT -WT population
TTD in patient -reported lung cancer sy mptoms, defined as time from randomization to 
deterioration (10 -point change) on each of the EORTC QLQ -C30 and EORTC QLQ -LC13 
symptom subscales (cough, dyspnea [single item], dy spnea [multi -item subscale], chest 
pain, and arm/shoulder pain) in the tGE-WT population and the ITT -WT population
Change from baseline in patient -reported lung cancer sy mptoms (chest pain, dyspnea, and 
cough) on the sy mptom severity score of the SILC scale in the tGE -WT population and the 
ITT-WT population
Safety Outcome M easures
The safety  outcome measures for this study are the following:
Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.0
Changes in vital signs, physical findings, and clinical laboratory results during and following 
atezolizumab administration
Incidence of ATA response to atezolizumab and potential correlation with PK, 
pharmacodynamic, safety, and efficacy  parameters
Pharmacokinetic Outcome Measures 
The PK outcome measures for this study are the following:
For patien ts randomized to atezolizumab carboplatin nab-paclitaxel:
Maximum observed serum atezolizumab concentration (C max) after infusion on Cycle 1, 
Day 1
Minimum observed serum atezolizumab concentration (C min) prior to infusion at 
selected cycles, at treatment discontinuation, and at 120 days ( 30 days) after the last 
dose of atezolizumab
Plasma concentrations for carboplatin (Arms A and B)
Plasma concentrations for nab -paclitaxel reported as total paclitaxel (Arms A and B)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
25/Protocol GO29537 , Version 7For patients randomized to carboplatin nab-paclitaxel who crossed over to receive open -
label atezolizumab as monotherapy (allowed under Study GO29537 Protocol 
Versions 14):
Cmaxof serum atezolizumab after infusion on Day [ADDRESS_743001] cy cle following crossover 
to atezolizumab a s monotherapy
Cmin of serum atezolizumab prior to infusion on Day 1 at selected cycles following 
crossover to atezolizumab as monotherapy, at treatment discontinuation, and at 
120(30days) after the last dose of atezolizumab
Exploratory Outcome Measure s
The exploratory outcome measures for this study are the following:
PFS at 6 months and at 1 year
OS rate at 3 years
Status of PD- L1, immune -, and NSCLC- related and other exploratory biomarkers in 
archival and/or freshly obtained tumor tissues and blood (or blood derivatives) collected 
before, during, or after treatment with atezolizumab or at progression and association with 
disease status and/or response to atezolizumab in combination with chemotherapy
Status of ICsand other explorator y biom arker s in mandator y biops y specim ens and blood 
collected at progression
Utility scores of the EQ -5D-3L 
Change from baseline in patient -reported outcomes of HRQoL, lung cancer -related 
symptoms, and functioning as assessed by [CONTACT_20368] -C30 and QLQ -LC13 
Investigational Medicinal Products
Test Product (Investigational Drug)
The investigational medicinal products (IMPs) for this study are atezolizumab and erlotinib.
Atezolizumab (1200 mg IV) will be administered on Day 1 of each 21 –day cycle.  Atezolizumab 
will be administered to patients who are randomized to Arm A and to patients in Arm B who 
cross over at progression.
Switch maintenance treatment with erlotinib is no longer permitted.  However, patients who had 
already started switch maintenance treatment with erlotinib under Protocol Versions 1 4may be 
allowed to continue treatment with erlotinib upon discussion of the risks, potential benefits and 
alternative treatment options with the investigator.  For those patients who receive switch 
maintenance, institutions should follow the dosage and administration instructions in the 
prescribing information.  
Comparator
Nab-paclitaxel (100 mg/m2IV) will be administered on Days 1, 8, and 15 of each 21- day c ycle 
for four or six cy cles during the induction phase.  Nab-paclitaxel will be considered an IMP for 
study purposes in countries where nab -paclitaxel is considered an IMP by [CONTACT_427] .
Non-Investigational Medicinal Products
Comparator 
Carboplatin will be administered by [CONTACT_109798] time curve of 6 mg/mL/min on Day [ADDRESS_743002] v1.1 
and OS.  PFS will be analyzed in the tGE -WT population and the ITT -WT population.  OS will 
be analyzed in the ITT -WT population.  The timing of the final PFS and OS analyses is 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
26/Protocol GO29537 , Version 7described below (see "Determination of Sample Size").   At least one interim OS analy sis will be 
performed.
PFS is defined as the time between the date of randomization and the date of first documented 
disease progression or death, whichever occurs first.  Patients who have not experienced 
disease progression or death at the time of analy sis will be censored at the time of the last 
tumor assessment.  Patients with no post -baseline tumor assessment will be censored at the 
date of randomization plus [ADDRESS_743003].  The HR for PFS and OS for 
treatment comparisons will be estimated using a stratified Cox regression model, respectively.  
The 95% CI for the HR will be provided.
The stratification factors will be those used during randomization, (i.e., sex [male vs. female], 
presence of liver metastases at baseline [yes vs. no], and PD -L1 tumor expression by [CONTACT_4658] [TC3 
and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1]), as recorded in an interactive voice or 
Web-based response s ystem.  
Results from an unstratified analysis will also be presented.  Kaplan- Meier methodolo gy will be 
used to estimate the median PFS and the median OS for each treatment arm, and a 
Kaplan -Meier curve will be constructed to provide a visual description of the difference between 
treatment arms.  The Brookmeyer -Crowley methodology will be used to construct the 95% CI 
for the median PFS and the median OS for each treatment arm.
Analyses will be conducted according to an analysis hierarchy and an -spending algorithm to 
control for the type I error rate and to account for an interim analy sis.
To cont rol the overall type I error rate for the one- sided test at 0.025, a one -sided type I error 
() of 0.003 and 0.022 (ratio of 3:22) will be allocated to PFS and OS, respectively.
The hypothesis testing will be performed in the order described below:
1.PFS in the tGE -WT population will be tested at 0.003 (one sided).  If the estimate of the 
HR is  [ADDRESS_743004] is 0.003, 
the null hypothesis will be rejected and it will be concluded that 
atezo lizumab carboplatin nab-paclitaxel prolongs the duration of PFS relative to control 
treatment in the tGE -WT population.
2.If the null hypothesis is rejected in the tGE -WT population (Step 1), PFS in the ITT -WT 
population will be tested at 0.003 (one sided).
3.recycling from PFS to OS will be conducted as follows: 
a.If the null hypothesis is not rejected for the PFS analy sis in the ITT -WT population 
(Step 2), OS in the ITT -WT population will be tested at 0.022 (one sided). 
b.If the null hypothesis is rejected for the PFS analy sis in the ITT -WT population (Step 2), 
OS in the ITT -WT population will be tested at 0.025 (one sided).
Determination of Sample Size
This study will randomize approximately 715 patients.  The ITT -WT population will include 
approximately 650 patients, assuming a prevalence of approximately 10% for sensitizing EGFR 
mutations or ALK translocations.  The tGE -WT population will include approximately 
325patients, assuming a 50% prevalence with the chosen t GEcutoff.
The sample size of this study is based on the number of events required to demonstrate 
efficacy  with regard to both PFS and OS (co -primary  endpoints).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
27/Protocol GO29537 , Version 7The estimate of the number of events required to demonstrate efficacy with regard to PFS in th e 
comparison of Arm A versus Arm B is based on the following assumptions:
93% power to detect an HR of 0.55, corresponding to an improvement in median PFS from 
6 months to 10.9 months in the tGE -WT population with a one -sided of 0.003
95% power to detect an HR of 0.65, corresponding to an improvement in median PFS from 
6 months to 9.2 months in the ITT -WTpopulation with a one -sided of 0.003
No interim analyses for PFS
Dropout rate of 5% per [ADDRESS_743005] to OS in the 
comparison of Arm A versus Arm B is based on the following assumptions :
80% power to detect an HR of 0.75, corresponding to an improvement in median OS from 
12 m onths to 16 months in the ITT -WT population with a one -sided of 0.022
One interim OS analy sis performed at the time of the final PFS analysis, at which time 
approximately 77% of the total number of OS events required for the final analysis are 
expected t o have occurred as determined through use of the Lan- DeMets approximation to 
the O'Brien -Fleming boundary
Dropout rate of 5% per [ADDRESS_743006] been met:  approximately [ADDRESS_743007] patient is enrolled.  This number of events would allow for a minimum detectable 
difference corresponding to an HR of 0.81 in the ITT -WT population.
Interim A nalyses
There are no interim analy ses planned for PFS in this study .  An external independent Data 
Monitoring Committee (iDMC) will be set up to evaluate safety data on an ongoing basis.  All 
summaries/analyses by [CONTACT_70097]’s review will be prepared by [CONTACT_70098].  Members of the iDMC will be external to the Sponsor 
and will follow a charter that outlines their roles and responsibilities.  Any outcomes of these 
safety reviews that affect study conduct will be communicated in a timely manner to the 
investigators for notification of the Institutional Review Boards and Ethics Committees.  A 
detailed plan will b e included in the iDMC Charter.
If approximately [ADDRESS_743008] occurred in the ITT -WT population at the time of the PFS 
final analysis, an interim OS analysis will be conducted in the ITT -WT population.  If there are 
significantly fewer than the expected 352 OS events at the final PFS analy sis, a nominal of 
0.01% (negligible impact on overall type I error rate) will be spent on the OS analysis at the time 
of the PFS fin al analysis and a second interim OS analysis will then be conducted after 
approximately [ADDRESS_743009] patient 
is enrolled.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
28/Protocol GO29537 , Version 7LIST OF A BBREVI ATIONS AND DEFINITIONS OF TERMS
Abbreviation Definition
ALK anaplastic ly mphoma kinase
anti-HBc antibody to hepatitis B core antigen
ATA anti-therapeutic antibody
AUC area under the concentration time curve
BSC best supportive care
CL clearance
Cmax maximum observed serum concentration
Cmin minimum observed serum concentration
CR complete response
CRC colorectal cancer
CRCL creatinine clearance
CRF Case Report Form
ctDNA circulating -tumor DNA
Ctrough trough concentration
DCR disease control rate
DLT dose -limiting toxicity
DOR duration of response
EC Ethics Committee
ECOG Eastern Cooperative Oncology Group
eCRF electronic Case Report Form
EDC electronic data capture
EORTC European Organi sation for Research and Treatment of Cancer
ePRO electronic PRO
EQ-5D-3L Euro QoL [ADDRESS_743010] ratio
HRQoL health- related quality of life
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
29/Protocol GO29537 , Version 7Abbreviation Definition
IC tumor- infiltrating immune cell
ICH International Council for Harmonisation
iDCC independent Data Coordinating Center
iDMC independent Data Monitoring Committee
Ig immunoglobulin
IHC immunohistochemistry
IMP Investigational Medicinal Product
IND Investigational New Drug 
IRB Institutional Review Board
IRF Independent Review Facility
ITT intent to treat
IV intravenous
IxRS interactive voice or W eb-based response system
LFT liver function test
MTD maximum tolerated dose
NCI CTCAE National Cancer Institute Common Terminology Criteria for 
Adverse Events
NGS next-generation sequencing
NSCLC non small cell lung cancer
ORR objective response rate
OS overall survival
PET positron emission tomography
PFS progression -free survival
PGIS Patient Global Impression of Severity
PK pharmacokinetic
PR partial response
PRO patient -reported outcome
PVC polyvinylchloride
Q3W every 3 weeks
QLQ -C30 Quality -of-Life Questionnaire Core 30
QLQ -LC13 Quality -of-Life Questionnaire Lung Cancer Module
qRT-PCR quantitative reverse transcriptase polymerase chain reaction
RCC renal cell carcinoma
RCR [COMPANY_002] Clinical Repository
RECIST Response Evaluation Criteria in Solid Tumors
RRR response rate ratio
SAP Statistical Analysis Plan
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
30/Protocol GO29537 , Version 7Abbreviation Definition
SILC Symptoms in Lung Cancer
TC tumor cell
TE thromboembolic events
tGE tumor gene expression
TIR time in response
TKI tyrosine kinase inhibitor
TNF tumor necrosis factor
TSH thyroid- stimulating hormone
TTD time to deterioration
UBC urothelial bladder cancer
ULN upper limit of normal
VEGF vascular endothelial growth factor
Vss volume of distribution at steady state
WT wild type
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
31/Protocol GO29537 , Version 71. BACKGROUND
1.1 BACKGROUND ON LUNG CA NCER
Lung cancer remains the leading cause of cancer deaths worldwide; it is the most 
common cancer in both men and women and accounted for approximately 13% of all 
new cancers in 2008 ( Jemal et al. 2011).  In 2012, it was estimated that there would be 
226,160 new cases of lung cancer and 160,340 lung cancer deaths in the [LOCATION_002] 
alone (Siegel et al. 2012 ).  Similar data from Europe estimate that there were 
288,000 new cases of lung cancer and 253,000 deaths in 2008 ( GLOBOCAN 2008 ). 
Nonsmall cell lung cancer (NSCLC) is the predominant subtype o f lung cancer, 
accounting for approximately 85% of all cases ( Molina et al. 2008 ; Howlader etal.2011 ). 
NSCLC can be divided into two major histologic types:  adenocarcinoma and squamous 
cell carcinoma ( Travis et al. 2011 ).  Adenocarcinoma histology accounts f or more than 
half of all NSCLC, while squamous cell histology accounts for approximately 25% 
(Langer et al. 2010 ).  The remaining cases of NSCLC are represented by [CONTACT_70099], neuroendocrine tumors, sarcomatoid carcinoma, and poorly differen tiated 
histology.
Theoverall 5 -year survival rate for advanced disease is 2% 4%, depending on 
geographic location (Cetin et al. 2011 ).  Poor prognostic factors for survival in patients 
with NSCLC include advanced stage of disease at the time of initial di agnosis, poor 
performance status, and a history of unintentional weight loss.  More than half of the 
patients with NSCLC are diagnosed with distant disease, which directly contributes to 
poor survival prospects.
There are recognized differences in disease characteristics between adenocarcinoma and 
squamous NSCLC.  First, squamous tumors commonly present in the central airways and 
typi[INVESTIGATOR_70038] ( Hirsch et al. 2008 ), whereas 
non-squamous tumors are more commonly located in the lung parenchyma distal to the 
central airways. Evaluation of NSCLC tumor tissue will reveal cytological differences 
between the squamous cell type (keratinization, intracellular bridges, and central necrosis) 
andadenocarcinoma (glandular ar chitecture).  In cases where the tumor sample is poorly 
differentiated or there is limited tissue available, immunohistochemical markers may 
support the histologic diagnosis.  Thyroid transcription factor [ADDRESS_743011], p63, CK5/6, 
and 34 E12 are strongly expressed in squamous cell carcinoma and less frequently in 
adenocarcinoma ( Travis et al. 2011 ).
Genetic changes that have prognostic and/or predictive significance in NSCLC include 
mutations in the EGFR , the rearrangement in the ALK genes, and mutations in the KRAS
gene.  The rates of these mutations differ between squamous cell carcinoma and 
adenocarcinoma.  For example, EGFR kinase domain mutations have been reported i n 
10%40% of patients with adenocarcinoma NSCLC but are infrequently observed in 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
32/Protocol GO29537 , Version 7squamous NSCLC ( Herbst et al. 2008 ).  Similarly, the ALK fusion oncogene, recognized 
as a driver of lung tumorigenesis, is observed in approximately 7% of patients with 
adenoc arcinoma but is very rare in the squamous histology ( Herbst et al. 2008; 
Langer etal.2010 ).  In addition, KRAS mutations are very rare in squamous NSCLC, 
while they can be observed in up to 30% of cases of adenocarcinoma NSCLC 
(Travis etal.2011 ). 
1.1.[ADDRESS_743012]-Line Treatment for A dvanced NSCLC with an EGFR
Mutation or ALK Rearrangement
Genotype- directed therapy has the potential to dramatically improve the balance of 
benefit and toxicity for selected patients with NSCLC characterized by [CONTACT_565748] o ncogenes, including sensitizing EGFR mutations and ALK rearrangements.  
However, these mutations are more prevalent in adenocarcinoma NSCLC and are very 
rare in squamous NSCLC.  Randomized Phase III studies of gefitinib (IPASS), erlotinib 
(EURTAC), and afa tinib (LUX -Lung3) showed significant improvement of progression -
free survival ( PFS)and objective response rate ( ORR) compared with platinum doublet 
chemotherapy ( Fukuoka et al. 2011; Rosell etal.2012 ; Sequist et al. 2013 ; 
respectively).  Similarly, the ALK inhibitor crizotinib has demonstrated efficacy in patients 
with NSCLC positive for ALK rearrangement as defined by [CONTACT_452720] ( Crino et al. 2011; Camidge et al. 2012; Shaw etal.2012 ; 
XALKORI®U.S. Package Insert).  Both EGFR tyrosine kinase inhibitors (TKIs) and 
crizotinib have been shown to be generally well tolerated.  
1.1.[ADDRESS_743013] evidence that chemotherapy produced a significant survival 
benefit in patients with advanced NSCLC came i n 1995; a meta -analysis showed that 
platinum -based doublet chemotherapy conferred a [ADDRESS_743014] supportive care (BSC) (NSCLC Collaborative Group 1995 ).  More 
recently, the European Big Lung Trial demonstrated the potential benefits of 
chemotherapy.  In this study, 725 patients with advanced NSCLC were randomly 
assigned to BSC plus cisplatin -based chemotherapy or BSC alone ( Spi[INVESTIGATOR_255830].2004 ).  
Patients allocated to chemotherapy had a significantly longer median sur vival than did 
those managed with BSC (8 vs. 5.7 months; hazard ratio [HR] 0.77, 95% CI: 0.66, 0.89).
The globally recognized standard of care for patients with inoperable Stage IIIB and 
Stage IV NSCLC is platinum -based chemotherapy for four to six cycle s followed by 
[CONTACT_565749].  This standard of care applies to both 
non-squamous and squamous NSCLC ( Pfister et al. 2004; D’Addario etal.2010 ; 
DeMarinis etal.2011 ; National Comprehensive Cancer Network [NCCN] 2014 ).  
Agents t hat have been partnered with either cisplatin or carboplatin include the 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
33/Protocol GO29537 , Version 7taxanes (paclitaxel, docetaxel), vinorelbine, gemcitabine, and pemetrexed.  
Combinations of these drugs with platinum analogs are superior to single -agent 
therapy and have been shown to prolong survival ( Azzoli etal.2009 ).  
The Eastern Cooperative Oncology Group (ECOG) conducted a Phase III study 
(Study E1594) to compare four commonly used platinum -based doublets in patients with 
Stage IIIB/IV NSCLC who had not previously received c hemotherapy 
(Schiller etal.2002 ).  Gemcitabine cisplatin, docetaxel cisplatin, 
andpaclitaxel carboplatin were compared with paclitaxel cisplatin.  N o significant 
clinical advantage of any one of the chemotherapy regimens over the others was 
observed; the median survival rates of the four treatment arms were approximately the 
same:  approximately 8 months.  T he regimen of paclitaxel carboplatin was chosen as 
the reference regimen for ECOG’s future studies because of its more favorable toxici ty 
profile.
Recently, immune checkpoint inhibitors, including PD -L1and PD-[ADDRESS_743015] 50% of tumor cells (TCs) .  Patients with sensitizing mutation of the EGFR gene or 
translocation of the ALK gene were excluded from this study.   In this study, median PFS 
was 10.3 months in the pembrolizumab group versus 6.0 month s in the chemotherapy 
group (HR 0.50; 95% CI: 0.37 , 0.68; p<0.001).  The estimated rate of overall survival 
(OS)at 6 months was 80.2% (95% CI:72.9%, 85.7%) in the pembrolizumab group 
versus 72.4% (95% CI: 64.5 %, 78.9%) in the chemotherapy group; median OS was not 
reached in either group.  OSwas significantly longer in the pembrolizumab group than in 
the chemot herapy group (HR 0.60; 95% CI: 0.41, 0.89; p 0.005) (Reck et al. 2016).  
On the basis of this study, pembrolizumab wasapproved for the first -line treatment of 
metastatic NSCLC in patients whose tumors have high PD -L1 expression ( tumor 
proportion score 50%) with no EGFR or ALK gene aberrations.
1.1.3 nab-Paclitaxel Carboplatin for First- Line NSCLC
Socinski et al. ( 2012 ) conducted a Phase III randomized study evaluating the efficacy 
and safety of albumin- bound paclitaxel (nab- paclitaxel; ABRAXANE)carboplatin 
compared with solvent -based paclitaxel carboplatin in 1052 previously untreated 
patients with NSCLC.  The primary efficacy endpoint of this study was ORR with 
secondary endpoints of PFS and OS.  Patients treated with nab- paclitaxel carbopla tin 
demonstrated a significantly improved ORR compared with patients treated with 
paclitaxel carboplatin (33% vs. 25%; response rate ratio [RRR] 1.31; p0.005), with 
patients with squamous histology experiencing the greatest improvement (41% vs. 
24%; RRR 1.68; p0.001).  In patients with non -squamous histology, nab-
paclitaxel carboplatin achieved a similar ORR as paclitaxel carboplatin ( 26% vs. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
34/Protocol GO29537 , Version 725%, respectively).  There was a comparable improvement in PFS (6.3 months vs. 
5.8months; HR0.902;95% CI: 0.767, 1.060) and OS (12.1 months vs. 11.2 months; 
HR0.922;95% CI: 0.797, 1 .066) in patients treated with nab -paclitaxel carboplatin 
compared with paclitaxel carboplatin in the intent -to-treat (ITT) population, 
respectively.  No clini cally meaningful differences were seen with respect to PFS 
(6.9months [nab -paclitaxel carboplatin] vs. 6.5 months [paclitaxel carboplatin]; 
HR0.933) or OS (13.1 months [nab -paclitaxel carboplatin] vs. 13.0 months 
[paclitaxel carboplatin]; HR0.950) in the non- squamous subgroups.  A statistically 
non-significant improvement in OS was seen in patients with squamous histology 
(10.7 months [nab -paclitaxel carboplatin] vs. 9.5 months [paclitaxel carboplatin]; 
HR0.890;95% CI: 0.719, 1.101), with no difference in PFS observed in this 
subgroup.  On the basis of these comparable clinical results, the regimen of 
nab-paclitaxel carboplatin was approved for the treatment of NSCLC in the first -line 
setting in all histologies. 
Despi[INVESTIGATOR_109771], the benefit conferred by [CONTACT_70101] -based chemotherapy 
regimens appears to have reached a plateau in the objective response rate 
(approximately 15% 25%) and median survival (7 11 months).  Pemetrexed 
(ALIMTA®) has recently demonstrated activity in the firs t-line setting where patients 
with non -squamous carcinoma had improved survival when treated with cisplatin and 
pemetrexed compared with those treated with cisplatin and gemcitabine (11.8 vs. 
10.4 months; p 0.005) ( Scagliotti et al. 2008 ).  Inaddition, cisplatin and pemetrexed 
was associated with better tolerability and safety and necessitated less supportive 
care.  More recently, the addition of bevacizumab to carboplatin and paclitaxel in 
patients with non -squamous NSCLC resulted in an inc rease in response rate from 
15% to 35% and an increase in median OS from 10 to 12 months (see Table 1). 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
35/Protocol GO29537 , Version 7Table 1Randomized Phase III Trials in Patients with Previously Untreated 
NSCLC
Treatment GroupORR
(%)Median 
PFS
(Months)Median 
OS
(Months)OS HR
(95% CI)
Chemotherapya
Cisplatin and paclitaxel (n 288) 21 3.4 7.8
Cisplatin and gemcitabine (n 288) 22 4.2 8.1
Cisplatin and docetaxel (n 289) 17 3.7 7.4
Carboplatin and paclitaxel (n 290) 17 3.1 8.1
Chemotherapy biologicb
Carboplatin and paclitaxel (n 444) 15 4.5 10.3 0.79
0.67, 0.92Carboplatin, paclitaxel, and bevacizumab 
(n434)35 6. 2 12.3
Chemotherapyc
Cisplatin and pemetrexed, overall ( n839) 31 4.8 10.3 0.94
0.84, 1.05Cisplatin and gemcitabine, overall ( n830) 28 5.1 10.3
Cisplatin and pemetrexed, non- squamous NR 5.3 11.8 0.81
0.70, 0.94Cisplatin and gemcitabine, non-squamous NR 4.7 10.4
Cisplatin and pemetrexed, squamous NR 4.4 9.4 1.23
1.00, 1.51Cisplatin and gemcitabine, squamous NR 5.5 10.8
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
36/Protocol GO29537 , Version 7Table 1Randomized Phase III Studies in Patients with Previously  
Untreated NSCLC (cont.)
Treatment GroupORR
(%)Median 
PFS
(Months)Median 
OS
(Months)OS HR
(95% CI)
Chemotherapyd
Carboplatin and nab -paclitaxel, overall 
(n521)33 6.3 12.1 0.922
0.797, 1.066
Carboplatin and paclitaxel, overall (n 531) 25 5.8 11.2
Carboplatin and nab -paclitaxel, 
non-squamous (n 221)26 6.9 13.1 0.950
NR
Carboplatin and paclitaxel, non -squamous 
(n292)25 6. 5 13.0
Carboplatin and nab -paclitaxel, squamous 
(n300)41 5.6 10.7 0.890
0.719, 1.101
Carboplatin and paclitaxel, squamous 
(n229)24 5.7 9.5
Chemotherapy biologice
Cisplatin and vinorelbine (n 568) 29 4.8 10.1 0.871
0.762, 0.996Cisplatin, vinorelbine, and cetuximab 
(n557)36 4.8 11.3
Immunotherapy f
Pembrolizumab, PD -L1 positive ( 50%) 
(n154)45 10.3 Not 
reached 0.60
0.41 0.89 Platinum -based chemotherapi[INVESTIGATOR_014] , PD-L1 
positive ( 50%) (n 151)28 6.0 Not 
reached
HRhazard ratio; NR not reported; NSCLC non small cell lung cancer; ORR objective 
response rate; OS overall survival; PFS progression -free survival.
aSchiller et al. 2002 .
bSandler et al. 2006.
cScagliotti et al. 2008.
dSocinski et al. 2012.
ePi[INVESTIGATOR_109772]. 2009.
fReck et al. 2016 .
1.1.4 AVAS TIN®and Vascular Endothelial Gro wth Factor
AVASTIN®(bevacizumab) is a recombinant humanized monoclonal antibody to vascular 
endothelial growth factor (VEGF) that recognizes all isoforms of VEGF.  It may exert a direct 
anti-angiogenic effect by [CONTACT_368460].  
Additi onal anti -tumor activity may be on tumor vasculature, interstitial pressure, and blood 
vessel permeability, providing for enhanced chemotherapy delivery to TCs (Jain 2001 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
37/Protocol GO29537 , Version [IP_ADDRESS] Clinical Studies of Bevacizumab and 
Platinum- Based Treatment in NSCLC 
Two Phase II I studies have demonstrated the benefit of bevacizumab in combination 
with platinum -based chemotherapy as first -line treatment of patients with unresectable, 
advanced, metastatic or recurrent non -squamous NSCLC. 
The first study, conducted by [CONTACT_253086] (Study E4599) was an open -label, randomized, 
Phase III study comparing the regimen of 15 mg/kg bevacizumab every 3 weeks ( Q3W) 
in combination with carboplatin and paclitaxel versus carboplatin and paclitaxel alone as 
first-line treatment of patients with advan ced non -squamous NSCLC.  The Phase III 
study was based on a randomized Phase II study in patients with recurrent or advanced 
NSCLC that evaluated carboplatin and paclitaxel (up to six cycles) with or without 
bevacizumab (7.5 or 15 mg/kg) and found that the combination of bevacizumab 
15mg/kg with carboplatin and paclitaxel for up to six cycles followed by [CONTACT_255865] (31.5% vs. 
18.8%) and prolonged time to progression (7.4 vs. 4.2 months; p0.023 ) compared with 
chemotherapy alone ( Johnson et al. 2004).  There was also a non -significant 
improvement in OS (17.7 vs. 14.9 months) ( Johnson et al. 2004 ).  A higher incidence of 
bleeding was noted in the bevacizumab- treated patients.  Sever e pulmonary 
hemorrhage, which was observed in 6 patients (9.1%) and led to 4 fatalities, was more 
common in patients with squamous cell histology, tumor necrosis, and cavitation, and 
central tumors ( Johnson et al. 2004).  On the basis of the results of this Phase II study, 
patients with squamous cell histology were excluded from this and other studies utilizing 
bevacizumab in NSCLC.  In Study E4599, p atients who received six cycles of 
bevacizumab plus chemotherapy without disease progress ion continued on single -agent 
bevacizumab until progression.  A total of 878 patients were enrolled.  Median OS was 
12.3 months versus 10.3 months ( HR0.79; p0.003); PFS was 6.2 months versus 
4.5months ( HR0.66; p0.001), and the response rate was 35% (133 of 381 patients ) 
versus 15% (59 of 392 patients ) (p0.001) for patients treated with bevacizumab versus 
chemotherapy alone (Sandler et al. 2006 ). 
The second study (Study BO17704 or AVAiL) was a randomized, double -blind, 
multicenter, two -stage , Phase III study of bevacizumab in combination with cisplatin and 
gemcitabine versus placebo, cisplatin, and gemcitabine as first -line treatment in patients 
with advanced or recurrent non -squamous NSCLC.  A total of 1043 patients were 
randomized.  Bevaciz umab -based therapy until disease progression reduced the risk of 
disease progression.  Bevacizumab at a dose level of 7.5 mg/kg resulted in an HR for 
PFS of 0.75 (median PFS, 6.7 vs. 6.1 months; p0.003), and bevacizumab at a dose 
level of 15 mg/kg resulted in an HR of 0.82 (median, 6.5 months vs. 6.1 months, 
p0.03).  These results were maintained with a longer follow -up.  OS was a secondary 
endpoint, and the PFS benefit did not translate into a significant OS benefit.  
Nevertheless, median OS in all treatment arms of the study exceeded 13 months 
(Reck et al. 2009 ; Reck etal.2010 ). 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
38/Protocol GO29537 , Version 7In summary, platinum -based regimens remain the standard first -line option for most 
patients with locally advanced and metastatic NSCLC not harboring an activating EGFR
mutation or ALK gene rearrangement.  In particular, for newly diagnosed 
advanced -stage non- squamous NSCLC, the current standard of care is a platinum 
doublet with either cisplatin or carboplatin and a taxane or pemetrexed, with or without 
bevacizumab.   However, these regimens are associated with substantial toxicities (such 
as febrile neutropenia, myelosuppression, nausea, alopecia, nephropathy, and 
neuropathy) and are generally poorly tolerated by [CONTACT_565750].  Therefore, novel therapi[INVESTIGATOR_565726]-squamous NSCLC .
1.1.5 Targeted Therapy  for NSCLC
Genotype- directed therapy has the potential to dramatically improve the balance of 
benefit and toxicity for selected patients with NSCLC (mainly non -squamous histology) 
characterized by [CONTACT_70105], including sensitizing EGFR mutations 
and ALK rearrangement.  Randomized Phase III studies of gefitinib (IPASS), erlotinib 
(EURTAC), and afatinib (LUX -Lung 3) show ed significant improvement of PFS and ORR 
compared with platinum doublet chemotherapy (Fukuoka et al. 2011, Rosell et al. 2012, , 
and Sequist et al. 2013 , respectively).  Similarly, the ALK inhibitors crizotinib and 
ceritinib have demonstrated efficacy in patients with NSCLC positive for ALK
rearrangement as defined by [CONTACT_26707] ( Crino et al. 2011; 
Camidge et al. 2012 ; Shaw etal.2012 ; Shaw and Engleman 2014 ; XALKORI®USPI ;
Zykadia USPI ).
Despi[INVESTIGATOR_70044], 
survival rates for advanced disease remain low and acquired resistance to targeted 
agents is a major clinical problem.  Therefore, alternative treatment options that yield 
durable responses and enhance OS remain an important focus of research.  Against this 
background, immunotherapeutic agents, such as cancer vaccines and antibodies that 
modulate immune cell activity, offer an alternative treatment approach that could 
potentially improve the prognosis of patient s with this disease.
1.1.6 Erlotinib or Pemetrexed Maintenance Therapy  for NSCLC
NCCN guidelines ( 2014 ) on chemotherapy for Stage IV NSCLC recommend that 
cytotoxic regimens consisting of two drugs should be given for no more than six cycles.  
The guidelines also recommend stoppi[INVESTIGATOR_565727] -line cytotoxic chemotherapy at disease 
progression.  At study initiation, switch maintenance treatment with erlotinib in 
unselected patients or pemetrexed in those with non -squamous histology could be 
considered for patients with stable disease or continued response to therapy after four to 
six cycles of chemotherapy (NCCN 2014 ).  This recommendation was based on two 
randomized Phase III studies, which had shown a PFS and OS benefit after the initiation 
of pemetrexed or erlotinib a fter induction treatment in patients with non -progressive 
disease.  In the sequential Tarceva unresectable NSCLC study (SATURN), the median 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
39/Protocol GO29537 , Version 7PFS in patients receiving maintenance therapy with erlotinib was significantly longer 
than in patients receiving pla cebo (12.3 vs. 11.1 weeks; HR 0.71;95% CI: 0.62, 0.81; 
p0.0001).  Maintenance treatment with erlotinib also yielded a statistically significant 
yet clinically modest improvement in OS (12.0 vs. 11.0 months; HR 0.81;95% CI: 0.70, 
0.95; p 0.0088).   A statistically significant improvement in PFS and OS was seen in 
patients with EGFR wild-type and EGFR mutation positive tumors 
(Cappuzzo etal.2010 ).  In the JMEN study evaluating pemetrexed maintenance therapy 
following four cycles of platinum -based doublet chemotherapy, pemetrexed significantly 
improved PFS (4.3 vs. 2.6 months; HR 0.50;95% CI: 0.42, 0.61; p 0.0001) and OS 
(13.4 vs. 10.6 months; HR 0.79;95% CI: 0.65, 0.95; p 0.012) when compared with 
placebo ( Ciuleanu etal.2009 ).  These Ph ase III studies resulted in regulatory approval 
(U.S. Food and Drug Administration [FDA] and European Medicines Agency) for erlotinib 
and pemetrexed, respectively, as maintenance therapy of patients with locally advanced 
or metastatic NSCLC whose disease has not progressed after four cycles of 
platinum -based first -line chemotherapy.  However, recent data from Study BO25460, a 
Phase III, randomized, double -blind, placebo -controlled study, have demonstrated that 
patients with advanced or recurrent (Stage IIIB) or metastatic (Stage IV) NSCLC whose 
tumor did not harbor an EGFR -activating mutation did not achieve benefit from first -line 
maintenance therapy with erlotinib compared with placebo.  OS was not superior in 
patients who were randomized to receive mainte nance erlotinib followed by 
[CONTACT_565751] (HR 1.02; 95% CI: 0.85, 1.22; p 0.82).  I n the maintenance 
phase, patients who received erlotinib also did not have superior PFS compared with 
patients who received placebo (HR 0.94; 95% CI: 0.80, 1.11; p 0.48).  This change in 
the benefit risk assessment of erlotinib as switch maintenance th erapy in patients 
whose tumors do not harbor an activating EGFR mutation has led to the removal of this 
treatment option from this protocol.
1.2 BACKGROUND ON ATEZOLIZUMA B 
Atezolizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody consisting of 
two heavy chains (448 amino acids) and two light chains (214 amino acids) and is 
produced in Chinese hamster ovary cells.  Atezolizumab was engineered to eliminate 
Fc-effector function via a single amino acid substitution at position 298 on the heavy 
chain , which results in a non -glycosylated antibody that has minimal binding to 
Fcreceptors and prevents Fc -effector function at expected concentrations in humans.  
Atezolizumab targets human PD-L1and inhibits its interaction with its receptors, PD-1
and B7.1 (CD80, B7- 1).  Both of these interactions are reported to provide inhibitory 
signals to T cells.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
40/Protocol GO29537 , Version 7Atezolizumab is being investigated as a potential therapy against solid tumors and 
hematologic malignancies in humans.   Atezolizumab is approved for the treat ment of
patients with metastatic NSCLC after prior chemotherapy and for the treatment of 
patients with locally advanced or metastatic urothelial carcinoma after prior 
chemotherapy .
1.2.1 Summary  of Nonclinical Studies
The nonclinical strategy of the atezolizumab program was to demonstrate in vitro and 
invivo activity, to determine in vivo pharmacokinetic (PK) behavior, to demonstrate an 
acceptable safety profile, and to identify a Phase I starting dose.  Comprehensive 
pharmacology, PK, and toxicology evaluations were thus undertaken with atezolizumab.
The safety, pharmacokinetics, and toxicokinetics of atezolizumab were investigated in 
mice and cynomolgus monkeys to support intravenous (IV) administration and toaid 
inprojecting the appropriate starting dose in humans.  Given the similar binding of 
atezolizumab for cynomolgus monkey and human PD -L1, the cynomolgus monkey was 
selected as the primary and relevant nonclinical model for understanding the safety, 
pharmacokinetics, and toxicokinetics of atezolizumab.
Overall, the nonclinical pharmacokinetics and toxicokinetics observed for atezolizumab 
supported entry into clinical studies, including providing adequate safety factors for the 
proposed Phase I starting doses.  The results of the toxicology program were consistent 
with the anticipated pharmacologic activity of downmodulating the PD -L1/PD -[ADDRESS_743016] 
and supported entry into clinical studies in patients.
Refer to the Atezolizumab Investigator’s Brochure for details on the nonclinical studies.
1.3 CLINICA L EXPERIENCE WITH A TEZOLIZUMA B
1.3.1 Ongoing Clinical Studies
Atezolizumab is currently being tested in multiple Phase I, II, and III studies, both as 
monotherapy and in combination with several anti- cancer therapi[INVESTIGATOR_014] (see the 
Atezolizumab Investigator’s Brochure f or study descriptions).  The single -agent safety 
and efficacy data include , but are not limited to, data from the following studies:
Study PCD4989g:  A Phase Ia, multicenter, first -in-human, open -label, 
dose- escalation study evaluating the safety, tolerabi lity, immunogenicity, 
pharmacokinetics, exploratory pharmacodynamics, and preliminary evidence of 
biologic activity of atezolizumab administered as a single agent by [CONTACT_16228] Q3W
to patients with locally advanced or metastatic solid malignanc ies or hematologic 
malignancies
Study GO28753 (POPLAR):  A randomized, Phase II, open -label study assessing 
the clinical benefit of atezolizumab as a single agent versus docetaxel in patients 
with locally advanced or metastatic NSCLC that has progressed during or fol lowing 
treatment wit h a platinum -containing regimen
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
41/Protocol GO29537 , Version 7Study GO28915 (OAK):  A randomized, Phase III, open- label study assessing the 
efficacy and safety of atezolizumab as a single agent versus docetaxel in patients 
with locally advanced or metastatic NSCLC t hat has progressed during or following 
treatment with a platinum -containing regimen
Study GP28328:  A Phase Ib study assessing the safety and pharmacology of 
atezolizumab in combination with bevacizumab and/or chemotherapy in patients 
with advanced solid t umors
1.3.2 Clinical Safety
[IP_ADDRESS] Single -Agent Clinical Safety  in Patients with NSCLC in 
Study PCD4989g
Study PCD4989g, in which atezolizumab is being used as a single agent in patients with 
locally advanced or metastatic solid tumors or hematologic malignancies, provides the 
majority of data (with 558 safety -evaluable patients as of the data extraction date of 
11May2015) for the safety profile of atezolizumab as monotherapy.
Currently, no maximum tolerated dose (MTD), no dose -limiting toxicities (DLTs), and no 
clear dose -related trends in the incidence of adverse events have been determined.
The safety profile of atezolizumab as a single agent is observed to be consistent across 
different indications.  The most common cancer types for these patients include NSCLC, 
urothelial bladder cancer (UBC) , melanoma, and renal cell carcinoma (RCC) .  Safety 
data for NSCLC are also derived from Studies GO28625 (FIR), GO28915 (OAK), and 
Study GO28753 (POPLAR).
Adverse Events
Of the 558 patients, 520 patients (93.2%) experienced at least one adverse event, 
including 376 patients (67.4%) who experienced one treatment -related adverse event.  
Commonly reported events (reported in 10% of all patients) included fatigue, decreased 
appetite, nausea, pyrexia, constipation, and cough ( see Table 2 ).  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
42/Protocol GO29537 , Version 7Table 2Study PCD4989g:  A dverse Ev ents with Frequency  10% of 
Patients for A ll Grades
Adverse EventAll Grades
n (%)All Grades 
Related
n (%)Grade s 34
n (%)Grade s 34 
Related
n (%)
Any adverse event 520 (93.2) 376 (67.4) 239 (42.8) 66 (11.8)
Fatigue 192 (34.4) 115 (20.6) 13 (2.3) 6 (1.1)
Decreased appetite 142 (25.4) 62 (11.1) 4 (0.7) 0 (0.0)
Nausea 136 (24.4) 65 (11.6) 5 (0.9) 2 (0.4)
Pyrexia 117 (21.0) 63 (11.3) 2 (0.4) 0 (0.0)
Constipation 116 (20.8) 8 (1.4) 2 (0.4) 0 (0.0)
Cough 113 (20.3) 11 (2.0) 1 (0.2) 1 (0.2)
Dyspnea 112 (20.1) 18 (3.2) 18 (3.2) 4 (0.7)
Diarrhea 110 (19.7) 53 (9.5) 2 (0.4) 1 (0.2)
Anem ia 104 (18.6) 26 (4.7) 23 (4.1) 5 (0.9)
Vomiting 96 (17.2) 28 (5.0) 3 (0.5) 2 (0.4)
Asthenia 88 (15.8) 53 (9.5) 8 (1.4) 4 (0.7)
Back pain 85 (15.2) 9 (1.6) 8 (1.4) 1 (0.2)
Headache 83 (14.9) 32 (5.7) 2 (0.4) 1 (0.2)
Arthralgia 79 (14.2) 35 (6.3) 2 (0.4) 0 (0.0)
Pruritus 75 (13.4) 55 (9.9) 0 (0.0) 0 (0.0)
Rash 73 (13.1) 53 (9.5) 0 (0.0) 0 (0.0)
Abdominal pain 63 (11.3) 12 (2.2) 8 (1.4) 0 (0.0)
Insomnia 62 (11.1) 7 (1.3) 1 (0.2) 0 (0.0)
Peripheral edema 59 (10.6) 7 (1.3)  
Chills 57 (10.2) 31 (5.6) 0 (0.0) 0 (0.0)
Note:  ""refers to missing Common Terminology Criteria grade.
Grade 3 or4adverse events (on the basis of National Cancer Institute Common 
Terminology Criteria for Adverse Events, Version 4 [NCI CTCAE v4 .0]) were reported in 
239 patients (42.8%), of which 66 patients (11.8%) were considered related.  Grade [ADDRESS_743017], increased gamma -glutamyl transf erase (GGT), 
lymphocyte count decreased, cardiac tamponade, asthenia, autoimmune hepatitis, 
pneumonia, influenza, and hypoxia.
Refer to the Atezolizumab Investigator’s Brochure for details on adverse events 
observed in patients treated with atezolizumab.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
43/Protocol GO29537 , Version 7Immune- Mediated A dverse Ev ents
Given the mechanism of action of atezolizumab, events associated with inflammation 
and/or immune- mediated adverse events have been closely monitored during the 
atezolizumab clinical program.  These include potential dermatolog ic, hepatic, 
endocrine, gastrointestinal, and respi[INVESTIGATOR_29343].  
Refer to the Atezolizumab Investigator’s Brochure for details on immune -mediated 
adverse events that were observed in patients treated with atezolizumab.  Guidelines for 
the management of immune -mediated adverse events are described in Section 5.1.8 .
[IP_ADDRESS] Single -Agent Clinical Safety  in Patients with NSCLC in Study 
GO28753 ( POPLA R)
As of the 1 December 2015 data cutoff date, the Phase II POPLAR study (GO28753) 
included data from 277 safety -evaluable patients treated with either atezolizumab as a 
fixed dose of 1200 mg IV every 3 weeks ( Q3W) (n142) or docetaxel 75 mg/m2IV Q3W
(n135).  The frequency of patients in the POPLAR study who reported any adverse 
event regardless of attribution was 95.8% for the atezolizumab arm and 96.3% for the 
docetaxel arm.  A higher frequency of Grade 3or 4adverse events wasobserved 
among patients in the docetaxel arm ( 52.6% vs. 40.8% ), explained primarily by [CONTACT_109804].  The frequency of 
patients who discontinued treatment because of adverse events was higher in the 
docetaxel arm than in the atezoliz umab arm (22.2% vs. 8.5%).  Adverse events reported 
in at least 10% of patients in either treatment arm are listed in Table 3 .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
44/Protocol GO29537 , Version 7Table 3Study GO28753 (POPLA R):  Adverse Events Reported in at 
Least 10% of Patients
No. of Patients (%)
Adverse EventAtezolizumab
(n142)Docetaxel
(n135)
Fatigue 55 (38.7) 54 (40.0)
Decreased appetite 49 (34.5) 28 (20.7)
Nausea 32 (22.5) 45 (33.3)
Cough 40 (28.2) 33 (24.4)
Dyspnea 39 (27.5) 27 (20.0)
Constipation 31 (21.8) 32 (23.7)
Diarrhea 25 (17.6) 38 (28.1)
Alopecia 3 (2.1) 52 (38.5)
Anem ia 25 (17.6) 27 (20.0)
Pyrexia 24 (16.9) 16 (11.9)
Vomiting 20 (14.1) 18 (13.3)
Asthenia 15 (10.6) 22 (16.3)
Arthralgia 22 (15.5) 12 (8.9)
Insomnia 22 (15.5) 11 (8.1)
Rash 16 (11.3) 16 (11.9)
Back pain 16 (11.3) 11 (8.1)
Myalgia 9 (6.3) 18 (13.3)
Musculoskeletal pain 19 (13.4) 7 (5.2)
Weight decreased 16 (11.3) 9 (6.7)
Hemopty sis 15 (10.6) 8 (5.9)
Pneumonia 17 (12.0) 4 (3.0)
Neuropathy peripheral 3 (2.1) 16 (11.9)
Neutropenia 2 (1.4) 17 (12.6)
For additional information, refer to the Atezolizumab Investigator’s Brochure.
[IP_ADDRESS] Single -Agent Clinical Safety  in Patients with NSCLC in Study 
GO28915 ( OAK)
As of the 7 July 2016 data cutoff date for the primary analysis , the Phase III study
GO28915 ( OAK )included data from 609 patients treated with atezolizumab as a fixed 
dose of 1200 mg IV Q3W and 578 patients treated with docetaxel 75 mg /m2IV Q3W.  
The frequency of patients who reported any adverse event regardless of attribution was 
94.1% for the atezolizumab arm and 96.0% for the docetaxel arm.   A higher frequency of 
Grade 3 or 4 adverse events was observed among patients in the doceta xel arm 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
45/Protocol GO29537 , Version 7(53.6% vs. 37.3%). The frequency of patients who discontinued treatment because of 
adverse events was higher in the docetaxel arm than in the ate zolizumab arm (18.7% 
vs. 7.6%). Table 4lists adverse events with a between -arm difference in frequency of at 
least 5 percentage points .
Table 4Adverse Events in Study GO28915 (OA K) with a Between -Arm 
Diffe rence in Frequency  of at Least 5 Percentage Points
Adverse Event Atezolizumab Docetaxel
Fatigue 26.8% 35.5%
Alopecia 0.5% 34.9%
Diarrhea 15.4% 24.4%
Anem ia 11.5% 23.5%
Nausea 17.7% 22.7%
Myalgia 6.4% 15.7%
Neutropenia 1.6% 15.6%
Peripheral edema 8.9% 14.2%
Peripheral neuropathy 3.9% 11.2%
Stom atitis 3.1% 10.9%
Febrile neutropenia 0.2% 10.7%
Dysgeusia 3.0% 10.0%
Musculoskeletal pain 10.5% 4.3%
Pruritus 8.2% 3.1%
Source: Rittmey er et al. 201 7.
[IP_ADDRESS] Clinical Safety  in Combination with Bevacizumab or 
Platinum- Based Doublet Chemotherapy
Study GP28328 is a Phase Ib study of atezolizumab in combination with bevacizumab or 
cytotoxic chemotherapy in patients with multiple tumor types including NSCLC, triple 
negative breast cancer , and colorec tal cancer.  As of 10 February 2015, 144 patients 
had been enrolled in this study:  39 patients in Arm A ( atezolizumab bevacizumab ), 
36patients in Arm B ( atezolizumab bevacizumab and FOLFOX), 14 patients in Arm C 
(atezolizumab carboplatin and paclitaxel), 24 patients in Arm D 
(atezolizumab carboplatin and pemetrexed), 20 patients in Arm E 
(atezolizumab carboplatin and nab -paclitaxel), and 11 patients in Arm F 
(atezolizumab nab-paclitaxel).  The treatment combinations have been genera lly well 
tolerated.  No DLTs have been reported during the dose- escalation stage in any study 
arm.  Patients are being enrolled in safety and biopsy expansion cohorts in Arms A 
andB as well as in additional arms testing atezolizumab in combination with co mmonly 
used NSCLC chemotherapy doublets.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
46/Protocol GO29537 , Version 7A total of 141 of 144 patients (97.9%) reported at least one adverse event while 
receiving study drug.  The majority of these event s were Grade [ADDRESS_743018] commonly reported adverse events a cross the study arms ( 10% of patients) 
included fatigue, nausea, diarrhea, decreased appetite, and pyrexia.   The adverse 
events were consistent with the known safety profile of each agent (atezolizumab 
monotherapy and chemotherapy).  No additive effects were observed when 
atezolizumab was administered with chemotherapy.
Table 5Study GP28328:  A ll Reported A dverse Events
ParameterArm A
(n39)
No. (%)Arm B
(n36)
No. (%)Arm C
(n14)
No. (%)Arm D
(n24)
No. (%)Arm E
(n20)
No. (%)Arm F
(n12)
No. (%)All 
Patients
(n145)
No. (%)
Any AEs 39 (100) 36 (100) 14 (100) 24 (100) 19 (95.0) 10 (83.3) 142 (97.9)
Related AEs 29 (74.4) 28 (77.8) 12 (85.7) 19 (79.2) 19 (95.0) 6 (50.0) 113 (77.9)
Grade 3 5 AEs 20 (51.3) 29 (80.6) 12 (85.7) 17 (70.8) 18 (90.0) 6 (50.0) 102 (70.3)
Related Grade 3 5 
AEs1 (2.6) 7 (19.4) 4 (28.6) 4 (16.7) 11 (55.0) 4 (33.3) 31 (21.4)
Serious AEs 14 (35.9) 15 (41.7) 5 (35.7) 10 (41.7) 8 (40.0) 3 (25.0) 55 (37.9)
Related serious AEs 0 (0) 1 (2.8) 1 (7.1) 2 (8.3) 2 (10.0) 2 (16.7) 8 (5.5)
AEs leading to 
discontinuation1 (2.6) 4 (11.1) 0 (0) 1 (4.2) 1 (5.0) 0 (0) 8 (5.6)
AEs leading to 
death (Grade 5)0 (0) 2 (2.8) 1 (7.1) 2 (8.3) 2 (10.0) 1 (8.3) 7 (4.8)
Related AEs leading to 
death (Grade 5)0 (0) 0 (0) 0 (0) 1 (4.2) 0 (0) 0 (0) 1 (0.7)
Immune -mediated AEs 12 (30.8) 28 (77.8) 8 (57.1) 11 (45.8) 11 (55.0) 2 (16.7) 72 (49.7)
AEadverse event.
All [ADDRESS_743019] frequently reported events were consistent with the overall population and 
included fatigue, nausea, diarrhea, decreased appetite, and pyrexia.  There were 
36patients enrolled in Arm B, and 97% of patients reported at least 1adverse event.  
The most freq uently reported adverse events ( 20% of patients) included fatigue, 
pyrexia, peripheral neuropathy, neutropenia, anemia, diarrhea, decreased appetite, 
temperature intolerance, constipation, vomiting, and nausea.  
All patients who were enrolled in Arms C and D experienced an adverse event; 95% of 
patients who were enrolled in Arm E experie nced an adverse event, and 83.3 % of 
patients enrolled in Arm F experienced an adverse event.  The adverse events 
commonly reported in 2 or more patients in Arms C, D, and E included anemia, 
decreased appetite, hypomagnesemia, nausea, neutropenia, constipation, vomiting, 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
47/Protocol GO29537 , Version 7fatigue, rash, cough, and diarrhea.  Adverse events commonly reported in 2 or more 
patients in Arm F included dermatitis, upper respi[INVESTIGATOR_4416], alop ecia, peripheral 
sensory neuropathy, fever, constipation, neutrophil count decreased, anemia, diarrhea, 
headache, nausea, and fatigue.
1.3.3 Clinical A ctivity
Anti-tumor activity, including Response Evaluation Criteria in Solid Tumors 
(RECIST) based responses (i .e., RECIST v1.1 responses), has been observed in 
patients with different tumor types treated with atezolizumab monotherapy in 
Study PCD4989g. 
Refer to the Atezolizumab Investigator’s Brochure for updated details on clinical activity 
in all patients treat ed to date, regardless of tumor type.
[IP_ADDRESS] Single -Agent Clinical A ctivity in Patients with NSCLC in 
Study PCD4989g
As of the clinical data cutoff of 2 December 2014, the efficacy evaluable population 
included 88 patients with locally advanced or metastatic NSCLC.  The median age was 
60.5 years (range :2484 years) and represented a heavily pre -treated patient 
population:  97% of the patients had received 2 prior systemic therapi[INVESTIGATOR_014], and 77.3% of 
the patients had received 4 prior systemic therapi[INVESTIGATOR_014].
Overall, responses were observed in 20 of 88 patients (22.7%) with NSCLC and 
included responses in patients with squamous and non -squamous NSCLC (4 in 
21patients and 16 in 67 patients, respectively).  A total of [ADDRESS_743020] contin ued to respond at the time of the clinical data cutoff.  
Table 6 displays the confirmed ORR, du ration of response (DO R), and 6- month PFS
rates by [CONTACT_4002] -L1 expression for patients with NSCLC.  These results are based on 
investigator -assessed RECIST v1.1.  Analyses of tumor -infiltrating immune cells (ICs) 
and TCs for PD -L1 expression on baseline tumor tissue from NSCLC patients have been 
perfor med.  Higher ORRs were associated with higher PD- L1 expression.
Refer to the Atezolizumab Investigator’s Brochure for details on the clinical activity in 
patients with NSCLC treated to date.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
48/Protocol GO29537 , Version 7Table 6Patients with NSCLC in Study  PCD4989g:  Investigator -Assessed 
Confirmed Objective Response Rate by  [CONTACT_70108] -L1 
Expression, Duration of Response, and Six-Month 
Progression -Free Survival Rates ( according to RECIST v1.1)
PD-L1 IHC 
Expression 
CategoryORR by [CONTACT_393] v1.1
n88SD
(n/N)PD
(n/N)DOR (range 
in months)6-month 
PFS 
% (95% CI)
TC3 or IC3 50.0% (11 of 22)
(95% CI: 28.22%, 
71.78%)13.6%
(3/22)31.8%
(7/22)7.16 25.26 50.0
(29.1, 70.9)
TC3 or IC2/3 37.5% (15 of 40)
(95% CI: 
22.73% 54.2%)12.5%
(5/40)45.0%
(18/40)7.16 26.74+ 44.9
(29.4, 60.3)
TC2/3 or IC2/3 33.3% (16 of 48)
(95% CI: 20.40%, 
48.41%)22.9%
(11/48)37.5%
(18/48)7.16 26.74+ 41.6
(27.6, 55.5)
TC0/1/2 and 
IC0/1/215.5% (9 of 58)
(95% CI: 7.35%, 
27.42%)37.9%
(22/58)37.9%
(22/58)7.16 26.74+ 41.1 
(28.4, 53.8)
TC0/1/2 and 
IC0/112.5% (5 of 40)
(95% CI: 4.19%, 
26.8%)37.5%
(15/40)40.0%
(16/40)9.92 24.74 42.3
(27, 57.7)
TC0/1 and IC0/1 12.5% (4 of 32)
(95% CI: 3.51%, 
28.99%)43.8%
(14/32)34.4%
(11/32)9.92 24.74 46.7
(29.3, 64.0)
DORduration of response; IC tumor-infiltrating immune cell; IHCimmunohistochemistry ; 
NSCLC non small cell lung cancer; ORR objective response rate; PFSprogression -free 
survival; SD stable disease; PD progressive disease ; RECIST v1.1Response Evaluation 
Criteria in Solid Tumors , Version 1.1 ; TCtumorcell.
Notes: This table is based on a data cutoff of 02 Dec 2014 of NSCLC patients. ORR includes 
confirmed responses. “ ” denotes a censored value.
[IP_ADDRESS] Single -Agent Clinical A ctivity in Patients with NSCLC in Study  
GO28753 ( POPLA R)
The primary OS analysis in Study GO28753 (POPLAR) was conducted when 
173deaths had occurred (clinical cutoff, 8 May 2015). Key efficacy results for the ITT 
population are sho wn in Table 7 . Atezolizumab showed significant improvement in OS
compared with docetaxel in patients with advanced, previously treated NSCLC 
unselected for PD -L1 expression.  OS was 12.6 months (95% CI: 9.7, 16.4 months ) for 
atezolizumab versus 9.7 months (95% CI: 8.6, 12.0 months ) for docetaxel (HR 0.73; 
95% CI: 0.5 3, 0.99; p 0.04).  PFS was similar between groups (2.7 months with 
atezolizumab vs. 3.0 months with docetaxel ) (see Table 7 ).Objectiv e responses with 
atezolizumab were durable, with a median duration of 14.3 months (95% CI: 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
49/Protocol GO29537 , Version 711.6 months , not estimable) compared with 7.2 months (95% CI:5.6, 12.5 months ) for 
docetaxel ( Fehrenbacher et al. 2016 ).
Table 7Efficacy  Results in Study GO28753 (POPLA R): Intent -to-Treat 
Population
Efficacy  EndpointAtezolizumab
(n144)Docetaxel
(n143)
Overall survival
No. of deaths (%) 78 (54.2 ) 95 (66.4 )
Median (months)
95% CI12.[ADDRESS_743021] ratio
95% CI0.73
0.53, 0.99
Progression -free survival
No. of events (%) 124 (86.1 ) 121 (84.6 )
Median (months)
95% CI2.[ADDRESS_743022] ratio
95% CI0.94
0.72, 1.23
Objective response rate (confirmed) 14.6% 14.7%
Duration of response
Median (months)
95% CI14.3 
11.6, NE7.2
5.6, 12.5
NEnot estimable.
At the time of an updated analysis representing an additional 7 months of follow -up 
(1December 2015 data cutoff date), 200 of 287 randomized patients (70%) had died.  
Improvement in OS benefit was observed for atezolizumab compared with docetaxel in 
the ITT population (stratified HR 0.69; 95% CI: 0.52, 0.92) (see Table 8 ).  The median 
OS in the ITT population was 12.6 months (95% CI: 9.7, 16.0 months) in the 
atezolizumab arm and 9.7 months (95% CI: 8.6, 12.0 months) in the docetaxel arm.  
PFS was similar between groups (2.7 months with atezolizumab vs. 3.4 months with 
docetaxel) (Smith et al. 2016).  
The updated OS and PFS analyses for t he ITT population and by [CONTACT_4002] -L1 expression 
levels are shown in Table 8.  Improvement in OS numerically increased with increasing 
PD-L1 expression, whereas patients with the lowest PD -L1 expression levels 
experienced OS similar to that in the docetaxel group (see Table 8 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
50/Protocol GO29537 , Version 7Table 8Study GO28753 (POPLA R) Efficacy  Results by  [CONTACT_109791]-L1 Diagnostic Subgroups with Comple mentary  Comparison 
Subgroupi[INVESTIGATOR_14839]:  Intent -to-Treat Population
PopulationHR (95% CI) Total No. of Patients
(Atezolizumab/
Docetaxel) OS PFS
ITT 0.69 (0.52, 0.92) 0.92 (0.71, 1.20) 287 (144/143)
TC3 or IC3 0.45 (0.22, 1.95) 0.60 (0.32, 1.13) 47 (24/23)
TC2/3 or IC2/3 0.50 (0.31, 0.80) 0.71 (0.47, 1.08) 105 (50/55)
TC1/2/3 or IC1/2/3 0.59 (0.41, 0.83) 0.86 (0.63, 1.16) 195 (93/102)
TC0 and IC0 0.88 (0.55, 1.42) 1.06 (0.68, 1.67) 92 (51/41)
HRhazard ratio; IC tumor -infiltrating immune cell; ITT intent to treat; OS overall 
survival; PFS progression -free survival; TC tumor cell.
Notes:  The data cutoff date is 1 December 2015.
The HRs are stratified for the ITT population and unstratified for the PD -L1 
expression subgroups.
In summary, the data from Study GO28753 (POPLAR )show that atezolizumab provides 
survival benefit compared with docetaxel in previously treated patients with NSCLC.
[IP_ADDRESS] Single -Agent Clinical A ctivity in Patients with NSCLC in Study  
GO28915 (OA K)
The co -primary endpoints of Study GO28915 (OAK) were OS in all randomized patients 
(ITT population) and OS in a PD -L1selected subgroup in the primary analysis 
population (TC1/2/3 or IC1/2/3).
At the time of the primary analysis (7 July 2016 data cutoff date), which included data 
from the first 850 randomized patients (425 in the atezolizumab arm and 425 in the 
docetaxel arm), the median duration of survival follow-up was 21 months and 
569patients had died.  In the ITT population, OS was significantly improved with 
atezolizumab compared with docetaxel (median OS, 13.8 vs. 9.6 months; HR 0.73; 
95% CI: 0.62, 0.87; p 0.0003).  For the TC1/2/3 or IC1/2/3 subgroup, OS was also 
significantly impro ved with atezolizumab compared with docetaxel (median OS, 
15.7 vs.10.3 months; HR 0.74; 95% CI: 0.58, 0.93; p 0.0102).  
PFS was similar between the atezolizumab and docetaxel arms (median PFS, 
2.8vs.4months; HR 0.95; 95% CI: 0.82, 1.10).  Fifty -eight patients (14%) in the 
atezolizumab arm and 57 patients (13%) in the docetaxel arm achieved a confirmed
objective response according to RECIST v1.1.  Objective responses with atezolizumab 
were durable, with a median duration of 16.3 months (95% CI: 10 .0 months, not 
estimable) in the atezolizumab arm compared with 6.2 months (95% CI: 4.9, 7.6 months) 
in the docetaxel arm (Rittmeyer et al. 2017).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
51/Protocol GO29537 , Version [IP_ADDRESS] Clinical Efficacy  in Combination with Platinum -Based Doublet 
Chemotherapy  in Patients with NSCLC
As of the [ADDRESS_743023] 
dose of atezolizumab by 10 November 2014 were evaluable for efficacy (n 41). 
Patients who were enrolled in Arms C, D, and E received 15 mg/kg atezolizumab 
administered Q3Win combination with carboplatin paclitaxel , carboplatin pemetrexed, 
and carboplatin nab-paclitaxel, respectively.  All patients had histologically or 
cytologically documented Stage IIIB, Stage IV ,or recurrent NSCLC and had not received 
prior chemotherapy for advanced disease.  The median age was 65 years, and 79% of 
patients had non -squamous histology.  The overall confirmed ORR according to
RECIST v1.1 in all three arms combined was 63% (26 of 41 patients). The ORR was 
50% (95% CI: 16%, 84%) in Arm C (4 partial responses [PRs] among 8 patients), 77% 
(95% CI: 50%, 93%) in Arm D (13 PRs among 17 patients), and 56% (95% CI: 30%, 
80%) in Arm E (5 PRs and 4 complete responses [CRs] among 16 patients). Patients 
with high levels of PD -L1 expression appeared to have higher response rates, but 
responses were also seen in patients with lower PD- L1 expression levels 
(Liuetal.2015 ).
1.3.4 Clinical Pharmacokinetics and Immunogenicity
On the basis of available preliminary PK data (0.03 20 mg/kg), atezolizumab appeared
to show linear pharmacokinetics at doses 1 mg/kg.  For the 1 -mg/kg and 20- mg/kg 
dose groups, the mean apparent clearance (CL) and the mean volume of dist ribution at 
steady state (V ss) had a range of 3.11 to 4.14 mL/kg and 48.1 to 67.0 mL/kg, 
respectively, which is consistent with the expected profile of an IgG1 antibody in 
humans.
The development of anti -therapeutic antibodies (ATAs) has been observed in p atients in 
all dose cohorts and was associated with changes in pharmacokinetics for some patients 
in the lower dose cohorts (0.3, 1, and 3 mg/kg).  The development of detectable ATAs 
has not had a significant impact on pharmacokinetics for doses from 10 to 20 mg/kg.  
Patients who were dosed at the 10 -, 15-, and 20 -mg/kg dose levels have maintained the 
expected target trough levels of drug despi[INVESTIGATOR_33384].  To date, no clear 
relationship between the detection of ATAs and adverse events or infus ion reactions has 
been observed.
1.3.5 Rationale for A tezolizumab Dosage
The fixed dose of 1200 mg (equivalent to an average body weight based dose of 
15 mg/kg) was selected on the basis of both nonclinical studies and available clinical 
data from Study PCD4989g as described below.
The target exposure for atezolizumab was projected on the basis of nonclinical tissue 
distribution data in tumor -bearing mice, target -receptor occupancy in the tumor, the 
observed atezolizumab interim pharmacokinetics in humans, and ot her factors. The 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
52/Protocol GO29537 , Version 7target trough concentration (C trough) was projected to be 6 g/mL on the basis of several 
assumptions, including the following:  1) 95% tumor -receptor saturation is needed for 
efficacy and 2) the tumor -interstitial concentration to plasma ratio is 0.30 based on tissue 
distribution data in tumor -bearing mice.
The atezolizumab dose is also informed by [CONTACT_33444], safety, 
pharmacokinetics, and immunogenicity data. Anti-tumor activity has been observed 
across doses from 1 mg/kg to 20 mg/kg. The MTD of atezolizumab was not 
reached, and no DLTs have been observed at any dose in Study PCD4989g.  Currently 
available PK and ATA data suggest that the 15 -mg/kg atezolizumab Q3Wregimen (or 
fixed -dose equivalent) for Phase II and Phase III studies would be sufficient to both 
maintain C trough6 g/mL and further safeguard against both interpatient variability and 
the potential effect of ATAs that could lead to subtherapeutic lev els of atezolizumab 
relative to the 10 -mg/kg atezolizumab Q3Wregimen (or fixed -dose equivalent).  From 
inspection of available observed C troughdata, moving further to the 20- mg/kg 
atezolizumab Q3Wregimen does not appear to be warranted to maintain targe ted C trough 
relative to the proposed 15 -mg/kg atezolizumab Q3Wlevel. 
Simulations ( Bai et al. 2012 ) do not suggest any clinically meaningful differences in 
exposure following a fixed dose or a dose adjusted for weight.  Therefore, a fixed dose 
of 1200 mg has been selected (equivalent to an average body weight based dose of 
15mg/kg).  Selection of an every -21-day dosing interval is supported by [CONTACT_33445].
Refer to the Atezolizumab Investigator’s Brochure for details regarding nonclinical and 
clinical pharmacology of atezolizumab.
1.4 STUDY RA TIONA LE A ND BENEFIT –RISK A SSESSMENT
Encouraging clinical data emerging in the field of tumor immunotherapy have 
demonstrated that therapi[INVESTIGATOR_33385] T-cell responses against cancer can 
result in a significant survival benefit in patients with Stage IV cancer ( Hodi etal.2010 ; 
Kantoff etal.2010 ; Chen et al. 2012 ).
PD-L1 is an extracellular protein that downregulates immune responses primarily in 
peripheral tissues through binding to its two receptors PD -1 and B7.1. PD-1 is an 
inhibitory receptor expressed on T cells following T -cell activation, which is sustained in 
states of chronic stimulation such as in chronic infection or cancer ( Blank etal.2005; 
Keiretal.2008 ).Ligation of PD -L1 with PD -1 inhibits T -cell proliferation, cytokine 
production, and cytolytic activity, leading to the functional inactivation or exhaustion of 
Tcells.  B7.1 is a molecule expressed on antigen -presenting cells and a ctivated T cells.  
PD-L1 binding to B7.1 on T cells and antigen -presenting cells can mediate 
downregulation of immune responses, including inhibition of T- cell activation and 
cytokine production ( Butte et al. 2007 ; Yang etal.2011 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
53/Protocol GO29537 , Version 7Overexpression of PD -L1 on TCs has been reported to impede anti -tumor immunity, 
resulting in immune evasion ( Blank and Mackensen 2007 ).  Therefore, interruption of the 
PD-L1/PD -[ADDRESS_743024] represents an attractive strategy to reinvigorate tumor -specific 
T-cell immunity.
PD-L1 expression is prevalent in many human tumors, and elevated PD -L1 expression 
is associated with a poor prognosis in patients with NSCLC ( Mu et al. 2011).
Targeting the PD -L1 pathway with atezolizumab has demonstrated activity in patients 
with advanced malignancies and who have failed standard of care therapi[INVESTIGATOR_014].  At the time 
of Study GO29537 initiation, Study PCD4989g, a Phase Ia dose -escalation and 
expansion study of patients treated with atezolizumab as a single agent had the 
following cl inical activity:  345 evaluable patients were dosed by 21 October 2013 (data 
cutoff date as of 21 April 2014) with a minimum of 6 months of follow -up; [ADDRESS_743025] v1.1 with an ORR of 18.0% 
(95% CI: 14.1% ,22.3%).  Objective responses were observed across a broad range of 
malignancies, including NSCLC, RCC, melanoma, and UBC.   In Studies GO28753 
(POPLAR) and GO28915 (OAK), there was significant improvement in OS with 
atezolizumab compared with docetaxel in patients with previously treated advanced 
NSCLC.
1.4.1 Rationale for Testing Atezolizumab in Combination with 
Carboplatin/nab -Paclitaxel
Platinum -based regimens remain the standard first -line option for patients with locally 
advanced or metastatic NSCLC not harboring EGFR mutations or ALK gene 
rearrangements.  However, the survival benefit conferred by [CONTACT_70109] a plateau, with overall response rates of approximately 20% and 1 -year survival 
ranging from 31% 36% ( Schiller et al. 2002 ), lea ving considerable room for 
improvement in outcomes.  TCkilling by [CONTACT_70110], and 
invigorating tumor -specific T -cell immunity in this setting by [CONTACT_70121]-L1/PD -[ADDRESS_743026] 
chemotherapy alone ( Merritt et al. 2003 ; Apetoh et al. 2007).  Evaluating the safety and 
efficacy of these treatment combinations in patients with NSCLC will enabl e future tests 
of this hypothesis.
Nivolumab, a fully human IgG4 PD -1 antibody, was evaluated in combination with 
platinum -based doublet therapy in PD -1unselected, chemotherapy -naive patients with 
NSCLC, and interim results were presented at the American Society of Clinical Oncology 
2014 meeting ( Antonia et al. 2014).  The ORR for patients treated with 
gemcitabine cisplatin , pemetrexed cisplatin, and paclitaxel carboplatin, in addition to 
10 mg nivolumab, was 33% ( n12), 47% (n 15), and 47% (n 15), respectively.  The 
median DOR ranged from 24 weeks with nivolumab in combination with 
paclitaxel carboplatin to 45 weeks with nivolumab in combination with 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
54/Protocol GO29537 , Version 7gemcitabine cisplatin.  The 1- year OS for patients treated with gemcitabine cisplatin, 
pemetrexed cisplatin, and paclitaxel carboplatin in addition to 10 mg nivolumab was 
50%, 87%, and 60%, respectively.  Grade 3/4 treatment -related adverse events were 
reported in 45% of patients across all treatment arms with the most common 
treatment -related Grade 3/4 adverse events being pneumonitis (7%), fatigue (5%), and 
acute renal failure (5%) ( Antonia et al. 2014 ).
Although the patient numbers are limited, these data, along with the preliminary efficacy 
and safety results from Study GP28328, offer e vidence of an acceptable safety profile 
when combining a PD -L1/PD -1 inhibitor with platinum -based doublet chemotherapy in a 
non PD-L1selected population.  
Carboplatin nab-paclitaxel was approved for the first -line treatment of patients with 
NSCLC on th e basis of results from the randomized Phase III study comparing 
nab-paclitaxel carboplatin with solvent -based paclitaxel carboplatin.  In nonclinical 
models, the combination with of nab -paclitaxel atezolizumab demonstrated significantly 
greater anti-tumor activity than either agent alone.
In light of these observations, Study GO29537 is designed to evaluate whether the 
anti-tumor effect seen in atezolizumab- treated patients would translate into a statistically 
significant and clinically relevant improvement in prolonged PFS when used in 
combination with carboplatin nab-paclitaxel compared with carboplatin nab-paclitaxel 
in patients with non- squamous NSCLC.  This study will allow for the evaluation of the 
efficacy of atezolizumab in both the ITT population, as well as in patients with 
PD-L1selected tumors (defined by [CONTACT_109807] -L1 in TCs and/or ICs).  A PD -L1 
immunohistochemistry (IHC)assay will be used to identify patients by [CONTACT_109808] -L1 
expression (see Appendix 7).  
Study GO29537 will enroll patients with Stage IV non -squamous NSCLC who are naive 
to chemotherapy treatment and for whom the experimental arm can represent a valuable 
treatment option and a reasonable benefit risk balance.  Patients whose tumors are 
known to harbor sensitizing EGFR mutations or ALK rearrangements must have 
experienced disease progression during or have proven intolerance during or after 
treatment wi th an EGFR tyrosine kinase or at least one ALK inhibitor, respectively (see 
specific inclusion criteria in Section 4.1.1 ), before they can enroll in the study. 
In order to account for the possibility of pseudoprogression/tumor -immune infiltration 
(i.e., radiographic increase in tumor volume due to the influx of immune cells) 
(Hales etal.2010 ) and the potential for delayed anti -tumor activity, this study will allow 
patients treated with atezolizumab to receive treatment beyond the initial apparent 
radiographic progression (see Section 3.3.5 and Section 4.6) and will use modified 
RECIST (in addition to RECIST v1.1) to evaluate clinical benefit.  Because it is not yet 
possible to reliably differentiate pseudoprogression/tumor -immune infiltration from true 
tumor progression, the risk exists that some patients who are not responding to 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
55/Protocol GO29537 , Version 7treatment but yet continuing to receive atezolizumab may experience further progression 
of NSCLC and delay treatment with subsequent therapi[INVESTIGATOR_33386].  
Investigators should make every effort to fully inform patients of this risk.
Atezolizumab has been generally well tolerated (see Section 1.3.2 ); adverse events with 
potentially immune- mediated causes consistent with an immunotherapeutic agent, 
including rash, hypothyroidism, hepatitis/transaminitis, colitis, and myas thenia gravis, 
have been observed in Study PCD4989g.  To date, these events have been 
manageable with treatment.
In summary, treatment with atezolizumab offers the potential for clinical benefit in 
patients with NSCLC, in addition to carboplatin nab-paclitaxel.  Patients will be fully 
informed of the risk of continuing study treatment in spi[INVESTIGATOR_109774] a careful assessment of the potential benefit 
of doing so, considering radiographic data, biopsy results, and the clinical status of 
thepatient.
2. OBJECTIVES
The following objectives will be assessed in chemotherapy -naive patients with Stage IV 
non-squamous NSCLC.  
2.1 EFFICA CY OBJECTIVES
The term "wildtype"(WT) refers to randomized patients who do not have a sensitizing 
EGFR mutation or ALK translocation.
The term "tumor gene expression "(tGE) refers to randomized patients with a defined 
level of expression of a PD-L1 and T -effector gene signature [CONTACT_109861] , as
analyzed through use of a centrally performed RNA -based assay.
Some efficacy endpoints will be analyzed in a population of randomized patients with a 
defined level of PD-L1 expression on TCs and ICs ,as analyzed through use of a 
centrally performed IHC test.
2.1.1 Co-Primary  Efficacy  Objectives
The co -primary objectives of this study are the following:
To evaluate the efficacy of atezolizumab carboplatin nab-paclitaxel compared 
with carboplatin nab-paclitaxel as measured by [CONTACT_1697] -assessed PFS 
according to RECIST v1.1 in the tGE -WTpopulation and the ITT -WT population
To evaluate the efficacy of atezolizumab carboplatin nab-paclitaxel compared 
with carboplatin nab-paclitaxel as measured by [CONTACT_255872] -WT population
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
56/Protocol GO29537 , Version 72.1.2 Secondary  Efficacy Objectives
The secondary efficacy objectives for this study are the following:
To evaluate the efficacy of atezolizumab as measured by [CONTACT_255873]-WT
population
To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
PFS according to RECIST v1.1 and OS in theTC2/3 or IC2/3 W T population and
theTC1/2/3 or IC1/2/3 WT population
To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
PFS according to RECIST v1.1 and OS in thetGE population and the ITT 
population
To evaluate the efficacy o f atezolizumab as measured by [CONTACT_1697] -assessed 
ORR according to RECIST v1.1 for the tGE-WT population and the ITT -WT 
population
To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
DOR according to RECIST v1.1 for the tGE-WT population and the ITT -WT 
population
To evaluate the OS rate at 1 and 2 years in each treatment arm in the tGE -WT 
population and the ITT -WT population
To determine the impact of atezolizumab as measured by [CONTACT_70113] 
(TTD) in patient -reported lun g cancer symptoms of cough, dyspnea (single- item and 
multi -item subscales), chest pain, or arm/shoulder pain, using the European 
Organisation for the Research and Treatment of Cancer (EORTC) Quality -of-Life 
Questionnaire Core 30 (QLQ -C30) and the supplemen tal lung cancer module 
(QLQ -LC13) in the tGE -WT population and the ITT -WT population
To determine the impact of atezolizumab as measured by [CONTACT_109793] 
(i.e., improvement or deterioration based upon presenting symptomatology) in 
patient -reported lung cancer symptom (chest pain, dyspnea, and cough) score using 
the Symptoms in Lung Cancer (SILC) scale symptom severity score in the tGE -WT 
population and the ITT -WT population
2.2 SAFETY OBJECTIVES
The safety objectives for this study are the following:
To evaluate the safety and tolerability of atezolizumab carboplatin nab-paclitaxel 
compared with carboplatin nab-paclitaxel
To evaluate the incidence and titers of ATAs against atezolizumab and to explore 
the potential relationship of the immunogenicity response with pharmacokinetics, 
safety, and efficacy
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
57/Protocol GO29537 , Version 72.3 PHA RMA COKINETIC OBJE CTIVES
The PK objectives for this study are the following:
To characterize the pharmacokinetics of atezolizumab when given in combination 
with carboplatin and nab-paclitaxel
To characterize the pharmacokinetics of carboplatin when given in combination with 
nab-paclitaxel with and without atezolizumab
To characterize the pharmacokinetics of nab -paclitaxel when given in combination 
with carboplatin with and without atezolizumab
2.4 EXPLORA TORY OBJECTIV ES
The exploratory objectives for this study are the following:
To evaluate PFS at 6 months and at 1 year in each treatment arm
To evaluate the OS rate at 3 years in each treatment arm
To assess predictive, prognostic, and pharmacodynamic exploratory biomarkers in 
archival and/or fresh tumor tissue and blood and their association with disease 
status, mechanisms of resistance, and/or response to study treatment
To evaluate the utility of biopsy at the time of apparent dise ase progression to 
distinguish apparent increases in tumor volume related to the immunomodulatory 
activity of atezolizumab (i.e., pseudoprogression/tumor immune infiltration) from true 
disease progression.
To evaluate and compare patient’s health status as assessed by [CONTACT_70090] 
5Dimensions 3 -Level (EQ -5D-3L) questionnaire to generate utility scores for use in 
economic models for reimbursement
To determine the impact of atezolizumab as measured by [CONTACT_120363] -reported outcomes of healt h-related quality of life, lung cancer related 
symptoms, and functioning as assessed by [CONTACT_20368] -C30 and QLQ -LC13 
3. STUDY DESIGN
3.1 DESCRIPTION OF THE S TUDY
This is a randomized, Phase III, multicenter, open -label study (IMpower130) designed to 
evaluate the safety and efficacy of atezolizumab in combination with 
carboplatin nab-paclitaxel compared with treatment with carboplatin nab-paclitaxel in 
approximately 715chemotherapy -naive patients with Stage IV non -squamous NSCLC.  
Figure 1illustra tes the study design.  The schedules of assessments are provided in 
Appendix 1through Appendix 3.
Tumor specimens will be prospectively tested for PD -L1 expression by a central 
laboratory. Eligible patients will be stratified by [CONTACT_4321] (male vs. female), presence of liver 
metastases at baseline (yes vs. no), and by [CONTACT_4002] -L1 tumor expression by [CONTACT_4658] (TC3 and 
any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1) .Patients will be randomized in a 
2:1 ratio to receive one of the following treatment regimens detailed in Table 9.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
58/Protocol GO29537 , Version 7Table 9Study GO29537 Treatment A rms
Treatment 
ArmInduction 
(Four or Six 21 -Day Cycles)Maintenance 
(21-Day Cycles)
A Atezolizumab carboplatin nab-paclitaxel Atezolizumab
B Carboplatin nab-paclitaxel Best supportive care 
or pemetrexed
The number of cycles of induction treatment (four or six) will be at the discretion of the 
investigator and will be determined and documented prior to randomization. Induction 
treatment will be administered on a 21- day cycle until one of the following occurs
(whichever occurs first):  1) administration of four or six cycles or 2) disease progression 
(Arm B) or loss of clinical benefit (Arm A) is documented.  
Following the induction phase, patients who are randomized to atezolizumab (Arm A) 
may continue treatment with atezolizumab beyond radiographic disease progression 
according to RECIST v1.1, provided they are experiencing clinical benefit as assessed 
by [CONTACT_093] (i.e., in the absence of unacceptable toxicity or symptomati c 
deterioration attributed to disease progression as determined by [CONTACT_388856], biopsy results [if available ], and clinical 
status ).  Patients randomized to carboplatin nab-paclitaxel (Arm B) will be offered best 
supportive care provided they have non -progressive disease.  Switch maintenance to 
pemetrexed is also permitted for patients randomized to Arm B.  Switch maintenance 
must be administered within [ADDRESS_743027] induction cycle.
Patients who entered Study GO29537 under Protocol Versions 1 4and are randomized 
to carboplatin nab-paclitaxel will be given the option to cross over to receive 
atezolizumab as monotherapy upon progressive disease according to RECIST v1.1, 
provided they continue to meet eligibility criteria (see Section 4.1.1 ).  Safety data for 
patients who crossed over from Arm B to receive atezoliz umab as allowed under 
Protocol Versions 1 4will be summarized for exploratory purposes.
For A tezolizumab -Treated Patients Only
During treatment (induction or maintenance), patients receiving atezolizumab (including 
patients in Arm B who entered Study GO29 537under Protocol Versions 1 4and
crossed over to receive atezolizumab after disease progression according to
RECIST v1.1) who show evidence of clinical benefit will be permitted to continue 
atezolizumab after the criteria according to RECIST v1.1 for progressive disease are met 
if they meet all of the following criteria:
Evidence of clinical benefit as assessed by [CONTACT_093]
Absence of symptoms and signs (including worsening of laboratory values, 
e.g., new or worsening hypercalcemia) indicating u nequivocal progression of 
disease
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
59/Protocol GO29537 , Version 7No decline in ECOG performance status that can be attributed to 
disease progression
Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal 
disease) that cannot be managed by [CONTACT_990] -allowed medical interventions
Patients must provide written consent to acknowledge deferring other treatment 
options in favor of continuing atezolizumab at the time of initial progression
Treatment with induction chemotherapy (Arms A and B) and pemetrexed (Arm B) as 
switch maintenance must be discontinued in all patients who exhibit evidence of 
progressive disease according to RECIST v1.[ADDRESS_743028] v1.1 (or loss of clinical 
benefit for atezolizumab- treated patients who had continued treatment with atezolizumab
after radiographic disease progression according to RECIST v1.1), withdrawal of 
consent, study termination by [CONTACT_2728], or death, whichever occurs first.  Patients who 
discontinue treatment for reasons other than radiographic disease progression according 
toRECIST v1.1 (e.g., toxicity , symptomatic deterioration ) will continue scheduled tumor 
assessments until radiographic disease progression according to RECIST v1.1 (or loss 
of clinical benefit for atezolizumab- treated patients who hadcontinued treatment with 
atezolizumab after radiographic disease progression according to RECIST v1.1), 
withdrawal of consent, study termination by [CONTACT_2728], or death, whichever occurs first, 
regardless of whether patients start a new anti-cancer therapy.
All primary imaging data used for tumo r assessment will be collected by [CONTACT_70117], independent review of response endpoints.  The independent 
reviews of the stored scans will be performed when requested.
Patients in all treatment arms will undergo a mandatory tumor biopsy sample collection, 
unless not clinically feasible as assessed and documented by [CONTACT_431], at the first 
evidence of radiographic disease progression.  These data will be used to explore 
whether radiographic findings are consistent with the presence of tumor.  Additionally, 
these data will be analyzed to evaluate the association between changes in tumor tissue 
and clinical outcome and to understand further the potential mechanisms of progression 
and resistance to atezolizumab as compared with such mec hanisms after treatment with 
chemotherapy alone.  This exploratory biomarker evaluation will not be used for any 
treatment -related decisions.  Patients in Arm A and patients in Arm B ( who entered 
Study GO29537 under Protocol Versions 1 4)who are unable to undergo biopsy sample 
collection but who otherwise meet the criteria listed above may contin ue/crossover to 
receive atezolizumab.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
60/Protocol GO29537 , Version 7Figure 1 Study Schema
Chem otherapy -Naive Patients with Stage IV Non-Squam ous NSCLC
(n=approx imately 715)
Arm A:
Atez olizumab(1200 mg IV)
+Carboplatin (AUC=6 IV)
+nab-Paclitax el (100 mg/m2IV)
Treat with  Atezolizumab until 
Loss of Clinical Benefit Treat until 
Disease Progression  per RECIST  v1.1
Survival Follow -Up2:1 Random ization
Stratification Factors :
•Sex
•Liver metastases
•PD-L1 expres sion (by [CONTACT_109812]-L1 s tatus)
Induction Treatm ent:  Four or Six, 21-Day Cycles
Arm A:
Atez olizumab(1200 mg IV)Arm B:
Best Supportive Care(switch m aintenance to pem etrex ed may be considered ) 
No Crossover Perm ittedArm B:
Carboplatin (AUC=6 IV)
+nab -Paclitax el 
(100 mg/m2IV)
Maintenance Trea tment:  Every 21 Days
AUC area under the concentration time curve; IV intravenous; NSCLC non small cell lung 
cancer; RECIST v1.1Response Evaluation Criteria in Solid Tumors, Version 1.1.
3.1.1 Independent Data Monitoring Committee
An independent Data Monitoring Committee (iDMC) will be used to evaluate safety 
during the study.  Unblinded safety data will be reviewed by [CONTACT_109813] a periodic 
basis, approximately every [ADDRESS_743029] patient in (FPI).  The safety 
data will include demographic data, adverse events, serious adverse events, and 
relevant laboratory data.
The Sponsor will remain blinded to the efficacy results until the final analysis of PFS.  All 
summaries and analyses by [CONTACT_565752] (iDCC).  Fo llowing the data review, the 
iDMC will provide a recommendation as to whether the study may continue, whether 
amendment(s) to the protocol should be implemented, or whether the study should be 
stopped.  The final decision will rest with the Sponsor.
Member s of the iDMC will be external to the Sponsor and will follow a separate iDMC 
Charter that outlines their roles and responsibilities, as well as a detailed monitoring 
plan. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
61/Protocol GO29537 , Version 7Any outcomes of these safety or efficacy reviews that affect study conduct will be
communicated in a timely manner to the investigators for notification of the Institutional 
Review Boards/Ethics Committees (IRBs/ECs). 
3.[ADDRESS_743030] been enrolled into an extension study.  The Sponsor may decide 
to terminate the study at any time.  If the Sponsor decides to end the study, patients 
who are still receiving study treatment or are in survival follow -up may be offered 
enrollment in an extension study or a non -interventional study. 
3.3 RATIONA LE FOR STUDY DESIGN
3.3.1 Rationale for Testing Atezolizumab in Patients with 
PD-L1–Unselected NSCLC
Despi[INVESTIGATOR_70046], the prognosis for patients with advanced 
NSCLC remains disma l, with a median OS of approximately 12.3 months 
(Sandler etal.2006 ).  Patients who receive second -line treatment for their disease have 
an even more limited prognosis, with median survival duration of approximately 
89months ( Stinchcombe et al. 2008).   Approved therapi[INVESTIGATOR_109775] (e.g., neuropathy, febrile neutropenia, myelosuppression, and 
alopecia) that negatively impact quality of life.  Therefore, there is a continuing need 
formore efficacious, better -tolerated tr eatments.
Inhibition of PD -L1/PD -1 signaling has been shown to produce durable responses in 
some patients, and expression of PD -L1 by [CONTACT_109815]/or ICs in several tumor types 
(including NSCLC) correlates with response to therapy (Topalian et al. 2012 ; 
Fehrenbacher et al. 2016).
Atezolizumab monotherapy has demonstrated clinical efficacy and is generally 
well-tolerated in patients with squamous or non -squamous NSCLC ( Besse et al. 2015; 
Horn et al. 2015; Spi[INVESTIGATOR_70048]. 2015; Fehrenbacher et al. 2016) .  In the sec ond- and 
third-line setting, the POPLAR study, the first randomized Phase II study of atezolizumab 
in advanced NSCLC, showed significant improvement in OS with atezolizumab (12.6 vs. 
9.7 months; HR 0.73;95% CI: 0.53, 0.99; p 0.04) versus docetaxel ( Fehrenbacher et 
al. 2016 ).In the Phase III study GO28915 (OAK) ,which investigated the efficacy and 
safety of atezolizumab compared with docetaxel in patients with previously treated 
locally advanced or metastatic NSCLC, OS was significantly prolonged with 
atezolizumab (median OS 13.8 months vs 9.6 months, HR 0.73;95% CI :0.62, 0.87;
p0.0003).   In patients with squamous and non- squamous disease, OS was 8.9versus 
7.7months (HR 0.73;95% CI: 0. 54, 0.98 ), and 15.6 versus 11.2months (HR 0.73;
95% CI: 0. 60, 0.89 ), respectively, in the atezolizumab arm compared with the docetaxel 
arm ( Rittmeyer et al. 2017 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
62/Protocol GO29537 , Version 7On the basis of promising efficacy of atezolizumab as a single agent ( Study GO28753
[POPLAR ],Study PCD4989g) and in combination with platinum -doublet therapy
(Study GP28328) and the safety findings from Study GP28328 indicating no additive 
toxicity of atezolizumab in combination with platinum -based chemotherapy, this study 
will evaluate atezolizumab in combination with platinum -based chemotherapy.  TCkilling 
by [CONTACT_123480], and invigorating tumor -specific T -cell immunity in this setting by [CONTACT_565753]-L1/PD -[ADDRESS_743031] chemotherapy alone ( Merritt et al. 2003 ; Apetoh et al. 2007 ), and this may 
reasonably occur in tumors regardless of PD -L1 expression.
3.3.2 Rationale for Control A rm
In this study, the control group will receive the platinum doublet of 
carboplatin nab-paclitaxel, an approved regimen in the first -line treatment of advanced 
stage non- squamous NSCLC.  Patients enrolled into the experimental arm will receive 
this standard chemotherapy regimen in addition to atezolizumab.  The emerging safety 
profile of atezolizu mab suggests that there is minimal risk of significant additive toxicity 
when it is administered with chemotherapy and that patients will be able to receive 
standard treatment for their disease in the setting of this clinical study.  In addition, 
treatment with this chemotherapy regimen does not require premedication with steroids, 
which may attenuate potential beneficial immunologic effects of treatment with 
atezolizumab.  This control group will be instrumental in assessing the relative benefit 
and safety of atezolizumab in combination with carboplatin nab-paclitaxel compared 
with chemotherapy alone in the front -line treatment setting.
Based on the results from a randomized Phase III study that has shown a PFS and OS 
benefit after the initiation of pemetrexed after induction treatment in patients with 
non-progressive disease, pemetrexed is approved as maintenance treatment for patients 
with NSCLC in the first -line setting.  Therefore, in accordance with the NCCN guidelines, 
switch maintenance therapy with pemetrexed may be considered for patients who are 
randomized to the control arm.
3.3.3 Rationale for Open -Label Study
An open -label study design was chosen for this study for the following reasons.  A 
blinded study would require prolonged administration o f placebo during the maintenance 
phase for patients who are randomized to Arm B, which could pose a significant burden 
to patients. Furthermore, because of the potential for pseudoprogression in patients 
randomized to atezolizumab- containing arms, a blind ed study would require the option 
that all patients continue treatment until loss of clinical benefit regardless of whether they 
were receiving atezolizumab.  In the absence of pseudoprogression, this could then 
delay subsequent treatment with approved the rapi[INVESTIGATOR_109776], as well as increase the complexity of treatment decisions.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
63/Protocol GO29537 , Version 7Adequate steps have been taken to ensure the validity of data in an open -label study 
design. This includes performing a sensitivity anal ysis to demonstrate the robustness of 
the primary endpoint, defining progression using established response evaluation criteria 
(RECIST v1.1), performing tumor assessments at the same frequency in all arms, 
adhering to protocol -defined schedules, and deter mining the strategy for the final 
analysis of the primary endpoint prior to database lock for the primary efficacy analyses , 
including predefined methods for handling missing data and censoring rules. Efficacy 
analyses will be performed only at the prespe cified analysis timepoints in the protocol.
3.3.[ADDRESS_743032] that OS may be a more sensitive endpoint for cancer 
immunotherapy than PFS.  For example, in the randomized Phase II Study GO28753 
(POPLAR) in patients with advanced NSCLC, an OS benefit in the atezolizum ab arm 
compared with the docetaxel arm was observed in the ITT population (HR0.73; 95% 
CI: 0.53, 0.99).  PFS in the ITT population was simil ar between both treatment arms 
(HR0.94; 95% CI: 0.72, 1.23) ( Fehrenbacher et al. 2016 ).  In addition, OS is th e most 
objective and best measure of clinical benefit for patients with advanced, unresectable, 
or metastatic lung cancer.
However, given that the majority of patients in this study will likely receive subsequent 
anti-cancer therapi[INVESTIGATOR_13265]/or palliative car e (Temel et al. 2010 ) post -disease progression, 
the OS analysis may be confounded ( Miller et al. 2012 ).  Therefore, PFS is being 
retained as a co- primary endpoint and crossover from the control arm to the 
experimental arm after the disease progression will not be permitted, with the aim of 
preserving the study’s ability to potentially demonstrate treatment benefit of 
atezolizumab on OS.
PFS as an endpoint can reflect tumor growth and can be assessed before the 
determination of a survival benefit.  W hether a n improvement in PFS represents a direct 
clinical benefit or a surrogate for clinical benefit depends on the magnitude of the effect 
and the benefit risk profile of the new treatment compared with available therapi[INVESTIGATOR_014] 
(Guidance for Industry 2007 ; European M edicines Agency 2012).  To ensure the validity 
of investigator -assessed PFS as a co- primary endpoint, a number of measures have 
been implemented:  a substantial target magnitude of benefit (target HR0.55 in the 
tGE-WT population and HR  0.65 in the ITT -WT population), and study assessments 
that will allow a robust evaluation of risk -benefit (standard RECIST to define progression 
with fixed assessment intervals that are identical in all treatment arms and a robust 
definition of PFS and prospectively defi ned methods to assess, quantify, and analyze 
PFS, including sensitivity analyses).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
64/Protocol GO29537 , Version 7New treatment modalities, such as targeted therapi[INVESTIGATOR_70050], are emerging 
as highly effective regimens that are providing improvements in patient outcomes far 
beyond what was achieved before ( Ellis et al. 2014).  In particular, immunotherapy has 
been correlated/associated with durable responses, significant prolongation of PFS, and 
improvement of quality of life.  In addition, meta -analyses have indicated that PFS can 
be considered a good measure of clinical benefit for patients with locally 
advanced/metastatic NSCLC ( Laporte et al. 2013 ). 
3.3.5 Rationale for A llowing Patients to Continue A tezolizumab 
Treatment until Loss of Clinical Benefit 
Conventional response criter ia may not adequately assess the activity of 
immunotherapeutic agents because progressive disease (by [CONTACT_70125]) does not necessarily reflect therapeutic failure.  Because of the potential for 
pseudoprogression/tumor -immune infiltrati on, this study will allow patients randomized to 
the atezolizumab treatment arm and those patients who cross edover (patients who 
entered Study GO29537 under Protocol Versions 1 4)to remain on atezolizumab after 
apparent radiographic progression, provided the benefit risk ratio is judged to be 
favorable.  Patients should be discontinued for unacceptable toxicity or symptomatic 
deterioration attributed to disease progression as determined by [CONTACT_565754] (see Section 3.1).
3.3.[ADDRESS_743033] negative impacts on health -related quality 
of life (HRQoL) ( Hyde and Hyde 1974 ; Hopwood and Stephens 1995 ; Sarna etal.2004 ).  
This is especially true for studies that use PFS as a primary endpoint, where it is 
important to better understand in what regard the delay in disease progression is 
meaningful to patients.
Chest pain, dyspnea, and cough have been regarded as the most frequent and clinically 
relevant disease- related symptoms experienced by [CONTACT_70127].  The BR.21 
study (erlotinib vs. best supportive care in second -or third- line NSCLC) demonstrated 
that longer TTD in the pain, dyspnea, and cough scales of the EORTC QLQ -C30 and 
EORTC QLQ -LC13 was consistent with superi or PFS, OS, and quality -of-life benefits in 
the erlotinib arm compared with the placebo arm ( Aaronson et al. 1993 ; 
Bergman etal.1994 ; Bezjak et al. 2006 ).  Patients in the afatinib LUX -Lung [ADDRESS_743034] -line 
study also reported significant delay of TTD in lun g cancer symptoms (chest pain, 
dyspnea, and cough) as measured by [CONTACT_20368] -C30 and EORTC QLQ -LC13. 
(Yang etal.2013).  In this study, the validated EORTC QLQ -C30 and EORTC 
QLQ -LC13 will be used to assess HRQoL and symptom severity. 
In addition, the SILC scale will be used to assess the effect/impact of atezolizumab on 
TTD of specific lung cancer symptoms (chest pain, dyspnea, and cough) in patients with 
Stage IV, non -squamous NSCLC in the first -line setting.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
65/Protocol GO29537 , Version 7The single -item Patient Global Impressions of Severity (PGIS) and the EQ -5D-3L 
instrument are included in the study to generate HRQoL and utility scores to confirm 
construct validity of the SILC scale and for use in economic models for reimbursement, 
respectively.  Results from the PGIS and EQ -5D-3L are not planned to be used for 
market authorization.
3.3.7 Rationale for Collection of A rchiv al and/or Fresh 
Tumor Specimens and Evaluation of PD -L1 and T -Effector
Gene Signature
[CONTACT_109862] -L1 in tumors correlates with
response to anti PD-1 therapy ( Topalian et al. 2012).  This correlatio n wasalso 
observed with atezolizumab in Studies PCD4989g ( Herbst et al. 2014 ; Horn etal.2015 ),
GO28625 (FIR) (Spi[INVESTIGATOR_70048]. 2015 ), GO28754 (BIRCH) (Besse et al. 2015 ), GO28753 
(POPLAR) (Fehrenbacher etal.2016 ), and GO28915 ( OAK )(Rittmeyer et al. 2017) .  In 
addition, POPLA R data suggest higher expression of genes related to PD -L1 and T-
effector biology in tumor tissue is associated with improved efficacy ofatezolizumab 
compared with docetaxel ( Fehrenbacher et al. 2016 ). Similar observations have been 
reported for other PD -L1or PD-1 inhibitors (Higgs et al. 2015; Muro et al. 2015; Seiwert 
et al. 2015) . Furthermore , expression of PD -L1 on ICswas reported to be associated 
with expression of T -effector gene signature , therefore representing a preexisting 
immunity ( Fehrenbacher et al. 2016 ).
In this study, archival and/or fresh tumor specimens from patients will be prospectively 
tested for PD -L1 expression by a central laboratory during the screening period.  
Patients will be stratified by [CONTACT_4002] -L1 expression.  T he primary analysis of t his study will
evaluate the efficacy of atezolizumab in the ITT population, as well as in patients with a 
defined level of expression of aPD-L1 and T -effector gene signature (tGE population) . 
Both populations will exclude patients with a sensitizing EGFR mutation or ALK 
translocation.  On the basis of an analysis of independent cohorts of patients with 
NSCLC, it is estimated that the primary tGE cutoff for this study will identify a population 
corresponding to approximately 50% of the first -line NSCLC patient population.
In addition to the assessment of PD -L1 status and T -effector gene signatur e status , 
other exploratory markers, such as potential predictive and prognostic markers related to 
the clinical benefit of atezolizumab, tumor immunobiology, mechanisms of resistance, or 
tumor type, may also be analyzed. DNA and/or RNA extraction and analysis may be 
performed to enable identification of somatic mutations by [CONTACT_109819]-generation 
sequencing ( NGS )and to evaluate expression of genes (including but not limited to 
PD-L1, PD -1, T-effector and others) to assess their association with efficacy and to 
increase understanding of disease pathobiology.
3.3.8 Rationale for Blood Sampling for Biomarkers
An exploratory objective of this study is to evaluate surrogate biomarkers (that may 
include circulating -tumor DNA [ctDNA], gene expression, tumor burden biomarkers, and 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
66/Protocol GO29537 , Version 7others) in blood samples.  Evaluation of blood biomarkers may provide evidence for 
biologic activity of atezolizumab in patients with NSCLC and may allow for the 
development of blood -based biomarkers to help predict which patients may benefit from 
atezolizumab. 
In addition, potential correlations of these biomarkers with the safety and activity of 
atezolizumab will be explored.  
3.3.9 Rationale for the Collection of Mandatory  Tumor Specimens 
atRadiographic Progression
Anti-tumor immune responses such as those associated with atezolizumab may result in 
objective responses that are delayed and can be preceded by [CONTACT_109820].  This initial apparent progression may occur as a result of either 
delayed anti -tumor activity and/or robust tumor -immune infiltration with a concomitant 
increase in tumor size.  In addition, lesions that would otherwise be undetectable with 
conventional imaging (i.e., micrometastatic disease) may increase in size as a result of 
these processes and be record ed as new lesions ( Hales et al. 2010 ).  
If clinically feasible, collection of a mandatory tumor biopsy at the time of radiographic 
progression is required in order to evaluate the utility of the biopsy in distinguishing 
pseudoprogression/tumor -immune infi ltration from true progression.  Additionally, 
mechanisms relating to progression, resistance, predictive, prognostic, and 
pharmacodynamic relationships in tumor biomarkers (including, but not limited to, 
PD-L1, CD8, mutation status, and others) and efficacy will be evaluated.  DNA and/or 
RNA extraction may be performed to enable identification of somatic mutations, by [CONTACT_565755], that are associated with disease progression or acquired resistance to 
atezolizumab and to increase understanding of disease pat hobiology.
3.4 OUTCOME MEA SURES 
3.4.1 Efficacy  Outcome Measures
[IP_ADDRESS] Co-Primary  Efficacy  Outcome Measures
The co-primary efficacy outcome measure s for this study areas follows:
PFS, defined as the time from randomization to the first occurrence of disease 
progression as determined by [CONTACT_3143] v1.[ADDRESS_743035] in the tGE -WT population and the ITT -WT 
population
OS, defined as the time from randomization to death from any cause , in the ITT -WT 
population
[IP_ADDRESS] Secon dary  Efficacy Outcome Measures
The secondary efficacy outcome measures for this study are the following:
OS in the tGE -WT population
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
67/Protocol GO29537 , Version 7PFS, as determined by [CONTACT_3143] v1.1 , and OS in the 
TC2/3 or IC2/3 WT population and the TC1/2/3 or IC1/2/3 W T population
PFS, as determined by [CONTACT_3143] v1.1 , and OS in the 
tGE population and the ITTpopulation 
Objective response, defined as PR or CR as determined by [CONTACT_70131] v1.1 for the tGE-WT population and the ITT-WT population
DOR, defined as the time interval from first occurrence of a documented objective 
response to the time of disease progression as determined by [CONTACT_26218] v1.[ADDRESS_743036] for the tGE-WT 
population and the ITT-WTpopulation
OS rates at 1 and 2 years for the tGE-WT population and the ITT -WT population
TTD in patient -reported lung cancer symptoms, defined as time from randomization 
to deterioration (10 -point change ) on each of the EORTC QLQ -C30 and EORTC 
QLQ -LC13 symptom subscales (cough, dyspnea [single item], dyspnea [multi -item 
subscale], chest pain, and arm/shoulder pain) in the tGE -WT population and the 
ITT-WT population
Change from baseline in patient -reported lung cancer symptoms (chest pain, 
dyspnea, and cough) on the symptom severity score of the SILC scale in the 
tGE-WT population and the ITT -WT population
3.4.2 Safety  Outcome Measures
The safety outcome measures for this study are the following:
Incidence, natu re, and severity of adverse events graded according to the 
NCICTCAE v4.0
Changes in vital signs, physical findings, and clinical laboratory results during and 
following atezolizumab administration
Incidence of ATA response to atezolizumab and potential correlation with PK, 
pharmacodynamic, safety, and efficacy parameters
3.4.3 Pharmacokinetic Outcome Measures
The PK outcome measures for this study are the following:
For patients randomized to atezolizumab carboplatin nab-paclitaxel:
Maximum observed serum atezolizumab concentration (C max) after infusion on 
Cycle 1 , Day 1
Minimum observed serum atezolizumab concentration (C min) prior to infusion at 
selected cycles, at treatment discontinuation, and at 120 days ( 30 days) after 
the last dose of atezolizumab
Plasma concentrations for carboplatin (Arms A and B)
Plasma concentrations for nab -paclitaxel reported as total paclitaxel (Arms A and B)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
68/Protocol GO29537 , Version 7For patients randomized to carboplatin nab-paclitaxel who crossed over to receive 
open -label atezolizumab as monotherapy (allowed under Study GO29537 Protocol 
Versions 1 4):
Cmaxof serum atezolizumab after infusion on Day [ADDRESS_743037] cycle following 
crossover to atezolizumab as monotherapy
Cmin of serum atezolizumab prior to infusion on Day 1 at selected cycles 
following crossover to atezolizumab as monotherapy, at treatment 
discontinuation, and at 120 (30 days) after the last dose of atezolizumab 
3.4.4 Exploratory  Outcome Measures
The exploratory outcome measures for this study are the following:
PFS at 6 months and at 1 year
OS rate at 3 years
Status of PD -L1, immune -, and NSCLC -related and other exploratory biomarkers 
in archival and/or freshly obtained tumor tissues and blood (or blood derivatives) 
collected before, during, or after treatment with atezolizumab o r at progression and 
association with disease status and/or response to atezolizumab in combination with 
chemotherapy
Status of ICsand other exploratory biomarkers in mandatory biopsy specimens and 
blood collected at progression
Utility scores of the EQ -5D-3L 
Change from baseline in patient -reported outcomes of HRQoL, lung cancer -related 
symptoms, and functioning as assessed by [CONTACT_20368] -C30 and QLQ -LC13 
4. MATERI ALS AND METHOD S
4.[ADDRESS_743038] meet all of the following criteria to be eligible for study entry:
Signed Informed Consent Form
Male or female, 18 years of age or older
ECOG performance status of 0 or 1 (s ee Appendix 11)
Histologically or cytologically confirmed, Stage IV non -squamous NSCLC (per the 
Union Internationale contre le Cancer/American Joint C ommittee on Cancer staging 
system, 7th edition; Detterbeck et al. 2009 ; see Appendix 4).
Patients with tumors of mixed histology (i.e., squamous and non -squamous) are 
eligible if the major histological component appears to be non -squamous.
No prior treatment for Stage IV non- squamous NSCLC
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
69/Protocol GO29537 , Version 7Patients with a sensitizing mutation in the EGFR gene must have experienced 
disease progression (during or after treatment) or intolerance to treatment with 
one or more EGFR TKIs, such as erlotinib, gefitinib, or another EGFR TKI 
appropriate for the treatment of EGFR -mutant NSCLC.
Patients known to have an ALK fusion oncogene must have experienced 
disease progression (during or after treatment) or intolerance to treatment with 
one or more ALK inhibitors (e.g., crizotinib) appropriate for the treatment of 
NSCLC in patients having an ALK fusion oncogene.
Patients with unknown EGFR and ALK status require test results at screening.  
ALK and/or EGFR may be assessed locally or at a central laboratory.
Patients who have received prior neo- adjuvant, adjuvant chemotherapy, 
radiotherapy, or chemoradiotherapy with curative intent for non -metastatic 
disease must have experienced a treatment -free interval of at least [ADDRESS_743039] chemotherapy, radiotherapy, or 
chemoradiotherapy cycle.
Patients with a history of treated asymptomatic CNS metastases are eligible, 
provided they meet all of the following criteria:
Only supratentorial and cerebellar metastases allowed (i.e., no metastases to 
midbrain, pons, medull a or spi[INVESTIGATOR_1831])
No ongoing requirement for corticosteroids as therapy for CNS disease
No stereotactic radiation within [ADDRESS_743040] receive radiation therapy and/or surgery for CNS metastases.  Following 
treatment, these patients may then be eligible without the need for an additional 
brain scan prior to randomization, if all other criteria are met.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
70/Protocol GO29537 , Version 7Known PD -L1 tumor status as determined by [CONTACT_109794] a central 
laboratory on previously obtained archival tumor tissue or tissue obtained fr om a 
biopsy at screening.  See Section [IP_ADDRESS].
A representative formalin- fixed paraffin -embedded (FFPE) tumor specimen in 
paraffin bl ock (preferred) or 15 or more unstained, freshly cut, serial sections on 
slides from an FFPE tumor specimen is required for participation in this study.  
If fewer than 15 slides are available at baseline (but no fewer than 10), the 
patient may still be eli gible, upon discussion with the Medical Monitor.  This 
specimen must be accompanied by [CONTACT_40869].
Fine-needle aspi[INVESTIGATOR_1516] (defined as samples that do not preserve tissue 
architecture and yield cell suspension and/or cell smears), brushing, cell pellet 
specimens (e.g., from pleural effusion, and lavage samples) are not acceptable.  
Tumor tissue from bone metastases that is subject to decalcification is not 
acceptable.  
For core -needle biopsy specimens, preferably at least three cores embedded in 
a single paraffin block, should be submitted for evaluation. 
Measurable disease, as defined by [CONTACT_393] v1.1
Previously irradiated lesions can only be considered as measurable disease if 
disease progression has been unequivocally documented at that site since 
radiation and the previously irradiated lesion is not the only site of disease. 
Adequate hematologic and end organ function, defined by [CONTACT_40855] 14 days prior to randomization:
ANC 1500 cells/ L without granulocyte colony -stimulating factor support
Lymphocyte count 500/ L
Platelet count 100,000/ L without transfusion 
Hemoglobin 9.0 g/dL
Patients may be transfused to meet this criterion.
INR or aPTT 1.5upper limit of normal ( ULN)
This applies only to patients who are not receiving therapeutic 
anticoagulation; patients receiving therapeutic anticoagulation should be on a 
stable dose.
AST, ALT, and alkaline phosphatase 2.5ULN, with the following exceptions:
Patients with documented liver metastases:  AST and/or ALT 5ULN
Patients with documented liver or bone metastases:  alkaline pho sphatase 
5ULN.
Serum bilirubin 1.25ULN
Patients with known Gilbert disease who have serum bilirubin level 3ULN 
may be enrolled.
Serum creatinine 1.5ULN
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
71/Protocol GO29537 , Version 7For female patients of childbearing potential agreement (by [CONTACT_109796]/or partner) 
to use a highly effective form(s) of contraception that results in a low failure rate 
(1% per year )when used consistently and correctly, and to continue its use for 
5months after the last dose of atezolizumab or fo r [ADDRESS_743041] refrain from donating eggs during 
this same period.   For male patients with female partners of childbearing potential, 
agreement (by [CONTACT_109796]/or partner) to use a highly ef fective form(s) of 
contraception that results in a low failure rate (1% per year )when used 
consistently and correctly, and to continue its use for [ADDRESS_743042] dose of 
nab-paclitaxel and/or carboplatin, whichever is later.  Such methods inclu de:  
combined (estrogen and progestogen containing) hormonal contraception, 
progestogen -only hormonal contraception associated with inhibition of ovulation 
together with another additional barrier method always containing a spermicide, 
intrauterine device (IUD), intrauterine hormone- releasing system (IUS), bilateral 
tubal occlusion or vasectomized partner (on the understanding that this is the only 
one partner during the whole study duration), and sexual abstinence.  Male patients 
should not donate sperm during this study and for at least [ADDRESS_743043] 
dose of nab -paclitaxel and/or carboplatin, whichever is late r.
Oral contraception should always be combined with an additional contraceptive 
method because of a potential interaction with the study drug.  The same rules are 
valid for male patients involved in this clinical study if they have a partner of 
childbearing potential.  Male patients must always use a condom.
Women who are not postmenopausal ( 12months of nontherapy -induced 
amenorrhea) or surgically sterile must have a negative serum pregnancy test result 
within 14 days prior to initiation of study drug.
4.1.2 Exclusion Criteria
Patients who meet any of the criteria below will be excluded from study entry.
[IP_ADDRESS] Cancer- Specific Exclusions
Active or untreated CNS metastases as determined by [CONTACT_109826]
Spi[INVESTIGATOR_33373]/or radiation or 
previously diagnosed and treated spi[INVESTIGATOR_565728]2weeks prior to randomization
Leptomeningeal disease
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
72/Protocol GO29537 , Version 7Uncontrolled tumor -related pain
Patients requiring pain medication must be on a stable regimen at study entry.
Symptomatic lesions amenable to palliative radiotherapy (e.g., bone 
metastases or metastases causing nerve impi[INVESTIGATOR_20804]) should be treated prior 
to randomization.  Patients should be recovered from the effects of radiation.  
There is no required minimum recovery period.
Asymptomatic metastatic lesions whose further growth would likely cause 
functional deficits or intractable pain (e.g., epi[INVESTIGATOR_70052]) should be considered 
forlocoregional therapy, if appropriate, prior to randomization.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent 
drainage procedures (once monthly or more frequently)
Patients with indwelling catheters (e.g., PleurX®) are allowed.
Uncontrolled or symptomatic hypercal cemia ( 1.5 mmol/L ionized calcium or Ca 
12 mg/dL or corrected serum calcium ULN) 
Patients who are receiving denosumab prior to randomization must be willing 
and eligible to receive a bisphosphonate instead while in the study.
Malignancies other than NSCLC within 5 years prior to randomization, with the 
exception of those with a negligible risk of metastasis or death (e.g., expected 
5-year OS90%) treated with expected curative outcome (such as adequately 
treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized 
prostate cancer treated surgically with curative intent, ductal carcinoma in situ 
treated surgically with curative intent)
Known tumor PD -L1 expression status as determined by [CONTACT_70133] (e.g., patients whose PD -L1 expression status was determined 
during screening for entry into a study with antiPD-1 or anti PD-L1 antibodies but 
were not eligible are excluded)
[IP_ADDRESS] General Medical Exclusions
Women who are pregnant, lactating, or intending to become pregnant during 
thestudy
History of severe allergic, anaphylactic, or other hypersensitivity reactions 
tochimeric or humanized antibodies or fusion proteins
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese 
hamster ov ary cells or any component of the atezolizumab formulation
History of autoimmune disease, including, but not limited to, myasthenia gravis, 
myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, 
inflammatory bowel disease, vas cular thrombosis associated with antiphospholipid 
syndrome, W egener’s granulomatosis, Sjögren’s syndrome, Guillain -Barré 
syndrome, multiple sclerosis, vasculitis, or glomerulonephritis (see Appendix 13for 
a more comprehensive list of autoimmune diseases)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
73/Protocol GO29537 , Version 7Patients with a history of autoimmune -related hypothyroidism on a stable dose 
of thyroid replacement hormone areeligible for this study.
Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin 
regimen are eligible for this study.
Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with 
dermatologic manifestations only (e.g., patients with psoriatic arthritis would be 
excluded) are permitted provided that they meet the following conditions: 
Rash must cover less than 10% of body surface area.
Disease is well controlled at baseline and only requiring low -potency 
topi[INVESTIGATOR_8826].
No acute exacerbations of underlying condition within the previous 
12months (not requiring PUVA [psoralen plus ultraviolet A radiation], 
methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, 
high-potency or oral steroids).
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis 
obliterans), drug -induced pneumonitis, idiopathic pneumonitis, or evidence of active 
pneumonitis on screening chest CT scan
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
Positive test for H IV
All patients will be tested for HIV prior to inclusion into the study; patients who 
test positive for HIV will be excluded from the clinical study.
Patients with active hepatitis B (chronic or acute; defined as having a positive 
hepatitis B surface antigen [HBsAg] test at screening )or hepatitis C
Patients with past hepatitis B virus (HBV) infection or resolved HBV infection 
(defined as the presence of hepatitis B core antibody [HBcAb] and absence of 
HBsAg) are eligible only if they are negative for HBV DNA .
Patients who are positive for hepatitis C virus (HCV) antibody are eligible only if 
PCR is negative for HCV RNA.
Active tuberculosis
Severe infections within 4 weeks prior to randomization, including but not limited to 
hospi[INVESTIGATOR_565729], bacteremia, or severe pneumonia
Received therapeutic oral or IV antibiotics within 2 weeks prior to randomization
Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract 
infection or to prevent chronic obstr uctive pulmonary disease exacerbation) are 
eligible.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
74/Protocol GO29537 , Version 7Significant cardiovascular disease, such as [LOCATION_001] Heart Association cardiac 
disease (Class II or greater), myocardial infarction, or cerebrovascular accident 
within 3 months prior to randomization, un stable arrhythmias, or unstable angina
Patients with known coronary artery disease, congestive heart failure not 
meeting the above criteria, or left ventricular ejection fraction 50% must be on 
a stable medical regimen that is optimized in the opi[INVESTIGATOR_33398], in consultation with a cardiologist if appropriate.
Major surgical procedure other than for diagnosis within 28 days prior to 
randomization or anticipation of need for a major surgical procedure during the 
course of the study
Prior allogeneic bone marrow transplantation or solid organ transplant
Administration of a live, attenuated vaccine within 4 weeks before randomization or 
anticipation that such a live attenuated vaccine will be required during the study
Any other diseases, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that 
contraindicates the use of an investigational drug or that may affect the 
interpretation of the results or render s the patient at high risk from treatment 
complications
Illness or condition that interferes with the patient’s capacity to understand, follow ,
and/or comply with study procedures
[IP_ADDRESS] Exclusion Criteria Related to Medications
Any approved anti -cancer therapy, including hormonal therapy within 21 days prior 
to initiation of study treatment; the following exceptions are allowed:
TKIs approved for treatment of NSCLC discontinued 7days prior to 
randomization; the baseline scan must be obtained after discontinua tion of prior 
TKIs.
Treatment with any other investigational agent with therapeutic intent within 28 days 
prior to randomization
Prior treatment with CD137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], 
antiPD-1, and anti PD-L1 therapeutic antibodies
Patients who have had prior antiCTLA-4 treatment may be enrolled, provided 
the following requirements are met:
Last dose of anti CTLA-[ADDRESS_743044] 6 weeks prior to randomization
No history of severe immune- mediated adverse effects from antiCTLA-4 
(NCI CTCAE Grades 3 and 4)
Treatment with systemic immunostimulatory agents (including, but not limited to, 
IFNs, IL -2) within 4 weeks or five half -lives of the drug, whichever is longer, prior to 
randomization
Prior treatment with cancer vaccines is allowed.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
75/Protocol GO29537 , Version 7Treatment with systemic immunosuppressive medications (including, but not limited 
to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and 
antitumor necrosis factor [anti -TNF] agents) within [ADDRESS_743045] received acute, low -dose ( 10mg oral prednisone or 
equivalent) , systemic immunosuppressant medications may be enrolled in the 
study.
The use of corticosteroids ( 10mg oral prednisone or equivalent) for chronic 
obstructive pulmonary disease, miner alocorticoids (e.g., fludrocortisone) for 
patients with orthostatic hypotension, and low -dose supplemental 
corticosteroids for adrenocortical insufficiency is allowed.
[IP_ADDRESS] Exclusions Related to Chemotherapy
Known history of severe allergic reactions to platin um-containing compounds 
ormannitol
Known sensitivity to any component of nab -paclitaxel
Grade 2peripheral neuropathy as defined by [CONTACT_4652] v4.0 
Known history of severe hypersensitivity reactions to products containing 
Cremophor®EL (e.g., cyclosporin for injection concentrate and teniposide for 
injection concentrate)
4.2 METHOD OF TREA TMENT ASSIGNMENT A NDBLINDING
This is an open -label study.
After written informed consent has been obtained and eligibility has been established, 
the study site will enter demographic and baseline characteristics in the interactive voice
or W eb-based response system (IxRS).  For those patients who are eligible for 
enrollment, the study site will obtain the patient’s randomization number and treatment 
assignment fr om the IxRS.  The number of cycles of induction treatment (four or six) will 
be determined by [CONTACT_70134].
Randomization to one of the two treatment arms will occur in a 2:1 ratio.  
Permuted- block randomization wi ll be applied to ensure a balanced assignment to each 
treatment arm.  Randomization will be stratified by [CONTACT_4868]:
Sex (male vs. female)
Presence of liver metastases at baseline (yes vs. no)
PD-L1 expression by [CONTACT_4658] (TC3 and any IC vs. TC0/1/ 2 and IC2/3 vs. TC0/1/2 and 
IC0/1) (see Section 6.4.1 )
Patients should receive their first dose of study drug on the day of randomization if 
possi ble.  If this is not possible, the first dose should occur within 5 days after 
randomization.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
76/Protocol GO29537 , Version 7Following disease progression, patients consented under Protocol GO29537, 
Versions 14,and randomized to Arm B will be given the option to receive atezolizumab 
monotherapy provided they continue to meet crossover eligibility criteria (except for no 
prior treatment for Stage IV non -squamous NSCLC and no prior treatment with immune 
checkpoint blockade therapy).
4.3 STUDY TRE ATMENT 
4.3.1 Formulation, Packaging, and Handling
[IP_ADDRESS] Atezolizumab (MPDL3280A )
The atezolizumab (MPDL3280A) drug product is provided as a sterile liquid in a 
single -use, 20 -mL glass vial.  The vial is designed to deliver 20 mL (1200 mg) of 
atezolizumab solution but may contain more than the stated volume to en able delivery 
ofthe entire 20 -mLvolume. 
For further details on the formulation and handling of atezolizumab, see the Pharmacy 
Manual and Investigator’s Brochure.
[IP_ADDRESS] Carboplatin and nab -Paclitaxel
Carboplatin will be obtained in commercially available formu lations.  nab -Paclitaxel will 
be supplied to the sites by [CONTACT_1034].  For countries in which the Sponsor is required 
to provide all study drugs, including standard- of-care drugs, carboplatin will be provided 
by [CONTACT_109827]. 
For information on the formulation, packaging, and handling of carboplatin and 
nab-paclitaxel, see the prescribing information for each drug.
[IP_ADDRESS] Erlotinib and Pemetrexed
Switch maintenance to pemetrexed is permitted for patients randomized to Arm B.  
Switch maintenance to erlot inib is no longer permitted.  However, patients randomized to 
Arm B who had already started switch maintenance treatment with erlotinib under 
Protocol Versions 1 [ADDRESS_743046] (IMP), 
erlotinib will be provided by [CONTACT_109828].   
Pemetrexed will be obtained from commercial sources at each participating site.  For 
information on the formulation, packaging, and handling of pemetrexed, see the 
prescribing information.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
77/Protocol GO29537 , Version 74.3.[ADDRESS_743047] of four or six cycles of chemotherapy.  Atezolizumab and carboplatin will be 
administered on Day 1 of each 21 -day cycle.  nab -Paclitaxel will be administered on 
Days 1, 8, and 15 of each 21- day cycle.  The Day 1 order of administration is as follows:
Arm A:  Atezolizumab nab-paclitaxel carboplatin
Arm B:   nab- Paclitaxel carboplatin
During the induction phase, a chemotherapy cycle counts toward the prespecified 
number of induction chemotherapy cycles (four or six) as long as at least one 
chemotherapy component has been administered at least once during a 21- day cycle.  
Cycles in which no chemotherapy component is given do not count toward the total 
number of induction chemotherapy cycles.  Additional guidance is provided in 
Appendix 16.
Patients who experience no further clinical benefit (for patients enrolled in Arm A, see 
Section 3.1for definition) or disease progression (f or patients enrolled in Arm B) at any 
time during the induction phase will discontinue all study treatment.  In the absence of 
the above criteria, after the [ADDRESS_743048] induction cycle.
During treatment (induction or maintenance), patients randomized to Arm A who show 
evidence of clinical benefit will be permitted to continue atezolizumab after RECIST v1.[ADDRESS_743049] of care and manufacturer’s instruction.  On days of 
scheduled infusions of atezolizumab (Arm A), carboplatin and nab -paclitaxel (i.e., Day 1 
of every cycle) chemotherapy should be administered in th e following manner:
1.Arm A only:  Atezolizumab administered over 60 ( 15) minutes (for the first infusion, 
shortening to 30 [ 10] minutes for subsequent infusions; see Table 10) followed by
2. nab- Paclitaxel (100 mg/m2) IV administered over 30 minutes followed immediately 
by
3.Carboplatin IV administered over 1530minutes to achieve an initial target area 
under the concentration time curve (AUC) of 6 mg/mL/ min (Calvert formula dosing)
On Days 8 and 15, nab -paclitaxel (100 mg/m2) IV will be administered over 30 minutes.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
78/Protocol GO29537 , Version 7Chemotherapy infusion times may be adapted in accordance with local standard of care 
in lieu of the suggested infusion times. Chemotherapy dose modifications are allowed 
only to address toxicities (see Section [IP_ADDRESS] and Section 5.1.9 for guidelines).  The 
investigator may use discretion in modifying or accelerating the chemotherapy dose 
modification, depending on the severity of toxicity and an assessment of the risk versus 
benefit for the patient, with the goal of maximizing patient compliance and access to 
supportive care.
Guidelines for dose modification and treatment interruption or discontinuation for 
carboplatin and nab- paclitaxel ar e provided in Section 5.1.7 and Section 5.1.9 . 
[IP_ADDRESS] Atezolizumab 
Patients randomized to atezolizumab will receive 1200 mg of atezolizumab administered 
by [CONTACT_33433] 21 days in a monitored setting where there is immediate access to 
trained personnel and adequate equipment/medicine to manage potentially serious 
reactions.
Atezolizumab infusions will be administered per the instructions outlined in Table 10.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
79/Protocol GO29537 , Version 7Table 10Administration of First and Subsequent Infusions 
ofAtezolizumab
First Infusion Subsequent Infusions
Nopremedication administered for 
atezolizumab specifically is permitted 
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature) within 60 min before starting 
infusion.
Infuse atezolizumab (1200 mg in a 250 mL 
0.9% NaCl IV infusion bag) over 60 (15) 
min.
If clinically indicated:  record patient’s vital 
signs ( pulse rate, re spi[INVESTIGATOR_697], blood 
pressure, and temperature) during the 
infusion at 15 min, 30 min, 45 min, and 
60min (5-min windows are allowed for all 
timepoints).
If clinically indicated:  record patient’s vital 
signs ( pulse rate, respi[INVESTIGATOR_697], blood 
pressur e, and temperature) at 30 min 
(10min) after the infusion.
Patients will be informed about the possibility 
of delayed post- infusion s ymptoms and 
instructed to contact [CONTACT_109829].If patient experienced infusion -related 
reaction during any previous infusion, 
premedication with antihistamines may be 
administered for C ycles  2 at the 
discretion of the treating physician.
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature) with in 60 min before starting 
infusion.
If the patient tolerated the first infusion 
well without infusion- associated adverse 
events, the second infusion may  be 
delivered over 30 (10) min. 
If no reaction occurs, subsequent 
infusions may be delivered over 30 (10) 
minutes.
Continue to record vital signs within 
60minutes before starting infusion.  
Record vital signs during and after the 
infusion if clinically indicated.
If the patient had an infusion -related 
reaction during the previous infusion, the 
subsequent infusion must be delivered 
over 60 ( 15) min.
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature) during the infusion if 
clinically indicated or patient experienced 
symptoms during the previous infusion. 
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature ) 30 min ( 10 min) after the 
infusion if clinically indicated or patient 
experienced s ymptoms during previous 
infusion.
Dose modifications to atezolizumab are not permitted.  Guidelines for treatment 
interruption or discontinuation and the management of specific adverse events are
provided in Sections 5.1.7 , [IP_ADDRESS], and 5.1.8 .
Refer to the Pharmacy Manual for detailed instructions on drug preparation, storage, 
andadministration.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
80/Protocol GO29537 , Version [IP_ADDRESS] Carboplatin and nab -Paclitaxel
nab-Paclitaxel
nab-Paclitaxel injection must be diluted prior to infusion.  nab -Paclitaxel should be 
diluted in 0.9% sodium chloride injection to a final concentration of 5 mg/mL.  Sites 
should follow their institutional standar d of care for determining nab- paclitaxel dose 
adjustments in the event of patient weight changes.  The infusion site should be closely 
monitored for possible infiltration during drug administration.  Limiting the infusion of 
nab-paclitaxel to 30 minutes, a s directed, reduces the likelihood of infusion -related 
reactions.  Following administration, the IV line should be flushed with sodium chloride 
9mg/mL (0.9%) solution for injection to ensure administration of the complete dose, 
according to local practice .
See the nab-paclitaxel prescribing information for more information.
Carboplatin
Carboplatin should be administered by [CONTACT_16228], immediately after the completion of 
nab-paclitaxel administration, over 15 30minutes to achieve an initial target AUC of 
6mg/mL/min (Calvert formula dosing) and with standard anti -emetics per local practice 
guidelines.  
The carboplatin dose of AUC 6 will be calculated using the Calvert formula 
(Calvert etal.1989 ):
Calvert Formula
Total dose (mg) (target AUC) (glomerular filtration rate [ GFR] 25)
NOTE:  The GFR used in the Calvert formula to calculate AUC -based dosing should 
not exceed 125 mL/min. 
For the purposes of this protocol, the GFR is considered to be equivalent to the 
creatinine clearance (CRCL).  The CRCL is calculated by [CONTACT_109831] ( 1976 ) using the following formula:
CRCL (140age) (wt)(0.85 if female)72Scr
Where: CRCL creatinine clearance in mL/min
agepatient's age in years 
wtpatient’s weight in kg
Scrserum creatinine in mg/dL 
NOTE:  For patients with an abnormally low serum creatinine level, estimate GFR using 
a minimum creatinine level of 0.8 mg/dL or cap the estimated GFR at 125 mL/min.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
81/Protocol GO29537 , Version 7If a patient’s GFR is estimated based on serum creatinine measurements by [CONTACT_70138], the FDA recommends that physicians consider 
cappi[INVESTIGATOR_109777] (AUC) to avoid potential toxicity 
due to overdosing. Based on the Calvert formula described in the carboplatin label, the 
maximum doses can be calculated as follows:
Maximum carboplatin dose (mg) target AUC (mg min/mL) (GFR 25 mL/min)
The maximum dose is based on a GFR estimate that is capped at 125mL/min for 
patients with normal renal function.  No higher estimated GFR values should be used.
For a target AUC6, the maximum dose is 6 150900 mg.
For a target AUC 5, the maximum dose is 5 150750 mg.
For a target AUC 4, the maximum dose is 4 150600 mg.
Refer to the FDA’s communication regarding carboplatin dosing using the following URL 
for more details:  
http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm
228974.htm. 
[IP_ADDRESS] Erlotinib and Pemetrexed
Switch maintenance treatment with erlotinib is no longer permitted.  However, patients 
who had already started switch maintenance tre atment with erlotinib under Study 
GO29537 Protocol Versions 1 4may be allowed to continue treatment with erlotinib 
upon discussion of the risks, potential benefits, and alternative treatment options with the 
investigator.  For those patients who receive switch maintenance, institutions should 
follow the dosage and administration instructions in the prescribing information.  
For those patients receiving switch maintenance treatment with erlotinib see the 
prescribing information for erlotinib for more infor mation on erlotinib dosing.
For those patients receiving switch maintenance treatment with pemetrexed, see the 
prescribing information for pemetrexed for more information on pemetrexed dosing.
[IP_ADDRESS] Additional Required Medication
Prophy lactic Measures for Carbop latin
Carboplatin is considered moderately to highly emetogenic.  Therefore, appropriate 
anti-emetic medication should be given prior to initiation of chemotherapy according to 
the local practice and standard of care. 
4.3.[ADDRESS_743050] (NIMP) or an IMP.  IMPs required for completion of this s tudy will be 
provided by [CONTACT_109828].  The Sponsor or 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
82/Protocol GO29537 , Version 7appointed designee will supply other medicinal products in accordance with local 
regulations.  
The study site will acknowledge receipt of the IMPs usin g IxRS to confirm shipment 
condition and content.  Any damaged shipments will be replaced.
IMPs will either be disposed of at the study site according to the study site’s institutional 
standard operating procedure or returned to the Sponsor with the approp riate 
documentation.  The site’s method of IMP destruction must be agreed to by [CONTACT_1034].  
The site must obtain written authorization from the Sponsor before any IMP is destroyed, 
and IMP destruction must be documented on the appropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of 
by [CONTACT_25729].
4.3.[ADDRESS_743051], available 
at the following W eb site:
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
These analyses may be conducted prior to completion of the study .  
4.4 CONCOMITA NT THERA PY
Concomitant therapy includes any medication (e.g., prescription drugs, over -the-counter 
drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from 
7days prior to screening until the treatment discontinua tion visit.  All such medications 
should be reported to the investigator. 
4.4.1 Permitted Therapy
Premedication with antihistamines may be administered for any atezolizumab infusions 
after Cycle 1.
The following therapi[INVESTIGATOR_565730] t he study:
Oral contraceptives
Hormone -replacement therapy
Prophylactic or therapeutic anticoagulation therapy (such as low molecular weight 
heparin or warfarin at a stable dose level)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
83/Protocol GO29537 , Version 7Palliative radiotherapy (e.g., treatment of known bony metastases) provi ded it does 
not interfere with the assessment of tumor target lesions (e.g., the lesion being 
irradiated is not the only site of disease as that would render the patient not 
evaluable for response by [CONTACT_33461] v1.1)
It is not a requirement to withhold atezolizumab during palliative radiotherapy.
Inactive influenza vaccinations 
Megastrol administered as an appetite stimulant 
Corticosteroids ( 10mg oral prednisone or equivalent) for chronic obstructive 
pulmonary disease
Mineralocorticoids (e.g., fludrocortisone) 
Low-dose corticosteroids for patients with orthostatic hypotension or 
adrenocortical insufficiency
Switch maintenance therapy with pemetrexed is permitted and can be considered for 
patients randomized to Arm B only.  Switch maintenance therapy with erlotinib is no 
longer permitted.  However, patients who had already started treatment with erlotinib 
unde rStudy GO29537 Protocol Versions 1 4may be allowed to continue treatment with 
erlotinib upon discussion of the risks, potential benefits, and alternative treatment 
options with the investigator.  
Switch maintenance must be administered within [ADDRESS_743052] induction 
cycle.  Investigators should follow the NCCN guidelines and dosage and administration 
instructions in the prescribing information for pemetrexed.  
In general, investigators should manage a patient’s care with supportive therap ies as 
clinically indicated per local standards.  Patients who experience infusion -associated 
symptoms may be treated symptomatically with acetaminophen, ibuprofen, 
diphenhydramine, and/or famotidine or another H 2-receptor antagonist as per standard
practi ce (for sites outside the [LOCATION_002], equivalent medications may be substituted 
perlocal practice).  Serious infusion -associated events manifested by [CONTACT_27926], 
hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, or 
respi[INVESTIGATOR_696] d istress should be managed with supportive therapi[INVESTIGATOR_33942] 
(e.g., supplemental oxygen and 2-adrenergic agonists; see Appendix 12). 
All concomitant medications must be recorded on the appropriate Concomitant 
Medications electronic Case Report Form (eCRF).  Erlotinib and pemetrexed use will be 
recorded on separate erlotinib and pemetrexed administration eCRFs.
4.4.2 Cautionary  Therapy for A tezolizumab -Treated Patients
Systemic corticosteroids and TNF -inhibitors may attenuate potential beneficial 
immunologic effects of treatment with atezolizumab.  Therefore, in situations wh ere 
systemic corticosteroids or TNF -inhibitors would be routinely administered, 
alternatives, including antihistamines, should be considered first by [CONTACT_565756] —F. Hoffmann- La [COMPANY_002] Ltd
84/Protocol GO29537 , Version 7physician.  If the alternatives are not feasible, systemic corticosteroids and TNF -
inhibi tors may be administered at the discretion of the treating physician except in the 
case of patients for whom CT scans with contrast are contraindicated (i.e., patients with 
contrast allergy or impaired renal clearance) (see also Section 4.4.3 ). 
Systemic corticosteroids are recommended, with caution at the discretion of the treating 
physician, for the treatment of specific adverse events when associat ed with 
atezolizumab therapy.  Guidelines for the management of immune- mediated adverse 
events are described in Section 5.1.8 .
4.4.3 Prohibited Therapy
Any concomitant therapy intended for the treatment of cancer, whether health 
authority approved or experimental, is prohibited for various time periods prior to 
starting study treatment, depending on the anti -cancer agent (see Section 4.1.2 ), and 
during study treatment until disease progression is documented and thepatient has 
discontinued study treatment.  This includes, but is not limited to, chemotherapy, 
hormonal therapy, immunotherapy, radiotherapy, non-approved experimental agents, or 
herbal therapy (unless otherwise noted) . 
The following medications are prohi bited while in the study, unless otherwise noted:
Denosumab; patients who are receiving denosumab prior to enrollment must be 
willing and eligible to receive a bisphosphonate instead while in the study. 
Any live, attenuated vaccine (e.g., FluMist®) within [ADDRESS_743053] atezolizumab dose (for patients 
randomized to atezolizumab).
Use of steroids to premedicate patients for whom CT scans with contrast are 
contraindicated (i.e., patients with contrast allergy or impaired renal clearance); in 
such patients, non- contrast CT of the chest and non -contrast CT or MRI scans of 
the abdomen and pelvis should be performed.
The concomitant use of herbal therapi[INVESTIGATOR_109779], 
safety profiles, and potential drug -drug interactions are generally unknown.  However, 
their use for patients in the study is allowed at the discretion of the investigator , provided 
that there are no known interactions with any study treatment .  Asnoted above, herbal 
therapi[INVESTIGATOR_109780].
4.[ADDRESS_743054] be performed and documented for each patient.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
85/Protocol GO29537 , Version 7Patients should be assessed for toxicity prior to each dose; dosing will occur only if the 
clinical assessment and local laboratory test values are acceptable.
4.5.[ADDRESS_743055] a biopsy of the progressing lesion (if clinically feasible) and to acknowledge 
deferring other treatment options available to them in favor of continuing t reatment with
atezolizumab.
Patients who entered Study GO29537 under Protocol Versions 1 4,who were assigned 
to the control arm ,andwho show disease progression by [CONTACT_393] v1.[ADDRESS_743056] sign a 
consent to cross over to atezolizumab treatment at the time of progression to 
acknowledge deferring other treatment options.
4.5.2 Medical History  and Demographic Data
Medical history includes clinically significant diseases, surgeries, cancer history 
(including prior cancer therapi[INVESTIGATOR_26649]), reproductive status, smoking history, 
and all medications (e.g., prescription drugs, over -the-counter drugs, herbal or 
homeopathic remedies, nutritional supplements) used by [CONTACT_25701] 7 days prior 
to the screening visit. 
NSCLC cancer history will include prior cancer therapi[INVESTIGATOR_014], procedures, and an 
assessment of tumor mutational status (e.g., sensitizing EGFR mutatio n, ALK fusion 
status).  For patients not previously tested for tumor mutational status, testing will be 
required at screening.  For patients not previously tested for tumor mutational status or 
who have not been previously treated with an EGFR TKI or ALK inhibitor, testing can 
either be performed locally or submitted for central evaluation during the screening 
period.  If EGFR mutations or ALK status testing is not performed locally, additional 
tumor sections may be required for central evaluation of the mu tational status of these 
genes.  The tissue requirements for central evaluation may be reviewed in the central 
laboratory instruction manual.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
86/Protocol GO29537 , Version 7Demographic data will include age, sex, and self -reported race/ethnicity.
4.5.3 Physical Examinations
A complete physica l examination should include an evaluation of the head, eyes, ears, 
nose, and throat, and the cardiovascular, dermatological, musculoskeletal, respi[INVESTIGATOR_696], 
gastrointestinal, genitourinary, and neurological systems.  Any abnormality identified at 
baseline s hould be recorded on the General Medical History and Baseline Conditions 
eCRF.
At subsequent visits (or as clinically indicated), limited, symptom -directed physical 
examinations should be performed.  Changes from baseline abnormalities should be 
recorded i n patient notes.  New orworsened clinically significant abnormalities should be 
recorded as adverse events on the Adverse Event eCRF.
4.5.4 Vital Signs
Vital signs will include measurements of temperature, pulse rate, respi[INVESTIGATOR_697], and 
systoli c and diastoli c blood pressures while the patient is in a seated position .
Vital signs will be measured and recorded as described in Table 11.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
87/Protocol GO29537 , Version 7Table 11Vital Sign Measurements at Cy cle 1 and A ll Subsequent Cycles
Cycle 1
Treatment Arm Timepoints
Arm A Within 60 minutes prior to atezolizumab infusion
During the infusion at 15 min, 30 min, 45 min, and 60 min
(5-min window) and within 30 ( 10) minutes after atezolizumab
infusion if clinically indicated
Within 30 (10)minutes after carboplatin infusion
Arm B Within 60 minutes prior to nab -paclitaxel infusion
Within 30 (10)minutes after carboplatin infusion
Subsequent Cycles
Treatment Arm Timepoints
Arm A Within 60 minutes prior to atezolizumab infusion
During (every 15 [5]minutes) and within 30 (10)minutes after
atezolizumab infusion if clinically indicated or s ymptoms occurred
during prior infusion
Arm B Within 60 minutes prior to nab -paclitaxel infusion
During infusion if clinically indicated or if sy mptoms occurred
during the prior infusions
Within30 (10) minutes after carboplatin infusion if clinically
indicated or if sy mptoms occurred during the prior infusion
For patients in the atezolizumab arm, also refer to Table  10.
4.5.[ADDRESS_743057] scans (with oral/IV cont rast unless 
contraindicated) or MRIs of the chest and abdomen.  A CT or MRI scan of the pelvis is 
required at screening and as clinically indicated or as per local standard of care at 
subsequent response evaluations.  A spi[INVESTIGATOR_565731] o btained but is 
not a requirement.
A CT (with contrast if not contraindicated) or MRI scan of the head must be done at 
screening to exclude CNS metastasis.  An MRI scan of the brain is required to confirm or 
refute the diagnosis of CNS metastases at baselin e in the event of an equivocal scan.  
Patients with active or untreated CNS metastases are not eligible for the study 
(see Section [IP_ADDRESS]).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
88/Protocol GO29537 , Version 7If a CT scan for tumor assessment is performed in a positron emission tomography 
(PET)/CT scanner, the CT acquisition must be consistent with the standards for 
afull-contrast diagnostic CT scan.
Bone scans and CT scans of the neck should also be performed if clinically indicated.  At 
theinvestigator’s discretion, other methods of assessment of measurable disease as 
according to RECIST v1.[ADDRESS_743058] be documented at screening and re -assessed at each 
subsequent tumor evaluation.   Patients with a history of irradiated brain metastases at 
screening are not required to undergo brain scans at subsequent tumor evaluations
unless scans are clinically indicated. The same radiographic procedure used to assess 
disease sites at screening should be used thr oughout the study (e.g., the same contrast 
protocol for CT scans).  Response will be assessed by [CONTACT_26218] v1.[ADDRESS_743059] for patients in the a tezolizumab -containing 
treatment arm (Arm A) and only according to RECIST v1.1 for patients in the 
carboplatin nab-paclitaxel treatment arm (Arm B).
Assessments should be performed by [CONTACT_22960], if possible, to ensure internal 
consistency across visits.  Results must be reviewed by [CONTACT_109834]. 
Tumor assessments should occur every 6 weeks ( 7 days) for 48 weeks following 
Cycle 1, Day 1, and then every 9 weeks ( 7 days) after completion of the 
Week48tumor assessment , regardless of treatment delays until radiographic disease 
progression according to RECIST v1.1 ( or loss of clinical benefit for 
atezolizumab- treated patients who hadcontinue dtreatment with atezolizumab beyond 
disease progression according to RECIST v1.1), withdrawal of consent, death, or study 
termination by [CONTACT_1034], whichever occurs first. 
Patients who discontinue treatment for reasons other than radiographic disease 
progression according to RECIST v1.1 (e.g., toxicity, symptomatic deter ioration) will 
continue scheduled tumor assessments until radiographic disease progression 
according to RECIST v1.1 (or loss of clinical benefit for atezolizumab- treated patients 
who hadcontinued treatment with atezolizumab after radiographic disease progression 
according to RECIST v1.1), withdrawal of consent, death, or study termination by [CONTACT_429], whichever occurs first.   
Patients who start a new anti -cancer therapy in the absence of radiographic disease 
progression according to RECIST v1.1 will continue scheduled tumor assessments until 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
89/Protocol GO29537 , Version 7radiographic disease progression according to RECIST v1.1, withdrawal of consent, 
death, or study termination by [CONTACT_1034], whichever occurs first.
Patients treated with atezolizumab continuing to experience clinical benefit, despi[INVESTIGATOR_255836], will continue tumor assessments as per the 
schedule listed above.  
Scans will be submitted to an IRF.
4.5.6 Laboratory  Assessments and Biomarker Samples
Samples for the f ollowing laboratory tests will be sent to the study site’s local laboratory 
for analysis:
Hematology (CBC, including RBC count, hemoglobin, hematocrit, W BC count with 
differential [neutrophils, eosinophils, lymphocytes, monocytes, basophils, and other 
cells], and platelet count)
Serum chemistries (glucose, BUN or urea, creatinine, sodium, potassium, 
magnesium, chloride, bicarbonate or total CO 2, calcium, phosphorus, total bilirubin, 
ALT, AST, alkaline phosphatase, LDH, total protein, and albumin)
Coagulation (aPTT or INR)
Serum pregnancy test for women of childbearing potential, including women who 
have had a tubal ligation; urine pregnancy tests will be performed on Day [ADDRESS_743060].
Childbearing potential is defined as not having undergone surgical sterilization, 
hysterectomy, and/or bilateral oophorectomy or not being postmenopausal 
(12months of amenorrhe a). 
Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood); dipstick 
permitted
Thyroid- function testing (thyroid- stimulating hormone [TSH], free T3, free T4)
Total T3 to be tested only at sites where free T3 testing is not performed.
HBV serology:  hepatitis B surface antigen (HBsAg), antibodies against HBsAg, and 
total hepatitis B core antibody (HBcAb)
HBV DNA test must be performed prior to randomization if patient has a 
negative serology for HBsAg and a positive serology for HBcAb.  HB V DNA test 
must be negative.
HCV serology:  hepatitis C virus antibody (anti -HCV)
HCV RNA test must be performed prior to randomization if the patient tests 
positive for anti -HCV.
HIV testing  
All patients will be tested for HIV prior to inclusion into the study, and 
HIV-positive patients will be excluded from the clinical study.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
90/Protocol GO29537 , Version 7A central laboratory will coordinate the sample collection of tissue and blood samples for 
research -related testing at central laboratories or by [CONTACT_1034].  Instruction manuals 
and supply kits will be provided for all central laboratory assessments.  Samples for the 
following laboratory tests will be sent to one or several central laboratories or to the 
Sponsor for analysis:  
ATA assays (all atezolizumab -treated patients)
Serum samples will be assayed for the presence of ATAs to atezolizumab with 
use of validated immunoassays.  Accompanying PK samples will be collected 
at the same timepoints.
PK assays 
Blood samples for PK assessments will be obtained according to the schedu le 
in Appendix 2and Appendix 3.  
Serum samp les will be assayed for atezolizumab concentration with use of a 
validated immunoassay.
At selected sites, a subset of 20 patients in each arm will undergo the additional 
PK assessments for carboplatin and nab -paclitaxel. 
Plasma carboplatin and nab -paclit axel concentrations (reported as total 
paclitaxel) will be assayed using validated methods.
Biomarker assays in blood samples
Blood samples will be obtained for biomarker evaluation (including but not 
limited to biomarkers that are related to NSCLC or tumo r immune biology)
from all eligible patients according to the schedule in Appendix 2and 
Appendix 3.  Samples will be processed to obtain plasma and serum for the 
determination of changes in blood -based biomarkers (e.g., ctDNA, cytokines).  
Whole blood samples may be processed to obtain their derivatives (e.g., RNA 
and DNA) and evaluated for immune -related, tumor typerelated , and other 
exploratory biomarkers (e.g., alterat ions in gene expression or 
singlenucleotide polymorphisms).
For patients who consent to the optional collection of samples for the [COMPANY_002] Clinical 
Repository (RCR), any leftover material from the above sample collection will be 
stored and used for explorat ory analyses as indicated in Section 4.5.11 .  For 
patients who consent to RCR optional future research on their whole blood samples 
collected at sc reening but are determined to be ineligible for study participation, 
these samples and their derivatives (e.g., DNA, RNA, protein) may be used for 
future development of biomarker and/or diagnostic tests as indicated in
Section 4.5.11.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
91/Protocol GO29537 , Version 74.5.7 Tumor Tissue Samples
[IP_ADDRESS] Archival and Freshly  Collected Tumor Tissue Samples 
forScreening
Representative tumor specimens in paraffin blocks (preferred) or 15 ( or more) freshly 
cut,serial unstained sections on slides , with an associated pathology report, must be 
submitted at screening for determination of PD -L1 status prior to study randomization.  If 
fewer than 15 slides are available at baseline (but no fewer than 10), the patient may still 
be eligible, upon discussion with the Medical Monitor.   In addition, expression of PD-L1 
and T -effector gene signature [CONTACT_109863]. Exploratory biomarkers (including, but 
not limited to, markers related to immune or NSCLC biology, such as T- cell markers or 
non-inherited biomarkers identified through NGS on extracted DNA and/or RNA) may
also be evaluated.   The biomarkers will be identified by [CONTACT_4658], quantitative reverse 
transcriptase -polymerase chain reaction (qRT -PCR), NGS, and/or other methods.
Tumor tissue should be of good quality based on total and viable tumor content (sites 
will be informed if the quality of the submitted specimen is inadequate to determine 
tumor PD -L1 status). 
An archival tumor specimen should be submi tted if available.  If an archival specimen is 
not available, the patient may still be eligible, with the assumption that the patient is 
willing to consent to and undergo a pre -treatment biopsy or resection of the tumor.  
For freshly collected biopsy specimens, acceptable samples include those outlined 
below, provided there is a minimum of 50 viable TCs that preserve cellular context and 
tissue architecture regardless of needle gauge or retrieval method:
Core -needle biopsies for deep tumor tissue:  at leas t three cores, embedded into a 
single paraffin block, should be submitted for evaluation.
Excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous or 
mucosal lesions 
Tumor tissue resections
Fine-needle aspi[INVESTIGATOR_1516] (defined as a samples that do not preserve tissue architecture 
and yield cell suspension and/or cell smears), brushing, cell pellets (e.g., from pleural 
effusion), and lavage samples are not acceptable.
Tumor tissue from bone metastases that is subject to decalcification is not acceptable.
For archival samples, the remaining tumor tissue block for all patients enrolled will be 
returned to the site upon request or 18 months after final closure of the study database, 
whichever is sooner.  Tissue samples from patients who are de emed ineligible to enroll 
in the study will be returned no later than 6 weeks after eligibility determination.
ALK and/or EGFR status may be assessed locally or at a central laboratory if unknown.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
92/Protocol GO29537 , Version [IP_ADDRESS] Tumor Samples at the Time of Radiographic Progression
Patients in all treatment arms will undergo a mandatory tumor biopsy to obtain a tumor 
sample, unless not clinically feasible, at the time of radiographic disease progression 
(within 40 days of radiographic progression or prior to the start of the next anti -cancer 
treatment), whichever is sooner.
Acceptable samples include the following:
Core -needle biopsies for deep tumor tissue; at least three cores, embedded into a 
single paraffin block, should be submitted for evaluation.
Excisional, incisional, punch, or fo rceps biopsies for cutaneous, subcutaneous, or 
mucosal lesions
Tumor tissue resection
The status of immune -related and tumor typerelated and other exploratory biomarkers 
(including but not limited to T -cell markers and non -inherited biomarkers identified
through NGS on extracted DNA and/or RNA) in tumor tissue samples may be evaluated. 
NGS may be performed by [CONTACT_33430]. If performed by [CONTACT_33430], 
the investigator can obtain results from the samples collected at the time of disease 
progression in the form of an NGS report, which is available upon request directly from 
Foundation Medicine. The investigator may share and discuss the results with the 
patient, unless the patient chooses otherwise. The Foundation Medicine NGS assay 
has not been cleared or approved by [CONTACT_941] U.S. FDA; results from these investigational 
tests should not be used to guide future treatment decisions.
[IP_ADDRESS] Tumor Samples at Other Timepoints
If a patient undergoes a medically indicated procedure (e.g., bronchoscopy, 
esophagogastroduodenoscopy, colonoscopy) any time during the course of the study 
that has the likelihood of yielding tumor tissue, any remaining samples or a portion of the 
sample not necessary for medical diagnosis (leftover tumor tissue) may be obtained 
forexploratory analysis.
Patients with additional tissue samples from procedures performed at different times 
during the course of their study participation (during treatment and during survival 
follow -up) who have signed the [COMPANY_002] Clinical Repository (RCR) optional consent will be 
requested (but not required) to also submit these optional fresh samples for central 
testing.  Tumor tissue samples collected at the time of clinical events (e.g., clinical 
response) are preferred.  Tissue samples obtained at multi ple times for individual 
patients will greatly contribute to an improved understanding of the dynamics of PD -L1 
expression and relationship with intervening anti -cancer therapy.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
93/Protocol GO29537 , Version [IP_ADDRESS] Use and Storage of Remaining Samples from 
Study -Related Procedures
Unless the patient gives specific consent for his or her leftover samples to be stored for 
optional explorat ory research (see Section 4.5.11 ), biological samples will be destroyed 
when the final Clinical Study Report has been completed, with the following exceptions:
Serum samples collected for PK or immunogenicity analysis may be needed for 
additional immunogenicity characterization and PK and i mmunogenicity assay 
development and validation; therefore, these samples will be destroyed no later than 
[ADDRESS_743061] ATAs at multiple 
timepoints before, during, and after treatment with atezolizumab (see Appendix 1, 
Appendix 2, and Appendix 3for the schedule).  The immunogenicity evaluation will 
utilize a risk -based immunogenicity strategy ( Rosenberg and W orobec 2004 ; 
Koren etal.2008 ) to char acterize ATA responses to atezolizumab in support of the 
clinical development program.  This tiered strategy may include an assessment of 
whether detected ATA responses correlate with relevant clinical endpoints.  
Implementation of ATA characterization assays will depend on the safety profile and 
clinical immunogenicity data.
4.5.[ADDRESS_743062] review, sign, and date all ECG 
tracings.  Paper copi[INVESTIGATOR_26650]'s permanent 
study file at the site.  Any morphologic waveform changes or other ECG abnormalities 
must be documented on the eCRF.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
94/Protocol GO29537 , Version 74.5.10 Patient -Reported Outcomes
PRO data will be collected via the EORTC QLQ -C30, the EORTC QLQ -LC13, SILC, 
PGIS, and EQ -5D-3L to more fully characterize the clinical profile of atezolizumab.  
The questionnaires will be translated as required in the local language.  To ensure 
instrument validity and that data standards meet health au thority requirements, 
questionnaires scheduled for administration during a clinic visit will be completed in their 
entirety by [CONTACT_40873] -PRO assessments and the 
administration of study treatment. 
Patients will use an elec tronic PRO (ePRO) device to capture PRO data.  The ePRO 
device and/or instructions for completing the PRO questionnaires electronically will be 
provided by [CONTACT_6649].  The data will be transmitted via a prespecified 
transmission method (e.g., Web or wireless) automatically after entry to a centralized 
database at the ePRO vendor.  The data can be accessed by [CONTACT_109835].  
The EORTC QLQ -C30 (see Appendix 8) is a validated and reliable self -report measure 
(Aaronson etal.1993 ; Fitzsimmons etal.1999 ) that consists of 30 questions that assess 
five aspects of patient functioning (physical, emotional, role, cognitive, and social), three 
symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six 
single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial 
difficulties).  Scale scores can be obtain ed for the multi -item scales.  The EORTC 
QLQ -C30 module takes approximately 15 minutes to complete.  This questionnaire will 
be completed on the ePRO tablet at each scheduled cycle visit during the treatment 
induction phase and then according to the tumor assessment schedule during the 
treatment maintenance phase.  During survival follow -up, the questionnaire will be 
completed at 3months and 6 months following disease progression (or loss of clinical 
benefit for atezolizumab- treated patients who had contin uedtreatment after radiographic 
disease progression according to RECIST v1.1).  
The EORTC QLQ -LC13 (see Appendix 9) module incorporates one multiple- item scale 
to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, 
dysphagia, peripheral neuropathy, alopecia, and hemoptysis.  The EORTC QLQ -LC13 
module takes approximately 15 minutes to complete.  This questionnaire will be 
completed on the ePRO tablet at each scheduled cycle visit during the treatment 
induction phase and then according to the tumor assessment schedule during the 
treatment maintenance phase.  During survival follow -up, the questionnaire will be 
comple tedat 3months and 6 months following disease progression (or loss of clinical 
benefit for atezolizumab- treated patients who hadcontinued treatment after radiographic 
disease progression according to RECIST v1.1).  
The SILC scale will be used to assess patient -reported severity of lung cancer 
symptoms (chest pain, dyspnea, and cough). The SILC scale is a 9 -item content valid 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
95/Protocol GO29537 , Version 7self-report measure of lung cancer symptoms. It measures severity of cough, dyspnea, 
and chest pain with a symptom severity score .This questionnaire will be completed 
using an ePRO device at the patient’s home on a weekly basis, then during survival 
follow -up every month for 6 months following disease progression (or loss of clinical 
benefit for atezolizumab- treated patients who had continued treatment after radiographic 
disease progression according to RECIST v1.1).
The EQ -5D-3L is a generic, preference -based health -utility measure with questions 
about mobility, self -care, usual activities, pain/discomfort, and anxiety/depression that is 
used to build a composite of the patient’s health status (see Appendix 10).  The 
EQ-5D-3L will be utilized in this study for economic modeling.   This questionnaire will be 
completed on the ePRO tablet at each scheduled cycle visit during the treatment 
induction phase and then according to the tumor assessment schedule during the 
treatment maintenance phase.  During survival follow -up, the questionnaire will be 
completed at 3months and 6 months following disease progression (or loss of clinical 
benefit for atezolizumab- treated patients who hadcontinued treatment after disease 
progression according to RECIST v1.1).  
The PGIS consists of a single question used to assess patient global impression of 
disease severity.  This question will be completed on the ePRO tablet at each scheduled
cycle visit during the treatment induction phase and then according to the tumor 
assessment schedule during the treatment maintenance phase .The PGIS is not 
required during survival follow -up.
Patients who discontinue study treatment for any reason other than progressive 
disease or loss of clinical benefit will complete the EORTC QLQ -C30, EORTC 
QLQ -LC13, PGIS, and EQ -5D-3L at each tumor assessment visit and will complete the 
SILC at home on a weekly basis, until radiographic disease progression according to
RECIST v1.1 (or loss of clinical benefit for atezolizumab- treated patients who had
continued treatm entwith atezolizumab after radiographic disease progression) as 
determined by [CONTACT_093] (unless the patient withdraws consent or the Sponsor 
terminates the study).
The Sponsor will not derive adverse events reports from PRO data.  However, any PRO 
responses suggestive of a possible adverse event that are identified during site review of 
the PRO data should be reported as outlined in Section [IP_ADDRESS].
Patients whose native language is not available on the ePRO device or who are deemed 
by [CONTACT_565757].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
96/Protocol GO29537 , Version 74.5.11 Samples for [COMPANY_002] Clinical Repository
[IP_ADDRESS] Overview  of the [COMPANY_002] Clinical Repository
The RCR is a centrally administered group of facilities used for the long -term storage of 
human biologi c specimens, including body fluids, solid tissues, and derivatives thereof 
(e.g., DNA, RNA, proteins, peptides).  The collection and analysis of RCR specimens will 
facilitate the rational design of new pharmaceutical agents and the development of 
diagnosti c tests, which may allow for individualized drug therapy for patients in the 
future.
Specimens for the RCR will be collected from patients who give specific consent to 
participate in this optional research.  RCR specimens will be used to achieve the 
follow ing objectives:
To study the association of biomarkers with efficacy, adverse events, or 
disease progression
To increase knowledge and understanding of disease biology
To study drug response, including drug effects and the processes of drug absorption 
and disposition
To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays
[IP_ADDRESS] Approval by [CONTACT_565758] n the 
review and approval of the exploratory research and the RCR portion of the Informed 
Consent Form by [CONTACT_25733]'s IRB/EC and, if applicable, an appropriate regulatory body.  
If a site has not been granted approval for RCR sampling, this section of the protocol 
(Section 4.5.11 ) will not be applicable at that site.
[IP_ADDRESS] Sample Collection
The following samples may be collected for patients who have signed the RCR optional 
consent:
Optional fresh biopsy samples
Leftover tumor tissue samples
Remaining fluids (serum, plasma, blood cell derivatives) after study -related tests 
have been performed 
Remaining FFPE tissue (with the exception of archival FFPE blocks , which will be 
returned to sites) after study -related tests have been performed
Whole blood samples collected at screening (for screen -fail patients only)
The following sample will be used for identification of genetic (inherited) biomarkers:
Whole blood sample for DNA extraction (6 mL) (see Appendix 1and Appendix 2)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
97/Protocol GO29537 , Version 7For all samples, dates of consent should be recorded on the associated RCR page of 
the eCRF.  For sampling procedures, storage conditions, and shipment instructions, see 
the laboratory manual.  
RCR specimens will be destroyed no later than 15 years after the date of final closure of 
the associated clinical database.  The RCR storage period will be in accordance with the 
IRB/EC -approved Informed Consent Form and applicable laws (e.g., health authority 
requirements).
The dynamic biomarker specimens will be s ubject to the confidentiality standards 
described in Section 8.4.  The genetic biomarker specimens collected for the RCR will 
undergo additional pro cesses to ensure confidentiality as described below.
[IP_ADDRESS] Confidentiality
Given the sensitive nature of genetic data, [COMPANY_002] has implemented additional processes 
to ensure patient confidentiality for RCR specimens and associated data.  Upon receipt 
by [CONTACT_25736], e ach specimen is “double -coded” by [CONTACT_70144] a new independent number.  Data generated from the use of these 
specimens and all clinical data transferred from the clinical database and considered 
relevant are also label ed with this same independent number.  A “linking key” between 
the patient identification number and this new independent number is stored in a secure 
database system.  Access to the linking key is restricted to authorized individuals and is 
monitored by [CONTACT_25738].  Legitimate operational reasons for accessing the linking key are 
documented in a standard operating procedure.  Access to the linking key for any other 
reason requires written approval from the Pharma Repository Governance Committee 
and [COMPANY_002]' s Legal Department, as applicable.
Data generated from RCR specimens must be available for inspection upon request by 
[CONTACT_70145], 
representatives, and collaborators, as appropriate.
Patient m edical information associated with RCR specimens is confidential and may be 
disclosed to third parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_4677], u nless permitted or required by [CONTACT_2371].
Data derived from RCR specimen analysis on individual patients will generally not be 
provided to study investigators unless a request for research use is granted.  The 
aggregate results of any research conducted using RCR specimens will be available in 
accordance with the effective [COMPANY_002] policy on study data publication.
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RCR data will become and remain the exclusive and unburdened property 
of [COMPANY_002], except where agreed otherwise.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
98/Protocol GO29537 , Version [IP_ADDRESS] Consent to Participate in the [COMPANY_002] Clinical Repository
The Informed Consent Form will contain a separate section that addresses participation 
in the RCR.  The investigator or authorized designee wi ll explain to each patient the 
objectives, methods, and potential hazards of participation in the RCR.  Patients will be 
told that they are free to refuse to participate and may withdraw their specimens at any 
time and for any reason during the storage per iod.  A separate, specific signature [CONTACT_20030] a patient's agreement to provide optional RCR specimens.  
Patients who decline to participate will not provide a separate signature.
The investigator should document whether the patient has given consent to participate 
by [CONTACT_26806].
In the event of an RCR participant's death or loss of competence, the participant’s 
specimens and data will continue to be used as part of the RCR research.
[IP_ADDRESS] Withdrawa l from the [COMPANY_002] Clinical Repository
Patients who give consent to provide RCR specimens have the right to withdraw their 
specimens from the RCR at any time for any reason.  If a patient wishes to withdraw 
consent to the testing of his or her specimens, the investigator must inform the Medical 
Monitor in writing of the patient's wishes through use of the RCR Subject W ithdrawal 
Form and, if the study is ongoing, must enter the date of withdrawal on the RCR 
Research Sample W ithdrawal of Informed Consent eCRF. A patient's withdrawal from 
Study GO29537 does not, by [CONTACT_5071], constitute withdrawal of specimens from the RCR.  
Likewise, a patient's withdrawal from the RCR does not constitute withdrawal from 
Study GO29537.
If a patient wishes to withdraw consent to th e testing of his or her specimens after 
closure of the site, the investigator must inform the Sponsor by [CONTACT_70146]:
global_rcr -[EMAIL_1377]
[IP_ADDRESS] Monitoring and Oversight
RCR specimens wil l be tracked in a manner consistent with Good Clinical Practice by a 
quality -controlled, auditable, and appropriately validated laboratory information 
management system to ensure compliance with data confidentiality, as well as 
adherence to authorized use of specimens as specified in this protocol and in the 
Informed Consent Form.  Monitors and auditors will have direct access to appropriate 
parts of records relating to patient participation in the RCR for the purposes of verifying 
the data provided to Roch e.  The site will permit monitoring, audits, IRB/EC review, and 
health authority inspections by [CONTACT_70148].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
99/Protocol GO29537 , Version 74.5.12 Timing of A ssessments
[IP_ADDRESS] Screening and Baseline A ssessments
Screening tests and ev aluations will be performed within [ADDRESS_743063] -of-care tests or examinations performed prior toobtaining informed 
consent and within 28 days prior to Cycle 1, Day 1 may be used; such tests do not need 
to be repeat ed for screening. 
See Appendix 1for the schedule of screening assessments and Appendix 2and 
Appendix 3for the schedule of PK, ATA, and biomarker sampling.
[IP_ADDRESS] Assessments during Treatment
All visit s must occur 3 days from the scheduled date unless otherwise noted 
(see Appendix 1).All assessments will be performed on the day of the specified visit 
unless a time window is specified.  Assessments scheduled on the day of study 
treatment administration (Day 1) of each cycle should be performed prior to study 
treatment infusion unless otherwise noted. 
Patients who are randomized to Arm B who had started erlotinib (allowed under Study 
GO29 537Protocol Versions 1 4)or pemetrexed switch maintenan ce after the induction 
phas e will continue with cycle visits as outlined in Appendix 1for the maintenance phase
until erlotinib or pemetrexed treatment termination , disease progression, withdrawal of 
consent, death, or study termination by [CONTACT_1034], whichever occurs first.
Patients who are randomized to Arm B who receive BSC after the induction phase are 
not required to continue with cycle visits.  Their treatment discontinuation visit will take 
place when patients discontinue BSC . 
If scheduled dosing and study assessments are precluded because of a holiday, 
weekend, or other event, then dosing may be postponed to the soonest following date, 
with subsequent dosing continuing on a 21-day schedule.  If treatment was postponed 
for fewer than 3 days, the patient can resume the original schedule.
After completion of the induction phase one of three cycles may be delayed by 1 week 
(28 days instead of 21 days for one cycle) to allow for vacations/holidays.  Following the 
delay, the next cycle must be delivered 21 days from the previ ous dose administration: 
two consecutive 28 cycles are not permitted.  If a dose modification is required due to 
toxicity, refer to Section 5.1.
Tumor assessments should occur every 6 weeks ( 7 days) for 48 weeks following 
Cycle 1, Day 1, and every 9 weeks ( 7 days) after the completion of the Week [ADDRESS_743064] v1.1 ( or loss of clinical benefit for patients who hadcontinue 
treatment with atezolizumab after disease progression according to RECIST v1.1), 
withdrawal of consent, death, or study termination by [CONTACT_1034], whichever occurs 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
100/Protocol GO29537 , Version 7first.Patients who discontinue treatment for reasons other than radiographic disease 
progression according to RECIST v1.1 (e.g., toxicity, symptomatic deterioration) will 
continue scheduled tumor assess ments until radiographic disease progression 
according to RECIST v1.1 (or loss of clinical benefit for atezolizumab- treated patients 
who hadcontinued treatment with atezolizumab after radiographic disease progression 
according to RECIST v1.1), withdrawal of consent, study termination by [CONTACT_2728], or 
death, whichever occurs first.
The following assessments may be performed 96hours before Day 1 of each cycle: 
ECOG performance status
Limited physical examination
Local laboratory tests
Screening assessments performed [ADDRESS_743065] also be performed prior t o nab -paclitaxel infusions on 
Day8 and Day 15.
See Appendix 1for the schedule of assessments performed during the treatment period 
and Appendix 2and Appendix 3for the schedule of PK, pharmacod ynamic, ATA, 
andbiomarker sampling. 
[IP_ADDRESS] Assessments for Treatment -Crossover Patients
The same treatment -phase schedule of assessments and procedures will apply to 
patients in Arm B who crossed over to Arm A (allowed under Study GO29537 Protocol 
Versions 1 4).That is, patients will begin on Cycle 1 (now to be called Cycle 1A )and 
will follow the same assessments and procedures as outlined in this protocol for this 
cycle (with the exception of an alternate schedule for PK and pharmacodynamic 
assessments [se e Appendix 3] and a biopsy upon progression will not be requested for 
these patients), as well as for all subsequent cycles (i.e., Cycle 2, which will now be 
called Cycle 2A, etc.).
In addition, patients who crossed over from Arm B to Arm A following disease 
progression (allowed under Study GO29537 Protocol Versions 1 4) will not follow the 
treatment -phase schedule for PRO assessments during crossover. These patients will 
complete PRO assessments according to the post -progression schedule (i.e., SILC 
monthly for the first 6 months only and EORTC QLQ -C30, QLQ -LC13 ,and EQ -5D 3L at 
3 and 6 months only).  
[IP_ADDRESS] Assessments at Study Drug Discontinuation Visit
When a patient discontinues all study treatment (including pemetrexed and erlotinib
[allowed under Study GO29537 Protocol Versions 1 4]switc h maintenance, and BSC),
regardless of the reason for discontinuation, the patient will be asked to return to the 
clinic within 30 days after the treatment for the study drug discontinuation visit.  The visit 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
101/Protocol GO29537 , Version 7at which the decision is made to discontinue treatment (e.g., loss of clinical benefit is 
confirmed) may be used as the study drug discontinuation visit.
Arm B C rossover Patients A llowed under Study GO29537, Protocol 
Versions 1–4
For patients who entered Study GO29537 under Protocol Versions 1 4, who w ere 
assigned to the control arm, and who are allowed tocross over to receive atezolizumab, 
the study drug discontinuation visit must be repeated when they discontinue receiving 
atezolizumab.  The same study drug discontinuation visit procedures as listed below and 
in Appendix 1must be performed for both study drug discontinuation visits.
See Appendix 1, Appendix 2, and Appendix 3for the schedule of follow -up 
assessments.
[IP_ADDRESS] Follow -Up A ssessments
After the study drug discontinuation visit, adverse events should be followed as outlined 
in Section 5.3.1 .
For patients who discontinue study treatment (including chemotherapy induction, switch 
maintenance oferlotinib [allowed under Study GO29537 Protocol Versions 1 4]or 
pemetrexed switch maintenance for patients randomized to Arm B) for any reason other 
than radiographic progressive disease according to RECIST v1.1, tumor assessments 
should continue at the same frequency as would have been followed if the patient had 
remained on study treatment until radiographic disease progression (or loss of clinical 
benefit for patients treated with atezolizumab [Arm A patients and Arm B patients who 
cross over] who hadcontinued treatment with atezolizumab after disease progression 
according to RECIST v1.1), withdrawal of consent, death, or study termination by [CONTACT_429] , whichever occurs first .  
Patients who start a new anti -cancer therapy in the absence of radiographic disease 
progression according to RECIST v1.[ADDRESS_743066].
Follow -up data collection will also include ePROs (the SILC will be completed monthly 
only for the first 6 months after disease progression [or loss of clinical benefit for 
atezolizumab- treated patients who had continued treatment with atezolizumab after 
radiographic di sease progression according to RECIST v1.1 ] using an ePRO device at 
the patient’s home and EORTC QLQ -C30, EORTC QLQ -LC13, and EQ -5D-3L will be 
completed 3 and 6 months after disease progression [or loss of clinical benefit for 
atezolizumab- treated patients ] at the site using the ePRO tablet), study 
treatment related adverse events (including serious adverse events), subsequent 
anti-cancer therapi[INVESTIGATOR_014], and date and cause of death.  Patients who discontinue study 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
102/Protocol GO29537 , Version 7treatment for any reason other than progressive disease or loss of clinical benefit will 
complete the EORTC QLQ -C30, EORTC QLQ -LC13, PGIS, and EQ -5D-3L at each 
tumor assessment visit and will complete the SILC at home on a weekly basis, until 
radiographic disease progression according to RECIST v1.1 (orloss of clinical benefit for 
atezolizumab- treated patients who hadcontinue dtreatment with atezolizumab after 
radiographic disease progression according to RECIST v1.1 ) as determined by [CONTACT_1275] (unless the patient withdraws consent or the Sponsor terminates the study).
Adverse events will be foll owed as described in Section 5.5.
Survival follow -upi[INVESTIGATOR_565732], patient medical 
records, and/or clinic visits every 3months or more frequently until death, loss to follow -
up, or study termination by [CONTACT_1034], whichever occurs first.  All patients will be 
periodically contact[CONTACT_565759] -cancer therapy information unless the 
patient requests to be withdrawn from the study (this request must be documented in the 
source documents and signed by [CONTACT_093]).   If the patient withdraws from study, 
the study staff may use a public information source (e.g., county records), when 
permissible, to obtain information about survival status only.
See Appendix 1, Appendix 2, and Appendix 3for the schedule of follow -up 
assessments.
[IP_ADDRESS] Assessments at Unplanned Visits
Assessments for unscheduled visits related to a patient’s underlying NSCLC, study drug, 
or adverse event should be p erformed as clinically indicated and entered on the 
Unscheduled Visit eCRFs.  
4.[ADDRESS_743067] the right to voluntarily withdraw from the study at any time for any reason.  
In additi on, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include, but are not limited to, the following:
Patient withdrawal of consent at any time
Any medical condition that the investi gator or Sponsor determines may jeopardize 
the patient’s safety if he or she continues in the study
Investigator or Sponsor determines it is in the best interest of the patient
Patient non -compliance
Every effort should be made to obtain information on pa tients who withdraw from the 
study.  The primary reason for withdrawal from the study should be documented on the 
appropriate eCRF.  However, patients will not be followed for any reason after consent 
has been withdrawn.  Patients who withdraw from the study will not be replaced.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
103/Protocol GO29537 , Version 74.6.[ADDRESS_743068] discontinue study treatment if they experience any of the following:
Symptomatic deterioration attributed to disease progression as determined by [CONTACT_565760], biopsy results, and 
clinical status.
Intolerable toxicity related to atezolizumab, including development of an 
immune -mediated adverse event determined by [CONTACT_70150]’s potent ial response to therapy and severity of the event
Intolerable toxicity related to other components of the study treatment 
If one component of study treatment is discontinued permanently due to tolerability 
concerns, the patient may continue with other components of study treatment until 
disease progression or loss of clinical benefit (for atezolizumab -treated patients who 
continue treatment after disease progression according to RECIST v1.1) if agreed 
upon by [CONTACT_70151]
Any medical condit ion that may jeopardize the patient’s safety if he or she continues 
on study treatment
Use of another non protocol -specified anti -cancer therapy (see Section 4.4.3 )
Pregnancy
Radiographic disease progression according to RECIST v1.1 
Exception for atezolizumab treatment:  patients randomized to atezolizumab 
treatment will be permitted to continue atezolizumab after RECIST v1.1 for 
progressive disease are met if they meet all of the following criteria (see Figure 2for 
the schematic representation):
Evidence of clinical b enefit as assessed by [CONTACT_33470] (including worsening of laboratory values 
[e.g., new or worsening hypercalcemia]) indicating unequivocal progression of 
disease
No decline in ECOG performance status 
Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal 
disease) that cannot be readily managed and stabilized by [CONTACT_990] -allowed 
medical interventions prior to repeat dosing
Patients must provide written consent to acknowledge deferring any standa rd 
treatment options that may exist in favor of continuing atezolizumab treatment 
at the time of initial progression
A mandatory biopsy sample collection, unless not clinically feasible as 
assessed by [CONTACT_473], at the site of local or metastatic p rogression
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF. 
Study and Site Discontinuation
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
104/Protocol GO29537 , Version 7Figure 2 Conditions for Continuing A tezolizumab in Presence of Increased 
Radiographic Tumor Size (A pplicable to A rm A and A rm B 
Crossover Patients Consented under Study GO29537 Protocol 
Versions 1 4)
ECOG PSEastern Cooperative Oncology Group performance status; ICF Informed Consent 
Form ; RECIST v1.1 Response Evaluation Criteria in Solid Tumors, Version 1.1.
4.6.3
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:
The incidence or severity of adverse events in this or other studies indicate s a 
potential health hazard to patients.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
105/Protocol GO29537 , Version 7Patient enrollment is unsatisfactory.
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.  
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:
Excessively slow recruitment
Poor protocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice
No study activity (i.e., all patients have completed and all obligations have been 
fulfilled)
5. ASSESSMENT OF SA FETY
The following information is based on results from nonclinical and clinical studies and 
published data on similar molecules.
5.1 SAFETY PLA N
Measure s will be taken to ensure the safety of patients participating in this study, 
including the use of stringent inclusion and exclusion criteria (see Sections 4.1.1
and4.1.2 ) and close monitoring (as indicated below and in Section 4.5).  
SeeSection 5.3(Methods and Timing for Capturi ng and Assessing Safety Parameters ) 
for complete details regarding safety reporting for this study.
Administration of atezolizumab will be performed in a setting with emergency medical 
facilities and staff who are trained to monitor for and respond to medi cal emergencies.  
All serious adverse events and adverse events of special interest will be recorded during 
the study and for up to [ADDRESS_743069] dose of study treatment (inclusive of 
erlotinib or pemetrexed switch maintenance for patients randomi zed to Arm B who 
receive erlotinib [allowed under Study GO29537 Protocol Versions 1 4] or pemetrexed 
switch maintenance) or until initiation of new systemic anti-cancer therapy after the last 
dose of study treatment, whichever occurs first.  All other adve rse events will be 
recorded during the study and for up to [ADDRESS_743070] dose of study treatment 
(inclusive of erlotinib or pemetrexed switch maintenance for patients randomized to Arm 
B who receive erlotinib [allowed under previous versions of th is protocol ] or pemetrexed 
switch maintenance) or until initiation of new systemic anti- cancer therapy after the last 
dose of study treatment, whichever occurs first.  
After the adverse event reporting period, all deaths should continue to be reported. In 
addition, the Sponsor should be notified if the investigator becomes aware of any serious 
adverse event or adverse event of special interest that is believed to be related to prior 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
106/Protocol GO29537 , Version 7exposure to study treatment (see Section 5.6).  The potential safety issues anticipated 
in this trial, as well as measures intended to avoid or minimize such toxicities, are 
outlined in the following sections.
5.1.1 Risks A ssociated with A tezolizumab
The PD -L1/PD -[ADDRESS_743071] is involved in peripheral tolerance; therefore, such therapy 
may increase the risk of immune -mediated adverse events, specifically the induction or 
enhancement of autoimmune condi tions.  Adverse events with potentially 
immune -mediated causes, including rash, hypothyroidism, hepatitis/transaminitis, colitis, 
pneumonitis, myositis, and myasthenia gravis, have been observed in the Phase Ia 
Study PCD4989g.  For further details regarding clinical safety, including a detailed 
description of the anticipated safety risks for atezolizumab, see the Atezolizumab 
Investigator’s Brochure.
Although most immune -mediated adverse events observed with immunomodulatory 
agents have been mild and self -limiting, such events should be recognized early and 
treated promptly to avoid potential major complications ( Di Giacomo et al. 2010).   
Suggested workup procedures for suspected immune -mediated adverse events are 
provided in Section 6 (Guidance for the Investigator) of the Atezolizumab Investigator’s 
Brochure.
5.1.2 Risks A ssociated with Carboplatin 
Carboplatin is known to cause bone marrow suppression including myelosuppression, 
anemia, and thrombocytopenia.  Carboplatin -based chemotherapy is considered to be 
moderately emetogenic.  Patients will be monitored for carboplatin -related adverse 
events.
For more details regarding the safety profile of carboplatin, refer to the prescribing 
information for carboplatin .
5.1.3 Risks A ssociated with nab -Paclitaxel 
In clinical studies, nab -paclitaxel has been associated with alopecia, myelosuppression 
(neutropenia, anemia, thrombocytopenia), peripheral neuropathy, cranial nerve palsies, 
hypersensitivity reactions, pneumonitis, gastrointestinal events (i.e., nausea, v omiting, 
diarrhea), myalgia, anthralgia, cardiotoxicity (myocardial disorders, cardiac failure, 
angina, tachycardia, ventricular arrhythmia), cystoid macular edema, Stevens -Johnson 
syndrome/toxic epi[INVESTIGATOR_194], sepsis, drug -induced lupus erythematous, infusion 
site reactions/extravasation, hepatic toxicity (drug- induced liver injury), acute renal 
failure, and hemolytic -uremic syndrome.
Patients will be monitored for nab -paclitaxel related adverse events, including 
hematologic, gastrointestinal and hepatic toxicities, and peripheral neuropathy.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
107/Protocol GO29537 , Version 7For more details regarding the safety profile of nab -paclitaxel, refer to the nab-paclitaxel 
prescribing information.
5.1.4 Risks A ssociated with Erlotini b
This section applies to patients already receiving erlotinib switch maintenance therapy 
under Study GO29537 Protocol Versions 1 4.  The most commonly reported adverse 
drug reactions with erlotinib were rash and diarrhea.  Most were Grade 1 or 2 in severi ty 
and were manageable without intervention.  In general, rash manifests as a mild or 
moderate erythematous and papulopustular rash and may occur or worsen in sun -
exposed areas.  For patients who are exposed to the sun, protective clothing and/or the 
use o f sunscreen (e.g., mineral -containing) may be advisable.
For more details regarding the safety profile of erlotinib, refer to the prescribing 
information for erlotinib.
5.1.[ADDRESS_743072] common side effects of pemetrexed include gas trointestinal symptoms 
(nausea, vomiting, diarrhea, or constipation), myelosuppression, infection, fatigue, 
stomatitis, loss of appetite, and rash.
For more details regarding the safety profile of pemetrexed, refer to the pemetrexed 
prescribing information.
5.1.6 General Plan to Manage Safety Concerns
[IP_ADDRESS] Monitoring
Safety will be evaluated in this study through the monitoring of all serious and 
non-serious adverse events defined and graded according to NCI CTCAE v4.0.  Patients 
will be assessed for safety (including laboratory values) according to the schedule in 
Appendix 1.  Laboratory values must be reviewed prior to each infusion.
General safety assessments will include serial interval histories, physical examinations, 
and specific laboratory studies, including serum chemistries and blood counts 
(see Appendix 1for the list and timing of study assessments).
During the study, patients will be closely monitored for the development of any signs or 
symptoms of autoimmune conditions and infection.
Allserious adverse events and protocol -defined events of specia l interest will be 
reported in an expedited fashion (see Sections 5.2.2 and 5.2.3 ).  In addition, the iDMC 
and Medical Monitor will review and evaluate observed adverse events on a regular 
basis.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
108/Protocol GO29537 , Version 7Patients will be followed for adverse events (including deaths, serious adverse events, 
and adverse events of special interest) during and after the adverse event reporting 
period as described in Section 5.3.1 , [IP_ADDRESS], 5.5, and 5.6.
5.1.7 Dose Modification
[IP_ADDRESS] General Notes Regarding Dose Modification
Reasons for dose modifications or delays, the supportive measures taken, and the 
outcomes will be documented in the patient's chart and recorded on the eCRF.  
Theseverity of adverse events will be graded according to the NCI CTCAE v4.0 grading 
system.
For any concomitant conditions already apparent at baseline, the dose modifications 
will apply according to the corresponding shift in toxicity grade, if the investigator 
feels it is appropriate.  For example, if a patient has Grade 1 asthenia at baseline 
that increases to Grade 2 during treatment, this will be considered a shift of one 
grade and treated as Grade 1 toxicity for dose -modification purposes.
When several toxicities with different grades of severity occur at the same time, 
thedose modifications should be according to the highest grade observed.
If, in the opi[INVESTIGATOR_871], a toxicity is considered to be due solely to one 
component of the study treatment (i.e., atezolizumab, carboplatin, or nab -paclitaxel) 
and the dose of that component is delayed or modified in accordance with the 
guidelines below, other components may be administered if there is no 
contraindication.
When treatment is temporarily interrupted because of toxicity caused by, 
atezolizumab, carboplatin and/or nab -paclitaxel , the treatment cycles will be 
restarted such that the atezolizumab infusions remain synchronized and aligned 
with the chemotherapy schedule.
If, in the opi[INVESTIGATOR_871], a toxicity is considered to be due solely to 
onechemotherapy drug, the do se of the other chemotherapy drug does not 
require modification.  (Exception for nab- paclitaxel and carboplatin:  In the case of 
peripheral neuropathy, hematologic, and gastrointestinal toxicities, nab -paclitaxel 
and carboplatin require modification.  See Section 5.1.9 )
The investigator may use discretion in modifying or accelerating the dose modification 
guidelines described below, depending on the severity of toxicity and anassessment of 
the risk versus benefit for the patient, with the goal of maximizing patient compliance and 
access to supportive care.
[IP_ADDRESS] Atezolizumab Dose Modification
There will be no dose reduction for atezolizuma b in this study.  Patients may temporarily 
suspend study treatment with atezolizumab for up to [ADDRESS_743073] dose , then 
the patient will be discontinued from atezolizumab treatment and will be followed for 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
109/Protocol GO29537 , Version 7safety and efficacy as specified in Section 5.2.[ADDRESS_743074] dose until steroids are 
discontinued or reduced to prednisone dose (or dose equivalent) 10mg/day .  The 
acceptable length of interruption will depend on agreement between the investigator and 
the Medical Monitor.
5.1.8 Management of A tezolizumab -Specific A dverse Ev ents
Management of systemic immune activation is presented below.  Refer to the 
Atezolizumab Investigator’s Brochure for details on management of atezolizumab -
specific adverse events.
Refer to Appendix 12for precautions for anaphylaxis.
Refer to Section [IP_ADDRESS] and Table 15for management of pulmonary events and 
pneumonitis when atezolizumab and nab -paclitaxel are administered together, or when 
nab-paclitaxel is administered without a tezolizumab.
Systemic Immune A ctivation
Systemic immune activation is a rare condition characterized by [CONTACT_33471].  Given the mechanism of action of atezolizumab, systemic immune activation 
is considered a potential risk when given in co mbination with other immunomodulating 
agents.  Systemic immune activation should be included in the differential diagnosis for 
patients who, in the absence of an alternate etiology, develop a sepsis -like syndrome 
after administration of atezolizumab, and t he initial evaluation should include the 
following:
CBC with peripheral smear
PT, PTT, fibrinogen, and D -dimer
Ferritin
Triglycerides
AST, ALT, and total bilirubin
LDH
Complete neurologic and abdominal examination (assess for hepatosplenomegaly)
If system ic immune activation is still suspected after the initial evaluation, contact [CONTACT_33472].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
110/Protocol GO29537 , Version 75.1.9 Carboplatin and nab -Paclitaxel Dose Modification and 
Management of Specific A dverse Events
Dose reductions, holds, and discontinuations for each study drug may be made as 
outlined below.  The investigator may use discretion in modifying or accelerating the 
dose modification guidelines described below, depending on the severity of toxicity and 
an assessment of the risk versus benefit for the patient, with the goal of maximizing 
patient compliance and access to supportive care.
When a treatment cycle is delayed or interrupted because of toxicity resulting from either 
component of the regimen, all study treatment should genera lly be withheld and 
resumed together to remain synchronized.  However, if it is anticipated that 
chemotherapy will be delayed by 2 weeks, then atezolizumab should be given without 
the chemotherapy if there is no contraindication; this should be discussed with the 
Medical Monitor prior to re -initiating therapy.
Investigators should be vigilant and alert to early and overt signs of myelosuppression, 
infection, or febrile neutropenia so that these complications can be promptly and 
appropriately managed.  Pat ients should be made aware of these signs and encouraged 
to seek medical attention at the earliest opportunity.
Dose modifications of carboplatin and nab -paclitaxel are allowed as described in the 
following sections.
[IP_ADDRESS] Hematologic Toxicity
In general, ANC must be 1500 cells/ L and platelet count must be 100,000/ L on 
Day1 of each cycle. When nab -paclitaxel is administered on Day 1, it should not be 
administered on Days 8 or15 of the cycle unless ANC 500cells/ L and platelets 
50,000 cells/ L.  In certain situations, a cycle may begin with the administration of 
atezolizumab alone (without nab -paclitaxel on Day 1).  If Day 1 of a cycle begins with 
only atezolizumab but without the administration of nab -paclitaxel due to low platelet or 
ANC lev els, nab -paclitaxel should not be administered subsequently within that cycle 
until ANC 1500 cells/ L and platelet count ≥100,000/ L. If the delay in re -starting nab -
paclitaxel is 7 days (i.e., counts do not recover until Day 15), dosing should be 
resumed with applicable reductions.  If the start of a cycle is delayed (i.e., both 
atezolizumab and nab- paclitaxel are withheld) for low counts, postpone Day [ADDRESS_743075] 
recovered to permissible levels.  W hen dosing resumes, the carboplatin and 
nab-paclitaxel doses should be permanently reduced as outlined in Table 12.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
111/Protocol GO29537 , Version 7Table 12nab-Paclitaxel and Carboplatin Permanent Dose Reductions 
Based on Nadir A NC and Platelets
Hematologic Toxicity OccurrenceWeekly 
nab-Paclitaxel 
Dose (mg/m2)Every -3-Week 
Carboplatin Dose 
(AUC mg min/mL)
Neutropenic fever ( ANC 500 cells /L
with fever 38°C)
OR
Delay of next scheduled dose by
7days for 
ANC  1500 cells/ L
OR
ANC 500 cells/ Lfor7daysFirst [ADDRESS_743076] Discontinue treatment
Platelet count 50,000 cells/ L First 75 4.5
Second Discontinue treatment
AUC area under the concentration time curve .
[IP_ADDRESS] Gastrointestinal Toxicity
For Grade 3 or 4 gastrointestinal toxicities, treatment should be delayed until resolution 
to less than or equal to the patient’s baseline value.  Dose reductions at the start of the 
subsequent cycle will be based on gastrointestinal toxicities from the do se administered 
in the preceding cycle.  Table 12provides the relevant dose adjustments for 
gastrointestinal toxicities.
Table 13Carboplatin and nab -Paclitaxel Dose Modification Based on 
Gastrointestinal Toxicities in the Preceding Cy cle
Toxicity OccurrenceAdjusted 
Carboplatin
Dose as % of 
Previous DoseaAdjusted 
nab-Paclitaxel
Dose as % of 
Previous Dose
Grade 3 diarrhea
OR
Grade 3 
mucositis/stomatitis
OR
Grade 3 or 4 
nausea/vomitingFirst 75% 75%
Second 50% 50%
Third Discontinue treatment
Grade 4 oral 
mucositis/stomatitisNA Discontinue treatment
Grade 4 diarrhea NA Discontinue treatment
AUC area under the concentration time curve .
aIf deemed appropriate by [CONTACT_1963], adjust carboplatin dose 
to the specified percentage of the previous AUC.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
112/Protocol GO29537 , Version 7Nausea and/or vomiting should be controlled with adequate anti -emetics.  If Grade 3 or 4 
nausea/vomiting occurs despi[INVESTIGATOR_560509] -emetics, the dose should be 
reduced by 25% for the next and subsequent courses.
If, on Day 1 of any treatment cycle, the patient has oral mucositis/stomatitis, the 
treatment should be withheld until the oral mucositis/stomatitis is cleared.  If the oral 
mucositis/stomatitis has not cleared in 3 weeks, the patient’s chemotherapy will be 
discontinued.  See Table 13for additional details on dose reductions.  Dose reductions 
listed are permanent.
[IP_ADDRESS] Neurological Toxicity 
nab-Paclitaxel and carboplatin should be withheld for Grade 34 peripheral neuropathy.  
nab-Paclitaxel and carboplatin may be resumed at reduced doses (see Table 14) when 
peripheral neuropathy recovers to Grade 1 or completely resolves.
Table 14nab-Paclitaxel and Carboplatin Permanent Dose Reductions for 
Neurological Toxicity 
Adverse Reaction OccurrenceWeekly nab-Paclitaxel 
Dose (mg/m2)Every -3-Week 
Carboplatin Dose 
(AUC mg min/mL)
Grade [ADDRESS_743077] Discontinue treatment
AUC area under the concentration time curve .
[IP_ADDRESS] Hepatic Toxicity  (nab -Paclitaxel Only )
For patients with no hepatic metastases at baseline who develop severe enzyme 
elevations during study treatment (ALT and/or AST 5ULN or total bilirubin 3ULN), 
study treatment should be interrupted, hepatic toxicity must resolve to baseline levels
prior to dosing.  If nab -paclitaxel is withheld because of hepatic toxicity, carboplatin 
should also be withheld and administered when the nab -paclitaxel is resumed.  If 
nab-paclitaxel is withheld, hepatic values must recover to baseline levels within 3 weeks 
or the patient’s nab -paclitaxel treatment will be discontinued.  No dose reductions for 
carboplatin will be made for hepatic toxicity.
For patients with mild hepatic impairment (total bilirubin 1 to 1.5ULN and ALT/AST 
5ULN), no dose adjustments are required.  Treat with the same doses as patients 
with normal hepatic function.
If moderate to severe hepatic elevations (total bilirubin 1.55.0ULN or ALT and/or 
AST 5 10ULN) occur at any time, the nab -paclitaxel dose should be perm anently 
reduced to 80% of the starting dose (i.e., to 80 mg/m2).  nab -Paclitaxel will be 
discontinued for patients with total bilirubin 5ULN or AST 10ULN. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
113/Protocol GO29537 , Version 7The investigator should make all efforts to exclude malignant disease progression as a 
cause of liver enzyme derangement.  All study treatment must be discontinued if the 
disease under investigation has progressed.
[IP_ADDRESS] Pulmonary  Events and Pneumonitis:  A tezolizumab and 
nab-Paclitaxel, or nab -Paclitaxel without Atezolizumab
Note:  W hen atezolizumab is administered without nab -paclitaxel, refer to the 
Atezolizumab Investigator’s Brochure for management of pulmonary events, including 
pneumonitis. 
Atezolizumab
Dyspnea, cough, fatigue, hypoxia, pneumonitis, and pulmonary infiltr ates have been 
associated with the administration of atezolizumab and have primarily been 
observed in patients with underlying NSCLC.
Mild to moderate events of pneumonitis have been reported with atezolizumab.  All 
pulmonary events should be thoroughly e valuated for other commonly reported 
etiologies such as pneumonia/infection, lymphangitic carcinomatosis, pulmonary 
embolism, heart failure, chronic obstructive pulmonary disease, or pulmonary 
hypertension:
Measurement of oxygen saturation (i.e., arterial blood gas)
High-resolution CT scan of the chest
Bronchoscopy with bronchoalveolar lavage and biopsy
Pulmonary function tests (diffusion capacity of the lung for carbon monoxide 
[DLCO])
Pulmonary function testing with a pulmonary embolism protocol
Patients will be assessed for pulmonary signs and symptoms throughout the study, and 
will also have CT scans of the chest at every tumor assessment.  See Table 15for 
management guidelines for pulmonary events and pneumonitis.
nab-Paclitaxel 
Interstitial pneumonitis has been observed in 1% of patients with nab- paclitaxel 
monotherapy and 4% with the use of nab -paclitaxel in combination with 
gemcitabine.  Patients should be monitored closely for signs and symptoms of 
pneumonitis. 
nab-Paclitaxel should be permanently discontinued upon ruling out infectious etiology 
and making a diagnosis of pneumonitis. Promptly initiate appropriate treatment and 
supportive measures.
Infections should be ruled out with routine microbiological and/or immunologic methods.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
114/Protocol GO29537 , Version 7After ruling out an infectious etiology, high -dose IV corticosteroid therapy should be 
instituted without delay, with appropriate premedication and seco ndary pathogen 
coverage.  Patients with an added immunological component may also require immune 
modulation with azathioprine or cyclophosphamide.
Table 15details the management of pulmonary events/pneumonitis when atezolizumab 
and nab- paclitaxel are administered together, or when nab -paclitaxel is administered 
alone.
Note:  W hen atezolizumab is administered alone, refer to the Atezolizumab 
Investigator ’s Brochure for management of pulmonary events, including pneumonitis.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
115/Protocol GO29537 , Version 7Table 15Management Guidelines for Pneumonitis:  A tezolizumab and 
nab-Paclitaxel, or nab -Paclitaxel with or without Atezolizumab
SeverityAtezolizumab
(in Combin ation with nab -Paclitaxel)nab-Paclitaxel
(with or without Atezolizumab)
Grade 1Withhold atezolizumab with close 
monitoring.
Resume when event improves to Grade 0.
Re-evaluate on serial imaging.
Consider pulmonary consultation.Permanently discontinue 
nab-paclitaxel.
After ruling out infection, 
start high -dose IV 
corticosteroids with 
appropriate premedication 
and secondar y pathogen 
coverage.
Grade 2Withhold atezolizumab.
Pulm onary and infectious disease 
consultation with consideration for 
bronchoscopy/BAL.
Start 60 mg prednisone or equivalent per 
day.
When im proves to Grade 0 or Grade 1, then 
taper steroids over 1 month.
Atezolizumab may  be resumed if the event 
improves to Grade [ADDRESS_743078] been 
reduced to the equivalent of oral prednisone 
10mg daily or less.
Treat as Grade 3 4 if recurrent epi[INVESTIGATOR_109787].Permanently discontinue 
nab-paclitaxel.
After ruling out infection, 
start high -dose IV 
corticosteroids with 
appropriate premedication 
and secondar y pathogen 
coverage.
Grade 
3or4Permanently discontinue atezolizumab and 
contact [CONTACT_1689].
Bronchoscopy/BAL is recommended.
Start 60 mg prednisone or equivalent per 
day.
Taper steroids over  1 month after 
symptoms improve to Grade 0 or Grade 1.
If not improving after 48 hours or worsening, 
add additional immunosuppression (e.g., 
infliximab, cyclophosphamide, IV Ig, or 
mycophenolate mofetil).Permanently discontinue 
nab-paclitaxel.
After ruling out infection, 
start high -dose IV
corticosteroids with 
appropriate premedication 
and secondar y pathogen 
coverage.
BALbroncho -alveolar lavage; Ig immunoglobulin; IV intravenous.
[IP_ADDRESS] Other Toxicities
For any Grade 3 or 4 toxicity not mentioned above, carboplatin or nab -paclitaxel should 
be withheld until the patient recovers completely or to Grade 1 toxicity.  nab-Paclitaxel 
and carboplatin may be resumed at reduced doses (see Table 16) when toxicity 
recovers to Grade 1 or completely resolves.  If recovery to Grade 1 toxicity does not 
occur within 3 weeks, the patient’s chemotherapy will be discontin ued.  For Grade 1 and 
2 toxicities, no dose reduction should be made.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
116/Protocol GO29537 , Version 7Table 16nab-Paclitaxel and Carboplatin Permanent Dose Reductions for 
Non- Hematologic, Non -Gastrointestinal, Non- Neurologic, and 
Non- Hepatic Toxicity
Adverse Reaction OccurrenceWeekly nab-Paclitaxel 
Dose (mg/m2)Every 3 -Week 
Carboplatin Dose 
(AUC mg min/mL)
Grade [ADDRESS_743079] Discontinue treatment
AUC area under the concentration time curve; GI gastrointestinal .
For guidelines on the dosing of other study drugs when carboplatin or nab -paclitaxel are 
withheld, see Section 5.1.7 .
5.1.10 Erlotinib and Pemetrexed Dose Modification and Management 
of Specific A dverse Events
For patients who had started switch maintenance therapy with erlotinib (allowed under
Study GO29537 Protocol Versions 1 4) and for patients who receive pemetrexed, refer 
to the prescribing information for erlotinib and pemetrexed for dose modifications for 
adverse event management.
5.1.[ADDRESS_743080] been associated with each agent separatel y (e.g., hepatotoxicity, skin, and 
gastrointestinal toxicity) may not be unambiguous when the agents are administered 
together.  It is theoretically possible that allergic or inflammatory adverse events 
associated with these chemotherapeutic agents (e.g., hepatotoxicity) could be 
exacerbated by [CONTACT_120382]. 
Toxicities should initially be managed according to the recommendations in 
Sections 5.1.7 and 5.1.8 , with dose holds and modifications (if applicable) applied to the 
component of the study drug judged to be the primary cause.  For severe ( Grade 3) or 
persistent Grade [ADDRESS_743081] dose (see Section [IP_ADDRESS] ).  
Exceptions require Medial Monitor approval.  Prompt symptomatic management is 
appropriate for mild immune -mediated adverse events.  In severe cases, 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
117/Protocol GO29537 , Version 7immune -mediated toxicities may be acutely managed with topi[INVESTIGATOR_11930], 
systemic corticosteroids, or TNF-inhibitors.  These cases should be discussed with the 
Medical Monitor. 
5.[ADDRESS_743082]; measurement of 
protocol -specified safety laboratory assessments; measurement of protocol -specified 
vital signs; and other protocol -specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.
5.2.[ADDRESS_743083], regardless of causal attribution.  An adverse event can 
therefore be any of the following:
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal prod uct, 
whether or not considered related to the medicinal product
Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition), except as described in 
Section [IP_ADDRESS]
Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline
Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug
Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies)
5.2.2 Serious A dverse Events (Immediately  Reportable to 
theSponsor)
A serious adverse event is any adverse event that meets any of the following criteria:
Is fatal (i.e., the adverse event actually causes or leads to death)
Is life threatening (i.e., the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)
This does not include any adverse event that had it occurred in a more severe 
form or was allowed to continue might have caused death.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
118/Protocol GO29537 , Version 7Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS])
Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient’s ability to conduct normal life 
functions)
Results in a congenital anomaly/birth defect in a neonate/infant born to a mother 
exposed to study drug
Is a signif icant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)
The terms "severe" and "serious" are notsynonymous.  Severity refers to the int ensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to NCI CTCAE; 
see Section 5.3.3 ); the event itself may be of rela tively minor medical significance (such 
as severe headache without any further findings).
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.
Serious adverse events are required to be reported by [CONTACT_565761] (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).
5.2.[ADDRESS_743084] (Immediately  Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by [CONTACT_33473] (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
include the following:
Confirmed treatment -emergent autoimmune condit ions:
Pneumonitis
Grade 3 hypoxia or dyspnea 
Colitis
Endocrinopathies:  diabetes mellitus, pancreatitis, or adrenal insufficiency
Vasculitis
Hepatitis
Transaminitis:  Grade 2 (AST or ALT3ULN and bilirubin 2ULN) OR 
AST/ ALT10ULN
Systemic lupus erythematosus
Guillain -Barré syndrome
Skin reactions:  vitiligo, pemphigoid
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
119/Protocol GO29537 , Version 7Events suggestive of hypersensitivity, cytokine release, influenza -like illness, 
systemic inflammatory response system, or infusion -reaction syndromes
Cases of poten tial drug- induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by 
[CONTACT_25742]’s law (see Section [IP_ADDRESS] )
Suspected transmission of an infectious agent by [CONTACT_5257], as defined below
Any organism, virus, or infectious particle (e.g., prion protein -transmitting 
transmissible spongiform encephalopathy), path ogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient who was exposed to a medicinal product.  This term 
applies only when a contamination of the study drug is suspected.
5.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETY PARAMETERS
The investigator is responsible for ensuring that all adverse events (see Section 5.2.1for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.45.6.
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see 
Section 5.3.3 ), and causality (see Section 5.3.4 ).  
5.3.[ADDRESS_743085].  All 
adverse events, whether reported by [CONTACT_25743], will be 
recorded in the patient’s medical record and on the Adverse Event eCRF.
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported 
(see Section 5.4.2 for instructi ons for reporting serious adverse events).
After initiation of study treatment, all serious adverse events and adverse events of 
special interest, regardless of relationship to study treatment, will be reported until 
90days after the last dose of study tr eatment (inclusive of switch maintenance with 
pemetrexed or erlotinib [for patients who received switch maintenance with erlotinib 
under Study GO29537 Protocol Versions 1 4]) or until initiation of new systemic anti -
cancer therapy after the last dose of study treatment, whichever occurs first.  All other 
adverse events, regardless of relationship to study treatment, will be reported until 
30days after the last dose of study treatment (inclusive of switch maintenance with 
pemetrexed or erlotinib [for pati ents who receive d switch maintenance with erlotinib 
under Study GO29537 Protocol Versions 1 4])oruntil initiation of new systemic 
anti-cancer therapy after the last dose of study treatment, whichever occurs first.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
120/Protocol GO29537 , Version 7Instructions for reporting adverse even ts that occur after the adverse event reporting 
period are provided in Section 5.6.
5.3.2 Eliciting A dverse Ev ent Information
A consistent m ethodology of non- directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:
“How have you felt since your last clinic visit?”
“Have you had any new or changed health problems since you were last here?”
5.3.3 Assessment of Severity  of A dverse Events
The adverse event severity grading scale for the NCI CTCAE (v4.0) will be used for 
assessing adverse event severity.  Table 17will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.
Table 17Adverse Event Severity Grading Scale for Events Not Specifically  
Listed in NCI CTCA E
Grade Severity
1 Mild; as ymptomatic or mild sy mptoms; clinical or diagnostic observations only; or 
intervention not indicated
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily livinga
3 Severe or medically significant, but not immediately life -threatening; hospi[INVESTIGATOR_12342]; disabling; or limiting self-care activities 
of daily livingb, c
4 Life-threatening consequences or urgent intervention indicatedd
5 Death related to adverse eventd
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events .
Note:  Based on the most recent version of NCI CTCAE (v4.0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
aInstrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_19640], using the telephone, managing money, etc.
bExamples of self -care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by [CONTACT_25744].
cIf an event is assessed as a “significant medical event,” it must be rep orted as a serious 
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.[ADDRESS_743086] be reported as serious adverse events (see Section 5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2 .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
121/Protocol GO29537 , Version 75.3.4 Assessment of Causality  of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether or 
not an adverse event is considered to be related to the study drug, indicating “yes” or 
“no” accordingly.  The following guidance should be taken into consideration:
Temporal relationship of event onset to the initiation of study drug
Course of the event, considering especially the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)
Known association of the event with the study drug or with similar treatments
Known association of the event with the disease under study
Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event
Presence of no ntreatment -related factors that are known to be associated with the 
occurrence of the event
For patients receiving combination ther apy, causality will be assessed individually for 
each protocol -mandated therapy.
5.3.[ADDRESS_743087] medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF.
[IP_ADDRESS] Diagnosis versus Signs and Sy mptoms
For all adverse events, a diagnosis (if known) should be recorded on the Adverse Event 
eCRF r ather than individual signs and symptoms (e.g., record only liver failure or 
hepatitis rather than jaundice, asterixis, and elevated transaminases).  However, if a 
constellation of signs and/or symptoms cannot be medically characterized as a single 
diagnos is or syndrome at the time of reporting, each individual event should be recorded 
on the Adverse Event eCRF.  If a diagnosis is subsequently established, all previously 
reported adverse events based on signs and symptoms should be nullified and replaced 
by[CONTACT_25746], with a starting date that 
corresponds to the starting date of the first symptom of the eventual diagnosis.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
122/Protocol GO29537 , Version [IP_ADDRESS] Adverse Events That A re Secondary  to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initi ating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.
If vomiting results in se vere dehydration, both events should be reported separately 
on the eCRF.
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF.
If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.
If neutropenia is accompanied by [CONTACT_25747], both events should be reported 
separately on the eCRF.
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
[IP_ADDRESS] Persistent or Recurrent A dverse Events
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 
Adverse Event eCRF .  The initial severity (intensity) of the event will be recorded at the 
time the event is first reported.  If a persistent adverse event becomes more severe, the 
most extreme intensity should also be recorded on the Adverse Event eCRF.  If the 
event becom es serious, it should be reported to the Sponsor immediately (i.e., no more 
than 24 hours after learning that the event became serious; see Section 5.4.2 for 
reporting instructions).  The Adverse Event eCRF should be updated by [CONTACT_70156] “non- serious” to “serious,” providing the date that the event became serious, 
and completing all data fields related to serious adverse events.
A recur rent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF.
[IP_ADDRESS] Abnormal Laboratory Values
Not every laboratory ab normality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it is a change from baseline and meets any of 
the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g ., dosage modification, treatment 
interruption, or treatment discontinuation)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
123/Protocol GO29537 , Version 7Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy
Is clinically significant in the investigator’s judgment 
It is the investigator’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 ULN associated with cholestasis), only the 
diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating if the test result is above or below the normal range (e.g., “elevated 
potassium,” as opposed to “abnormal potassium”).  If the laboratory abnormality can be 
characterized by a precise clinical term per standard definitions, the clinical term should 
be recorded as the adverse event.  For example, an elevated serum potassium level of 
7.0mEq/L should be recorded as “hyperkalemia.”
Observations of the same clinically significant laboratory abnormality from visit to visit 
should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology 
changes.  The initial severity of the event should be recorded, and the severity or 
seriousness should be updated any time the event worsens.
[IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it is a change from baseline and meets any of the 
following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Is clinically significant in the investigator’s judgment 
It is the investigator’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
124/Protocol GO29537 , Version 7Observations of the same clinically significant vital sign abnormality from visit to visit 
should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology 
changes.  The initial severity of the event should be recorded, and the severit y or 
seriousness should be updated any time the event worsens.
[IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3baseline value) in combination with either 
an elevated total bilirubin ( 2ULN) or clinical jaundice in the absence of cholestasis or 
other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury.  
Therefore, investigators must report as an adverse event the occurrence of either of the 
following:
Treatment -emergent ALT or AST 3baseline value in combination with total 
bilirubin 2ULN (of which 35% is direct bilirubin)
Treatment -emergent ALT or AST 3baseline value in combination with 
clinical jaundice
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section [IP_ADDRESS]) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest (see 
Section 5.4.2 ).
[IP_ADDRESS] Death s
For this protocol, mortality is an efficacy endpoint.  Deaths that occur during the 
protocol -specified adverse event reporting period (see Section 5.3.1 ) that are attributed 
by [CONTACT_200046].  All other deaths occurring during the adverse event reporting 
period, regardless of relationship to study drug, must be recorded on the Adverse Event 
eCRF and immediately reported to the Sponsor (see Section 5.4.2 ).  An iDMC will 
monitor the frequency of deaths from all causes.
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such even t should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, “unexplained death” should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), “unexplained death” should 
be replaced by [CONTACT_25749]. The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").
During survival follow -up, deaths attributed to progression of NSCLC should be recorded 
on the Study Discontinuation eCRF. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
125/Protocol GO29537 , Version [IP_ADDRESS] Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Basel ine 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  W hen 
recording such events on the Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by [CONTACT_9672] 
(e.g., “more frequent headaches”).
[IP_ADDRESS] Worsening of NSCLC
Events that are clearly consistent with the expected pattern of progression of the 
underlying disease should not be recorded as adverse events.  These data will be 
captured as efficacy assessment data only.  In most cases, the expected pattern of 
progressi on will be based on RECIST.  In rare cases, the determination of clinical 
progression will be based on symptomatic deterioration.  However, every effort should 
be made to document progression through use of objective criteria.  If there is any 
uncertainty as to whether an event is due to disease progression, it should be reported 
as an adverse event.
[IP_ADDRESS] Hospi[INVESTIGATOR_26663] (i.e., in -patient admission to a hospi[INVESTIGATOR_307]) 
or prolonged hospi[INVESTIGATOR_255838] a serious adverse 
event (per the definition of serious adverse event in Section 5.2.2 ), except as outli ned 
below.  
An event that leads to hospi[INVESTIGATOR_26664] a serious adverse event:
Hospi[INVESTIGATOR_25678]
Planned hospi[INVESTIGATOR_33402] (e.g., for study drug administration or 
to perform an efficacy measurement for the study)
Hospi[INVESTIGATOR_272] a preexisting condition, provided that all of the following criteria 
aremet:
The hospi[INVESTIGATOR_70064]
Hospi[INVESTIGATOR_33404] —F. Hoffmann- La [COMPANY_002] Ltd
126/Protocol GO29537 , Version 7An event that leads to hospi[INVESTIGATOR_436229] a serious adverse event, but should be reported as an adverse event 
instead:
Hospi[INVESTIGATOR_565733]
[IP_ADDRESS] Adverse Events A ssociated with an Overdose or Error in 
Drug Administration
Study overdose is the accidental or intentional use of a drug in an amount higher than 
the dose being studied.  An overdose or incorrect administration of study treat ment is not 
itself an adverse event, but it may result in an adverse event.  All adverse events 
associated with an overdose or incorrect administration of study drug should be 
recorded on the Study Drug Administration eCRF.
All adverse events associated wi th an overdose or incorrect administration of study drug 
should be recorded on the Adverse Event eCRF.  If the associated adverse event fulfills 
serious criteria, the event should be reported to the Sponsor immediately (i.e., no more 
than 24 hours after learning of the event; see Section 5.4.2 ).
[IP_ADDRESS] Patient -Reported Outcome Data
Adverse event reports will not be derived from PRO data, and safety analyses will not be 
performed using PRO data.  However, if any PRO responses suggestive of a possible 
adverse event are identified during site review of the PRO data, the investigator will 
determine whether the criteria for an adverse event have been met and, if s o, will report 
the event on the Adverse Event eCRF.
5.[ADDRESS_743088] report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_743089] report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:
Serious adverse events
Adverse events of special interest
Pregnancies
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:
New signs or symptoms or a change in the diagnosis
Significant new diagnostic test results
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
127/Protocol GO29537 , Version 7Change in causality based on new information
Change in the event’s outcome, including recovery
Additional narrative information on the clinical course of the event
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.
5.4.[ADDRESS_743090] Information 
Medical Monitor: , M.D. (Primary)
Telephone No.:
Mobile Telephone No.:
Medical Monitor: , M.D., Ph.D. (Secondary)
Telephone No.:
Mobile Telephone No.:
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the [COMPANY_002] Medical Emergency List, escalate emergency medical calls, provide 
medical translation service (if necessary), connect the investigator with a [COMPANY_002] Med ical 
Monitor, and track all calls.  The Emergency Medical Call Center Help Desk will be 
available [ADDRESS_743091]
[IP_ADDRESS] Events That Occur prior to Study  Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events that are caused by a protocol -mandated intervention should be 
reported.  The Serious Adverse Event/Adverse Event of Special Interest Reporting Form 
provided to investigators should be completed and submitted to [COMPANY_002] or its designee 
immediately (i.e., no more than 24 hours after learning of the event), either by [CONTACT_40879].
[IP_ADDRESS] Events That Occur after Study  Drug Initiation
After initiation of study drug, serious adverse events and adverse events of special 
interest will be reported until [ADDRESS_743092] dose of study treatment (inclusive of 
switch maintenance with pemetrexed or erlotinib [for patients who received switch 
maintenance with erlotinib under Study GO29537 Protocol Versions 1 4]) or until 
initiation of new systemic anti -cancer therapy after the last dose of study treatment, 
whichever occurs first.  All other adverse events, regardless of relationship to study 
treatment, will be reported until [ADDRESS_743093] dose of study treatment (inclusive 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
128/Protocol GO29537 , Version 7of switch maintenance with pemetrexed or erlotinib [for patients who received switch 
maintenance with erlotinib under Study GO29537 Protocol Versions 1 4) or until 
initiation of new systemic anti -cancer therapy after the last dose of study treatment, 
whichever occurs first.  
Investigators should record all case details that can be gathered immediately (i.e., within 
24 hours after learning of the event) on the Adverse Event eCRF and submit the report 
via the electronic data capture (EDC) system.  A report will be generated and sent to 
[COMPANY_002] Safety Risk Management by [CONTACT_27950].
In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse 
Event of Special Interest Reporting Form prov ided to investigators should be completed 
and submitted to [COMPANY_002] or its designee immediately (i.e., no more than 24 hours after 
learning of the event), either by [CONTACT_77003].  Once the EDC system is 
available, all information will need to be entered and submitted via the EDC system.  
Instructions for reporting adverse events that occur after the adverse event reporting 
period are provided in Section 5.6.
5.4.3 Reporting Requirements for Pregnancies
[IP_ADDRESS] Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study or within [ADDRESS_743094] dose of nab -paclitaxel.  A Clinical 
Trial Pregnancy Reporting Form should be completed and submitted to the Sponsor or 
its designee immediately (i.e., no more than 24 hours after learning of the pregnancy) , 
either by [CONTACT_565762] .  Pregnancy should not be recorded on the 
Adverse Event eCRF.  The investigator should discontinue study drug and counsel the 
patient, discussing the risks of the pregnancy and the possible effects on the fet us.  
Monitoring of the patient should continue until conclusion of the pregnancy.  Any serious 
adverse events associated with the pregnancy (e.g., an event in the fetus, an event in 
the mother during or after the pregnancy, or a congenital anomaly/birth de fect in the 
child) should be reported on the Adverse Event eCRF.   In addition, the investigator will 
submit a Clinical Trial Pregnancy Reporting Form when updated information on the 
course and outcome of the pregnancy becomes available.
[IP_ADDRESS] Pregnancies in Fema le Partners of Male Patients 
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
6months after the last dose of nab -paclitaxel and/or carbo platin .  A Clinical Trial 
Pregnancy Reporting Form should be completed and submitted to the Sponsor or its 
designee immediately (i.e., no more than 24 hours after learning of the pregnancy) , 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
129/Protocol GO29537 , Version 7either by [CONTACT_565763]. Attempts should be made to collect and report 
details of the course and outcome of any pregnancy in the partner of a male patient 
exposed to study drug.  When permitted by [CONTACT_779], the pregnant partner would need to 
sign an Authorization for Use and Disclosure of Pregnancy Health Information to allow 
for follow -up on her pregnancy.  If the authorization has been signed, the investigator 
should submit a Clinical Trial Pregnancy Reporting Form when updated information on 
the course and outcome of the pregnancy becomes available.  An investigator who is 
contact[CONTACT_408072], to support an informed 
decision in cooperation with the treating physician and/or obstetrician.
[IP_ADDRESS] Abortions
A spontaneous abortion should be classified as a serious adverse event (as the Sponsor 
considers abortions to be medically significant), recorded on the Adverse Event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event; see Section 5.4.2 ).  
If a therapeutic or elective abortion was performed because of an underlying maternal 
or embryofetal toxicity, the toxicity s hould be classified as a serious adverse event, 
recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2).   A therapeutic or 
elective abortion performed for reasons other than an underlying maternal or 
embryofetal toxicity is not considered an adverse event.
All abortions should be reported as pregnancy out comes on the paper Clinical Trial 
Pregnancy Reporting Form.
[IP_ADDRESS] Congenital A nomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a serious adverse event, recorded on the Adverse Event eCRF, and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 ).
5.[ADDRESS_743095] to 
follow -up, or the patient withdraws consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study drug or study -related procedures 
until a final outcome can be repo rted.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
130/Protocol GO29537 , Version 7During the study period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient’s medical record to facilitate source data 
verification.  If, after follow -up, return to baseline status or stabiliza tion cannot be 
established, an explanation should be recorded on the Adverse Event eCRF. 
All pregnancies reported during the study should be followed until pregnancy outcome.  
If the EDC system is not available at the time of pregnancy outcome, follow reporting 
instructions provided in Section [IP_ADDRESS] .
5.5.[ADDRESS_743096], and pregnancies, the 
Sponsor or a designee may follow up by [CONTACT_756], fax, electronic mail, and/or a 
monitoring visit to obtain additional case details and outcome information (e.g., from 
hospi[INVESTIGATOR_8838], consultant reports, autopsy reports) in order to perf orm 
an independent medical assessment of the reported case.
5.6 ADVERSE EVENTS THA T OCCUR AFTER THE A DVERSE 
EVENT REPORTING PERI OD
After the end of the adverse event reporting per iod (as defined in Section 5.3.1 ), all 
deaths should be reported through use of the Study Discontinuation eCRF.  In addition, 
if the investigator becomes aware of a serious adverse event or adverse event of special
interest that is believed to be related to prior exposure to study treatment, the event 
should be reported through use of the Adverse Event eCRF.  However, if the EDC 
system is not available, the investigator should report these events directly to the 
Sponsor or its designee, either by [CONTACT_200052]/Adverse Event of Special Interest Reporting Form using the 
fax number or email address provided to investigators.
5.[ADDRESS_743097] experience to identify and expeditiously 
commun icate possible new safety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events using the following as reference :
Atezolizumab Investigator’s Brochure
Tarceva® (erlotinib) Summary of Product Characteristics (SmPC)/Local Label
Abraxane® (nab -paclitaxel) Summary of Product Characteristics (SmPC)/Local 
Label
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
131/Protocol GO29537 , Version 7The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and ser iousness, with allowance for upgrading by [CONTACT_25753].
An iDMC will monitor safety data during the study.  An aggregate report of any clinically 
relevant imbalances that do not favor the test product will be submitted to health 
authorities.
6. STATISTICA L CONSIDERA TION S AND ANAL YSIS PLA N
This is a Phase III, randomized, multicenter, open -label study designed to evaluate the 
safety and efficacy of atezolizumab in combination with carboplatin nab-paclitaxel 
compared with treatment with carboplatin nab-paclitaxel alone in approximately 
715patients with Stage IV, non -squamous NSCLC in the first -line setting.  
Efficacy analyses will be performed in one or more populations (tGE -WT, ITT-WT, tGE, 
ITT, TC2/3 or IC2/3 WT, or TC1/2/3 or IC1/2/3 WT), with patients grouped according to 
the treatment assigned at randomization, regardless of whether they received any 
assigned study treatment.
Safety analyses for the primary treatment phase will be performed on all randomized 
patients who received any amount of any component of protocol treatment, with patients 
grouped according to whether any full or partial dose of atezolizumab was received.  
Safety analyses for the crossover phase (for patients who entered Study GO29537
under Protocol Versions 1 4) will be performed on patients assigned to the control arm 
who received any amount of atezolizumab as subsequent treatment.  
6.1 DETERMINA TION OF SA MPLE SIZE
The primary endpoint of PFS will be analyzed in the tGE -WT population and in the ITT -
WT population, and the prim ary endpoint of OS will be analyzed in the ITT -WT 
population.  Analyses of PFS and OS will be conducted according to an analysis 
hierarchy and an -spending algorithm to control for the type Ierror rate (see Figure 3) 
and to account for an interi m OS analysis (see Section 6.8.1 ).  The PFS and OS 
analysis hierarchy and allocation, including possible recycling, are shown in 
Figure 3.  A detailed descript ion of the hypothesis test ing is provided in Section 6.4.1 .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
132/Protocol GO29537 , Version 7Figure 3 Progression -Free Survival and Overall Survival A nalysis 
Hierarchy , Alpha Allocation, and A lpha Recy cling
0.022 0.003
PFS OS
1. PFS in tGE-WT
α=0.0033. OS in ITT-WT
If Step 1 or Step 2 is not statistically significant, α=0.022
If Step 2 is statistically significant, α=0.025Arm Avs. Arm B
1-sided α=0.025 a
2. PFS in ITT-WT
If Step 1 is statistically significant, α=0.003
ITTintent to treat; OS overall survival; PFS progression -free survival; tGEtumor gene 
expression; W Twild type
aTo control the overall type I error rate for the one- sided test at 0.025, a one -sided type I error 
() of 0.003 and 0.022 (ratio of 3:22) will be allocated to PFS and OS, respectively, for 
comparison of Arm A versus Arm B.
This study will randomize approximately 715 patients .  The ITT -WT population will 
include approximately 650 patients, assuming a prevalence of approximately 10% for 
sensitizing EGFR mutations or ALK translocations.   The tGE -WT population will include
approximately 325patients ,assuming a 50% prevalence with the chosen tGE cutoff.
The sample size of this study is based on the number of events required to demonstrate 
efficacy with regard to both PFS and OS (co -primary endpoints).
The estimate of the number of events required to demonstrate efficacy with regard to 
PFS in the comparison of Arm A versus Arm B is based on the following assumptions:
93% power to detect an HR of 0.55, corresponding to an improvement in median 
PFS from 6 months to 10.9 months in the tGE-WT population with a one -sided of 
0.003
95% power to detect an HR of 0.65, corresponding to an improvement in median 
PFS from 6 months to 9.2 months in the ITT -WTpopulation with a one -sided of 
0.003
No interim analyses for PFS
Dropout rate of 5% per 12 months
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
133/Protocol GO29537 , Version 7The estimate of the number of events required to demonstrate efficacy with regard to OS 
in the comparison of Arm A versus Arm B is based on the following assumptions:
80% power to detect an HR of 0.75, corresponding to an improvement in median 
OS from 12 months to 16 months in the ITT -WTpopulation with a one- sided of 
0.022
One interim OS analysis performed at the time of the fi nal PFS analysis, at which 
time approximately 77% of the total number of OS events required for the final 
analysis are expected to have occurred ,as determined through use of the 
Lan-DeMets approximation to the O'Brien -Fleming boundary
Dropout rate of 5% per [ADDRESS_743098] been met:   approximately [ADDRESS_743099] to inclusion/exclusion 
criter ia, will be reported and summarized by [CONTACT_255895] -WTpopulation.
6.3 SUMMA RIES OF TREA TME NT GROUP COMPA RABILITY
Demographic characteristics such as age, sex, race/ethnicity, and baseline disease 
characteristics (e.g., ECOG performance status), w ill be summarized by [CONTACT_565764]-WTpopulation and the ITT-WTpopulation.  Descriptive statistics (mean, 
median, standard deviation, and range) will be presented for continuous data, and 
frequencies and percentages will be presented for cate gorical data.
Baseline measurements are the last available data obtained prior to the patient receiving 
the first dose of any component of protocol treatment.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
134/Protocol GO29537 , Version 76.[ADDRESS_743100] one interim OS analysis will be 
performed (see Section 6.8.1 ).
PFS is defined as the time between the date of randomization and the date of first 
documented disease progression or death, whichever occurs first.  Patien ts who have 
not experienced disease progression or death at the time of analysis will be censored 
atthe time of the last tumor assessment.  Patients with no post -baseline tumor 
assessment will be censored at the date of randomization plus [ADDRESS_743101].  The HR
for PFS and OS for treatment comparisons will be estimated using a stratified Cox 
regression model, respectively.  The 95% CI for the HR will be provided.
The stratification factors will be those used during randomization (i.e., sex [male vs. 
female], presence of liver metastases at baseline [yes vs. no], and PD -L1 tumor 
expression by [CONTACT_4658] [TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1]), as 
recorded in the IxRS.
Results from an unstratified analysis will also be presented.  Kaplan -Meier met hodology 
will be used to estimate the median PFS and the median OS for each treatment arm, 
and a Kaplan- Meier curve will be constructed to provide a visual description of the 
difference between treatment arms.  The Brookmeyer -Crowley methodology will be us ed 
to construct the 95% CI for the median PFS and the median OS for each treatment arm 
(Brookmeyer andCrowley 1982 ).
Analyses will be conducted according to an analysis hierarchy and an -spending 
algorithm to control for the type I error rate (see Figure 3in Section 6.1) and to account 
for an int erim analysis (see Section 6.8.1 ).  
To control the overall type I error rate for the one -sided test at 0.025, a one -sided type I 
error ( ) of 0.003 and 0.022 (ratio of 3:22) will be allocated to PFS and OS, respectively. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
135/Protocol GO29537 , Version 7The hypothesis testing will be performed in the order described below :
1.PFS in the tGE -WT population will be tested at 0.003 (one sided).  If the estimate 
of the HR i s [ADDRESS_743102] is 0.003, the null hypothesis will be rejected and it will be concluded that 
atezolizumab carboplatin nab-paclitaxel prolongs the duration of PFS relative to 
control treatm ent in the tGE -WT population. 
2.If the null hypothesis is rejected in the tGE -WT population (Step 1), PFS in the 
ITT-WT population will be tested at 0.003 (one sided). 
3.recycling from PFS to OS will be conducted as follows: 
a.If the null hypothesis is not rejected for the PFS analysis in the ITT -WT
population (Step 2), OS in the ITT -WT population will be tested at 0.022 (one 
sided). 
b.If the null hypothesis is rejected for the PFS analysis in the ITT -WTpopulation 
(Step 2), OS in the ITT-WTpopulation will be tested at 0.025 (one sided).
Details on the hypothesis testing will be provided in the SAP. On the basis of emerging 
external data, the testing strategy may be modified to improve the efficiency of the 
design. Should this occur, modifications to the testing strategy will be documented in the 
SAP prior to any unblinding of the data.
6.4.2 Secondary  Efficacy Endpoints
[IP_ADDRESS] Progression -Free S urvivaland O verall Survivalin Secondary  
Populations
PFS will be analyzed in the TC2/3 or IC2/3 W T population, the TC1/2/3 or IC1/2/3 WT 
population, the tGEpopulation, and the ITTpopulation, through use of the same 
methods described for the primary PFS analysis (see Section 6.4.1 ).
OS will be analyzed in the tGE -WT population, the TC2/3 or IC2/3 W T population, the 
TC1/2/3 or IC1/2/3 WT population, the tGEpopulation, and the ITT population, through 
use of the same methods described for the primary OS analysis (see Section 6.4.1 ). 
If the difference in OS between Arm A and Arm B in the ITT -WT population is statistically 
significant, a comparison of Arm A versus Arm B will be conducted in the tGE population 
and ITT population.  The allocation will follow the same -spending algorithm and 
allocation ratio described for analysis of the co -primary efficacy endpoints (see 
Section 6.4.1 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
136/Protocol GO29537 , Version [IP_ADDRESS] Objective Response Rate
An objective response is defined as either an unconfirmed CR or PR as determined by 
[CONTACT_26309] v1.1.  Patients not meeting these criteria, including 
patients without any post -baseline tumor assessment, will be considered 
non-responders.  
ORR is defined as the proportion of patients who had an objective response.  ORR will 
be analyzed in the tGE-WT population and the ITT-WT population.  Patients must have 
measurable disease at baseline to be included in the analysis.  An estimate of ORR and 
its 95% CI will be calculated using the Clopper -Pearson method for each treatment arm.  
CIs for the difference in ORRs between the two arms will be determined using the 
normal approximation to the binomial distribution. The ORR will be compared between 
thetwo arms using the stratified Mantel -Haenszel test.   The stratification factors of this 
analysis will be the same as those described in Section 6.4.1 .  
[IP_ADDRESS] Duration of Response
DOR will be analyzed in the tGE-WT population and the ITT-WTpopulation.  DOR will 
be assessed in patients who had an objective response as determined by [CONTACT_70163] v1.1.  DOR is defined as the time interval from the date of the 
first occurrence of a complete or partial response (whichever status is recorded first) 
until the first date that progressive disease or death is documented, whichever occurs 
first.  Patients who have not progressed and who have not died at the time of analysis 
will be censored at the time of last tumor assessment date.  If no tumor assessments 
were performed after date of the first occurrence of a complete or partial response, DOR 
will be censored at the date of the first occurrence of a complete or partial response plus 
1 day.  
DOR is based on a non -randomized subset of patients (specifically, patients who 
achieve an objective response); therefore, formal hypothesis testing will not be 
performed for this endpoint.  Comparisons between t reatment arms will be made for 
descriptive purposes.  The methodology detailed for the PFS analysis will be used for 
the analysis of DOR. 
[IP_ADDRESS] Overall Survival Rate at Landmark Timepoints
OS rate at 1 and 2 years will be analyzed in the tGE-WT population and t he ITT-WT 
population.  The OS rates at 1 and 2 years will be estimated using Kaplan -Meier 
methodology for each treatment arm, along with 95% CIs calculated using the standard 
error derived from the Greenwood formula.  The 95% CI for the difference in OS ra tes 
between the two treatment arms will be estimated using the normal approximation 
method.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
137/Protocol GO29537 , Version [IP_ADDRESS] Patient -Reported Outcomes
TTD in lung cancer symptoms as determined by [CONTACT_565765]-WT 
population and the ITT-WT population.
TTD using EORTC is defined as the time from baseline to the first time the patient’s 
score shows a 10-point increase above baseline in any of the following 
EORTC -transformed symptom subscale scores (whichever comes first):  cough, 
dyspnea (single item), dyspnea (multi -item subscale), chest pain, or arm/shoulder pain.  
A10-point change in the symptoms subscale score is perceived by [CONTACT_200057] ( Osoba et al. 1998). 
Change fro m baseline per SILC scale will be analyzed in patients with a baseline and a 
post-baseline PRO assessment.
Further details regarding all PRO analyses will be described in the Statistical Analysis 
Plan (SAP).
6.4.[ADDRESS_743103] -baseline tumor 
assessment is available, PFS will be censored at the date of randomization plus 1 day.  
Data for patients with a PFS event who missed two or more scheduled assessments 
immediately prior to the PFS event will be handled as described in the sens itivity 
analysis in Section [IP_ADDRESS]. 
For objective response, patients without any post -baseline assessment will be 
considered non -responders.
For OS, data for patients who are not reported as having died will be analyzed as 
censored observations on the date when they were last known to be alive.  If no 
post-baseline data are available, OS will be censored at the date of randomization plus 
1day. 
For DOR, data for patients who have not progressed and who have not died at the time 
of analysis will be censored at the time of last tumor assessment date.  If no tumor 
assessments were performed after the date of the first occurrence of a CR or PR, DOR 
will be censored at the date of the first occurrence of a complete or partial response plus 
1day.
For TTD usi ng EORTC, data for patients who have not deteriorated at the time of 
analysis will be censored at the last time they completed an assessment.  If no 
post-baseline assessment is performed, data for patients will be censored at the 
randomization date plus 1 day.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
138/Protocol GO29537 , Version 76.5 SAFETY ANAL YSES
For the primary treatment phase, safety analyses will include all treated patients, defined 
as randomized patients who received any amount of any component of study treatment.  
Safety data will be summarized by [CONTACT_255901] a primary safety -
evaluable population consisting of patients in the tGE-WT population and/or theITT-WT 
population (depending on the results of the primary endpoint analyses).  Safety data will 
also be summarized by [CONTACT_565766]-evaluable population.
Safety analyses for patients who entered Study GO29537 under Protocol Versions 1 [ADDRESS_743104] study drug dose will be summarized by [CONTACT_26736].  In 
addition, serious adverse events, severe adverse events (Grade 3), adverse events of 
special interest, and adverse events leading to study drug discontinuation or interruption 
will be summarized accordingly.  Multiple occurrences of the same event will be counted 
once at the maximum severity.
Laboratory data with values outside the normal ranges will be identified.  In addition, 
selected laboratory data will be summarized by [CONTACT_70165].
Changes in vital signs will be summarized by [CONTACT_2939].
Deaths reported during the study tre atment period and those reported during the 
follow -up period after treatment completion/discontinuation will be summarized by 
[CONTACT_2939].
6.5.2 Crossover Phase (For Patients Who Entered Study GO29537
under Protocol Versions 1 –4)
Crossover is no longer permitted; however, patients who were randomized to the control 
arm and who entered Study GO29537 under Protocol Versions 1 4have the option for 
crossover to atezolizumab following disease progression according to RECIST v1.1 .  
Drug exposure and safety data after receiving atezolizumab as subsequent treatment for 
the patients in the control arm will be summarized separately from the safety analyses.  
The analyses for drug exposure and adverse events described for that phase will be 
conducted.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
139/Protocol GO29537 , Version 76.6 PHA RMA COKINETIC A NALYSES
PK samples will be collected in this study as outlined in Appendix 2and Appen dix3.  
Atezolizumab serum concentration data (C minand C max) will be tabulated and 
summarized.  Descriptive statistics will include means, medians, ranges, and standard 
deviations, as appropriate.
Plasma concentrations of carboplatin and nab- paclitaxel (reported as total paclitaxel) will 
be collected in this study as outlined in Appendix 2.  The concentrations of carboplatin 
and paclitaxel will be summarized using descriptive statistics as described above.
Additional PK analyses will be conducted, as appropriate, based on the availability 
ofdata.
6.7 EXPLORA TORY ANALYSES
6.7.1 Exploratory  Analyses of Progression -Free Survival
[IP_ADDRESS] Progression -Free Survival Rate at Landmark Timepoints
The PFS rates at various timepoints (e.g., at 6 months and at 1 year after randomization) 
will be estimated using Kaplan -Meier methodology for each treatment arm, along with 
95% CIs calculated using Greenwood’s formula.  The 95% CI for the difference in PFS 
rates between the two arms will be estimated using the normal approximation method.
[IP_ADDRESS] Non–Protocol -Specified A nti-Cancer Therapy
The impact of non protocol -specified an ti-cancer therapy on PFS will be assessed 
depending on the number of patients who receive non protocol -specified anti -cancer 
therapy before a PFS event.  If 5% of patients received non protocol -specified 
anti-cancer therapy before a PFS event in any treatment arm, a sensitivity analysis will 
be performed in which data for patients who receive non protocol -specified anti -cancer 
therapy before a PFS event will be censored at the last tumor assessment date before 
receiving non protocol -specified anti -cancer therapy.
[IP_ADDRESS] Subgroup A nalysis
To assess the consistency of the study results in subgroups defined by [CONTACT_70166] 
(e.g., age, sex, and race/ethnicity), baseline prognostic characteristics (e.g., ECOG 
performance status, presence of liver metastases at baselin e), and PD -L1 tumor 
expression status, the duration of PFS in these subgroups will be examined.  Summaries 
of PFS, including unstratified HRs estimated from Cox proportional hazards models and 
Kaplan -Meier estimates of median PFS, will be produced separate ly for each level of the 
categorical variables.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
140/Protocol GO29537 , Version [IP_ADDRESS] Sensitivity Analyses 
Sensitivity analyses will be performed to evaluate the potential impact of missing 
scheduled tumor assessments on the primary analysis of PFS, as determined by [CONTACT_70167] a P FS event imputation rule.  The following two imputation rules will 
be considered:
If a patient missed two or more scheduled tumor assessments immediately prior to 
the date of the PFS even t according to RECIST v1.1, the patient will be censored at 
the last tumor assessment prior to the first of these missed visits .
If a patient missed two or more scheduled tumor assessments immediately prior to 
the date of the PFS event according to RECIST v1.[ADDRESS_743105] of these missing assessments.
The imputation rule will be applied to patients in both treatment arms.  Statistical 
methodologies analogous to those used in the primary analysis of PFS as specified in 
Section 6.4.1 will be used for this sensitivity analysis.
6.7.2 Exploratory  Analyses of Overall Survival
[IP_ADDRESS] Loss to Follow -Up
The impact of loss to follow -up on OS will be assessed depending on the number of 
patients who are lost to follow -up.  If 5% of patients are lost to follow -up for OS in either 
treatment arm, a sensitivity analysis will be performed in which patients who are lost to 
follow -up will b e considered as having died at the last date they were known to be alive.
[IP_ADDRESS] Subgroup A nalysis
To assess the consistency of the study results in subgroups defined by [CONTACT_70166] 
(e.g., age, sex, and race/ethnicity), baseline prognostic characteristics (e.g., ECOG 
performance status, presence of liver metastases at baseline), and PD -L1 tumor 
expression status, the duration of OS in these subgroups will be examined.  Summaries 
of survival, including unstratified HRs estimated from Cox proportional hazards model s 
and Kaplan -Meier estimates of median survival time, will be produced separately for 
each level of the categorical variables for the comparisons.
[IP_ADDRESS] Overall Survival Rate at Three -Year Landmark
The methodologies for landmark OS analysis that are outlined in Section [IP_ADDRESS] will 
beused.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
141/Protocol GO29537 , Version [IP_ADDRESS] Milestone Overall Survival A nalysis
To assess the effect of long -term survival and delayed clinical effects, a milestone OS 
analysis will be conducted (Chen 2015 ).  The milestone OS is an OS endpoint with 
cross- sectional assessment at a pre -specified timepoint.  The milestone OS analysis will 
be performed using the same methods as those specified for the primary OS analysis, 
and the spe cific definition of milestone will be documented in the SAP.
6.7.3 Exploratory  Biomarker A nalysis
Exploratory biomarker analyses will be performed in an effort to understand the 
association of these markers with study drug response, including efficacy and/or adv erse 
events.  The tumor biomarkers include, but are not limited to, PD -L1 and CD8, as 
defined by [CONTACT_4658], qRT- PCR, or other methods.  Additional pharmacodynamic analyses will 
be conducted as appropriate.
6.7.[ADDRESS_743106] -baseline PRO 
assessment. 
Compliance rates will be summarized by [CONTACT_565767].  Reasons for 
non-completion will be summarized if available.
6.8 INTERIM A NALYSES
6.8.1 Planned Interim A nalysis
There are no interim analyses planned for PFS in this study .  An external iDMC will be 
set up to evaluate safety data on an ongoing basis.  All summaries/analyses by 
[CONTACT_70097]’s review will be prepared by [CONTACT_70168].  Members of the 
iDMC will be external to the Sponsor and will follow a charter that outlines their roles and 
responsibilities.  Any outcomes of these safety reviews that affect study conduct will be 
communicated in a timely manner to the investigators for notification of the IRBs/ECs.  
Adetailed plan will be included in the iDMC Charter. 
If approximately [ADDRESS_743107] occurred in the ITT -WT population at the time o f 
the PFS final analysis (see criteria for final PFS analysis in Section 6.1), an interim OS 
analysis will be conducted in the ITT -WT population.  If there are significantly fewer than 
the expected 352 OS events at the final PFS analysis, a nominal of 0.01% (negligible 
impact on overall type I error rate) will be spent on the OS analysis at the time of the 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
142/Protocol GO29537 , Version 7PFS final analysis and a second interim OS analysis will then be conducted after 
approximately [ADDRESS_743108] patient is enrolled.
Stoppi[INVESTIGATOR_565734] h use 
of the Lan -DeMets approximation to the O'Brien -Fleming boundary.  The stoppi[INVESTIGATOR_565735] 18.
Table 18Analysis Timing and Stoppi[INVESTIGATOR_565736]-WTPopulation
Analysis TimingStoppi[INVESTIGATOR_109789] y:  HR (p -value)
If 0.022 If 0.025
Interim OS analy sisHR0.766
(p0.0091)HR0.771
(p0.0107)
Final OS analy sisHR0.814
(p0.0193)HR0.819
(p0.0218)
HRhazard ratio; ITT intent to treat; OS overall survival. 
Note:  values and p -values are one -sided.  The p -value will be used to claim crossing of a 
boundar y.
6.8.[ADDRESS_743109] the optional interim analysis, along with the rationale, timing, 
and statistical details for the analysis, will be documented in the Statistical Analysis Plan 
(SAP), and the SAP will be submitted to relevant health authorities at least [ADDRESS_743110] of the interim analysis.  The iDMC Charter will document potential 
recommendations the iDMC can make to the Sponsor as a result of the analysis 
(e.g., stop the study for positi ve efficacy, stop the study for futility), and the iDMC Charter 
will also be made available to relevant health authorities.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
143/Protocol GO29537 , Version 77. DATA COLLECTION A ND MANAGEMENT
7.[ADDRESS_743111] data clarification from the sites, which the sites 
will resolve electronically in the EDC system.
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laboratory data will be sent 
directly to the Sponsor, usi ng the Sponsor’s standard procedures to handle and process 
the electronic transfer of these data.
eCRFs and correction documentation will be maintained in the EDC system’s audit trail.  
System backups for data stored by [CONTACT_565768] r the study data 
will be consistent with the Sponsor’s standard procedures.
7.[ADDRESS_743112] that is att ributable, secure, and accurate, in compliance with U.S. FDA regulations 
for electronic records (21 Code of Federal Regulations, Part 11).  The data will be 
transmitted to a centralized database at the ePRO vendor.  The data from the ePRO 
devices are avail able for view access only via secure access to a W eb portal provided 
by [CONTACT_70170].  Only identified and trained users may view the data, and their 
actions become part of the audit trail.  The Sponsor will have view access only.  Regular 
data transfer s will occur from the centralized database at the vendor to the database at 
the Sponsor.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
144/Protocol GO29537 , Version 7Once the study is complete, the ePRO data, audit trail, and study and system 
documentation will be archived.  The Sponsor will receive all data entered by [CONTACT_70171] e -diary and tablet device and all study documentation.
Details regarding patient reported data and the electronic device are available in the 
Study Reference Manual.  System backups for data stored by [CONTACT_565769] a will be consistent with the Sponsor’s standard procedures.
7.4 SOURCE DA TA DOCUMENT ATION
Study monitors will perform ongoing source data verification to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by [CONTACT_565770], complete, and verifiable from source documents. 
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and o ffice charts, laboratory notes, memoranda, patient -reported outcomes, 
evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_565737] e, microfiche, photographic negatives, microfilm or magnetic media, X -rays, 
patient files, and records kept at pharmacies, laboratories, and medico- technical 
departments involved in a clinical study.
Before study initiation, the types of source documents t hat are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.6.
To facilitate source data verification, the investigators and institutions must provide the 
Sponsor direct access to applicable source documents and reports for study -related 
monitoring, Sponsor audits, and IRB/EC review.  The study site must also allow 
inspection by [CONTACT_25756].
7.5 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site’s computerized medical 
record system (i.e., in lieu of or iginal hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized dat a collection system allows preservation of the original entry 
of data.  If original data are modified, the system should maintain a viewable audit trail 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
145/Protocol GO29537 , Version 7that shows the original data, as well as the reason for the change, the name [CONTACT_565795] c hange, and the date of the change.
7.[ADDRESS_743113] to local regulations.  
No records may be disposed of without the written approval of the Sponsor.  W ritten 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to an other location.
[COMPANY_002] will retain study data for 25 years after the final Clinical Study Report has been 
completed or for the length of time required by [CONTACT_109851], whichever is longer.
8. ETHICA L CONSIDERA TIONS
8.1 COMPLIA NCE W ITH LA WS A ND REGULAT IONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the laws and 
regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the [LOCATION_002] or under a U.S. 
Investigational New Drug (IND) Application will comply with U.S. FDA regulations and 
applicable local, state, and federal laws.  Studies conducted in the European Union or 
European Economic Area will comply with the E.U. Clinical Tri al Directive (2001/20/EC).
8.2 INFORMED CONSENT
The Sponsor’s sample Informed Consent Form will be provided to each site.  If 
applicable, it will be provided in a certified translation of the local language.  The 
Sponsor or its designee must review and approve any proposed deviations from the 
Sponsor's sample Informed Consent Forms or any alternate consent forms proposed by 
[CONTACT_779] (collectively, the "Consent Forms") before IRB/EC submission.  The final 
IRB/EC approved Consent Forms must be provided to the Spo nsor for health authority 
submission purposes according to local requirements.
The Informed Consent Form will contain a separate section that addresses the use of 
remaining samples for optional exploratory research.  The investigator or authorized 
designee will explain to each patient the objectives of the exploratory research.  Pati ents 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
146/Protocol GO29537 , Version 7will be told that they are free to refuse to participate and may withdraw their specimens 
at any time and for any reason during the storage period.  A separate, specific signature 
[CONTACT_22862] a patient's agreement to allow any remaini ng specimens to 
be used for exploratory research.  Patients who decline to participate will not provide a 
separate signature.
The Informed Consent Form will also contain the following additional signature [CONTACT_1787]:
A signature [CONTACT_565796], if approved by [CONTACT_47806], to continue treatment beyond initial radiographic disease 
progression according to RECIST v1.[ADDRESS_743114] be signed and dated by [CONTACT_12718]’s legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each patient shall document t he informed consent process and that 
written informed consent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC -approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.
Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical records for each patient shall document the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.
A copy of each signed Consent Form must be provided to the patient or the patient’s 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient’s study file or in the site file and must be available for verification by [CONTACT_33483].
For sites in the [LOCATION_002], each Consent Form may also include patie nt authorization 
to allow use and disclosure of personal health information in compliance with the U.S. 
Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of personal 
health information under the HIPAA regulations, the review, approval, and other 
processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
147/Protocol GO29537 , Version 78.[ADDRESS_743115] be submitted to the IRB/EC by [CONTACT_9532] [INVESTIGATOR_25684]/EC before the study i s initiated.  
Inaddition, any patient recruitment materials must be approved by [CONTACT_1201]/EC. 
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the 
requirements, policies, and procedures established by [CONTACT_1201]/EC.  Investigators are 
also responsible for promptly informing the IRB/EC of any protocol amendments (see 
Section 9.6).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safety -related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by [CONTACT_11577]/EC, and 
archived in the site’s study file. 
8.[ADDRESS_743116] parties only as permitted by [CONTACT_25734] ( orseparate 
authorization for use and disclosure of personal health information) signed by [CONTACT_4677], unless permitted or required by [CONTACT_2371].
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsib le for the patient’s welfare, for treatment purposes.
Data generated by [CONTACT_26832] U.S. FDA and other national and local health authorities, Sponsor 
monitors, representatives, and coll aborators, and the IRB/EC for each study site, as 
appropriate.
8.5 FINA NCIA L DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accu rate 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
148/Protocol GO29537 , Version 79. STUDY DOCUMENTATION, MONIT ORING, 
ANDADMINISTRA TION
9.[ADDRESS_743117] of 
the study to be fully documented, including but not limited to the protocol, protocol 
amendments, Inform ed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes 
todata.
9.[ADDRESS_743118] on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with esta blished IRB/EC 
policies and procedures.   The Sponsor or designee will review all protocol deviations 
and assess whether any represent a serious breach of Good Clinical Practice guidelines 
and require reporting to health authorities. As per the Sponsor's s tandard operating 
procedures, prospective requests to deviate from the protocol, including requests to 
waive protocol eligibility criteria, are not allowed.
9.3 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833], patients’ medical records, and eCRFs.  The investigator will 
permit national and local health authorities, Sponsor monitors, representatives, and 
collaborators, and the IRBs/ECs to inspect facilities and records relevant to this st udy.
9.4 ADMINISTRA TIVE STRUC TURE
This study will be sponsored and managed by F. Hoffmann -La [COMPANY_002] Ltd.  
Approximately 105 sites globally will participate in the study, and approximately 
715patients will be randomized.
Randomization will occur through an IxRS.  Central facilities will be used for study 
assessments throughout the study (e.g., specified laboratory tests, and PK analyses).  
Accredited local laboratories will be used for routine monitoring; local laboratory ranges 
will be collected.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
149/Protocol GO29537 , Version 79.5 PUBLICA TION OF DATA AND PROTECTION OF 
TRADESECRETS
Regardless of the outcome of a study, the Sponsor is dedicated to openly providing 
information on the study to healthcare professionals and to the public, both at scientific 
congresses and in peer -reviewed journals. The Sponsor will comply with all 
requirements for publication of study results.  For more information, refer to the [COMPANY_002] 
Global Policy on Sharing of Clinical Trials Data at the following W eb site:
http:// www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical studies in patients involving an IMP for which a marketing authorization 
application has been filed or approved in any country, the Sponsor aims to submit a 
journal manuscript reporting primary clinical study results within [ADDRESS_743119] editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
center data.  In this case, a coo rdinating investigator will be designated by [CONTACT_231692].
Authorship will be determined by [CONTACT_109852]’ authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_26834].
Any inventions and resulting patents, improvements, and/or know -how originating fro m 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
9.6 PROTOCOL A MENDMENTS
Any protocol amendments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitte d to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact [CONTACT_3031]).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
150/Protocol GO29537 , Version 710. REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Resea rch 
and Treatment of Cancer QLQ -C30: a quality -of-life instrument for use in 
international clinical trials in oncology. J Natl Cancer Inst 1993;85:365 76.
Amit O, Mannino F, Stone AM, et al. Blinded independent central review of progression 
in cancer clinical trials: results from a meta -analysis. Eur J Cancer 
2011;47:1772 8. doi: 10.1016/j.ejca.2011.02.013. Epub: 21March 2011.
Antonia SJ, Brahmer JR, Gettinger S, et al. Nivolumab (anti -PD-1; BMS -936558, 
ONO- 4538) in combination with platinum -based doublet chemotherapy (PT -DC) in 
advanced non -small cell lung cancer (NSCLC). J Clin Oncol 2014;32:abstract 
8113.
Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll -like receptor 4- dependent contribution of 
the immune system to anti -cancer chemotherapy and radiotherapy. Nat Med 
2007;13:1050 –9.
Azzoli CG, Baker Jr S, Temin S, et al. American Society of Clinical Oncology Clinical 
Practice Guideline update on chemotherapy for stage IV non small -cell lung 
cancer. J Clin Oncol 2009;27:6251 66.
Bai S, Jorga K, Xin Y, et al. A guide to rational dosing of monoclonal antibodies. Clin 
Pharmacokinet 2012;51:119 35.
Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ -LC13: a modular 
supplement to the EORTC Core Quality of Life Questionnaire (QLQ -C30) for use in 
lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 
1994;30A:635 42.
Besse B, Johnson M, Janne PA, et al. Phase II, single -arm trial (BIRCH) of atezolizumab 
as first -line or subsequent therapy for locally advanced or metastatic 
PD-L1selected non small cell lung cancer (NSCLC) [abstract]. Eur J Cancer 
2015;51(Suppl 3):S717 18.
Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated 
with erlotinib: quality of life analysis of the National Cancer Institute of Canada 
Clinical Trials Group Study BR21. J Clin Oncol 2006;24:3831 7.
Blank C, Gajewski TF, Mackensen A. Interaction of PD -L1 on tumor cells with PD -1 on 
tumor -specific T cells as a mechanism of immune evasion: implications for tumor 
immunotherapy. Cancer Immunol Immunother 2005;54:307 14.
Blank C, Mackensen A. Contribution of the PD -L1/PD -[ADDRESS_743120] to T -cell exhaustion: 
anupdate on implications for chronic infections and tumor evasion. Cancer 
Immunol Immunother 2007;56:739 45.
Borghaei H, Paz -Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced 
nonsquamous non small -cell lung cancer. N Engl J Med. 2015;373:1627 39. 
doi:10.1056/NEJMoa1507643. Epub :27 September 2015.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
151/Protocol GO29537 , Version 7Brookmeyer R, Crowley J. A confidence interval for the median survival tim e. Biometrics 
1982;38:29 41.
Burman CF, Sonesson C, Guilbaud O, et al. A recycling framework for the construction 
of Bonferroni -based multiple tests. Stat Med 2009;28:739 61.
Butte MJ, Keir ME, Phamduy TB. Programmed death -1 ligand 1 interacts specifically
with the B7- 1 costimulatory molecule to inhibit T cell responses. Immunity 
2007;27:111 22.
Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation 
of a simple formula based on renal function. JClinOncol 1989;7:1748– 56.
Cami dge DR, Bang Y, Kwak EL, et al. Activity and safety of crizotinib in patients with 
ALK-positive non -small cell lung cancer: updated results from a phase I study. 
Lancet Oncol 2012;13:1011 9.
Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenan ce treatment in 
advanced non -small -cell lung cancer: a multicentre, randomised, 
placebo -controlled phase 3 study. Lancet Oncol 2010;11:521 9.
Cetin K, Ettinger DS, Hei YJ, et al. Survival by [CONTACT_565771] small
cell lung cancer based on data from the Surveillance, Epi[INVESTIGATOR_33407]. Clin Epi[INVESTIGATOR_5541] 2011;3:139 48.
Chen DS, Irving BA, Hodi FS. Molecular pathways: next -generation 
immunotherapy inhibiting programmed death -ligand 1 and programmed de ath-1. 
ClinCancer Res 2012;18:6580 7.
Chen TT. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint 
Inhibitors. J Natl Cancer Inst 2015;107: djv156.
Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best 
supportive care versus placebo plus best supportive care for non -small -cell lung 
cancer: a randomised, double -blind, phase 3 study. Lancet 2009;374:1432
40.
Cockcroft D W, Gault MH. Prediction of creatinine clearance from serum creatinine. 
Nephron 1976;16:31– 41.
Crino L, Kim D, Riely GJ, et al. Initial Phase II results with crizotinib in advanced 
ALK-positive non -small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 
2011;29:abstract 7514.  
D’Addario G, Fruh M, Reck M, et al. Metastatic non small -cell lung cancer: ESMO 
clinical practice guidelines for diagnosis, treatment and follow -up. Ann Oncol 
2010;21 (suppl 5):v115 –9.
De Marinis F, Rossi A, Di Maio M, et al. Treatment of advanced non -small -cell lung 
cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice 
guidelines. Lung Cancer 2011;73:1– 10.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
152/Protocol GO29537 , Version 7Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 
2009;136:260 71.
Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti CTLA -4 
antibodies across clini cal indications. Semin Oncol 2010;37:499 507.
Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology 
perspective: raising the bar for clinical trials by [CONTACT_70179]. J Clin Oncol 2014;32:1277– 80. 
European Medicines Agency. Guideline on the evaluation of anti -cancer medicinal 
products in man. EMA/CHPM/205/95/Rev.4 [Dec 2012]. 
[FDA] U.S. Food and Drug Administration. Clinical trial endpoints for the approval of 
non small cell lung cancer drugs and biologics: guidance for industry. Fed Regist 
2015;80:[ZIP_CODE] 7.
Fehrenbacher L, Spi[INVESTIGATOR_20116] A, Ballinger M, et al., for the POPLAR Study Group. 
Atezolizumab versus docetaxel for patients with previously treated non -small -cell 
lung cancer (POPLAR): a multicentre, open -label, phase 2 rand omised controlled 
trial. Lancet 2016; 387:1837 46. doi: 10.1016/S0140- 6736(16)[ZIP_CODE] -0. Epub: 10 
March 2016.
Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality 
of life (QoL) questionnaire module to supplement the EORTC core cancer QoL 
questionnaire, the QLQ -C30 in patients with pancreatic cancer. EORTC Study 
Group on Quality of Life. Eur J Cancer 1999;35:939 41.
Fukuoka M, W u YL, Thongprasert S, et al. Biomarker analyses and final overall survival 
results from a Phase III, randomized, open -label, first -line study of gefitinib versus 
carboplatin/paclitaxel in clinically selected patients with advanced non small -cell 
lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866 74.
GLOBOCAN 2008. Estimated cancer incidence: mortality, prevalence and 
disability -adjusted life years (DALYs) Worldwide in 2008. Available at: 
http://globocan.iarc.fr/factsheets/cancers/lung.asp.
Guidance for Industry. Clinical trial endpoints for the approval of cancer drugs and 
biolo gics. May 2007.
Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of 
immunotherapy agents. Ann Oncol 2010;21:1944 51.
Herbst RS, Baas P, Kim D W, et al. Pembrolizumab versus docetaxel for previously 
treated, PD -L1-positi ve, advanced non -small -cell lungcancer (KEYNOTE -010): a 
randomized controlled trial Lancet 2016; 387:1540 50. 
doi:10.1016/S0140 -6736(15)[ZIP_CODE] -7. Epub: [ADDRESS_743121] RS, Heymach JV, Lippman SM. Lung Cancer. N Engl J Med 2008;359:1367 80.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
153/Protocol GO29537 , Version 7Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the 
anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563 67.
Higgs B W, Robbins PB, Blake- Haskins JA, et al. High tumoral IFN mRNA, PD -L1 
protein, and combined IFN mRNA /PD-L1 protein expression associates with 
response to durvalumab (anti -PD-L1) monotherapy in NSCLC patients. Eur J 
Cancer 2015;51(Suppl 3):S717.
Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology 
in advanced non- small cell lung cancer: a literature review. J Thorac Oncol 
2008;3:1468 –81.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipi[INVESTIGATOR_33410]. N Engl J Med 2010;363:711 23.
Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung 
cancer: implications for the evaluation of palliative treatment. The Medical 
Research Council (MRC) Lung Cancer Working Party. Br J Cancer 
1995;71:633 6.
Horn L, Spi[INVESTIGATOR_43942], Gettinger SN, et al. Clinical activity, s afety and predictive biomarkers 
of the engineered antibody MPDL3280A (anti -PDL1) in non small cell lung cancer 
(NSCLC): update from a phase Ia study. J Clin Oncol 2015;33(suppl):abstr 8029. 
[[ZIP_CODE]].
Howlader N, Noone AM, Krapcho M, et al.  SEER Cancer Stat istics Review, 1975 2011, 
National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, 
based on November [ADDRESS_743122] 1 974;65:299 306.
Jain RK. Normalizing tumor vasculature with anti -angiogenic therapy: a new paradigm 
for combination therapy. Nat Med 2001;7:987 9.
Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Cancer 
JClin2011;61:69– 90.
Johnson DH, Fehrenbacher L, Novotny W F, et al. Randomized phase II trial comparing 
bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone 
in previously untreated locally advanced or metastatic non -small -cell lung cancer. 
JClin O ncol 2004;22:2184 91.
Kantoff P W, Higano CS, Shore ND, et al. Sipuleucel -T immunotherapy for 
castration -resistant prostate cancer. N Engl J Med 2010;363:411 22.
Keir ME, Butte MJ, Freeman GJ, et al. PD -1 and its ligands in tolerance and immunity. 
Annual Re v Immunol 2008;26:677 704.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
154/Protocol GO29537 , Version 7Koren E, Smith H W, Shores E, et al. Recommendations on risk -based strategies for 
detection and characterization of antibodies against biotechnology products. 
JImmuno Methods 2008;333:1 9.
Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the 
management of advanced non –small -cell lung cancer. J Clin Oncol 
2010;28:5311 20.
Laporte S, Squifflet P, Baroux N, et al. Prediction of survival benefits from 
progression -free survival benefits in advanced non -small ce ll lung cancer: 
evidence from a meta -analysis of 2334 patients from 5 randomized trials. BMJ 
Open 2013;3:1 6.
Liu SV, Powderly JD, Camidge DR, et al. Safety and efficacy of MPDL3280A 
(anti-PDL1) in combination with platinum -based doublet chemotherapy in pa tients 
with advanced non- small cell lung cancer. J Clin Oncol 2015;33(suppl), abstr 8030.
Merritt RE, Mahtabifard A, Yamada RE, et al. Cisplatin augments cytotoxic 
T-lymphocyte -mediated antitumor immunity in poorly immunogenic murine lung 
cancer. J Thorac Cardiovasc Surg 2003;126:1609 17.
Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, 
metastatic non -small -cell lung cancer after failure of erlotinib, gefitinib, or both, and 
one or two lines of chemotherapy (LUX -Lung 1): a phase 2b/3 randomised trial. 
Lancet Oncol 2012;12:528 38.
Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epi[INVESTIGATOR_623], risk 
factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584 94.
Mu CY, Huang JA, Chen Y, et al. High expression of PD -L1 in lung cancer may 
contribute to poor prognos is and tumor cells immune escape through suppressing 
tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682 8.
Muro K, Bang Y -J, Shankaran V, et al. Relationship between PD -L1 expression and 
clinical outcomes in patients (Pts) with advanced g astric cancer treated with the 
anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK -3475) in 
KEYNOTE -012 [abstract]. J Clin Oncol 2015;33(suppl 3; abstr 3).
National Comprehensive Cancer Network (NCCN). Guidelines for non small cell lung 
cancer 2014.
NonSmall Cell Lung Cancer Collaborative Group. Chemotherapy in non -small cell lung 
cancer: a meta -analysis using updated data on individual patients from 
52randomised clinical trials. BMJ 1995;311:899 909.
Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in 
health- related quality -of-life scores. J Clin Oncol 1998;16:139 44.
Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology 
treatment of unresectable non -small -cell lung cancer guideline: update 2003. JClin 
Oncol 2004;22:330 53.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
155/Protocol GO29537 , Version 7Pi[INVESTIGATOR_70041] R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with 
advanced non small -cell lung cancer (FLEX): an open -label randomised phase III 
trial. Lancet 2009;373:1525 31. doi: 10.1016/S0140- 6736(09)60 569-9.
Reck M, Rodríguez -Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy 
for PD -L1-positive non -small -cell lung cancer. N Engl J Med 2016;375:1823 1833. 
Epub: [ADDRESS_743123] -line therapy for nonsquamous non -small -cell lung 
cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 
2010;21:1804 9.
Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with 
either placebo or bevacizumab  as first -line therapy for nonsquamous non -small 
cell lung cancer. AVAiL. J Clin Oncol 2009;27:1227 34.
Rittmeyer A, Barlesi F, W aterkamp D, et al. Atezolizumab versus docetaxel in patients 
with previously treated non- small cell lung cancer (OAK): a phase 3, open -label, 
multicentre randomised controlled trial. Lancet 2017;389:255 65. 
doi: 10.1016/S0140 -6736(16)[ZIP_CODE] -X. Epub: [ADDRESS_743124]-line treatment for European patients with advanced EGFR mutation -positive 
non-small -cell lung cancer (EURTAC): a multicentre, open -label, randomised 
phase 3 trial. Lancet Oncol 2012;13:239 46. 
Rosenberg AS, W orobec AS. A risk -based approach to immunogenicity concerns of 
therapeutic protein products. BioPharm Intl 2004; Nov:2226;Dec:34 42.
Sandler A, Gray R, Perry MC, et al. Paclitaxel –carboplatin alone or with bevacizumab for 
non– small -cell lung cancer. N Engl J Med 2006;355:2542 50.
Sarna L, Evangelista L, Tashkin D, et al. Impact of respi[INVESTIGATOR_70071] -term survivors of non -small cell lung cancer. 
Chest 2004;125:439 45.
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus 
gemcitabine with cisplatin plus pemetrexed in chemotherapy -naive patients with 
advanced -stage non– small -cell lung cancer. J Clin Oncol 2008;26:3543– 51.
Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Onc ology Group. 
Comparison of four chemotherapy regimens for advanced non– small -cell lung 
cancer. N Engl J Med 2002;346:92 8.
Sequist LV, Yang JC -H, Yamamo N, et al. Phase III Study of Afatinib or Cisplatin Plus 
Pemetrexed in Patients W ith Metastatic Lung Ade nocarcinoma W ith EGFR 
Mutations. J Clin Oncol 2013;31:3327 38.
Shaw AT, Engelman JA. Ceritinib in ALK -rearranged non -small -cell lung cancer. N Engl 
J Med 2014;370: 25379.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
156/Protocol GO29537 , Version 7Shaw AT, Kim D W, Nakagawa K, et al. Phase III study of crizotinib versus pemetrexed 
or docetaxel in patients with advanced ALK -positive non -small cell lung cancer 
(NSCLC). European Society of Medical Oncology Meeting 2012:abstract LBA1 PR.
Seiwert TY, Haddad RI, Gupta S, et al. Antitumor activity and safety of pembrolizumab in 
patients (p ts) with advanced squamous cell carcinoma of the head and neck 
(SCCHN): preliminary results from KEYNOTE -012 expansion cohort [abstract]. J 
Clin Oncol 2015;33(suppl; abstr LBA6008).
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin
2012;62:10 29.
Smith DA, Vansteenkiste JF, Fehrenbacher L, et al. Updated survival and biomarker 
analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L 
NSCLC (POPLAR)[abstract]. J Clin Oncol 2016;34(suppl):abstr 9082.
Socinski MA, B ondarenko I, Karaseva NA, et al. Weekly nab -paclitaxel in combination 
with carboplatin versus solvent -based paclitaxel plus carboplatin as first -line 
therapy in patients with advanced non -small -cell lung cancer: final results of a 
phase III trial. J Clin O ncol 2012;30:2055 62. 
Spi[INVESTIGATOR_43942], Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II 
study (FIR) of MPDL3280A (anti -PDL1) in PD -L1selected patients with non small 
cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl; abstr 8028).
Spi[INVESTIGATOR_26189], Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in 
advanced non -small cell lung cancer: improved survival without detriment to quality 
of life. Thorax 2004;59:828 36.
Stinchcombe TE, Socinski MA, Lee CB, et al.  Considerations fo r second -line therapy 
ofnon-small cell lung cancer. Oncologist 2008;13:128 36.
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with 
metastatic non -small -cell lung cancer. N Engl J Med 2010;363:733 42.
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of 
antiPD-1 antibody in cancer. N Engl J Med 2012;366:2443 54.
Travis W D, Brambilla E, Noguchi M, et al. International association for the study of lung 
cancer/american thoracic society/european respi[INVESTIGATOR_33411]. JThorac Oncol 
2011;6:244– 85.
XALKORI®(crizotinib) U.S. Package Insert, Pf izer.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
157/Protocol GO29537 , Version 7Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX -Lung 3: a 
phase III study of afatinib versus pemetrexed and cisplatin as first -line treatment 
afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinom a 
with EGFR mutations. J Clin Oncol 2013;31:3342 –50.
Yang J, Riella LV, Chock S. The novel costimulatory programmed death ligand 1/B7.[ADDRESS_743125] is functional in inhibiting alloimmune responses in vivo. J Immunol 
2011;187:1113 9.
ZYKADIA (ceritinib) U.S. P ackage Insert, [COMPANY_001].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
158/Protocol GO29537 , Version 7Appendix 1
Schedule of A ssessments
ProcedureScreeningInduction Phase
Cycles 1 to 4 or 6
(21-Day Cycle) aMaintenance Phase
(21-Day Cycle) aTreatment 
Discontinuation
Visit Survival Follow -Up 
Days –28
to –1Day 1
(3 Days) bDay 1
(3 Days) b[ADDRESS_743126] Dose of Study 
TreatmentEvery 3 Months after 
Disease Progression or 
Loss of Clinical Benefit
Informed consent x
Tumor tissue specimen for PD -L1 testing (15 FFPE 
slides required; blocks preferred) c
Fresh or archival tissue can be usedx
ALK and/or EGFR assessment if status is unknown 
(may be done locally or centrally)x
Demographic data x
Medical history and baseline conditions x
NSCLC cancer history x
Vital signsdx xdxdx
Weight x x x x
Height x
Complete physical examination x
Limited physical examination ex x x
ECOG performance status x x x x
12-Lead ECG x x fx fx f
Hematologygx x x x
Serum chemistryhx x x x
Coagulation test (aPTT or INR) x x
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
159/Protocol GO29537 , Version 7Appendix 1
Schedule of Assessments (cont.)
ProcedureScreeningInduction Phase
Cycles 1 to 4 or 6 
(21-Day Cycle) aMaintenance Phase
(21-Day Cycle) aTreatment 
Discontinuation 
Visit Survival Follow -Up
Days –28
to –1Day 1
(3 Days)bDay 1
(3 Days)b[ADDRESS_743127] (women of childbearing -potential 
ONLY)xixjxjxj
TSH, freeT3, free T4kx xkxkx
HIV, HBV, HCV serologylx
Urinalysismx x x x
Determination of duration of induction treatment x
Induction treatment administration:
Arm A: atezolizumab carboplatin nab-paclitaxel
Arm B: carboplatin nab-paclitaxelxn
Maintenance treatment administration:
Arm A: atezolizumab
Arm B: Best supportive care (switch maintenance
to pemetrexed permitted)xn
Tumor response assessment xoxpxpxq
Serum sample for atezolizumab ATA assessment 
(atezolizumab -treated patients only)rx x x120 (30)days after last 
dose of atezolizumab
Serum sample for PK sampling (atezolizumab -
treated patients only)rx x x120 (30)days after last 
dose of atezolizumab
Carboplatin and nab -paclitaxel PK sampling 
(20patients per arm)rx
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
160/Protocol GO29537 , Version 7Appendix 1
Schedule of A ssessments (cont.)
ProcedureScreeningInduction Phase
Cycles 1 to 4 or 6 
(21-Day Cycle) aMaintenance Phase
(21-Day Cycle) aTreatment 
Discontinuation 
Visit Survival Follow -Up
Days –28
to –1Day 1
(3 Days)bDay 1
(3 Days)b[ADDRESS_743128] Dose of Study 
TreatmentEvery 3 Months after 
Disease Progression or 
Loss of Clinical Benefit
Blood samples for PD bio markers r
x x x x120 (30)days after last 
dose of atezolizumab
Optional blood for DNA extraction 
(RCR only)r, sx
Informed consent to continue treatment beyond 
radiographic progression (Arm A 
atezolizumab -treated patients)At time of radiographic progression
Tumor biopsy At time of radiographic progressiont
Optional tumor biopsy at other timepoints 
(RCR only)Any time during study treatment or during survival follow-up
Adverse eventsux x x x x
Concomitant medications From 
7days 
before 
screeningx x x
Patient -reported outcomesvxvxvxv
Survival and anti -cancer therapy follow -upwx
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
161/Protocol GO29537 , Version 7Appendix 1
Schedule of Assessments (cont.)
ATAanti-therapeutic antibody; ECOG Eastern Cooperative Oncology Group; EORTC European Organization for Research and Treatment of Cancer; 
ePRO electronic Patient -Reported Outcome; EQ -5D-3LEuro QoL5 Dimensions 3 -Level Version ; FFPE formalin-fixed, paraffin -embedded; HBcAb hepatitis 
B core antibody; HBV hepatitis B virus; HCV hepatitis C virus; IV intravenous; LC13 Lung Cancer module; NSCLC nonsmall cell lung cancer; 
PDpharmacodynamic; PGIS Patient Global Impression of Severity; PK pharmacokinetic; QLQ -C30Quality -of-Life Questionnaire Core 30; RCR [COMPANY_002] 
Clinical Repository; SILC Symptoms in Lung Cancer; TSH thyroid -stimulating hormone.
Notes:  Patients who are randomized to Arm B who received erlotinib switch maintenance allowed under Study GO29537 Protocol Versions 1 4,or who receive 
pemetrexed switch maintenance, will continue with cycle visits at the same frequency as those patients randomized to Arm A until disease progression, 
withdrawal of consent, death, or study termination by [CONTACT_1034], whichever occurs first.
The same treatment -phase schedule of assessments and procedures will apply to the crossover patients, i.e., patients will begin on Cycle 1 (now called Cycle 1A) 
and will follow the same assessments and procedures as outlined in this protocol for this cycle (with the exception of an alternate schedule for PK and 
pharmacodynamic assessments (see Appendix 3) and a biopsy upon progression will not be requested for these patients), as well as for all subsequent cycles 
(i.e., Cycle 2, which will now be called Cycle 2A, etc.).  In addition, patients who entered Study GO29537 under Protocol Version s 1[ADDRESS_743129] progression sch edule (i.e., SILC monthly for the first 6 months only and EORTC QLQ -C30 , QLQ ,LC13 and EQ-5D -3L 
at 3 and 6 months only).
aAssessments should be performed before study drug infusion unless otherwise noted. 
bCycle 1, Day 1, must be performed within 5 days after the patient is randomized.  Screening assessments performed 96 hours before Cycle 1, Day 1 are not 
required to be repeated for Cycle 1, Day 1 .  In addition, ECOG performance status, limited physical examination, and local laboratory tests may be performed 
96 hours before Day 1 of each cycle as specified in Section [IP_ADDRESS] .
cIf a representative FFPE tumor specimen in paraffin block (preferred) or 15 (or more ) freshly cut, unstained sections on slides from an FFPE tumor specimen 
are not available for PD -L1 testing, contact [CONTACT_565772].  Fine -needle aspi[INVESTIGATOR_1516] 
(defined as a samples that do not preserve tissue architecture and yield cell suspension and/or cell smears ), brushing, cell pellets from pleu ral effusion, and 
lavage samples are NOT acceptable.  For core -needle biopsy specimens, at least three cores should be submitted for evaluation.  Retrieval of archival tumor 
sample may occur outside the 28-day screening period prior to enrollment.  See Sec tion 4.1.1 , Inclusion Criteria, and Section [IP_ADDRESS] . 
dVital signs include pulse rate, respi[INVESTIGATOR_697], blood pressures, and temperature.  Vital signs should be recorded as described in Section 4.5.4 .
eSymptom -directed physical examinations; see Section 4.5.3 for details. 
fECG recordings will be obtained when clinically indicated.
gHematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with differential (neutrophils, lymphocytes, eosinophils, monocytes, 
basophils, and other cells), and platelet count.  Hematology tests must be performed prior to Day 1 infu sions and for nab -paclitaxel administration, also prior to 
Day 8 and Day 15 infusions. See Section [IP_ADDRESS] (Table 11) for dose modifications due to hematologic toxicities.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
162/Protocol GO29537 , Version 7Appendix 1
Schedule of A ssessments (cont.)
hSerum chemistry includes BUN or urea, creatinine, sodium, potassium, magnesium, chloride, bicarbonate or total CO 2, calcium, phosphorus, glucose, 
total bilirubin, ALT, AST, alkaline phosphatase, LDH, total protein, and albumin. See Section [IP_ADDRESS] (Table 15) for carboplatin and nab -paclitaxel dose 
modification management due to serum chemist ry toxicities.
iSerum pregnancy test within 14 days before Cycle 1, Day 1.
jUrine pregnancy tests; if aurine pregnancy test is positive, it must be confirmed by a serum pregnancy test.
kThyroid -function testing (thyroid -stimulating hormone [TSH], free T3, free T4) collected at Cycle 1, Day 1, and every fourth cycle thereafter.  Total T3 will be 
tested only at sites at sites where free T3 testing is not tested.
lAll patients will be teste d for HIV prior to the inclusion into the study, and HIV-positive patients will be excluded from the clinical study. Patients with active 
hepatitis B (chronic or acute; defined as having a positive HBsAg test result at screening) will be excluded from the study.  Patients with past or resolved HBV 
infection (defined as the presence of HBcAb and absence of HBsAg) are eligible only if their HBV DNA test is negative .  Patients with HCV will be excluded 
from the study; patients who test positive for HCV antibo dy are eligible only if polymerase chain reaction is negative for HCV RNA.
mUrinalysis by [CONTACT_5230] (specific gravity, pH, glucose, protein, ketones, and blood).
nFor atezolizumab, the initial dose will be delivered over 60 ( 15) minutes.  If the first infusion is well tolerated, all subsequent infusions may be delivered over 
30 (10)minutes.  For carboplatin nab-paclitaxel, administer nab -paclitaxel over 30 minutes followed immediately by [CONTACT_565773] 1530
minutes.  Administer nab -paclitaxel alone on Days 8 and 15.  See Section [IP_ADDRESS] for details . Atezolizumab will be delivered as monotherapy during the 
mainten ance phase (Arm A only) and for patients who cross over from Arm B (allowed under Study GO29537 Protocol Versions 14). See Section [IP_ADDRESS] for 
details .
oCT scans (with oral/IV contrast unless contraindicated) or MRI of the chest and abdomen.  A CT or MRI scan of the pelvis is required at screening and as 
clinically indicated or as per local standard of care at subsequent response evaluations.  A CT (with contrast) or MRI scan of the head must be done at 
screening to evaluate CNS metastasis in all patients.  See Section 4.5.5 for details.
pPerform every 6 weeks ( 7days) (approximately every two cycles) for 48 weeks following Cycle 1, Day 1, and then every 9 weeks ( 7 days) after the 
completion of the W eek 48 tumor assessment , regardless of treatment delays, until radiographic disease progression (loss of clinical benefit for patients 
assigned to atezolizumab who continue treatment after disease progression according to RECIST v1.1), withdrawal of consent, d eath, or study termination by 
[CONTACT_1034], whichever occurs first.  See Section 4.5.[ADDRESS_743130] v1.1 (e.g., toxicity, symptomatic 
deterioration , tumor assessments will continue at the same frequency as would have been followed if the patient had remained on study treatment until 
radiographic disease progression (loss of clinical benefit for patients treated with atezolizumab who continue treatment after disease progression according to 
RECIST v1.1 ), withdrawal of consent, death, or study termination by [CONTACT_1034] , whichever occurs first , even if thepatient starts another anti -cancer therapy 
after study treatment discontinuation.
rSee Appendix 2for detailed schedule.
sThe optional RCR whole blood sample requires an additiona l informed consent and may be collected at any time during the course of the study.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
163/Protocol GO29537 , Version 7Appendix 1
Schedule of A ssessments (cont.)
tA mandatory biopsy is required, if clinically feasible, within 40 days of radiographic progression or prior to the start of the next anti-cancer therapy, whichever is 
sooner (see Section [IP_ADDRESS] ).
uAllserious adverse events and adverse events of special interest, regard less of relationship to study treatment, will be reported until [ADDRESS_743131] dose 
of study treatment (inclusive of erlotinib [allowed under Study GO29537 Protocol Versions 1 4] or pemetrexed switch maintenance for patients randomized to 
Arm B who receive switch maintenance) or initiation of new systemic anti- cancer therapy.  All other adverse events, regardless of relationship to study 
treatment, will be reported until [ADDRESS_743132] dose of study treatment (inclusive of erlotinib [allowed under Study GO29537 Protocol Versions 1 4] or 
pemetrexed switch maintenance for patients randomized to Arm B who receive switch maintenance) or initiation of new non -protocol systemic anti -cancer 
therapy after last dose of study treatment.  After this per iod,all deaths will be reported.  In addition, the Sponsor should be notified if the investigator becomes 
aware of any serious adverse event or adverse event of special interest that is believed to be related to prior exposure to study treatment (see Section 5.6).
vEORTC QLQ -C30, EORTC QLQ -LC13, PGIS, and EQ -5D-3L questionnaires will be completed by [CONTACT_565774](s).  SILC will be completed on an ePRO device at the patient’s home on a weekly basis.  During survival follow -
up, the EORTC QLQ -C30, EORTC QLQ -LC13, and EQ -5D-3L will be completed at 3 and 6 months following disease progression or loss of clinical benefit (for 
atezolizumab -treated patients).  The SILC will be completed monthly during survival follow -up for [ADDRESS_743133] v1.1 or loss of clinical benefit (for atezolizumab-treated patients who hadcontinue d treatment with atezolizumab
after radiographic disease progression) as determined by [CONTACT_093] (unless the patient withdraws consent or the Sponsor term inates the study).   Study 
personnel should review all questionnaires for completeness before the patient leaves the investigational site.  Patients whose native language is not available 
on the ePRO device or who are deemed by [CONTACT_565775].
wSurviva l follow -up information will be collected via telephone calls, patient medical records, and/or clinic visits every [ADDRESS_743134].  All patients will b e periodically contact[CONTACT_109856] -cancer therapy information unless the patient requests to be withdrawn from follow -up (this request must be documented in the source 
documents and signed by [CONTACT_093]).  If the patient withdraws fro m the study, study staff may use a public information source (e.g., 
county records) when permissible, to obtain information about survival status only.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
164/Protocol GO29537 , Version 7Appendix 2
Schedule of Pharmacokinetic, Biomarker,
and Anti-Therapeutic Antibody  Assessments
Study Visit Time Arm A Arm B
Screening N/A Biom arkersbBiom arkersb
Cycle 1, 
Day 1ePre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Carboplatin pharmacokineticsa
nab-Paclitaxel pharmacokineticsa
Biom arkersdCarboplatin 
pharmacokineticsa
nab-Paclitaxel 
pharmacokineticsa
Biom arkersd
30 min ( 10 min) 
after end of 
atezolizumab
infusionAtezolizumab pharmacokinetics
510 min before the 
end of nab-paclitaxel 
infusionanab-Paclitaxel pharmacokineticsanab-Paclitaxel 
pharmacokineticsa
1 hr after end of nab-
paclitaxel infusionanab-Paclitaxel pharmacokineticsanab-Paclitaxel 
pharmacokineticsa
510 min before the 
end of carboplatin 
infusionaCarboplatin pharmacokineticsaCarboplatin 
pharmacokineticsa
1 hrafter end of 
carboplatin infusion aCarboplatin pharmacokineticsaCarboplatin 
pharmacokineticsa
Cycle 2, 
Day 1 
(3days)Pre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkers d Biom arkersd
Appendix 2
Schedule of Pharmacokinetic , Biomarker, 
and A nti-Therapeutic A ntibody Assessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
165/Protocol GO29537 , Version 7Study Visit Time Arm A Arm B
Cycle 3, 
Day 1 
(3days)Pre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Carboplatin pharmacokineticsa
nab-Paclitaxel pharmacokineticsa
Biom arkersd Carboplatin 
pharmacokineticsa
nab-Paclitaxel 
pharmacokineticsa
Biom arkersd
30 min ( 10 min) 
after end of 
atezolizumab
infusionAtezolizumab pharmacokinetics
510 min before the 
end of nab -paclitaxel 
infusionanab-Paclitaxel pharmacokineticsanab-Paclitaxel 
pharmacokineticsa
1 hr after end of nab -
paclitaxel infusionanab-Paclitaxel pharmacokineticsanab-Paclitaxel 
pharmacokineticsa
510 min before the 
end of carboplatin 
infusionaCarboplatin pharmacokineticsaCarboplatin 
pharmacokineticsa
1 hrafter end of 
carboplatin infusionaCarboplatin pharmacokineticsaCarboplatin 
pharmacokineticsa
Cycles 4, 8, 
and 16,
Day 1 
(3days)Pre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersd Biom arkersd
After 
Cycle16 and 
every eighth 
cycle, Day 1 
(3days)Pre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersdBiom arkersd
At time of 
fresh biopsy 
(on-treatment 
or at 
progression, 
including 
during 
follow -up)At visit Biom arkers dBiom arkersd
Appendix 2
Schedule of Pharmacokinetic , Biomarker, 
and A nti-Therapeutic A ntibody Assessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
166/Protocol GO29537 , Version 7Study Visit Time Arm A Arm B
Treatment 
discontinuation 
visitAt visit Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersdBiom arkers d
12030days 
after last dose 
of 
atezolizumabAt visit Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersd
At any 
timepoint 
during study 
(RCR consent 
required)Optional RCR blood (DNA 
extraction)cOptional RCR blood 
(DNA extraction)c
ATAanti-therapeutic antibody; RCR [COMPANY_002] Clinical Repository.
Note:  Serum pharmacokinetic samples for atezolizumab; plasma pharmacokinetic samples for 
carboplatin, and nab -paclitaxel.
aAt selected centers, 20 patients in each treatment arm will undergo the additional PK 
assessments for carboplatin and nab-paclitaxel.
bWhole blood for biomarkers.
cThe optional RCR blood sample (for DNA extraction) requires an additional informed consent 
and can be collected at any time during the course of the study.
dPlasma and serum for biomarkers.
eBiomarker sampling before Cycle 1, Day [ADDRESS_743135] 
dose of steroids.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
167/Protocol GO29537 , Version 7Appendix 3
Schedule of Pharmacokinetic, Biomarker, and Anti-Therapeutic
Antibody Assessments for A rm B Patients Who Cross Over to 
Receive Atezolizumab as A llowed under Protocol Versions 14
Study Visit Time Arm B Crossover Patients
Cycle 1A, 
Day 1Pre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersa
30 min ( 10 min) after 
end of atezolizumab
infusionAtezolizumab pharmacokinetics
Cycle 2A, 
Day 1 ( 3days)Pre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersb 
Cycle 3A, 
Day 1 ( 3days)Pre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersb 
30 min ( 10 min) after 
end of atezolizumab
infusionAtezolizumab pharmacokinetics
Cycles 4A, 8A, 
and 16A, Day 1 
(3days)Pre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersb 
After Cycle 16A, 
every eighth 
cycle, Day 1 
(3days)Pre-dose (same day 
as treatment 
administration)Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersb
Treatment 
discontinuation 
visitAt visit Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersb
12030days 
after last dose of 
atezolizumabAt visit Atezolizumab ATA
Atezolizumab pharmacokinetics
Biom arkersb
ATAanti-therapeutic antibody.
Notes:  Serum pharmacokinetic samples for atezolizumab.
aPlasma, serum, and whole blood for biomarkers.
bPlasma and serum for biomarkers.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
168/Protocol GO29537 , Version 7Appendix 4
American Joint Committee on Cancer
Non Small Cell Lung Cancer Staging, 7th Edition

Appendix 4
American Joint Committee on Cancer 
Non Small Cell Lung Cancer Staging, 7th Edition (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
169/Protocol GO29537 , Version 7Reference:  Lung. In: Edge S, By[CONTACT_3238], Compton CC, et al., editors. AJCC Cancer Staging 
Manual, Seventh Edition. Chicago: Springer, 2010:267 –70.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
170/Protocol GO29537 , Version 7Appendix 5
Response Evalua tion Criteria in Solid Tumors:  
Modified Excerpt from Original Publication
Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), 
Version 1.11are presented below, with slight modifications and the addition of 
explanatory text as needed for clarity.2
MEA SURA BILITY OF TUM OR AT BASELINE
DEFINITIONS
At baseline, tumor lesions/lymph nodes will be categorized measurable or 
non-measurable as follows.
a.Measurable Tumor Lesions
Tumor Lesions.   Tumor lesions must be accurately measured in at least one dimension 
(longest diameter in the plane of measurement is to be recorded) with a minimum 
sizeof:
[ADDRESS_743136] or MRI scan (CT/MRI scan slice thickness/interval no greater 
than 5mm)
10-mm caliper measurement by [CONTACT_12148] (lesions that cannot be 
accurately measured with calipers should be recorded as non- measurable)
[ADDRESS_743137] be 15 mm in the short axis when assessed by [CONTACT_70182] (CT scan 
slice thickness recommended to be no greater than 5 mm).  At baseline and in follow -up, 
only the short axis will be measured and followed.  See also notes below on “Baseline 
Documentation of Target and Non -Target Lesions” for information on lymph node 
measurement.
b.Non- Measurable Tumor Lesions
Non-measurable tumor lesions encompass small lesions (longest diameter 10mm or 
pathological lymph nodes with 10 to 15 mm short axis), as well as truly 
non-measurable lesions.  Lesions considered truly non -measurable include  
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal 
                                           
1Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumors: Revised RECIST guideline (Version 1.1). Eur J Cancer 2009; 45:228 47.
2For consistenc ywithin this document, the section numbers and cross -references to other 
sections within the article have been deleted and minor formatting changes have been made.
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
171/Protocol GO29537 , Version 7masses/abdominal organomegaly identified by [CONTACT_33486].
c.Special Considerations Regarding Lesion Measurability
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below.
Bone lesions:
Bone scan, positron emission tomography (PET) scan, or plain films are not 
considered adequate imaging techniques to me asure bone lesions.  However, these 
techniques can be used to confirm the presence or disappearance of bone lesions.
Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components , that can be evaluated by [CONTACT_12783] -sectional imagi ng techniques such 
asCTor MRI can be considered measurable lesions if the soft tissue component 
meets the definition of measurability described above.
Blastic bone lesions are non -measurable.
Cystic lesions:
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered malignant lesions (neither measurable nor non- measurable) since they 
are, by [CONTACT_108], simple cysts.
Cystic lesions thought to represent cystic metastases can be considered 
measurable lesions if they m eet the definition of measurability described above.  
However, if non -cystic lesions are present in the same patient, these are preferred 
for selection as target lesions.
Lesions with prior local treatment:
Tumor lesions situated in a previously irradiate d area or in an area subjected to 
other loco -regional therapy are usually not considered measurable unless there has 
been demonstrated progression in the lesion.  Study protocols should detail the 
conditions under which such lesions would be considered measurable.
TARGET LESIONS:  SPE CIFICA TIONS BY [CONTACT_109857]
a.Measurement of Lesions
All measurements should be recorded in metric notation, using calipers if clinically 
assessed.  All baseline evaluations should be performed as close as possible to the 
treatment start and never more than 4 weeks before the beginning of the treatment.
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
172/Protocol GO29537 , Version 7b.Method of Assessment
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and durin g study.  
Imaging -based evaluation should always be the preferred option.
Clinical Lesions.   Clinical lesions will be considered measurable only when they are 
superficial and 10 mm in diameter as assessed using calipers (e.g., skin nodules).
Chest X -Ray.   Chest CT is preferred over chest X -ray, particularly when progression is 
an important endpoint, since CT is more sensitive than X -ray, particularly in identifying 
new lesions.  However, lesions on chest X -ray may be considered measurable if they 
are clea rly defined and surrounded by [CONTACT_6776].
CT, MRI.   CT is the best currently available and reproducible method to measure lesions 
selected for response assessment.  This guideline has defined measurability of lesions 
on CT scan on the basis of the assumption that CT slice thickness is [ADDRESS_743138] scans with 
intravenous (IV) contrast because of allergy or renal insufficiency, the decision as to 
whether a non- contrast CT or MRI (without IV contrast) will be used to evaluate the 
patient at baseline and during the study should be guided by [CONTACT_33488].  For patients who develop 
contraindications to contrast after baseline contrast CT is done, the decision as to 
whether non- contrast CT or MRI (enhanced or non -enhanced) will be performed should 
also be based on the tumor type and the anatomic location of the disease and should be 
optimized to allow for comparison with the prior studies if possible.  Each case should be 
discussed with the radiologist to determine if substitution of these other approaches is 
possible and, if not, the patient should be considered not evaluable from that point 
forward.  Care must be taken in measurement of target lesions on a different modality 
and interpretation of non -target disease or new lesions since the same lesion may 
appear to have a different size using a new modality.
Ultrasound.   Ultrasound is not useful in assessment of lesion size and should not be 
used as a method of measurement.
Endoscopy , Laparoscopy , Tumor Markers, Cy tology , Histology.   The utilization of 
these techniques for objective tumor evaluation cannot generally be advised.
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
173/Protocol GO29537 , Version 7TUMOR RESPONSE EVA LUATION
ASSESSMENT OF OVERA LL TUMOR BURDEN A ND 
MEA SURA BLE DISEA SE
To assess objective response or future progression, it is necess ary to estimate the 
overall tumor burden at baseline and to use this as a comparator for subsequent 
measurements.  Measurable disease is defined by [CONTACT_70185], as detailed above.
BASELINE DOCUMENTA TION OF TA RGET A ND NON -TARGET LESIONS
When more than one measurable lesion is present at baseline, all lesions up to a 
maximum of five lesions total (and a maximum of two lesions per organ) representative 
of all involved organs should be identified as target lesions and will berecorded and 
measured at baseline.  This means in instances where patients have only one or two 
organ sites involved, a maximum of two lesions (one site) and fourlesions (two sites), 
respectively, will be recorded.  Other lesions (albeit measurable) in those organs will be 
recorded as non -target lesions (even if the size is 10mm by [CONTACT_3610]).
Target lesions should be selected on the basis of their size (lesions with the longest 
diameter) and be representative of all involved organs but, additionally, should lend 
themselves to reproducible repeated measurements .  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement, in which 
circumstance the next largest lesion that can be measured reproducibly should be
selected.
Lymph nodes merit special mention since they are normal anatomical structures that 
may be visible by [CONTACT_33490].  As noted above, pathological 
nodes that are defined as measurable and may be identified as target lesion s must meet 
the criterion of a short axis of [ADDRESS_743139] in which the image is obtained (for CT scan, this 
is almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal, 
or coronal).  The smaller of these measures is the short axis.  For example, an 
abdominal node that is reported as being 20 mm30 mm has a short axis of 20 mm and 
qualifies as a malignant, measurable node.  In this example, 20 mm should be recorded 
as the node measurement.  All other pathological nodes (those with short axis 10 mm 
but 15mm) should be considered non- target lesions.  Nodes that have a short axis 
10 mm are considered non -pathological and should not be recorded or followed.
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
174/Protocol GO29537 , Version 7Lesions irradiated within 3 weeks prior to Cycle 1 Day 1 m ay not be counted as target 
lesions.
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated and reported as the baseline sum of diameters.  If lymph 
nodes are to be included in the sum , then, as noted above, only the short axis is added 
into the sum.  The baseline sum of diameters will be used as a reference to further 
characterize any objective tumor regression in the measurable dimension of the disease.
All other lesions (or sites of disease), including pathological lymph nodes, should be 
identified as non -target lesions and should also be recorded at baseline.  Measurements 
are not required and these lesions should be followed as “present,” “absent,” or in rare 
cases “unequivocal prog ression.”
In addition, it is possible to record multiple non- target lesions involving the same organ 
as a single item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph 
nodes” or “multiple liver metastases”).
RESPONSE CRITERIA
a.Evaluati on of Target Lesions
This section provides the definitions of the criteria used to determine objective tumor 
response for target lesions.
Complete response (CR):  disappearance of all target lesions
Any pathological lymph nodes (whether target or non -target) must have 
reduction in short axis to 10 mm.
Partial response (PR):  at least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum of diameters
Progressive disease (PD):  at least a 20% increase in the sum of d iameters of target 
lesions, taking as reference the smallest sum on study (nadir), including baseline
In addition to the relative increase of 20%, the sum must also demonstrate 
anabsolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered progression.
Stable disease (SD):  neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum on study
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
175/Protocol GO29537 , Version 7b.Special Notes on the A ssessment of Target Lesions
Lymph Nodes.   Lymph nodes identified as target lesions should always have the actual 
short axis measurement recorded (measured in the same anatomical plane as the 
baseline examination), even if the nodes regress to 10 mm on study.  This means that 
when lymph n odes are included as target lesions, the sum of lesions may not be zero 
even if CR criteria are met since a normal lymph node is defined as having a short axis 
10mm.
Target Lesions That Become Too Small to Measure.   While on study, all lesions 
(nodal and non -nodal) recorded at baseline should have their actual measurements 
recorded at each subsequent evaluation, even when very small (e.g., 2 mm).  However, 
sometimes lesions or lymph nodes that are recorded as target lesions at baseline 
become so faint on CT scan that the radiologist may not feel comfortable assigning an 
exact measure and may report them as being too small to measure.  W hen this occurs, it 
is important that a value be recorded on the CRF as follows:
If it is the opi[INVESTIGATOR_26191], 
themeasurement should be recorded as 0 mm.
If the lesion is believed to be present and is faintly seen but too small to measure, a 
default value of 5 mm should be assigned and BML (below measurable limit) should 
be ticked.  (Note:  It is less likely that this rulewill be used for lymph nodes since 
they usually have a definable size when normal and are frequently surrounded by 
[CONTACT_12156]; however, if a lymph node is believed to be 
present and isfaintly seen but too small to measure, a default value of 5 mm should 
beassigned in this circumstance as well and BML should also be ticked.)
To reiterate, however, if the radiologist is able to provide an actual measure, that should 
be recorded, even if it is below [ADDRESS_743140] diameter for the coalesced lesion.
c.Evaluation of Non -Target Lesions
This section provides the definitions of the criteria used to determine the tumor response 
for the group of non -target lesions.  Although some non -target lesions may actually be 
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
176/Protocol GO29537 , Version 7measurable, they need not be measured and, instead, should be assessed only 
qualitatively at the timepoints specified in the protocol.
CR:  disappearance of all non -target lesions and (if applicable) nor malization of 
tumor marker level)
All lymph nodes must be non- pathological in size ( 10 mm short axis).
Non-CR/Non -PD:  persistence of one or more non- target lesion(s) and/or (if 
applicable) maintenance of tumor marker level above the normal limits
PD:  unequivocal progression of existing non -target lesions
The appearance of one or more new lesions is also considered progression.
d.Special Notes on A ssessment of Progression of Non -Target Disease
When the Patient A lso Has Measurable Disease.   In this sett ing, to achieve 
unequivocal progression on the basis of the non -target disease, there must be an overall 
level of substantial worsening in non -target disease in a magnitude that, even in the 
presence of SD or PR in target disease, the overall tumor burden has increased 
sufficiently to merit discontinuation of therapy.  A modest increase in the size of one or 
more non -target lesions is usually not sufficient to qualify for unequivocal progression 
status.  The designation of overall progression solely on the basis of change in 
non-target disease in the face of SD or PR of target disease will therefore be extremely 
rare.
When the Patient Has Only  Non -Measurable Disease.   This circumstance arises in 
some Phase III studies when it is not a criterion of study entr y to have measurable 
disease.  The same general concepts apply here as noted above; however, in this 
instance, there is no measurable disease assessment to factor into the interpretation of 
an increase in non -measurable disease burden.  Because worsening i n non -target 
disease cannot be easily quantified (by [CONTACT_108]:  if all lesions are truly non -
measurable), a useful test that can be applied when assessing patients for unequivocal 
progression is to consider if the increase in overall disease burden based on the change 
in non- measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease; that is, an increase in tumor burden 
representing an additional 73% increase in volume (which is equivalent to a 
20% increase in diameter in a measurable lesion).  Examples include an increase in 
apleural effusion from “trace” to “large” or an increase in lymphangitic disease from 
localized to widespread or may be described in protocols as “sufficient to require a
change in therapy.”  If unequivocal progression is seen, the patient should be considered 
to have had overall PD at that point.  Although it would be ideal to have objective criteria 
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
177/Protocol GO29537 , Version 7toapply to non -measurable disease, the very nature of that disease makes it impossible 
todo so; therefore, the increase must be substantial.
e.New Lesions
The appearance of new malignant lesions denotes disease progression; therefore, some
comments on detection of new lesions are important.  There are no specific criteria f or 
theidentification of new radiographic lesions; however, the finding of a new lesion 
should be unequivocal, that is, not attributable to differences in scanning technique, 
change in imaging modality, or findings thought to represent something other than tumor 
(for example, some “new” bone lesions may be simply healing or flare of preexisting 
lesions).  This is particularly important when the patient’s baseline lesions show PR or 
CR.  For example, necrosis of a liver lesion may be reported on a CT scan re port as a
“new” cystic lesion, which it is not.
A lesion identified during the study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression.
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow -up evaluation will clarify if it represents truly new disease.  If repeat scans confirm 
there is definitely a new lesion, then progression should be declared using the date of 
the initial scan.
EVALUATION OF RESPONSE
a.Timepoint Response ( Overall Response)
It is assumed that at each protocol -specified timepoint, a response assessment occurs.  
Table [ADDRESS_743141] non- measurable (therefore non -target) disease only, Table 2 is to 
be used.
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
178/Protocol GO29537 , Version 7Table 1   Timepoint Response:  Patients with Target Lesions (with 
or without Non -Target Lesions)
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non -PD No PR
CR Not evaluated No PR
PR Non-PD or not all 
evaluatedNo PR
SD Non-PD or not 
allevaluatedNo SD
Not all evaluated Non-PD No NE
PD Any Yes or no PD
Any PD Yes or no PD
Any Any Yes PD
CRcomplete response; NE not evaluable; PD progressive disease; 
PRpartial response; SD stable disease.
Table 2   Timepoint Response:  Patients with Non -Target 
Lesions Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non -PD No Non-CR/non -PDa
Not all evaluated No NE
Unequivocal PD Yes or no PD
Any Yes PD
CRcomplete response; NE not evaluable; PD progressive disease.
a“Non -CR/non -PD” is preferred over “stable disease” for non -target 
disease since stable disease is increasingly used as an endpoint for 
assessment of efficacy  in some studies; thus, assigning “stable disease” 
when no l esions can be measured is not advised.
b.Missing A ssessments and Not -Evaluable Designation
When no imaging/measurement is done at all at a particular timepoint, the patient is not 
evaluable at that timepoint.  If only a subset of lesion measurements are made at an 
assessment, usually the case is also considered not evaluable at that timepoint, u nless a 
convincing argument can be made that the contribution of the individual missing 
lesion(s) would not change the assigned timepoint response.  This would be most likely 
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
179/Protocol GO29537 , Version 7to happen in the case of PD.  For example, if a patient had a baseline sum of [ADDRESS_743142] a sum of 80 mm; the patient will have achieved PD status, regardless of the 
contribution of the missing lesion.
If one or more target lesions were not assessed either because the scan was not done 
or the scan could not be assessed because of poor image quality or obstructed view, the 
response for target lesions should be “unable to assess” since the patient is not 
evaluable.  Similarly, if one or more non -target lesions are not assessed, the response 
for non -target lesions should be “unable to assess” except where there is clear 
progression.  Overall response would be “unable to assess” if either the target response 
or the non -target response is “unable to as sess,” except where this is clear evidence of 
progression as this equates with the case being not evaluable at that timepoint.
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
180/Protocol GO29537 , Version 7Table [ADDRESS_743143] Overall Response
CR CR CR
CR PR SD, PD, or PRa
CR SD SD, provided minimum duration for SD 
was met; otherwise, PD
CR PD SD, provided minimum duration for SD 
was met; otherwise, PD
CR NE SD, provided minimum duration for SD 
was met; otherwise, NE
PR CR PR
PR PR PR
PR SD SD
PR PD SD, provided minimum duration for SD 
was met; otherwise, PD
PR NE SD, provided minimum duration for SD 
was met; otherwise, NE
NE NE NE
CRcomplete response; NE not evaluable; PD progressive disease; PR partial response; 
SDstable disease.
aIf a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, 
even disease meeting PR criteria relative to baseline, qualifies as PD at that point 
(since disease must have re appeared after CR).  Best response would depend on whether 
the minimum duration for SD was met.  However, sometimes CR may  be claimed when 
subsequent scans suggest small lesions were likely still present and in fact the patient had 
PR, not CR, at the first timepoint.  Under these circumstances, the original CR should be 
changed to PR and the best response is PR.
c.Special Notes on Response A ssessment
When nodal disease is included in the sum of target lesions and the nodes decrease to 
“normal” size ( 10mm), they may still have a measurement reported on scans.  This 
measurement should be recorded even though the nodes are normal in order not to 
overstate progression should it be based on increase in size of the nodes.  As noted 
earlier, this means that p atients with CR may not have a total sum of “zero” on the CRF.
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
“symptomatic de terioration.”  Every effort should be made to document objective 
Append ix5
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
181/Protocol GO29537 , Version 7progression even after discontinuation of treatment.  Symptomatic deterioration is not a 
descriptor of an objective response; it is a reason for stoppi[INVESTIGATOR_12003].  The 
objective respons e status of such patients is to be determined by [CONTACT_70186]- target disease as shown in Tables 1 3.
For equivocal findings of progression (e.g., very small and uncertain new lesio ns; cystic 
changes or necrosis in existing lesions), treatment may continue until the next scheduled 
assessment.  If at the next scheduled assessment progression is confirmed, the date of 
progression should be the earlier date when progression was suspecte d.
If a patient undergoes an excisional biopsy or other appropriate approach (e.g., multiple 
passes with large core needle) of a new lesion or an existing solitary progressive lesion 
that following serial sectioning and pathological examination reveals no evidence of 
malignancy (e.g., inflammatory cells, fibrosis, etc.), then the new lesion or solitary 
progressive lesion will not constitute disease progression.
In studies for which patients with advanced disease are eligible (i.e., primary disease still 
or partially present), the primary tumor should also be captured as a target or non -target 
lesion, as appropriate.  This is to avoid an incorrect assessment of CR if the primary 
tumor is still present but not evaluated as a target or non -target lesion.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
182/Protocol GO29537 , Version 7Appendix [ADDRESS_743144] been 
developed that account for the possible appearance of new lesions and allow 
radiological progression to be confirmed at a subsequent assessment.
Modified Response Evaluation Criteria in Solid Tumors (RECIST) is deriv ed from 
RECIST, Version 1.1 (v1.1) conventions3and immune -related response criteria4(irRC).  
When not otherwise specified, RECIST v1.[ADDRESS_743145] v1.1:  Summary  of Changes
RECIST v1.1Modified RECIST
New lesions after baseline Define progression New measurable lesions are 
added into the total tumor burden 
and followed.
Non-target lesions May contribute to the 
designation of overall 
progressionContribute only in the assessment 
of a complete response
Radiographic progression First instance of 20% 
increase in the sum of 
diam eters or unequivocal 
progression in non -target 
diseaseDetermined only on the basis of 
measurable disease
RECIST Response Evaluation Criteria in Solid Tumors.
A. DEFINITIONS OF MEAS URA BLE/NON -MEA SURABLE LESIONS
All measurable and non -measurable lesions should be assessed at Screening and at the 
protocol -specified tumor assessment timepoints.  Additional assessments may be 
performed, as clinically indicated for suspi[INVESTIGATOR_565738].  
                                           
3Eisenhauer et al. Eur J Cancer 2009;45: 228 47; Topalian et al. N E ngl J Med
2012;366:2443 54;and W olchok et al., Clin C an Res 2009;15:7412 20.
4Wolchok et al. Clin Can Res 2009;15:7412 20; Nishino et al. J Immunother Can 2014;2:17; 
Nishino et al. Clin Can Res 2013;19: 393643.
Appendix 6
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
183/Protocol GO29537 , Version 7A.[ADDRESS_743146] one dimension 
(longest diameter in the plane of measurement is to be recorded) with a minimum size 
as follows:
10 mm by [CONTACT_20420] (CT) or magnetic resonance imaging (MRI) scan 
(CT/MRI scan slice thickness/interval no greater than 5 mm)
10-mm caliper measurement by [CONTACT_12148] (lesions that cannot be 
accurately measured with calipers should be recorded as non- measurable)
Malignant Ly mph N odes.  To be considered pathologically enlarged and measurable, 
alymph node must be [ADDRESS_743147] scan (CT scan 
slice thickness recommended to be no greater than 5 mm).  At baseline and follow -up, 
only the short axis will be measured and followed.
A.2 NON- MEASURA BLE L ESIONS
Non-measurable tumor lesions encompass small lesions (longest diameter 10mmor 
pathological lymph nodes with short axis 10 but 15 mm), as well as truly 
non-measurable lesions.  Lesions considered t ruly non- measurable include 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal 
mass/abdominal organomegaly identified by [CONTACT_565776].
A.3 SPECIA L CONSIDERA TIONS REG ARDING LESION 
MEA SURA BILITY
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below.
Bone Lesions
Bone scan, positron emission tomography (PET) scan, or plain films are not considered 
adequate imaging techniques for measuring bone lesions.  However, these techniques 
can be used to confirm the presence or disappearance of bone lesions.
Lytic bone lesions or mixed lytic –blastic lesions, with identifiable soft tissue components, 
that can be evaluated by [CONTACT_12783] -sectional imaging techniques such as CT or MRI can be 
considered as measurable lesions if the soft tissue component meets the definition of 
measurability described above.
Blastic bone lesions are non -measurable.
Appendix 6
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
184/Protocol GO29537 , Version 7Cystic Lesions
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non -measurable) since they 
are, by [CONTACT_108], simple cysts.
Cystic lesions thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above.  However, if 
non-cystic lesions are present in the same patient, these are preferred for selection as 
target lesions.
Lesions with Prior Local Treatment
Tumor lesions situated in a previously irradiated area or in an area subjected to other 
loco-regional therapy are usually not considered measurable unless there has been 
demonstrated progression in the lesion.  Study protocols should detail the conditions 
under which such lesions would be considered measurable.
B. TUMOR RESPONSE EVA LUATION
B.1 DEFINITIONS OF T ARGET/NON -TARGET LESIONS
Target Lesions
When more than one mea surable lesion is present at baseline, all lesions up to a 
maximum of five lesions total (and a maximum of two lesions per organ) representative 
of all involved organs should be identified as target lesions and will be recorded and 
measured at baseline.  T his means that, for instances in which patients have only one 
ortwo organ sites involved, a maximum of two lesions (one site) and four lesions 
(two sites), respectively, will be recorded.  Other lesions (albeit measurable) in those 
organs will be recorded as non -target lesions (even if the size is 10mm by [CONTACT_3610]).
Target lesions should be selected on the basis of their size (lesions with the longest 
diameter) and be representative of all involved organs, but in addition, should lend 
themselves to reproducible repeated measurements .  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement, in which 
circumstance, the next largest lesion that can be measured reproducibly should be 
selected.
Lymph nodes merit special mention since they are normal anatomical structures 
thatmay be visible by [CONTACT_33490].  As noted above, 
pathological nodes that are defined as measurable and may be identified as target 
lesions must meet the criterion o f a short axis of [ADDRESS_743148] scan.  Only the short 
axis of these nodes will contribute to the baseline sum.  The short axis of the node is the 
diameter normally used by [CONTACT_48861] a node is involved by [CONTACT_70188].  
Appendix 6
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
185/Protocol GO29537 , Version 7Nodal size is normally reported as two dimensions in the plane in which the image is 
obtained (for CT, this is almost always the axial plane; for MRI, the plane of acquisition 
may be axial, sagittal, or coronal).  The smaller of these measures is the short axis.  For 
example, an abdominal node that is reported as being 20 mm30 mm has a short axis 
of 20mm and qualifies as a malignant, measurable node.  In this example, 20 mm 
should be recorded as the node measurement.  All other pathological nodes (those with 
short axis 10 m m but 15mm) should be considered non -target lesions.  Nodes that 
have a short axis of 10 mm are considered non- pathological and should not be 
recorded or followed.
Lesions irradiated within 3 weeks prior to Cycle 1 Day 1 may not be counted as target 
lesions.
Non- Target Lesions
All other lesions (or sites of disease), including pathological lymph nodes, should be 
identified as non -target lesions and should also be recorded at baseline.  Measurements 
are not required.
It is possible to record multiple non- target lesions involving the same organ as a single 
item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph nodes” or 
“multiple liver metastases”).
After baseline, changes in non -target lesions will contribute only in the assessment 
ofcomplete response (i.e., a complete response is attained only with the complete 
disappearance of all tumor lesions, including non -target lesions) and will not be used 
toassess progressive disease.
New Lesions
During the study, all new lesions identified a nd recorded after baseline must be 
assessed at all tumor assessment timepoints.  New lesions will also be evaluated for 
measurability with use of the same criteria applied to prospective target lesions at 
baseline according to RECIST, (e.g., nonlymph node lesions must be 10mm; see note 
for new lymph node lesions below).  Up to a maximum of five new lesions total (and a 
maximum of two lesions per organ), all with measurements at all timepoints, can be 
included in the tumor response evaluation.  New lesion types that would not qualify as 
target lesions according to RECIST cannot be included in the tumor response 
evaluation.
New lesions that are not measurable at first appearance but meet measurability criteria 
at a subsequent timepoint will be measured from that point on and contribute to the sum 
Appendix 6
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
186/Protocol GO29537 , Version 7of longest diameters (SLD), if the maximum number of 5 measurable new lesions being 
followed has not been reached. 
B.2 CALCULA TION OF S UM OF THE DIA METERS
A sum of the diameters (longest for non -nodal lesions, shor t axis for nodal lesions) for all 
target lesions will be calculated as a measure of tumor burden.
The sum of the diameters is calculated at baseline and at each tumor assessment for 
the purpose of classification of tumor responses.
Sum of the Diameters at Baseline:  The sum of the diameters for all target lesions 
identified at baseline prior to treatment on Day 1.
Sum of the Diameters at Tumor A ssessment :  For every on -study tumor assessment 
collected per protocol or as clinically indicated the sum of the d iameters at tumor 
assessment will be calculated using tumor imaging scans.  All target lesions selected at 
baseline and up to five new measurable lesions (with a maximum of two new lesions per 
organ) that have emerged after baseline will contribute to the sum of the diameters at 
tumor assessment.  Hence, each net percentage change in tumor burden per 
assessment with use of modified RECIST accounts for the size and growth kinetics of 
both old and new lesions as they appear.
Note:  In the case of new lymph nodes, RECIST v1.1 criteria for measurability 
(equivalent to baseline target lesion selection) will be followed.  That is, if at first 
appearance the short axis of a new lymph node lesion 15 mm, it will be considered a 
measureable new lesion and will be tracked and included in the SLD.  Thereafter, the 
lymph node lesion will be measured at subsequent timepoints and measurements will be 
included in the SLD, even if the short axis diameter decreases to 15 mm (or even 
10mm).  However, if it subsequently decreases to 10 mm, and all other lesions are 
no longer detectable (or have also decreased to a short axis diameter of 10 mm if 
lymph nodes), then a response assessment of CR may be ass igned.
If at first appearance the short axis of a new lymph node is 10 mm and 15 mm, the 
lymph node will not be considered measurable but will still be considered a new lesion. It 
will not be included in the SLD unless it subsequently becomes measurabl e (short axis 
diameter 15 mm).
The appearance of new lymph nodes with diameter 10 mm should not be considered 
pathological and not considered a new lesion.
Appendix 6
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
187/Protocol GO29537 , Version 7B.[ADDRESS_743149] measurable disease at baseline.
Complete Response (CR) :  Disappearance of all target and non -target lesions.  Lymph 
nodes that shrink to 10 mm short axis are considered normal.
Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of all 
target and all new mea surable lesions, taking as reference the baseline sum of 
diameters, in the absence of CR.
Note: the appearance of new measurable lesions is factored into the overall tumor 
burden, but does not automatically qualify as progressive disease until the sum of the 
diameters increases by 20% when compared with the sum of the diameters at nadir.
Stable Disease (SD) :  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of the diameters while 
on study.
Progressive Disease (PD) :  At least a 20% increase in the sum of diameters of all 
target and selected new measurable lesions, taking as reference the smallest sum on 
study (nadir SLD; this includes the baseline sum if that is the smallest on study).  In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least [ADDRESS_743150] tumor response.
Missing A ssessments and Not Evaluable Designation
When no imaging/measurement is done at all at a particular timepoint, the patient is 
considered not evaluable (NE) at that timepoint.  If only a subset of lesion 
measurements are made at an assessment, usually the case is also considered NE at 
that timepoint, unless a convincing argument can be made that the contrib ution of the 
individual missing lesion(s) would not change the assigned timepoint response.  This 
would only happen in the case of PD.  For example, if a patient had a baseline sum of 
50mm with three measured lesions and at follow -up only two lesions were assessed but 
Appendix 6
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
188/Protocol GO29537 , Version 7those gave a sum of [ADDRESS_743151] Timepoint Response Definitions
% Change in Sum of the DiametersaNon-Target Lesion 
Response 
AssessmentOverall Modified RECIST 
Timepoint Response
100% from baselinebCR CR
100% from baselinebNon-CR or not all 
evaluatedPR
 30% from baseline Any PR
 30% to 20% Any SD
Not all evaluated Any NE
 20%from  nadir SLD Any PD
CRcomplete response; NEnot evaluable; PD progressive disease; PR partial response; 
RECIST Response Evaluation Criteria in Solid Tumors; SD stable disease; SLD sum of the 
longest diameter.
aPercent change in sum of the diameters (including me asurable new lesions when present).
bWhen lymph nodes are included as target lesions, the % change in the sum of the 
diam eters may not be 100% even if complete response criteria are met, because a normal 
lymph node is defined as having a short axis of 10 mm.  Any pathological ly mph nodes 
(whether target or non -target) must have reduction in short axis to 10 mm in order to meet 
the definition of CR.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
189/Protocol GO29537 , Version 7Appendix 7
AntiPD-L1 Immunohistochemistry
OVERVIEW
The Ventana antiPD-L1 (SP142) rabbit monoclonal primary antibody 
immunohistochemistry (IHC) assay will be used to determine PD-L1 IHC status.  The 
antiPD-L1 (SP142) rabbit monoclonal antibody IHC assay is currently being developed 
by [CONTACT_200066] a companion diagnostic to atezolizumab.  For 
Study GO29537, the anti PD-L1 (SP142) IHC assay will be used for investigational 
purposes only.
The V entana antiPD-L1 (SP142) rabbit monoclonal primary antibody is intended for 
laboratory use in the semi -quantitative immunohistochemical assessment of the PD -L1 
protein in formalin -fixed, paraffin -embedded non small cell lung carcinoma (NSCLC) 
tissue stain ed on a Ventana BenchMark ULTRA automated slide stainer.  It is indicated 
as an aid in the selection of patients with NSCLC with locally advanced or metastatic 
disease who might benefit from treatment with atezolizumab.
This assay is for investigational us e only.  The performance characteristics of this 
product have not been established.
DEVICE DESCRIPTION
The Ventana antiPD-L1 (SP142) rabbit monoclonal primary antibody is a pre -dilute, 
ready -to-use antibody product optimized for use with the Ventana Medic al Systems 
OptiView DAB IHC Detection Kit and the OptiView Amplification Kit on Ventana Medical 
Systems automated BenchMark ULTRA platforms.  One 5- mL dispenser of anti PD-L1 
(SP142) rabbit monoclonal primary antibody contains approximately 36 g of rabbit
monoclonal antibody directed against the PD -L1 protein and contains sufficient reagent 
for 50 tests.  The reagents and the IHC procedure are optimized for use on the 
BenchMark ULTRA automated slide stainer, utilizing Ventana system software (VSS). 
SCORIN G SYSTEM
PD-L1 staining with anti PD-L1 (SP142) rabbit monoclonal primary antibody in NSCLC 
can be observed in both tumor cells and tumor -infiltrating immune cells.
Details of the criteria for PD -L1 diagnostic assessment are described in the IDI 
document.
Atezolizumab —F.Hoffmann- La [COMPANY_002] Ltd
190/Protocol GO29537 , Version 7Appendix 8
EORTC QLQ -C30

Atezolizumab —F.Hoffmann- La [COMPANY_002] Ltd
191/Protocol GO29537 , Version 7Appendix 8
EORTC QLQ -C30 (cont.)

Atezolizumab —F.Hoffmann- La [COMPANY_002] Ltd
192/Protocol GO29537 , Version 7Appendix 9
EORTC QLQ -LC13

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
193/Protocol GO29537 , Version 7Appendix 10
EQ-5D -3L

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
194/Protocol GO29537 , Version 7Appendix 10
EQ-5D -3L(cont.)

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
195/Protocol GO29537 , Version 7Appendix 10
EQ-5D -3L(cont.)

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
196/Protocol GO29537 , Version 7Appendix 11
Eastern Cooperative Oncology  Group Performance Status Scale
Grade Description
0 Fully active, able to carry on all predisease performance without restriction
1 Restricted in phy sically  strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature; e.g., light housework or office work
2 Ambulator y and capable of all self -care but unable to carry out any work 
activities; up and about 50% of waking hours
3 Capable of only limited self -care, confined to a bed or chair 50% of 
waking hours
4 Completely disabled; cannot carry on any self -care; totally confined to 
bed or chair
5 Dead
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
197/Protocol GO29537 , Version 7Appendix 12
Anaphy laxis Precautions
EQUIPMENT NEEDED
Tourniquet
Oxygen
Epi[INVESTIGATOR_33414], intravenous, and/or endotracheal use in accordance 
with standard practice
Antihistamines
Corticosteroids
Intravenous infusion solutions, tubing, catheters, and tape
PROCEDURES
In the event of a suspected anaphylactic reaction during study drug infusion, 
thefollowing procedures should be performed:
Stop the study drug infusion.
Apply a tourniquet proximal to the injection site to slow systemic absorption of study 
drug.  Do not obstruct arterial flow in the limb.
Maintain an adequate airway.
Administer antihistamines, epi[INVESTIGATOR_238], or oth er medications as required by [CONTACT_27964].
Continue to observe the patient and document observations
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
198/Protocol GO29537 , Version 7Appendix 13
Preexisting A utoimmune Diseases
Patients should be carefully questioned regarding their history of acquired or congenital 
immune deficiencies or autoimmune disease.  Patients with any history of immune 
deficiencies or autoimmune disease listed in the table below are excluded from 
participating in the stud y.  Possible exceptions to this exclusion could be subjects with a 
medical history of such entities as atopic disease or childhood arthralgias where the 
clinical suspi[INVESTIGATOR_33415].  Patients with a history of 
autoimmune- related hypothy roidism on a stable dose of thyroid replacement hormone 
may be eligible for this study.  In addition, transient autoimmune manifestations of an 
acute infectious disease that resolved upon treatment of the infectious agent are not 
excluded (e.g., acute Lyme arthritis).  Contact [CONTACT_351883].
Autoimmune Diseases and Immune Deficiencies
Acute disseminated
encephalomyelitis
Addison’s disease
Ankylosing spondylitis
Antiphospholipid antibody syndrome
Aplastic anemia
Autoimmune hemolytic anemia
Autoimmune hepatitis
Autoimmune hypoparathyroidism
Autoimmune hypophysitis
Autoimmune myocarditis
Autoimmune oophoritis
Autoimmune orchitis
Autoimmune thrombocytopenic 
purpura
Behcet’s disease
Bullous pemphigold
Chronic fatigue syndrome
Chronic inflammatory demyelinating 
polyneuropathy
Chung -Strauss syndrome
Crohn’s disease 
Derm atomyositis
Diabetes mellitus type 1Dysautonomia
Epi[INVESTIGATOR_33416]’ s syndrome
Graves’ disease
Guillain -Barré syndrome
Hashimoto’s disease
IgA nephropathy
Inflammatory bowel disease
Interstitial cystitis
Kaw asaki’s disease
Lambert -Eaton myasthenia 
syndrome
Lupus erythematosus
Lyme disease -chronic
Meniere’s syndrome
Mooren’s ulcer
Morphea
Multiple sclerosis
Myasthenia gravis
Neuromyotonia
Opsoclonus myoclonus 
syndromeOptic neuritis
Ord’s thyroiditis
Pemphigus
Pernicious anemia
Polyarteritis nodusa
Polyarthritis
Polyglandular autoimmune 
syndrome
Primary biliary cirrhosis
Psoriasis
Reiter’s syndrome
Rheumatoid arthritis
Sarcoidosis
Scleroderma
Sjögren’s syndrome
Stiff-Person syndrome
Takayasu’s arteritis
Ulcerative colitis
Vitiligo
Vogt -Kovanagi -Harada 
disease
Wegener’s granulomatosis
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
199/Protocol GO29537 , Version 7Appendix 14
Symptoms in Lung Cancer

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
200/Protocol GO29537 , Version 7Appendix 14
Symptoms in Lung Cancer (cont.)

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
201/Protocol GO29537 , Version 7Appendix 14
Symptoms in Lung Cancer (cont.)

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
202/Protocol GO29537 , Version 7Appendix 15
Patient Global Impression of Severit y

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
203/Protocol GO29537 , Version 7Appendix [ADDRESS_743152] the total number of 
induction chemotherapy cycles.  For example, if four cycles of induction chemotherapy 
were planned, but no component of chemotherapy could be administered during 
Cycle 4, Cycle 5 counts as the fourth cycle of induction chemotherapy (as shown below). 
All chemotherapy components may be withheld for up to a maximum of [ADDRESS_743153] 
one time during  the 
cycleCycle 1 Cycle 4 Cycle 3 Cycle 2
1 Cycle
All chemotherapy 
components skipped 
by 1 cycle3 Cycles 2 Cycles 2 CyclesInduction Phase
Example: 4 Cycles
2 Cycles 4 Cycles 3 Cycles
1 CycleCycle 5
All chemotherapy 
components skipped 
by 2 cycles2 Cycles 3 Cycles 2 Cycles 3 Cycles 1 Cycle 4 CyclesCycle 6
4 Cycles
Appendix 16
Additional Guidance on Chemotherapy  Administration (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
204/Protocol GO29537 , Version 7total of two consecutive or a total of three non- consecutive cycle s before chemotherapy 
should be permanently discontinued.
The recommended time window for administration of all study treatment components 
within a cycle is [ADDRESS_743154] component of 
study treatment would be more than 3 days, carboplatin should be delayed until Day 1 of 
the next cycle and nab- paclitaxel administered on Day 8 and/or Day [ADDRESS_743155] the site on how to open the appropriate visits and electronic Case Report Form 
(eCRF) so that the site can then record the interrup tion and reintroduction accordingly on 
the eCRF.
STATISTICAL ANALYSIS PLAN AMENDMENT APPROVAL 
CONFIDENTIAL  
This is an F. Hoffmann-La [COMPANY_002] Ltd document that  contains confidential information.  Nothing 
herein is to be disclosed without written consent from F. Hoffmann-La [COMPANY_002] Ltd. 
 
Atezolizumab—F. Hoffmann-La [COMPANY_002] Ltd 
Statistical Analysis Plan GO29537 STATISTICAL ANALYSIS PLAN  
TITLE: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL 
STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI PD-L1 ANTIBODY) IN 
COMBINATION WITH CARBOPLATIN  NAB-PACLITAXEL 
FOR CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV 
NON-SQUAMOUS NON SMALL CELL LUNG CANCER 
PROTOCOL NUMBER: GO29537 
STUDY DRUG: Atezolizumab (RO5541267) 
VERSION NUMBER: 4 
IND NUMBER: [ADDRESS_743156] NUMBER: 2014-003206-32 
SPONSOR: F. Hoffmann-La [COMPANY_002] Ltd 
PLAN PREPARED BY: , Ph.D. 
DATE FINAL: 19 May 2017 
DATE AMENDED Version 2:  17 October 2017 
Version 3:  13 March 2018 Version 4:  See electronic date stamp below 
 
Name                                                             [CONTACT_68230]
(UTC)
04-May-2018 17:22:12
Company Signatory

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
3/Statistical Analysis Plan GO29537   TABLE OF CONTENTS 
 
1. BACKGROUND  ............................................................................................ [ADDRESS_743157]  ..................................................... 15 
4.3 Analysis of Treatment Group Comparability  .......................... 16 
4.4 Efficacy Analysis  .................................................................... 16 
4.4.1  Primary Efficacy Endpoint  ...................................................... 16 
4.4.2  Secondary Efficacy Endpoints  ............................................... 18 
[IP_ADDRESS]  PFS and OS in the ITT Population ....................................... 18 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
4/Statistical Analysis Plan GO29537   [IP_ADDRESS]  PFS and OS in PD- L1 Expression and PD -L1 
Expression WT Populations  ............................................................... 18 
[IP_ADDRESS]  Objective Response Rate ..................................................... 18 
[IP_ADDRESS]  Duration of Response  ........................................................... 18 
[IP_ADDRESS]  OS Rate at the 1- and 2- Year Landmark 
Timepoints  .......................................................................................... 19 
[IP_ADDRESS]  Patient -Reported Outcomes  ................................................. 19 
4.4.3  Exploratory Efficacy Endpoints  .............................................. 21 
[IP_ADDRESS]  PFS, OS, ORR, and DOR in Teff -High and Teff -
High WT Populations  .......................................................................... 21 
[IP_ADDRESS]  Progression- Free Survival Rates at 6 Months 
and 1 Year  .......................................................................................... 21 
[IP_ADDRESS]  Overall Survival Rate at 3 Years  .......................................... 21 
[IP_ADDRESS]  EQ-5D-3L Health Status Data .............................................. 21 
[IP_ADDRESS]  Additional Patient -Reported Outcome Analyses  .................. 21 
4.4.4  Sensitivity Analyses  ............................................................... 22 
[IP_ADDRESS]  Missing Tumor Assessment  ................................................. 22 
[IP_ADDRESS]  Non-Proportional Hazard ...................................................... 22 
[IP_ADDRESS]  Loss to Follow -up ................................................................. 23 
[IP_ADDRESS]  Progression- Free Survival by [CONTACT_565777]  ................................................................................... 24 
4.4.5  Subgroup Analyses  ............................................................... 24 
4.5 Pharmacokinetic and Pharmacodynamic 
Analyses  ................................................................................ 24 
4.6 EXPLORATORY BIOMARKER ANALYSES ......................... 25 
4.7 Safety Analyses  ..................................................................... 25 
4.7.1  Exposure of Study Medication  ............................................... 25 
4.7.2  Adverse Events  ..................................................................... 25 
4.7.3  Laboratory Data ..................................................................... 26 
4.7.4  Vital Signs  .............................................................................. 26 
4.7.5  Anti-Drug Antibody  ................................................................ 26 
4.8 Missing Data  .......................................................................... 26 
5. REFERENCES  ........................................................................................... 27 
 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
5/Statistical Analysis Plan GO29537    LIST OF TABLES  
Table [ADDRESS_743158] OF APPENDICES 
Appendix  1 Protocol Synopsis  ....................................................................... 28 
Appendix  2 Schedule of Assessments  ........................................................... 41 
Appendix  3 Schedule of Pharmacokinetic, Biomarker, and Anti -Drug 
Antibody Assessments  ................................................................ 47 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
6/Statistical Analysis Plan GO29537   1. BACKGROUND  
This Statistical Analysis Plan (SAP) provides details of the planned analyses and 
statistical methods for Study  GO29537 (IMpower130), “A Phase III, Multicenter, 
Randomized, Open-L abel Study Evaluating the Efficacy and Safety of A tezolizumab 
(MPDL3280A, Anti −PD-L1 Antibody) in Combination with Carboplatin  + Nab-Paclitaxel  
for Chemotherapy −Naïve Patients with Stage IV Non -Squamous  Non−Small  Cell Lung 
Cancer.”  The background for the study can be found in the study protocol. 
2. STUDY DESIGN 
This is a randomized, Phase III, multicenter, open -label  study  designed to evaluate the 
efficacy and safety of atezolizumab in combination with carboplatin  + nab-paclitaxel  as 
compared with treatment with carboplatin  + nab-paclitaxel  in approximately  
715 chemotherapy −naïve patients with Stage IV non-squamous  non− small  cell lung 
cancer (NSCLC) . 
Eligible patients were  stratified by [CONTACT_4321] (male vs. female), presence of liver metastases at 
baseline (yes vs. no), and programmed death− ligand 1 (PD-L1) tumor expression by 
[CONTACT_9064] (IHC) (tumor cell [TC] 3 and any tumor -infiltrating immune cell [IC] 
vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC 0/1) tested by a central laboratory.   TC0, TC1, 
TC2, and TC3 a re defined as PD-L1 staining in < 1%,  ≥ 1% to  < 5%,  ≥ 5% to  < 50%, 
and  ≥ 50% of the TCs, respectivel y.  IC0, IC1, IC2, and IC3 are defined as 
PD-L1− stained ICs covering  < 1%,  ≥ 1% to  < 5%,  ≥ 5% to  < 10%, and  ≥ 10% of the tumor 
area, respectively.  
Eligible patients were  randomized in a 2:1 ratio to one of the following treatment 
regimens: 
• Treatment Arm A:  Atezolizumab  + carboplatin  + nab-paclitaxel  (induction: four or six  
21-day  cycles); atezolizumab (maintenance: 21- day cycles)  
• Treatment Arm B:  Carboplatin  + nab-paclitaxel  (induction: four or six 21-day  cycles); 
best supportive care, erlotinib (only for patients who started switch maintenance 
treatment under Versions 1− 4 of the protocol)  or pemetrexed 
 
Patients who were  randomi zed to Arm A may continue treatment with atezolizumab 
beyond radiographic progression by [CONTACT_565778] 1 .1 (RECIST v1.1), provided they are experiencing clinical benefit as assessed 
by [CONTACT_093] (i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by [CONTACT_200023], biopsy results [if available], and clinical status).  
In Protocol GO29537, Versions 1−4, patients who are randomized to Arm B following 
disease progression will be given the option to receive atezolizumab monotherapy provided they continue to meet crossover eligibility criteria.  In Protocol  GO29537, 
Atezolizumab—F. Hoffmann-La [COMPANY_002] Ltd 
7/Statistical Analysis Plan GO29537  Version 5 and thereafter, crossover from the control arm to the experimental arm after 
the disease progression will not be permitted, with the aim to preserve the study’s ability to potentially demonstrate treatment benefit of  atezolizumab on overall survival (OS). 
Figure 1 illustrates the study design of which details can be found in the study protocol. 
Figure 1 Study Schema 
 
AUC   area under the concentration time curve; IV   intravenously; NSCLC   nonsmall cell lung 
cancer; PD-L1   programmed death ligand 1; RECIST v.1.1   Response Evaluation Criteria in 
Solid Tumors, Version 1.1   
Patients undergo tumor assessments at baseline and every 6 weeks (   7 days) for the 
first 48 weeks following Cycle 1, Day 1, regardless of dose delays.  After 48 weeks, 
tumor assessment is required every 9 weeks (   7 days).  Patients undergo tumor 
assessments until radiographic disease progression per RECIST v1.1 or loss of clinical benefit (for atezolizumab-treated patients who continue treatment after radiographic disease progression according to RECIST v1.1), withdrawal of consent, study termination by [CONTACT_2728], or death, whichever occurs first.  Patients who discontinue 
treatment for reasons other than radiographic disease progression per RECIST v1.1 (e.g., toxicity) will continue scheduled tumor assessments until radiographic disease progression per RECIST v1.1 or loss of clinical benefit (for atezolizumab-treated patients Chemotherapy-Naive Patients with Stage IV Non-Squamous NSCLC
(n=approximately 715)
Arm A:
Atezolizumab (1200 mg IV)
+Carboplatin (AUC=6 IV)
+nab-Paclitaxel (100 mg/m2IV)
Treat with  Atezolizumab until 
Loss of Clinical Benefit Treat until 
Disease Progression per RECIST v1.1
Survival Follow-Up2:1 Randomization
Stratification Factors:
•S e x
• Liver metastases
• PD-L1 expression (by [CONTACT_109812]-L1 status)
Induction Treatment:  Four or Six, 21-Day Cycles
Arm A:
Atezolizumab
(1200 mg IV)Arm B:
Best Supportive Care
(switch maintenance to 
pemetrexed may be considered ) 
No Crossover PermittedArm B:
Carboplatin (AUC=6 IV)
+nab-Paclitaxel 
(100 mg/m2IV)
Maintenance Treatment:  Every 21 Days
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
8/Statistical Analysis Plan GO29537   who continue treatment after radiographic disease progression according to 
RECIST  v1.1), withdrawal of consent, study termination by [CONTACT_2728], or death, whichever 
occurs first, regardless of whether patients start a new anti -cancer therapy. 
The co -primary efficacy endpoints are progression-free survival (PFS) as assessed by 
[CONTACT_26309] v1.1 and OS.  See Section 2.2  for details on co-primary 
efficacy endpoints, secondary endpoints, and other endpoints such as safety, pharmacokinetic (PK), and exploratory outc ome measures . 
The primary analyses of PFS and all OS analyses  will be performed on all randomized 
patients excluding p atients with  an activating EGFR mutation or ALK translocation 
ITT−WT.  EGFR mutations include all EGFR -activating mutations in exons 18 through 21.  
See Section 4.1 for details on analysis populations . 
There are no interim analyses planned for PFS and one interim analysis planned for O S 
in this study.  See Section 2.4 for detailed analysis timing. 
An external independent Data Monitoring Committee (iDMC) will be set up to evaluate safety data on an ongoing basis . 
2.1 PROTOCOL SYNOPSIS 
The Protocol Synopsis i s in Appendix  1.  For additional details, see the Schedules of 
Assessments in  Appendix  2 and Appendix  3. 
2.2 OUTCOME MEASURES  
2.2.1 Primary Efficacy Measures  
The co-primary efficacy outcome measures for this study are the following: 
• PFS, defined as the time between the date of randomization and the date of first 
documented disease progression as determined by [CONTACT_3142]  v1.[ADDRESS_743159], in the ITT −WT 
population  
• OS, defined as the time between the date of randomization and date of death from 
any cause in the ITT− WT population  
 
2.2.2 Secondary Efficacy Measures  
The secondary efficacy outcome measures for this study are the following : 
• PFS, as determined by [CONTACT_3143] v1.1, and OS in the ITT population 
• PFS, as determined by [CONTACT_3143] v1.1, and OS in the PD-L1 expression population (as described in Section 4.1.1) , and the 
aforementioned population excluding p atients with an activating EGFR  mutation or 
ALK translocation, namely, the PD -L1 expression WT  population  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
9/Statistical Analysis Plan GO29537   • Objective response, defined as either complete response (CR) or partial response 
(PR), as determined by [CONTACT_3143] v 1.1 in the same 
populations as defined in the PFS measure: ITT −WT, ITT, PD -L1 expression, PD -L1 
expression WT; confirmation of objective response is not required 
• Duration of response ( DOR ), defined for patients with an objective response as the 
time from the first documented objective response to documented disease progression as determined by [CONTACT_3143] v1.[ADDRESS_743160], in the same populations as defined in the objective response measure: ITT− WT, ITT, PD -L1 expression, PD-L1 expression 
WT  
• OS rates at 1 and 2 years, defined as the proportion of patients alive at 1 and 
2 years after randomization estimated using Kaplan-Meier (KM) methodology in the 
same populations as defined in the OS measure:  ITT−WT, ITT, PD-L1 expression, PD-L1 expression WT  
• Time to deterioration (TTD) in patient -reported lung cancer symptoms, defined as 
time from randomization to confirmed deterioration ( 10-point  change) on the 
combined European Organization for the Research and Treatment of Cancer 
Quality of Life Questionnaire−Core  (EORTC QLQ-C30)  and supplemental  lung 
cancer module (EORTC QLQ-LC13)  symptom subscales in th e ITT− WT population  
• Change from baseline in patient-reported lung cancer symptoms (cough, dyspnea, and chest pain) on the symptom severity score of the Symptoms in Lung Cancer (SILC) scale for the ITT− WT population 
 
2.2.3 Exploratory Efficacy Measures  
The exploratory efficacy measures for this study are the following: 
• PFS, ORR, and DOR, as determined by [CONTACT_3143] v1.1, and OS in the T-effector high (Teff-high) population (with Teff gene signature [CONTACT_565797] [IP_ADDRESS], previously referred to as 
tGE) and the aforementioned population excluding patients with an activating EGFR mutation or ALK translocation, namely, the Teff-high WT 
• PFS rates at [ADDRESS_743161]  v1.1 at 
6 months  and 1 year after randomization estimated using KM methodology  
• OS rate at 3 years , defined as the proportion of patients alive at 3 years  after 
randomization estimated using KM methodology  
• Status of PD-L1− , immune-, and NSCLC-related and other exploratory biomarkers 
in archival and/or freshly obtained tumor tissues, and blood (or blood derivatives) collected before, during, or after treatment with atezolizumab or at progression and association with disease status and/or response to atezolizumab in combination with 
chemotherapy  
• Status of ICs  and other exploratory biomarkers in mandatory biopsy specimens and 
blood collected at progression  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
10/Statistical Analysis Plan GO29537   • Utility scores of the Euro QoL5 Di mensions 3−Level  Version (EQ-5D -3L) 
• Change from baseline and the number and proportion of patients with a clinically 
meaningful change in patient-reported outcomes  (PROs) of health-related quality  of 
life (HRQoL) , lung cancer− related symptoms, and health status as assessed by [CONTACT_120372]-C30  and EORTC QLQ-LC13, as described in Section [IP_ADDRESS] 
 
2.2.4 Pharmacokinetic Outcome Measures  
The PK outcome measures for this study are: 
• For patients randomized to atezolizumab  + carboplatin  + nab-paclitaxel : 
Maximum observed serum atezolizumab concentration (C max) after infusion on 
Cycle  1, Day 1 
Minimum observed serum atezolizumab concentration (C min) prior to infusion at 
selected cycles, at treatment discontinuation, and at 120 days  ( ± 30 days)  after 
the last dose of atezolizumab  
• Plasma concentrations for carboplatin ( Arms A and B)  
• Plasma concentrations for nab-paclitaxel  reported as total paclitaxel (Arms A and B) 
• For patients randomized to carboplatin  + nab-paclitaxel  who crossed over to receive 
open-label  atezolizumab  as monotherapy (allowed under Protocol  GO29537, 
Versions 1− 4): 
Cmax of serum atezolizumab after infusion on Day [ADDRESS_743162] cycle following 
crossover to atezolizumab as monotherapy  
Cmin of serum atezolizumab prior to infusion on Day 1 at selected cycles 
following crossover to atezolizumab as monotherapy, at treatment 
discontinuation, and at 120 (  ± 30 days) after the last dose of atezolizumab 
 
2.2.5 Safety Outcome Measures  
The safety outcome measures for this study are: • Incidence, nature, and severity of adverse events  graded according to the National 
Cancer Institute Common Terminology Criteria in Adverse Events, Version 4 .0 
(NCI CTCAE  v4.0) 
• Changes in vital signs  and clinical laboratory results during and following 
atezolizumab administration 
• Incidence of anti -drug antibody (ADA), also known as anti -therapeutic  antibody 
(ATA), response to atezolizumab and potential correlation with PK, 
pharmacodynamic, safety, and efficacy parameters  
 
2.3 DETERMINATION OF SAMPLE SIZE 
This study randomized approximately  715 patients .  Patients with an activating 
EGFR  mutation or ALK translocations will be excluded from the primary analysis 
populations.  There are expected to be approximately 650 patients in the ITT−WT 
population given the approximately 10% prevalence of these genetic variations. 
$WH]ROL]XPDE²)+RIIP DQQ/D5RFKH/WG
6WDWLVWLFDO$QDO\VLV3ODQ*2 7RFRQWUROWKHRYHUDOOW\SH,HUURUUDWHIRUWKHRQHVLGHGWHVW DWDRQHVLGHG DRI
DQGDRQHVLGHG DRIDUHDOORFDWHGWR3)6DQG26UHVSHFWLYHO\
7KHSULPDU\FRPSDULVRQRI3)6ZLOOEHWHVWHGDWDRQHVLGHG DOHYHORILQWKH
,77:7SRSXODWLRQ7KHSULPDU\FRPSDULVRQRI26ZLOOEHWHVWHGLQ WKH,77:7
SRSXODWLRQDWWKHDOORFDWHG DWRJHWKHUZLWKWKH DUHF\FOHGIURPWKH3)6DQDO\VLVLIWKH
3)6FRPSDULVRQLVVWDWLVWLFDOO\VLJQLILFDQW
7KH3)6DQG26DQDO\VLVKLHUDUFK\DQG DDOORFDWLRQ %XUPDQHWDO LQFOXGLQJ
SRVVLEOHDUHF\FOLQJDUHVKRZQLQ )LJXUH  
)LJXUH 3URJUHVVLRQ)UHH6XUYLYDODQG2YHUDOO6XUYLYDO$QDO\VL V+LHUDUFK\
DD$OORFDWLRQDQG D5HF\FOLQJ
,77 LQWHQWWRWUHDW26  RYHUDOOVXUYLYDO3)6  SURJUHVVLRQIUHHVXUYLYDO:7  ZLOGW\SH
D7RFRQWUROWKHRYHUDOOW\SH,H UURUUDWHIRUWKHRQHVLGHGWHVWD WDRQHVLGHGW\SH,HUURU
DDQGUDW LRRIZLOOEHDOORFDWHGWR3)6DQG 26UHVSHFWLYHO\IRU
FRPSDULVRQRI$UP$YHUVXV$UP%
26ZLOOEHWHVWHGXVLQJWKHJURXSVHTXHQWLDOPHWKRGDWWKHLQWH ULPDQGILQDO26DQDO\VHV
EDVHGRQWKH DDOORFDWHGWRWKHSULPDU\FRPSDULVRQRI26DVGHVFULEHGDERYH 
6WDWLVWLFDOVLJQLILFDQFH DWWKHLQWHULPDQGILQDODQDO\VHVRI2 6ZLOOEHWHVWHGDVGHVFULEHG
LQ6HFWLRQ 
7KHVDPSOHVL]HRIWKLVVWXG\LV EDVHGRQWKHQXPEHURIHYHQWV UHTXLUHGWRGHPRQVWUDWH
HIILFDF\ZLWKUHJDUGWRERWK3)6DQG26FRSULPDU\HQGSRLQWV 
7KHHVWLPDWHVRIWKHQXPEHURIHYH QWVUHTXLUHGWRGHPRQVWUDWHH IILFDF\ZLWKUHJDUGWR
3)6LQWKHSULPDU\FRPSDULVRQVDUHEDVHGRQWKHIROORZLQJDVVXP SWLRQV
x 2QHVLGHGVLJQLILFDQFHOHYHORILQWKH,77 :7SRSXODWLRQ
x SRZHUWRGHWHFWDQKD]DUGUDWLR+5RIFRUUHVSRQGLQ JWRDQLPSURYHPHQW
LQPHGLDQ3)6IURPPRQWKVWRPRQWKVLQWKH,77 :7SRSXODWLRQ
x 1RLQWHULPDQDO\VLVIRU3)6
x 'URSRXWUDWHRISHUPRQWKV
Į 
RQHVLGHG
3)6LQ,77:7Į  Į 
26LQ,77:7
,I6WHSLVVWDWLVWLFDOO\VLJQLILFDQW
Į RWKHUZLVHĮ 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
12/Statistical Analysis Plan GO29537   The estimates of the number of events required with regard to OS in the primary 
comparisons are based on the following assumptions : 
• One-sided significance level of 0.022 in the ITT −WT population 
• 80% power to detect an HR of 0.75, corresponding to an improvement in 
median OS from 12 months to 16 months  in the ITT −WT population  
• One OS interim analyses performed when approximately  77% of the total OS events 
required for the final analysis have occurred using the Lan-DeMets  approximation to 
the O’Brien-Fleming boundary  
• Dropout rate of 5% per [ADDRESS_743163] approximately 650 patients  in the ITT− WT 
population.  Note that the OS boundaries have been updated to use the Lan-DeMets  
approximation to the Pocock boundaries (described in Section 2.4.2) ; therefore the 
overall power for the OS in the ITT-WT  population is reduced from 80% to 77% (Table 2). 
2.4 ANALYSIS TIMING  
2.4.1 Primary Analysis Timing for PFS  
No interim analyses are planned for the co-primary endpoint of PFS in this study.  
The PFS primary analysis will be conducted at the time of the OS interim analysis 
(see Section  2.4.2).  At this timepoint, it is expected that approximately  [ADDRESS_743164] occurred in the ITT−WT  population based on the assumptions specified in 
Section 2.3.  These numbers of events correspond to a minimum detectable difference 
(MDD) in HR of approximately 0.76 in the ITT−WT  population. 
Table 1 Primary Analysis for Progression- Free Survival  
Population  Analysis Timing 
(Months from FPI)  No. of Events 
(Event Ratio, %)  MDD in Hazard  Ratio  Power, % 
ITT-WT 32 475 (73) 0.76 95 
FPI  = first patient in; ITT  = intent -to-treat; MDD  = minimum detectable difference;  WT  = wild 
type.   
2.4.[ADDRESS_743165] occurred in the ITT−WT population.  Based on the 
assumptions in Section 2.3, the OS interim analysis is expected to occur approximately  
[ADDRESS_743166] patient is randomized. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
13/Statistical Analysis Plan GO29537   The final OS analysis will be conducted when there are approximately  457 OS events  in 
the ITT− WT population.  The OS final analysis is expected to occur approximately  
[ADDRESS_743167] patient is randomized. 
The expected analysis timing for the OS interim and final analyses is shown in Table 2. 
Table 2 Analysis for Overall Survival  
Type of Analysis  Analysis Timing  ITT-WT Population  
Months from 
FPI [INVESTIGATOR_565739], %  No. of Events 
(Event Ratio, %)  Power, % a 
OS interim analysis  32 77 352 (54) 68  
OS final analysis  42 100 457 ( 70) 77 
FPI  = first patient in; ITT  = intent -to-treat; OS  = overall survival; WT  = wild type.  
a Power is calculated using one -sided α of 0.022.   
The stoppi[INVESTIGATOR_565740] α  recycling are calculated using the Lan-DeMets  approximation to the 
Pocock  boundary, assuming the specified observed number of events (352 and 457, 
respectively), and are shown in Table 3.  The p- value will be used to claim crossing of 
the boundaries.  For example, if approximately  [ADDRESS_743168] occurred in the ITT −WT 
population at the time of the OS interim analysis, statistical significance of the OS 
endpoint in ITT −WT population will be declared if p  ≤ 0.0211 when PFS has claimed 
significance in the ITT− WT population. 
Table 3 Analysis Timing and Stoppi[INVESTIGATOR_565741] -to-Treat Wild-Type Population 
Analysis  Stoppi[INVESTIGATOR_120345] (p- value)  
If α  = 0.022 If α  = 0.025 
OS interim  analysis  HR  ≤ 0.790   
(p-value  ≤ 0.0185) HR  ≤ 0.795   
(p-value  ≤ 0.0211) 
OS final analysis  HR  ≤ 0.795   
(p-value  ≤ 0.0103) HR  ≤ 0.799   
(p-value  ≤ 0.0119) 
HR  = hazard ratio;  OS  = overall surviva l. 
Note:  α and p-value  are one-sided .  
3. STUDY CONDUCT  
3.1 RANDOMIZATION ISSUES  
Randomization to the treatment and control arms will occur in a 2:1 ratio using a 
permuted-block randomization method.  Randomization will be stratified by [CONTACT_15006]:  
• Sex (male vs. female)  
• Presence of liver metastases at baseline (yes vs. no)  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
14/Statistical Analysis Plan GO29537   • PD-L1 expression by [CONTACT_4658] (TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC  0/1/2 and 
IC0/1) 
 
3.2 INDEPENDENT REVIEW F ACILITY 
An Independent Review Facility ( IRF) will be used to conduct a blinded radiology review 
of the imaging data and will provide an independent assessment of tumor response and 
progression for all patients according to a separate IRF C harter.  IRF-assessed  
endpoints may be used for sensitivity  analyses (see Section 4.4.4). 
3.[ADDRESS_743169] patient in until the time the database is loc ked and the study is unblinded for the primary PFS analysis and interim 
OS analysis .  All summaries and analyses by [CONTACT_565779].  Following the data review, the 
iDMC will pro vide a recommendation as to whether the study may continue, whether 
amendment(s) to the protocol should be implemented, or whether the study should be stopped.  The final decision will rest with the Sponsor. 
Members of the iDMC will be external to the Sponsor and will follow a separate 
iDMC  Charter  that outlines their roles and responsibilities, as well  as a detailed 
monitoring plan. 
4. STATISTICAL METHODS  
The analyses described in this SAP will supersede those specified in Protocol  GO29537 
for the purposes of a regulatory filing. 
4.1 ANALYSIS POPULATIONS 
4.1.1 Efficacy Analysis P opulations 
The randomized population or ITT population is defined as all randomized patients, 
whether or not the patient received the assigned treatment. 
The ITT− WT population is defined as the ITT population excluding p atients with an 
activating EGFR  mutation or ALK translocation. 
The PD -L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 
or IC1/2/3 population, defined as ITT patients with PD -L1 IHC TC1/2/3 or 
IC1/2/3 expression in baseline tumor tissue; PD -L1 IHC TC2/3 or IC2/3 population, 
defined as ITT patients with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor 
tissue; PD -L1 IHC TC3 or IC3 population, defined as ITT patients with PD -L1 IHC TC3 
or IC 3 expression in baseline tumor tissue.  The PD-L1 expression WT population is 
defined as the PD-L1 expression population excluding patients with an activating EGFR  
mutation or ALK translocation.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
15/Statistical Analysis Plan GO29537   Analyses of primary and select secondary efficacy endpoints will be performed in the 
PD-L1 IHC TC1/2/3 or IC 1/2/3 population and the PD -L1 IHC TC1/2/3 or IC1/2/3-WT 
population.  Analyses of primary and select secondary efficacy endpoints may be conducted in other PD-L1 expression populations and PD -L1 expression WT populations 
(e.g., TC2/3 or TC2/3-WT, TC3 or IC3-WT, TC2/3 or IC2/3, TC3 or IC3, and the 
corresponding complementary groups, as well as  TC0 and IC0-WT, TC0 and IC0) . 
The primary analyses of PFS  and all OS analyses  will be performed on the ITT−WT  
population.  Patients are grouped according to the treatment assigned at randomization, regardless of whether they received any assigned study drug. 
Objective response rate (ORR ; confirmation not required)  will be analyzed for  patients in 
the aforementioned populations who have measurable disease as assessed by 
[CONTACT_455160].  
DOR  will be assessed in patients in the aforementioned populations  who have an 
objective response and measurable disease as assessed by [CONTACT_455160].  
OS rate at the 1- and 2-year landmark time points  will be analyzed in the same 
populations as defined for the OS analyses. 
TTD analyses will be conducted on the ITT− WT population.  Change from baseline 
analysis in PROs will be performed for patients in the ITT− WT population who have both 
a non-missing baseline assessment and at least  one non-missing  post-baseline 
assessment . 
4.1.[ADDRESS_743170] 
Study enrollment, major protocol deviations , including major deviations from  
inclusion/exclusion criteria, and reasons for study termination will be summarized overall and by [CONTACT_120388].  Analysis of study conduct may also be summarized for the ITT− WT if needed.  Study treatment administration and reasons for 
discontinuation from study treatment will be summarized for the safety population.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
16/Statistical Analysis Plan GO29537   4.3 ANALYSIS OF TREATMENT GROUP COMPARABILIT Y 
Demographic characteristics, such as age, race/ethnicity, baseline disease 
characteristics (e.g., Eastern Cooperative Oncology Group [ECOG] performance status), and stratification factors (sex, presence of liver metastasis at baseline, PD-L1 tumor 
expression by [CONTACT_4658] ) will be summarized by [CONTACT_565780]− WT population.  
Other populations may also be summarized as deemed needed.  Descriptive statistics 
(mean, median, standard deviation, and range) will be presented for continuous data, and frequencies and percentages will be presented for categorical data.  
Unless otherwise stated, baseline values are the last available data obtained prior to the patient receiving the first dose of any component of study treatment on Cycle  1, Day 1. 
4.[ADDRESS_743171]-baseline information will be censored at the date of randomization plus 1 day. 
The null and alternative hypotheses regarding PFS and OS i n a population can be 
phrased in terms of the survival functions S
A(t) for the atezolizumab arm (Arm A) and 
SB(t) for the control arm (Arm B): 
H0:  SA(t) = SB(t) versus H 1:  SA(t) > SB(t) 
 
The HRs, λ A/λB where λ A, and λ B represent the hazard of having a PFS event in Arm A 
and Arm B, respectively, comparing the treatment effect between the two treatment arms  
will be estimated using a stratified Cox regression model with the same stratification 
variables used for the stratified log-rank  test, and the 95%  CI will be provided. 
For PFS and OS  analyses  in the ITT −WT population, the stratification factors will be sex 
(male vs. female), presence of liver metastases at baseline (yes vs. no), and PD-L1 
tumor expression by [CONTACT_4658] ( [TC3 and any IC, TC0/1/2 and IC2/3 combined] vs. TC0/1/2 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
17/Statistical Analysis Plan GO29537   and IC 0/1).  The stratification factors will be those used during randomization as 
recorded in the i nteractive voice/web response system.  Due to the potential risk of over -
stratification ( Akazawa et al. 1997), if at least one stratum (i.e., a combination of 
stratification factor levels across sex, presence of liver metastasis at baseline, and 
PD-L1 tumor expression by [CONTACT_565781]) has less than 1 5 events (PFS or OS events), 
the stratification factor (one of three stratification factors: sex, presence of liver 
metastasis at baseline, and PD-L1 tumor expression by [CONTACT_565781]) which contains 
the level with the smallest number of patients will be removed from the stratified analyses. The removal of the stratification factor will continue until there is no stratum 
with less than 1 5 events (PFS or OS events).  The final set of stratification factors used 
in stratified analyses will be applied to all endpoints where stratified analyses are 
planned.  The analyses based on stratification factors as recorded on the electronic 
Case Report Form  (eCRF) may  also be provided.  Results from an unstratified analysis 
will also be provided. 
Treatment comparisons will be conducted by [CONTACT_557448] A versus Arm B based on 
stratified log -rank tests in the ITT− WT population for the PFS and the OS endpoints .  For 
each comparison, analyses will be conducted according to an analysis hierarchy and an α−spending algorithm to control for the type I error rate (see Figure 2  in Section 2.3)  and 
to account for an interim analysis (see Section 2.4.2). 
To control the overall type I error rate for the one-sided test at 0.025, the hypothesis 
testing will be done at the specified significance levels in the order described below:
 
1. PFS in the ITT− WT population will be tested at α  = 0.003 (one -sided).  If the 
estimate of the HR is  < [ADDRESS_743172] is ≤  0.003, the null hypothesis will be rejected, and it will 
be concluded that atezolizumab  + carboplatin  + nab-paclitaxel  prolongs the 
duration of PFS relative to the control arm in the ITT−WT  population. 
2. α recycling from PFS to OS  will be conducted as follows : 
a) If PFS resul t is not statistically significant in the ITT −WT population, then OS 
in the ITT−WT population will be tested at α  = 0.022 (one-sided ). 
b) If PFS result is statistically significant in the ITT− WT population, then OS in 
the ITT− WT population will be tested at α  = 0.025 (one-sided ). 
 
KM methodology will be used to estimate median PFS and OS and to construct survival 
curves for each treatment arm for a visual description of the difference among arms .  
The Brookmeyer-Crowley methodolo gy will be used to construct the 95%  CI for the 
median PFS  and OS  (Brookmeyer and Crowley 1982). 
Follow -up for OS , defined as the time from randomization to death or last known date 
alive, will be summarized for all patients included in the analysis (whether patient is alive 
or has died).  Follow -up will be summarized using the KM method with data for patients 
who died censored at the date of death. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
18/Statistical Analysis Plan GO29537   4.4.2 Secondary Efficacy Endpoints 
[IP_ADDRESS] PFS and OS in the ITT Population 
PFS and OS  in the ITT populations will be analyzed using the same methods as 
described in  Section 4.4.1.  PFS and OS in patients with an activating EGFR  mutation or 
ALK translocation may be analyzed using the same methods to provide the evaluation of 
the population complementary to the ITT-WT population.  
If the difference in OS  between Arm A and Arm B in the ITT− WT population is 
statistically significant, a comparison of Arm A versus Arm B will be conducted in the 
ITT population, similarly as shown in Figure 2 .  The α  allocation will follow the same 
α-spending algorithm and allocation ratio (3:22) d escribed for analysis of the co-primary 
efficacy endpoints as described in Section 2.3.  
[IP_ADDRESS] PFS and OS in PD-L1 Expression and PD -L1 Expression WT 
Populations 
PFS and OS in the TC1/2/3 or IC1/2/3 −WT, and the TC1/2/3 or IC1/2/3 populations will 
be analyzed using similar methods as described in Section 4.4.1 .  Analyses of PFS and 
OS may be conducted in other PD -L1 expression populations and PD -L1 expression WT 
populations (e.g., TC2/3 or TC2/3-WT, TC3 or IC3-WT, TC2/3 or IC2/3, TC3 or IC3, and 
the corresponding complementary groups, as well as  TC0 and IC0-WT, TC0 and IC0) . 
[IP_ADDRESS] O bjective Response Rate 
ORR (confirmation not required) is defined as the proportion of patients with an objective response, either CR or PR, with the use of RECIST  v1.1, as determined by [CONTACT_1275].  Patients  not meeting these criteria, including those without any 
post-baseline assessment, will be considered non-responders.  Confirmation of 
response according to RECIST v1.[ADDRESS_743173].  The 95% CI for the difference in 
ORRs between the two treatment arms will be computed using the normal approximation to the binomial distribution.  An estimate of ORR and its 95% CI will be calculated for 
each treatment arm using the Clopper -Pearson method. 
[IP_ADDRESS] D uration of Response 
DOR is defined for patients with an objective response as the time from the first documented objective response to documented disease progression as determined by [CONTACT_26309] v1.1, or death from any cause, whichever occurs first.  
Data for patients who are alive and who have not experienced disease progression at the time of analysis will be censored at the date of the last tumor assessment.  If no tumor assessments were performed after the date of the first occurrence of the objective response (CR or PR), DOR will be censored at the date of the first occurrence of the objective response.  Because the determination of DOR is based on a non -randomized 
subset of patients, formal hypothesis testing will not be performed.  DOR will be 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
19/Statistical Analysis Plan GO29537   estimated using KM methodology .  Comparisons between treatment arms will be made 
using the stratified and unstratified log-rank  test for descriptive purposes only . 
Confirmation of response according to RECIST v1.1 will not be required, but for 
exploratory purposes, DOR for patients with confirmed response may be reported. 
[IP_ADDRESS] OS Rate at the 1- and 2-Year Landmark Timep oints 
The OS rate at the 1- and 2-year  landmark time points after randomization will be 
estimated for each treatment arm using KM methodology , along with 95% CI calculated 
with the standard error derived from  the Greenwood formula.  The 95% CI for the 
difference in OS rates between the two treatment arms will be estimated using the normal approximation method, with standard errors computed using the Greenwood method. 
[IP_ADDRESS] Patient-Reported Outcomes  
Through the use of the SILC scale, the EORTC QLQ- C30, and EORTC  QLQ-LC13 , lung 
cancer symptom  data will be collected about symptoms commonly associated with 
cancer treatments, and disease and treatment impact on patients’ functioning.  
The EORTC QLQ- C30 and EORTC QLQ-LC13  will be scored according to the 
EORTC  scoring manual (Fayers et al. 2001).  The QLQ-C30  and QLQ-LC13  consist  of 
both multi -item scales and single-item  measures such as functional scales, symptom 
scales, and a global health status/quality -of-life scale.  
For multi -item subscales, if  ≤ 50% of items within the multi -item  subscale are missing at a 
given timepoint, the multi -item  score will be calculated on the basis of the non-missing 
items.  If >  50% of items are missing or if a single -item  measure is missing, the subscale 
is missing.  
All EORTC scales and single-item measures will be linearly transformed so that each score has  a range of 0
 − 100.  A high score for a functional scale represents a high or 
healthy level of functioning, and a high score for the global health status and HRQoL 
represents a high HRQoL; however, a high score for a symptom scale or item represents a high level of symptomatology or problems. 
The SILC questionnaire comprises three individual symptoms (dyspnea, cough, chest 
pain) and will be scored at the individual symptom level, thus will have a dyspnea score, chest pain score, and cough score.  Each individual symptom score will be calculated as 
the average of responses for the symptom items (e.g., Chest Pain Score = mean [item 1; 
item 2]).  An increase in score is suggestive of a worsening in symptomology (i.e., 
frequency or severity).  A score change of ≥ 0.3 points for the dyspnea and cough 
symptom scores is considered to be clinically significant; whereas a score change of ≥ 0.[ADDRESS_743174]  pain score is considered to be clinically significant. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
20/Statistical Analysis Plan GO29537   Time to Deterioration in Patient -Reported Outcomes 
TTD with use of the EORTC is defined as the time from baseline to the first confirmed 
clinically meaningful deterioration in the EORTC symptom score. 
TTD will be documented for a 3-symptom composite endpoint using the following 
EORTC QLQ-LC13 symptom scores: cough, chest pain, and dyspnea multi -item scale.  
In this instance, symptom  deterioration will be determi ned as confirmed clinically 
meaningful deterioration in any of the listed symptom scores, whichever occurs first (cough, chest pain, and dyspnea multi -item scale).  Confirmed clinically meaningful 
deterioration in lung cancer symptoms is defined as a
 ≥ 10-point increase above baseline 
in a symptom score that must be held for at least two consecutive assessments or an initial ≥
 10-point increase above baseline followed by [CONTACT_279358] [ADDRESS_743175] 
assessment.  A  ≥ 10-point change in the EORTC scale score is perceived by [CONTACT_565782] (Osoba et al. 1998). 
TTD analyses will be performed for the ITT−WT  population and will include all data 
collected through disease progression and survival follow  up.  TTD analyses may be 
performed for the ITT population when a PFS or an OS benefit has been demonstrated 
for the ITT population.  The methodologies that are outlined for the analysis of OS will be 
used for the analyses of TTD for prespecified symptoms of the EORTC  QLQ- C30 and 
EORTC  QLQ-LC13 measures.  TTD of prespecified symptoms will be summarized using 
the KM method.  Comparison of TTD using the EORTC  QLQ-C30  and 
EORTC  QLQ-LC13 measures between treatment arms will be performed using the 
stratified log-rank  test; the stratified HRs and 95% CIs will  also be reported.  If no 
baseline or post-baseline assessment is performed, patients will be censored at the randomization date plus [ADDRESS_743176]-baseline data for the TTD analysis . 
Change from Baseline per SILC Scale  
Summary statistics (mean, SD, median, 25th and 75th percentiles, and range) of the change from baseline per SILC scale may  be provided.  The analysis may  be performed 
for patients in the ITT− WT population with a non-missing  baseline and a non-missing  
post-baseline PRO assessment.  Graphs of the mean changes and standard errors over time from the baseline assessment for the total score and subscales may  be provided for 
each treatment arm. 
The analysis of SILC change from baseline may  be performed at all on-t reatment 
timepoints, as well as at the time of disease progression per RECIST v1.1 
(PRO  assessment completed within
 ± 7 days  of date of radiographic disease 
progression), at the last dose of treatment received before treatment discontinuation for 
any cause, and at the survival follow -up visits through 6 months . 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
21/Statistical Analysis Plan GO29537   4.4.3 Exploratory Efficacy Endpoints  
[IP_ADDRESS] PFS, OS, ORR, and DOR in Teff- High and Teff -High WT 
Populations 
The Teff-high  (−1.91) population is defined as the ITT patients with a Teff signature 
[INVESTIGATOR_32005]  ≥ −1.91 in baseline tumor tissues .  The Teff-high (− 0.91) population is defined as 
ITT patients with a Teff signature [INVESTIGATOR_32005] ≥− 0.91 in baseline tumor tissues .  The Teff-high 
(−2.38) population is defined as ITT patients with a Teff signature [INVESTIGATOR_32005] ≥− 2.38 in 
baseli ne tumor tissues .  The Teff-high (− 2.93) population is defined as ITT patients with 
a Teff signature [INVESTIGATOR_32005] ≥− 2.93 in baseline tumor tissues .  The Teff signature [CONTACT_565798]-L1 (CD274), CXCL9, and interferon-gamma 
(IFN-γ) genes  relative to a reference gene using RNA isolated from the patient’s 
formalin− fixed paraffin- embedded tumor tissue, as measured using a quantitative real -
time polymerase chain reaction on a [COMPANY_002] Molecular System Cobas [ADDRESS_743177] v1.1, and 
OS in the Teff-high and Teff-high WT populations may not be included in the Clinical 
Study Report (CSR) for this study.  
[IP_ADDRESS] Progression- Free Survival  Rates at 6 Months and 1 Year 
PFS rates at 6 months and 1 year will be estimated and analyzed using the same method as described in  Section [IP_ADDRESS].  
[IP_ADDRESS] Overall Survival Rate at 3 Years 
OS rate at 3 years will be estimated and analyzed using the same method as described in Section [IP_ADDRESS].  
[IP_ADDRESS] EQ-5D-3L Health Status Data 
The EQ-5D -3L questionnaire will also be collected to generate HRQoL and utility scores 
for use in economic models for reimbursement. 
Health status is assessed by [CONTACT_20367]-5D -3L.  For the EQ-5D -3L health-state profiles, 
descriptive statistics that summarize the proportions of patients who reported having “no,” 
“some,” or “extreme” problems at each timepoint will be reported.  Frequencies and percentages of missing data will also be reported at each timepoint.  Patients without post-baseline assessments will be excluded from this analysis.  A single summary index 
from the EQ-5D -3L health status will be used in this study for economic modeling.  This 
analysis will not be included in the CSR for this study. 
[IP_ADDRESS] Additional Patient -Reported Outcome Analyses  
EORTC score  changes from baseline will be descriptively analyzed using means, SDs, 
medians, and range by [CONTACT_565783] a baseline assessment and at 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
22/Statistical Analysis Plan GO29537   least one post -baseline assessment .  The analyses will be performed at timepoints 
similar to those used for the analyses of change from baseline per SILC scale.  
TTD may also be documented for each of the following individual lung cancer symptoms  
(i.e., cough, dyspnea, chest pain)  with use of the EORTC. 
To help interpret the results from the change from baseline analyses, the number and 
proportion of patients with a clinically meaningful change may be summarized by [CONTACT_2939], for the EORTC QLQ -C30 global health status and physical function scale 
scores and for the SILC cough, chest pain, and dyspnea scale scores at each cycle post-baseline. 
Compliance rates will be summarized by [CONTACT_565784] -evaluable subset who completed the PRO assessments at each timepoint by 
[CONTACT_2939].  Reasons for non-completion will be summarized if available in the CRF.  
Thes e additional PRO analyses may not be included in the CSR for this study. 
4.4.4 Sensitivity Analyses  
[IP_ADDRESS] Missing Tumor Assessment  
The impact of missing scheduled tumor assessments on PFS will be assessed depending on the number of patients who missed assessments scheduled immediately prior to the date of disease progression per RECIST v1.1 or the data cutoff.  If
 > 5% of 
patients missed two or more assessments scheduled immediately prior to the date of disease progression per RECIST v1.1 or death in any treatment arm, the following two sensitivity analyses will be performed: 
• Patients who missed two or more scheduled assessments immediately prior to the 
date of disease progression per RECIST v1.[ADDRESS_743178] tumor assessment prior to the missed visits.  
• Patients who missed two or more scheduled assessments immediately prior to the date of disease progression per  RECIST v1.[ADDRESS_743179] of these missing assessments.  
 
Statistical methodologies analogous to those used in the primary analysis of PFS as 
specified in Section [IP_ADDRESS] will be used for this sensitivity analysis.  
[IP_ADDRESS] Non-Proportional Hazard 
Non −Protocol -Specified Anti-Cancer Therapy  
The impact of non− protocol -specified anti-cancer therapy (NPT) on PFS as determined 
by [CONTACT_565785], depending on the number of patients who received NPT before a PFS event.  If
 > 5% of patients received NPT  before a PFS event in the 
control arm, a sensitivity analysis may be performed for the comparisons between two 
treatment arms in which data from patients who receive NPT  before a PFS event will be 
censored at the last tumor assessment date before receipt of NPT . 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
23/Statistical Analysis Plan GO29537   The impact of subsequent NPT on OS will be assessed depending on the number of 
patients who received NPT.  If  > 10% of patients received a NPT in the control arm, the 
following analyses may be performed to compare treatment arms: 
• The discount method uses a ‘discounted’ survival time after switching for patients 
who switch treatments based on a user -specified assumption for the effect on OS.  
OS may  be discounted according to a range of possible effects on OS of the 
subsequent NPT after treatment switching occurred (e.g., 10%, 20%, 30%, etc.).  
• Rank preserving structural  failure time provides an estimate of the OS time for the 
control group had NPT not occurred ( Robins and Tsiatis 1991) .  It estimates OS 
measured from the time of NPT by [CONTACT_565786] .  
The total OS time (sum of time to NP T and the estimated survival time after NPT 
started) may then be analyzed using the same methodology as for the primary 
analysis of OS.  
• The inverse probability of censoring weighting method censors patients at start of NPT and uses the control arm patients to create  weights that represent how NPT 
treated patient is like  a non −NPT-treated patient (Robins and Finkelstein 2000).  
These time-varying weights are included into the OS analysis to correct the effect of NPT by [CONTACT_565787]-censored patients with similar characteristics 
to censored patients . 
 
Delayed Clinical Effect 
If a delayed separation of the KM curves is observed at the beginning of the curves and 
the delay is  ≥ [ADDRESS_743180] for the treatment group. 
• Weighted Log-Rank Analysis  
Where the delayed clinical effect is  > 10% of the median survival time of the control 
group, an analysis of OS may be performed using the weighted log-rank  test based 
on the Rho-Gamma weight function family ( Fleming and Harrington 1991)  or pi[INVESTIGATOR_13959]-
wise linear weight functions ( Lin and Leon 2017)  that weight more on late events to 
account for the delayed clinical effect ( Fine et al. 2007).  In addition, in or der to 
enhance clinical interpretation of the treatment effect that varies over time, hazard 
ratio estimates may also be provided based on the corresponding Cox models ( Lin 
and Leon 2017), for example, the models that assume a minimal treatment effect 
during the first few months (e.g., 3 months, 6 months) then a full treatment effect afterwards. 
[IP_ADDRESS] Loss to Follow-up 
The impact of loss to follow -up on OS will be assessed depending on the number of 
patients who are lost to follow -up.  If  > 5% of patients are lost to follow -up for OS in either 
treatment arm, a sensitivity analysis may be performed for the comparisons between two 
treatment arms in which patients who are lost to follow -up will be considered as having 
died at the last date they were known to be alive. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
24/Statistical Analysis Plan GO29537   [IP_ADDRESS] Progression- Free Survival by [CONTACT_565788]  v1.[ADDRESS_743181]. 
PFS as assessed by  [CONTACT_565789] a sensitivity analysis  using the same 
methods that will be used for PFS as assessed by [CONTACT_093]. 
4.4.5 Subgroup Analyses  
The consistency of PFS and OS results in subgroups will be examined in the populations 
where PFS and/or OS benefit has been demonstrated.  The subgroups are defined by 
[CONTACT_716]: 
• D emographic s (age, sex, race/ethnicity)  
• Baseline disease characteristics (e.g., ECOG performance status ; presence of liver 
metastases at baseline; smoking status ; metastatic sites such as brain, bone, etc.; 
EGFR  mutation status; KRAS  mutation status ) 
• PD-L1 IHC status (e.g., TC3 or IC3, TC2/3 or IC2/3, TC1/2/3 or IC1/2/3, and their 
corresponding complementary groups  as determined by [CONTACT_200003]142 as say; 
subgroups with PD-L1 expression on at least 1%, 25%, or 50% of TC [and their 
corresponding complementary subgroups] as determined by [CONTACT_200003]263 assay may 
also be performed pending data availability)  
• Intended cycles during induction phase (4 cycles vs. 6 cycles) 
 
Summaries of PFS and OS, including the unstratified HR estimated from a 
Cox proportional  hazards model and KM estimates of median PFS and OS, will be 
produced separately for each level of the subgroup for the comparisons between treatment arms  and displayed in a f orest plot (Lewis  and Clarke 2001).  KM plots of PFS 
and/or OS will also be produced for selected subgroups . 
Summaries of ORR by [CONTACT_565790]. 
4.5 PHARMACOKINETIC AND PHARMACODYNAMIC ANAL YSES 
Atezolizumab PK samples will be collected in this study  as outlined in Appendix  3.  
Atezolizumab serum concentration data (C min and C max) will be tabulated and 
summarized.  Descriptive statistics will include means, medians, ranges, and standard deviations, as appropriate. 
Plasma concentrations of carboplatin and nab-paclitaxel  will be collected in this study as 
outlined in Appendix 3 .  The concentrations of carboplatin and nab-paclitaxel  will be 
summarized using descriptive statistics as described above. 
Additional PK analyses will be conducted, as appropriate, based on the availability of 
data.  These additional analyses may not be included in the CSR for this study . 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
25/Statistical Analysis Plan GO29537   4.6 EXPLORATORY BIOMARKER ANALYSES 
Exploratory biomarker analyses will be performed in an effort to understand the 
association of these markers with response to study drug, including efficacy  (PFS, OS, 
and/or ORR).  The biomarkers  include but are not limited to tumor mutational burden (in 
blood and/or tumor tissue).  Additional predictive, prognostic, and pharmacodynamic  
exploratory biomarkers in archival and/or fresh tumor tissue and/or blood may  be 
examined for their association with disease status and/or clinical outcomes.  These exploratory analyses will not be included in the CSR for this study. 
4.7 SAFETY ANALYSES  
The safety population includes treated patients, defined as  randomized patients who 
received any protocol treatment.  For the safety analyses, patients will be grouped 
according to whether any full or partial dose of atezolizumab was received, including when atezolizumab was received in error.  Specifically , for patients randomized to Arm B, 
if atezolizumab was received in error, the patients will be grouped to Arm A for the safety analyses . 
Patients who were consented prior to approval of Protocol  GO29537, Version 5 and are 
randomized to carboplatin
 + nab-paclitaxel  will be given the option to cross over to 
receive atezolizumab as monotherapy upon progressive disease per RECIST  v1.1, 
provided they continue to meet eligibility criteria.  Safety data observed after those 
patients who crossed over from Arm  B to receive atezolizumab (as allowed under 
previous protocol versions ) may be summarized separately. 
4.7.1 Exposure of Study Medication 
Study drug exposure, including treatment duration, number of cycles, and dose intensity, will be summarized for each treatment arm with descriptive statistics.  
4.7.2 Adverse Events 
Verbatim description of adverse events will be mapped to Medical Dictionary for Regulatory Activities  thesaurus terms.  Adverse events will be graded by [CONTACT_565791]  v4.0.  Treatment-emergent adverse events will be 
summarized by [CONTACT_27940], appropriate thesaurus level, NCI CTCAE grade, and 
treatment arm.  Multiple occurrences of the same event will be counted once at the maximum grade.  Adverse events , serious adverse events, treatment-related serious 
adverse events, severe adverse events ( Grade
 ≥ 3), adverse events of special interest, 
immune -mediated adverse events, and adverse events  that lead to study drug 
discontinuation or interruption will be summarized. 
“Treatment emergent” is defined for all events with onset on or after the first study drug 
treatment up to the data cutoff date.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
26/Statistical Analysis Plan GO29537   Listings of adverse events  will include all adverse events  with onset on or after the first 
study drug treatment up to the data cutoff date.  
Deaths during the study treatment period and those reported during the follow -up period 
after treatment completion or discontinuation and causes of death will be summarized by 
[CONTACT_2939] . 
4.7.[ADDRESS_743182] of 
immunogenicity  as appropriate. 
4.8 MISSING DATA  
Please refer to Sections  4.4.1 and 4.4.2 for methods of handling missing data for the 
primary and secondary efficacy endpoints.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
27/Statistical Analysis Plan GO29537   5. REFERENCES  
Akazawa K, Nakamura T, Palesch Y. Power of logrank test and Cox regression model in 
clinical trials with heterogeneous samples. Statistics in Medicine 1997;16:583-597. 
Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 
1982;38:29−41. 
Burman CF, Sonesson C, Guilbaud O, et al. A recycling framework for the construction 
of Bonferroni -based multiple tests. Stat Med 2009;28:739−61. 
Chen TT. Milestone survival: a potential intermediate endpoint for immune checkpoint 
inhibitors. J Natl Cancer Inst 2015;107(9). 
Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ -C30 scoring manual. 3rd 
ed. Brussels: European Organisation for Research and Treatment of Cancer, 2001.  
Fine GD. Consequences of delayed treatment effects on analysis of time-to-event 
endpoints. Ther Innov Regul Sci 2007;41:535− 9. 
Fleming TR, Harrington DP. Counting processes and survival analysis. [LOCATION_001]: John 
Wiley & Sons, 1991.  
Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ 
2001;322:1479− 80. 
Lin RS, Leon LF. Estimation of treatment effects in weighted log-rank tests. Contemp 
Clin Trials Commun. 2017;8:147-55. 
Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-
related quality -of-life scores. J clin oncol. 1998;16:139-44. 
Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank 
preserving structural failure time models. Commun Stat Theory Methods 
1991;20:2609−31. 
Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in 
an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000;56:779−88. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
28/Statistical Analysis Plan GO29537   Appendix  1 Protocol Synopsis  
PROTOCOL SYNOPSIS 
TITLE: A PHASE  III, MULTICENTER, RANDOMIZED, OPEN -LABEL 
STUDY EVALUATING THE EFFICACY AND SAFETY OF 
ATEZOLIZUMAB (MPDL32 80A, ANTI −PD-L1 ANTIBODY) IN 
COMBINATION WITH CARBOPLATIN  + NAB-PACLITAXEL FOR 
CHEMOTHERAPY -NAIVE PATIENTS WITH STAGE IV 
NON-SQUAMOUS NON −SMALL CELL LUNG CANCER 
PROTOCOL NUMBER:  GO29537  
VERSION NUMBER:  [ADDRESS_743183] NUMBER:  2014 -003206 -32 
IND NUMBER:  [ADDRESS_743184]:  Atezolizumab (MPDL3280A, RO5541267)  
PHASE:  III 
INDICATION: Non-squamous non −small cell lung cancer  
SPONSOR:  F. Hoffmann -La [COMPANY_002] Ltd 
 
Objectives 
The term " wild -type " (WT) refers to randomized patients who do not have a sensitizing 
EGFR mutation or ALK translocation.  
The term "tumor gene expression" (tGE) refers to randomized patients with a defined level of 
expression of a programmed death −ligand 1 (PD- L1) and T -effector gene signature [CONTACT_565799], as analyzed through use of a centrally performed RNA -based assay.  
Some efficacy endpoints will be analyzed in a population of randomized patients with a defined level of PD -L1 expression on tumor cells (TCs) and tumor- infiltrating immune cells 
(ICs), as analyzed through use of a centrally performed immunohistochemistry (IHC) test.  
Efficacy Objectives 
The co -primary objectives of this study are the following:  
• To evaluate the eff icacy of atezolizumab
 + carboplatin  + nab-paclitaxel compared with 
carboplatin  + nab-paclitaxel as measured by [CONTACT_1697] -assessed  progression -free survival 
(PFS) according to Response Evaluation Criteria in Solid Tumors,  Version 1.1 
(RECIST  v1.1) in the  tGE-WT populati on and the intent -to-treat wild -type  (ITT -WT) 
population  
• To evaluate the efficacy of atezolizumab  + carboplatin  + nab-paclitaxel compared with 
carboplatin  + nab-paclitaxel as measured by [CONTACT_70085] (OS) in the ITT- WT population  
 
The secondary efficacy objectives for this study are the following:  
• To evaluate the efficacy of atezolizumab as measured by [CONTACT_255853]- WT population  
• To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697]- assessed PFS 
according to RECIST v1.1 an d OS in the TC2/3 or IC2/3 WT population and the TC1/2/3 
or IC1/2/3 WT population  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
29/Statistical Analysis Plan GO29537   • To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697]- assessed PFS 
according to RECIST v1.1 and OS in the tGE population and the ITT population  
• To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed objective 
response rate according to RECIST v1.1 for both the tGE-WT population and the ITT -WT 
population  
• To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed duration of 
response according to RECIST v1.1 for both the tGE-WT population and the ITT -WT 
population  
• To evaluate the OS rate at 1 and 2 years in each treatment arm  in the tGE- WT population 
and the ITT- WT population  
• To determine the impact of atezolizumab as measured by [CONTACT_70113] (TTD) in 
patient -reported lung cancer symptoms of cough, dyspnea (single- item and multi -item 
subscales), chest pain, or arm/shoulder pain, using the European Organisation for the Research and Treatment of Cancer (EORTC) Qualit y-of-Life Questionnaire −Core  30 
(QLQ -C30) and the supplemental lung cancer module ( QLQ -LC13) in the tGE -WT 
population and the ITT -WT population  
• To determine the impact of atezolizumab as measured by [CONTACT_109793] 
(i.e., improvement or deterioration based upon presenting symptomatology) in 
patient -reported lung cancer symptom (chest pain, dyspnea, and cough) score using the 
Symptoms in Lung Cancer (SILC) scale symptom severity score in the tGE- WT population 
and the ITT- WT population  
 
Safety Objectives  
The safety objectives for this study are the following:  
• To evaluate the safety and tolerability of atezolizumab  + carboplatin  + nab-paclitaxel 
compared with carboplatin  + nab-paclitaxel 
• To evaluate the incidence and titers of anti-therapeutic  antibodies (ATAs) against 
atezolizumab and to explore the potential relationship of the immunogenicity response with 
pharmacokinetics, safety, and efficacy  
 
Pharmacokinetic Objectives  
The pharmacokinetic (PK) objectives for this study are the following: 
• To characterize the pharmacokinetics of atezolizumab when given in combination with carboplatin and nab-paclitaxel 
• To characterize the pharmacokinetics of carboplatin when given in combination with 
nab-paclitaxel w ith and without atezolizumab  
• To characterize the pharmacokinetics of nab-paclitaxel when given in combination with 
carboplatin with and without atezolizumab 
 
Exploratory Objectives 
The exploratory objectives for this study are the following:  
• To evaluate PF S at 6 months and at 1 year in each treatment arm  
• To evaluate the OS rate at 3 years in each treatment arm  
• To assess predictive, prognostic, and pharmacodynamic exploratory biomarkers in archival 
and/or fresh tumor tissue and blood and their association with disease status, mechanisms 
of resistance, and/or response to study treatment  
• To evaluate the utility of biopsy at the time of apparent disease progression to distinguish 
apparent increases in tumor volume related to the immunomodulatory activity of atezolizumab (i.e., pseudoprogression/tumor immune infiltration) from true disease 
progression  
• To evaluate and compare patient’s health status as assessed by [CONTACT_70090] 5 D imensions 3- Level ( EQ-5D-3L) questionnaire to generate utility scores for use 
in economic models for reimbursement  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
30/Statistical Analysis Plan GO29537   • To determine the impact of atezolizumab as measured by [CONTACT_120363] -reported outcomes of health- related quality  of life, lung cancer -related symptoms, 
and functioning as assessed by [CONTACT_20368] -C30 and QLQ -LC13 
 
Study Design  
Description of Study  
This is a randomized, Phase III, multicenter, open -label study (IMpower130)  designed to 
evaluate the safety and efficacy of atezolizumab in combination with carboplatin  + nab-paclitaxel 
compared with treatment with carboplatin  + nab-paclitaxel in approximately 
715 chemotherapy −naive patients with Stage IV non-squamous  non−small cell lung cancer  
(NSCLC).  
Tumor specimens will  be prospectively tested for PD-L1 expression by a central laboratory.  
Eligible patients will be stratified by [CONTACT_4321] (male vs. female), presence of liver metastases at 
baseline (yes vs. no), and by [CONTACT_4002] -L1 tumor expression by [CONTACT_4658] (TC3 and any IC vs. TC0/1/2 and 
IC2/3 vs. TC0/1/2 and IC0/1) and randomized in a 2:1 ratio to receive one of the following 
treatment regimens.  
Treatment Arm A:  Atezolizumab  + carboplatin  + nab-paclitaxel (Induction: four or six 21- day 
cycles); atezolizumab (Maintenance: 21 -day cycles)  
Treatment Arm B:  Carboplatin  + nab-paclitaxel  (Induction: four or six 21-day cycles); best 
supportive care or pemetrexed (Maintenance: 21-day cycles)  
 
The number of cycles of induction treatment (four or six) will be at the discretion of the investigator and will be determined and documented prior to randomization.  Induction treatment 
will be administered on a 21-day cycle until the following occurs (whichever occurs first):  
1) administration of four or six cycles or 2) disease progression (Arm B) or loss of clinical benefit 
(Arm A) is documented.  
Following the induction phase, patients who are randomized to atezolizumab (Arm A) may 
continue treatment with atezolizumab beyond radiographic disease progression according to RECIST v1.1 , provided they are experiencing clinical benefit as assessed by [CONTACT_093] 
(i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by [CONTACT_200023], biopsy results [if available], and clinical status).  Patients randomized to 
carboplatin
 + nab-paclitaxel (Arm B) will be offered best supportive care provided they have 
non-progressive disease.  Switch maintenance to pemetrexed is also permitted for patients 
randomized to Arm B.  Switch maintenance m ust be administered within [ADDRESS_743185] induction cycle. 
Patients who entered Study GO29537 under Protocol Versions 1  − 4 and are randomized to 
carboplatin  + nab paclitaxel will be given the option to cross over to receive atezolizumab as 
monotherapy upon progressive disease per RECIST  v1.1, provided they continue to meet 
eligibility criteria.  Safety data for patients who crossed over from Arm B to receive atezolizumab 
as allowed under Protocol Versions 1 − 4 will be summarized for exploratory purposes.  
For Atezolizumab- Treated Patients Only  
During treatment (induction or maintenance), patients receiving atezolizumab (including patients in Arm B who  entered Study GO29537 under Protocol Versions 1
 − [ADDRESS_743186] v1.1) who show evidence 
of clinical benefit will be permitted to continue atezolizumab after the criteria per RECIST v1.1 for progressive disease are met if they meet all of the following criteria:  
• Evidence of  clinical benefit as assessed by [CONTACT_093] 
• Absence of symptoms and signs (including worsening of laboratory values, e.g., new or worsening hypercalcemia) indicating unequivocal progression of disease  
• No decline in Eastern Cooperative Oncology Group (ECOG) performance status that can be attributed to disease progression  
• Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal disease) that 
cannot be managed by [CONTACT_990] -allowed medical interventions  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
31/Statistical Analysis Plan GO29537   • Patients must provide written consent to acknowledge deferring other treatment options in 
favor of continuing atezolizumab at the time of initial progression  
 
Treatment with induction  chemotherapy (Arms A and B) and pemetrexed (Arm B) as switch 
maintenance must be discontinued in all patients who exhibit evidence of progressive disease 
according to RECIST v1.[ADDRESS_743187] v1.1 (or loss of clinical benefit for atezolizumab- treated 
patients who had continued treatment  with atezolizumab  after radiographic disease 
progression according to RECIST v1.1), withdrawal of consent, study termination by [CONTACT_2728], or death, whichever occurs first.  Patients who discontinue treatment for reasons other than 
radiographic disease progression according to RECIST v1.1 (e.g., toxicity , symptomatic 
deterioration ) will continue scheduled tumor assessments until radiographic disease 
progression according to RECIST v1.1 (or loss of clinical benefit for atezolizumab- treated 
patients who had continued treatment  with atezolizumab  after radiographic disease 
progression according to RECIST v1.1), withdrawal of consent, study termination by [CONTACT_2728], 
or death, whichever occurs first, regardless of whether patients start a new anti -cancer therapy.  
All primary imaging d ata used for tumor assessment will be collected by [CONTACT_70093], independent review of response endpoints.  The independent reviews of the stored 
scans will be performed when requested.  
Patients in all treatment arms will undergo a mandatory tumor biopsy sample collection, unless not clinically feasible as assessed and documented by [CONTACT_431], at the first evidence of radiographic disease progression.  These data will be used to explore whether radiographic 
findings are consistent with the presence of tumor.  Additionally, these data will be analyzed to 
evaluate the association between changes in tumor tissue and clinical outcome and to understand further the potential mechanisms of progression and resistance to atezolizumab as 
compa red with such mechanisms after treatment with chemotherapy alone.  This exploratory 
biomarker evaluation will not be used for any treatment -related decisions.  Patients in Arm A 
and patients in Arm B ( who entered Study GO29537 under Protocol Versions 1
 − 4) who are 
unable to undergo biopsy sample collection but who otherwise meet the criteria listed above 
may continue /crossover to receive atezolizumab.  
Number of Patients  
Approximately [ADDRESS_743188] meet all of the following criteria to be eligible for study entry:  
• Signed Informed Consent Form  
• Male or female, 18 years  of age or older  
• ECOG performance status of 0 or 1 
• Histologically or cytologically confirmed, Stage IV non- squamous NSCLC (per the Union 
Internationale contre le Cancer/American Joint Committee on Cancer staging system, 
7th edition) 
Patients with tumors of mixed histology (i.e., squamous and non-squamous ) are eligible 
if the major histological component appears to be non-squamous . 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
32/Statistical Analysis Plan GO29537   • No prior treatment for Stage IV non-squamous  NSCLC  
Patients with a sensitizing mutation in the EGFR  gene must have experienced disease 
progression (during or after treatment) or intolerance to treatment with one or more 
EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, or another EGFR  TKI 
appropriate for the treatment of EGFR -mutant  NSCLC.  
Patients known to have an ALK fusion oncogene must have experienced disease 
progression (during or after treatment) or intolerance to treatment with one or more 
ALK inhibitors  (e.g., crizotinib) appropriate for the treatment of NSCLC in patients 
having an ALK fusion oncogene.   
Patients with unknown EGFR and ALK status require test results at screening.  
ALK and/or EGFR may be assessed locally or at a central laboratory. 
Patie nts who have received prior neo-adjuvant , adjuvant chemotherapy, radiotherapy, 
or chemoradiotherapy with curative intent for non- metastatic  disease must have 
experienced a treatment -free interval of at least [ADDRESS_743189] chemotherapy, radiotherapy, or chemoradiotherapy cycle.  
• Patients with a history of treated asymptomatic central nervous system (CNS) metastases 
are eligible, provided they meet all of the following criteria:  
Only supratentorial and cerebellar  metastases allowed (i.e., no metastases to midbrain, 
pons, medulla or spi[INVESTIGATOR_1831])  
No ongoing requirement for corticosteroids as therapy for CNS disease  
No stereotactic radiation within [ADDRESS_743190] 
receive radiation therapy and/or surgery for CNS metastases.  Following treatment, these patients may then be eligible without the need for an additional brain scan prior to 
randomization, if all other criteria are met.  
• Known PD-L1 tumor status as determined by [CONTACT_109794] a central 
laboratory on previously obtained archival tumor tissue or tissue obtained from a biopsy at 
screening  
A representative formalin -fixed  paraffin -embedded (FFPE) tumor specimen in paraffin 
block (preferred) or 15 or more unstained, freshly cut, serial sections on slides from an 
FFPE tumor specimen is required for participation in this study.  If fewer than 15 slides 
are available at baseline (but no fewer than 10), the patient may still be eligible, upon 
discussion with the Medical Monitor.  This specimen must be accompanied by [CONTACT_109795].  
Fine-needle aspi[INVESTIGATOR_1516] (defined as samples that  do not preserve tissue architecture and 
yield cell suspension and/or cell smears), brushing, cell pellet specimens (e.g., from 
pleural effusion, and lavage samples) are not acceptable. 
Tumor tissue from bone metastases that is subject to decalcification is not acceptable.  
For core- needle biopsy specimens, preferably at least three cores  embedded in a single 
paraffin block, should be submitted for evaluation.  
• Measurable disease, as defined by [CONTACT_393] v1.1  
Previously irradiated lesions can only be considered as measurable disease if disease 
progression has been unequivocally documented at that site since radiation and the 
previously irradiated lesion is not the only site of disease. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
33/Statistical Analysis Plan GO29537   • Adequate hematologic and end organ function, defined by [CONTACT_40843] 14 days prior to randomization:  
ANC  ≥ 1500 cells/ µL without granulocyte colony -stimulating factor support  
Lymphocyte count  ≥ 500/µL 
Platelet count  ≥ 100,000/ µL without transfusion  
Hemoglobin  ≥ 9.0 g/dL  
Patients may be transfused to meet this criterion.  
INR or aPTT  ≤ 1.5  × upper  limit of normal ( ULN) 
This applies only to patients who are not receiving therapeutic anticoagulation; 
patients receiving therapeutic anticoagulation should be on a stable dose.  
AST, ALT, and alkaline phosphatase  ≤ 2.5  × ULN, with the following exceptions:  
Patients with documented liver metastases:  AST and/or ALT ≤ 5 × ULN 
Patients with documented liver or bone metastases:  alkaline phosphatase ≤ 5 × ULN. 
Serum bilirubin  ≤ 1.25 × ULN 
Patients with known Gilbert disease who have serum bilirubin level ≤ 3 × ULN may be 
enrolled. 
Serum creatinine  ≤ 1.5  × ULN  
• For female patients of childbearing potential agreement (by [CONTACT_109796]/or partner) to use a 
highly effective form(s) of contraception that results in a low failure rate [ < 1% per year] 
when used consistently and correctly, and to continue its use for [ADDRESS_743191] dose of nab-paclitaxel, whichever is later.  
For male patients with female partners of childbearing potential, agreement (by [CONTACT_109796]/or partner) to use a highly effective form(s) of contraception that results in a low failure 
rate [ <
 1% per year] when used consistently and correctly, and to continue i ts use for 
[ADDRESS_743192] dose of nab-paclitaxel  and/or carboplatin, whichever is later.  Such 
methods include:  combined (estrogen and progestogen containing) hormonal contraception, progestogen -only hormonal contraception associated with inhibition of ovulation together 
with another additional barrier method always containing a spermicide, intrauterine device, 
intrauterine hormone -releasing system, bilateral tubal occlusion or vasectomized partner 
(on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.  Male patients should not donate sperm during this study and for at least [ADDRESS_743193] dose of nab- paclitaxel and/or carboplatin, whichever is later.  
• Oral contraception should alway s be combined with an additional contraceptive method 
because of a potential interaction with the study drug.  The same rules are valid for male patients involved in this clinical study if they have a partner of childbirth potential.  Male patients must always use a condom.  
• Women who are not postmenopausal ( ≥
 12 months of non− therapy -induced amenorrhea) or 
surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug.  
 
Exclusion Criteria  
Patients who meet any of the criteria below will be excluded from study entry:  
Cancer-Specific Exclusions  
• Active or untreated CNS metastases as determined by [CONTACT_565792] s 
• Spi[INVESTIGATOR_33373]/or radiation or previously 
diagnosed and treated spi[INVESTIGATOR_70036]
 > 2 weeks prior to randomization  
• Leptomeningeal disease 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
34/Statistical Analysis Plan GO29537   • Uncontrolled tumor -related pain  
Patients requiring pain medication must be on a stable regimen at study entry.  
Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or 
metastases causing nerve impi[INVESTIGATOR_20804]) should be treated prior  to randomization.  
Patients should be recovered from the effects of radiation.  There is no required 
minimum recovery period.  
Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epi[INVESTIGATOR_246696]) should be considered for  locoregional therapy, if appropriate, 
prior to randomization.  
• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)  
Patients with indwelling catheters (e.g., PleurX
®) are allowed.  
• Uncontrolled or symptomatic hypercalcemia ( > 1.5 mmol/L ionized calcium or Ca  > 12 mg/dL 
or corrected serum calcium  > ULN)  
Patients who are receiving denosumab prior to randomization must be willing and 
eligible to receive a bisphosphonate instead while in the study.  
• Malignancies other than NSCLC within 5 years prior to randomization, with the exception of 
those with a negligible risk of metastasis or death (e.g., expected 5-year OS  > 90%) treated 
with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, 
basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)  
• Known tumor PD-L1 expression status as determined by [CONTACT_70095] (e.g., patients whose PD-L1 expression status was determined during screening for 
entry into a study with anti −PD-1 or anti−PD-L1 antibodies but were not eligible are 
excluded)  
 
General Medical Exclusions  
• Women who are pregnant, lactating, or intending to become pregnant during the study  
• History of severe allergic, anaphylactic, or other hypersensitivity reactions  to chimeric or 
humanized antibodies or fusion proteins  
• Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation  
• History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis,  
autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosi s, Sjögren’s syndrome, Guillain- Barré  syndrome, multiple sclerosis, vasculitis, 
or glomerulonephritis  
Patien ts with a history of autoimmune -related hypothyroidism on a stable dose of 
thyroid replacement hormone are
 eligible for this study.  
Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin regimen are 
eligible for this study  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
35/Statistical Analysis Plan GO29537   Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic 
manifestations only (e.g., patients with psoriatic arthritis would be excluded) are 
permitted provided that they meet the following conditions:  
Rash must cover less than 10% of body surface area.  
Disease is well controlled at baseline and only requiring low -potency topi[INVESTIGATOR_28709].  
No acute exacerbations of underlying condition within the prev ious 12 months (not 
requiring psoralen plus ultraviolet A radiation [ PUVA] , methotrexate, retinoids, 
biologic agents, oral calcineurin inhibitors, high- potency or oral steroids)  
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), 
drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on 
screening chest CT scan  
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.  
• Positive test for HIV  
All patients will be tested for HIV prior to inclusion into the study; patients who test 
positive for HIV will be excluded from the clinical study.  
• Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis  B 
surface antigen [HBsAg] test at screening) or hepatitis C  
Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible only if  they are negative for HBV DNA.  
Patients who are positive for hepatitis C virus (HCV) antibody are eligible only  if PCR is 
negative for HCV RNA.  
• Active tuberculosis  
• Severe infections within 4 weeks prior to randomization, including but not limited to 
hospi[INVESTIGATOR_33377], bacteremia, or severe pneumonia  
• Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks  prior to 
randomization 
Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pul monary disease exacerbation) are eligible.  
• Significant cardiovascular disease, such as [LOCATION_001] Heart Association cardiac disease 
(Class II or greater), myocardial infarction, or cerebrovascular accident within the 3 months  
prior to randomization, unstable arrhythmias, or unstable angina  
Patients with known coronary artery disease, congestive heart failure not meeting the 
above criteria, or left ventricular ejection fraction
 < 50% must be on a stable medical 
regimen that is optimized in the opi[INVESTIGATOR_021], in consultation with a cardiologist if appropriate.  
• Major surgical procedure other than for diagnosis within 28 days  prior to randomization or 
anticipation of need for a major surgical procedure during the course of the study  
• Prior allo geneic bone marrow transplantation or solid organ transplant  
• Administration of a live, attenuated vaccine within 4 weeks before randomization  or 
anticipation that such a live, attenuated vaccine will be required during the study 
• Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that contraindicates 
the use of an investigational drug or that may affect the interpretation of the results or 
render s the patient at high risk from treatment complications  
• Illness or condition that interferes with the patient’s capacity to understand, follow and/or comply with study procedures  
 
Exclusion Criteria Related to Medications 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
36/Statistical Analysis Plan GO29537   • Any approved anti -cancer therapy, including hormonal therapy within 21 days  prior to 
initiation of study treatment; the following exceptions are allowed:  
TKIs approved for treatment of NSCLC discontinued > [ADDRESS_743194] be obtained after discontinuation of prior TKIs. 
• Treatment with any other investigational agent with therapeutic intent within 28 days prior to 
randomization 
• Prior treatment with CD137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], anti−PD-1, 
and anti −PD-L1 therapeutic antibodies  
Patients who have had prior anti −cytotoxic T -lymphocyte -associated protein 4 (anti −CTLA -4) 
treatment may be enrolled, provided the following requirements are met : 
Last dose of anti−CTLA -[ADDRESS_743195] 6 weeks prior to randomization 
No history of severe immune- mediated adverse effects from anti−CTLA-4 (National Cancer 
Institute Common Terminology Criteria for Adverse Events [NCI  CTCAE] Grades 3 and 4)  
• Treatment with systemic immunostimulatory agents (including but not limited to interferons and interleukin-2 ) within 4 weeks or five half-lives of the drug, whichever is longer, prior to 
randomization 
Prior treatment with cancer vaccines is allowed.  
• Treatment with systemic immunosuppressive medications (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti −tumor  
necrosis factor [ anti-TNF] agents) within [ADDRESS_743196] received acute, low -dose (
≤ 10 mg oral prednisone or equivalent) , 
systemic immunosuppressant medications may be enrolled in the study.  
The use of corticosteroids ( ≤ 10 mg oral prednisone or equivalent)  for chronic 
obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low -dose supplemental corticosteroids for 
adrenocortical insufficiency is allowed.  
 
Exclusions Related to Chemotherapy  
• Known history of severe allergic reactions to platinum -containing compounds or mannitol  
• Known sensitivity to any component of nab-paclitaxel  
• Grade  ≥ 2 peripheral neuropathy as defined by [CONTACT_4652] v4.0 
• Known history of severe hypersensitivity reactions to products containing Cremophor EL 
(e.g., cyclosporin for injection concentrate and teniposide for injection concentrate) 
 
Length of Study  
The final PFS analysis will be conducted when all of the following criteria have been met:  
approximately [ADDRESS_743197] 
patient is enrolled.  
End of Study  
The end of study is defined as  when the required number of deaths for the final analysis of OS 
has been observed.  Additionally, the Sponsor may decide to terminate the study at any time.   
If the Sponsor decides to terminate the study, patients who are still receiving study treatment 
or undergoing survival follow -up may be enrolled into an extension study or a non -
interventional study.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
37/Statistical Analysis Plan GO29537   Outcome Measures  
Efficacy Outcome Measures  
The co -primary effi cacy outcome measures for this study are as follows:  
• PFS, defined as the time from randomization to the first occurrence of disease progression 
as determined by [CONTACT_3143] v1.[ADDRESS_743198] in th e tGE -WT population and the ITT -WT population  
• OS, defined as the time from randomization to death from any cause, in the ITT- WT 
population  
The secondary efficacy outcome measures for this study are the following:  
• OS in the tGE -WT population  
• PFS, as determi ned by [CONTACT_3143] v1.1, and OS in the TC2/3 
or IC2/3 WT population and the TC1/2/3 or IC1/2/3 WT population  
• PFS, as determined by [CONTACT_3143] v1.1, and OS in the tGE 
population and the ITT population  
• Objec tive response, defined as a partial response or a complete response as determined by 
[CONTACT_3143] v1.1 for the tGE- WT population and the ITT -WT 
population  
• DOR, defined as the time interval from first occurrence of a documented objective response to the time of disease progression as determined by [CONTACT_26309] v1.[ADDRESS_743199]  for the tGE- WT population and the ITT -WT 
population  
• OS rates at 1 and 2 years  for the tGE- WT population an d the ITT- WT population  
• TTD in patient -reported lung cancer symptoms, defined as time from randomization to 
deterioration (10 -point change) on each of the EORTC QLQ -C30 and EORTC QLQ -LC13  
symptom subscales (cough, dyspnea [single item], dyspnea [multi -item subscale], chest 
pain, and arm/shoulder pain)  in the tGE -WT population and the ITT -WT population  
• Change from baseline in patient- reported lung cancer symptoms (chest pain, dyspnea, and 
cough) on the symptom severity score of the SILC scale in the tGE- WT population and the 
ITT- WT population  
 
Safety Outcome Measures  
The safety outcome measures for this study are the following:  
• Incidence, nature, and severity of adverse events gr aded according to the NCI  CTCAE  v4.0 
• Changes in vital signs, physical findings, and clinical laboratory results during and following atezolizumab administration 
• Incidence of ATA response to atezolizumab and potential correlation with PK, 
pharmacodynamic, safety, and efficacy parameters  
 
Pharmacokinetic Outcome Measures  
The PK outcome measures for this study are the following:  
• For patients randomized to atezolizumab  + carboplatin  + nab-paclitaxel:  
Maximum observed serum atezolizumab concentration (C max) after in fusion on Cycle  1, 
Day 1 
Minimum observed serum atezolizumab concentration (C min) prior to infusion at 
selected cycles, at treatment discontinuation, and at 120 days  (± 30 days) after the last 
dose of atezolizumab  
Plasma concentrations for carboplatin (Arms A and B)  
Plasma concentrations for nab- paclitaxel reported as total paclitaxel (Arms A and B)  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
38/Statistical Analysis Plan GO29537   • For patients randomized to carboplatin  + nab-paclitaxel who crossed over to receive open-
label atezolizumab as monotherapy (allowed under Study GO29537 Protocol, 
Versions 1  − 4): 
Cmax of serum atezolizumab after infusion on Day [ADDRESS_743200] cycle following crossover 
to atezolizumab as monotherapy  
Cmin of serum atezolizumab prior to infusion on Day 1 at selected cycles following 
crossover t o atezolizumab as monotherapy, at treatment discontinuation, and at 
120 ( ± 30 days) after the last dose of atezolizumab  
 
Exploratory Outcome Measures  
The exploratory outcome measures for this study are the following:  
• PFS at 6 months and at 1 year 
• OS rate at 3 years  
• Status of PD-L1−, immune -, and NSCLC -related and other exploratory biomarkers in 
archival and/or freshly obtained tumor tissues and blood (or blood derivatives) collected 
before, during, or after treatment with atezolizumab or at progression and association with 
disease status and/or response to atezolizumab in combination with chemotherapy  
• Status of ICs and other exploratory biomarkers in mandatory biopsy specimens and blood 
collected at progression  
• Utility scores of the EQ-5D-3L  
• Change from baseline in patient -reported  outcomes of health- related quality -of-life, lung 
cancer -related symptoms, and functioning as assessed by [CONTACT_20368] -C30 and 
QLQ -LC13   
 
Investigational Medicinal Products  
Test Product (Investigational Drug)  
The investigational medicinal products (IMPs) for this study are atezolizumab and erlotinib.  
Atezolizumab (1200 mg IV) will be administered on Day 1 of each 21– day cycle.  Atezolizumab 
will be administered to patients who are randomized to Arm A and to patients in Arm B who cross over at progression.  
Switch maintenance treatment with erlotinib is no longer permitted.  However, patients who had already started switch maintenance treatment with erlotinib under Protocol Versions 1
−4 may 
be allowed to continue treatment with erlotinib upon discussion of the risks, potential benefits 
and alternative treatment options with the investigator.  For those patients who receive switch 
maintenance, institutions should follow the dosage and administration instructions in the prescribing information.  
Comparator 
Nab-paclitaxel  (100 mg/m2 IV) will be administered on Days  1, 8, and 15 of each 21-day cycle 
for four or six cycles d uring the induction phase.  Nab-paclitaxel  will be considered an IMP for 
study purposes in countries where nab -paclitaxel is considered an IMP by [CONTACT_427] . 
Non-Investigational Medicinal Products  
Comparator  Carboplatin will be administered by [CONTACT_109798] −time curve of 6 mg/mL/min on Day [ADDRESS_743201] v1.1 
and OS.  PFS will be analyzed in the tGE -WT population  and the ITT- WT population.  
OS will be analyzed in the ITT- WT population.  The timing of the final PFS and OS analyses 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
39/Statistical Analysis Plan GO29537   is described below (see "Determination of Sample Size").  At least one interim OS analysis 
will be performed.  
PFS is defined as the time between the date of randomization and the date of first documented disease progression or death, whichever occurs first.  Patients who have not experienced disease progression or death at the time of analysis will be censored at  the time of the last 
tumor assessment.  Patients with no post-baseline tumor assessment will be censored at the 
date of randomization plus [ADDRESS_743202] ratio ( HR) for 
PFS and OS for treatment comparisons will be estimated using a stratified Cox regression 
model, respectively.  The 95% CI for the HR will be provided.  
The stratification factors will be those used during randomization, (i.e., sex [male vs. female], presence of liver metastases at baseline [yes vs. no], and PD-L1 tumor expression by [CONTACT_4658] [TC3 
and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1]), as recorded in an interactive voice or Web-based response system.   
Results from an unstratified analysis will also be presented.  Kaplan- Meier  methodology will be 
used to estimate the median PFS and the median OS for each treatment arm, and a Kaplan -Meier curve will be constructed to provide a visual description of the difference between 
treatment arms.  The Brookmeyer -Crowley  methodology will be used to construct the 95%  CI 
for the median PFS  and the median OS  for each treatment arm.  
Analyses will be conducted according to an analysis hierarchy and an 
α-spending algorithm 
to control for the type I error rate and to account for an interim analysis.  
To control the overall type I error rate for the one- sided test at 0.025, a one -sided  type I error 
(α) of 0.003 and 0.022 (ratio of 3:22) will be allocated to PFS and OS, respectively.  
The hypothesis testing will be performed in the order described below:  
1. PFS in the tGE -WT population will be tested at α = 0.003 (one -sided ).  If the estimate of 
the HR is < [ADDRESS_743203] 
is < 0.003, the null hypothesis will be rejected and it will be concluded that 
atezolizumab  + carboplatin  + nab-paclitaxel  prolongs the duration of PFS relative to 
control treatment in the tGE -WT population.  
2. If the null hypothesis is rejected in the tGE- WT population (Step 1), PFS in the ITT -WT 
population will be tested at α=  0.003 (one -sided ). 
3. α recycling from PFS to OS will be conducted as follows:  
a. If the null hypothesis is not rejected for the PFS analysis in the ITT- WT population 
(Step 2), OS in the ITT -WT population will be tested at α = 0.022 (one -sided ).  
b. If the null hypothesis is rejected for the PFS analysis in the ITT- WT population 
(Step  2), OS in the ITT -WT population will be tested at α = 0.025 (one -sided ). 
 
Determination of Sample Size  
This study will randomize approximately 715 patients.  The ITT -WT population will include 
approximately 650 patients, assuming a prevalence of approximate ly 10% for sensitizing 
EGFR mutations or ALK translocations.  The tGE- WT population will include approximately 
325 patients, assuming a 50% prevalence with the chosen tGE cutoff.  
The sample size of this study is based on the number of events required to demonstrate 
efficacy with regard to both PFS and OS (co -primary endpoints). 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
40/Statistical Analysis Plan GO29537   The estimate of the number of events required to demonstrate efficacy with regard to PFS in the 
comparison of Arm A versus Arm B is based on the following assumptions:  
• 93% power to detect an HR of 0.55, corresponding to an improvement in median PFS from 6 months to 10.9 months in the tGE-WT population with a one- sided α of 0.003 
• 95% power to detect an HR of 0.65, corresponding to an improvement in median PFS from 6 months to 9.2 months in the ITT- WT population with a one-sided  α of 0.003 
• No interim analyses for PFS  
• Dropout rate of 5% per [ADDRESS_743204] to OS in the 
comparison of Arm A versus Arm B is based on the following assumptions:  
• 80% power to detect an HR of 0.75, corresponding to an improvement in median OS from 
12 months to 16 months in the ITT -WT population with a one-sided  α of 0.022  
• One interim OS analysis performed at the time of the final PFS  analysis, at which time 
approximately 77% of the total number of OS events required for the final analysis are expected to have occurred as determined through use of the Lan -DeMets approximation to 
the O'Brien -Fleming boundary  
• Dropout rate of 5% per [ADDRESS_743205] been met:  approximately [ADDRESS_743206] patient is enrolled.  This number of events would allow for a minimum detectable difference corresponding to an HR of 0.81 in the ITT -WT population.  
Interim Analyses  
There are no interim analyses planned for PFS in this study.  An external independent Data Monitoring Committee (iDMC) will be set up to evaluate safety data on an ongoing basis.  All summaries/analyses by [CONTACT_70097]’s review will be prepared by [CONTACT_70098].  Members of the iDMC will be external to the Sponsor 
and will follow a charter that outlines their roles and responsibilities.  Any outcomes of these safety reviews that affect study conduct will be communicated in a timely manner to the 
investigators for notification of the Institutional Review Boards and Ethics Committees.  
A detailed plan will be included in the iDMC Charter.  
If approxim ately [ADDRESS_743207] occurred in the ITT- WT population at the time of the 
PFS final analysis, an interim OS analysis will be conducted in the ITT- WT population.  If 
there are significantly fewer than the expected 352 OS events at the final PFS analysis, a nominal 
α of 0.01% (negligible impact on overall type I error rate) will be spent on the OS 
analysis at the time of the PFS final analysis and a second interim OS analysis will then be conducted after approximately [ADDRESS_743208] 
patient is enrolled.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
41/Statistical Analysis Plan GO29537  Appendix  2 Schedule of Assessments 
 
Procedure  Screening  Induction Phase 
Cycles 1  to 4 or 6  
(21-Day Cycle) a Maintenance Phase  
(21-Day Cycle) a Treatment 
Discontinuation 
Visit Survival Follow-Up  
Days –28 
to –1 Day 1  
(± 3 Days ) b Day 1  
(± 3 Days ) b  ≤ [ADDRESS_743209] Dose of Study 
Treatment  Every 3 Months after 
Disease Progression or 
Loss of Clinical Benefit  
Informed consent  x     
Tumor tissue specimen for PD-L1 testing ( 15 FFPE  
slides required; blocks preferred) c 
Fresh or archival tissue can be used  x  
   
ALK and/or EGFR assessment if status is unknown 
(may be done locally or centrally)  x     
Demographic data  x     
Medical history and baseline conditions  x     
NSCLC cancer history  x     
Vital signs d x x d x d x  
Weight  x x x x  
Height  x     
Complete physical examination x     
Limited physical examination e  x x x  
ECOG performance status  x x x x  
12-Lead ECG  x x f x f x f  
Hematology g x x x x  
Serum chemistry h x x  x  x  
Coagulation test (aPTT or INR)  x   x  
 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
42/Statistical Analysis Plan GO29537  Appendix  2 Schedule of Assessments (cont.)  
Procedure Screening  Induction Phase 
Cycles 1  to 4 or 6  
(21-Day Cycle) a  Maintenance Phase  
(21-Day Cycle) a  Treatment 
Discontinuation 
Visit Survival Follow-Up  
Days –28 
to –1 Day 1 
(± 3 Days ) b Day 1 
(± 3 Days ) b  ≤ [ADDRESS_743210]  (women of childbearing-potential 
ONLY)  x i x j x j x j  
TSH, free T3, free T4 k x x k x k x  
HIV, HBV, HCV serology l x     
Urinalysis m x x x x  
Determination of duration of induction treatment  x     
Induction treatment administration:  
Arm A: atezolizumab  + carboplatin  + nab-paclitaxel  
Arm B: carboplatin  + nab-paclitaxel    x n    
Maintenance treatment administration:  
Arm A: atezolizumab  
Arm B: Best supportive care (switch maintenance 
to pemetrexed permitted)    x n   
Tumor response assessment  x o x p x p  x q 
Serum sample for atezolizum ab ATA assessment 
(atezolizumab- treated patients only) r  x x x 120 ( ± 30) days after last 
dose of atezolizumab  
Serum sample for PK sampling (atezolizumab-
treated patients only) r  x x x 120 ( ± 30) days after last 
dose of atezolizumab  
Carboplatin and nab-paclitaxel PK sampling 
(20 patients per arm) r  x    
 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
43/Statistical Analysis Plan GO29537  Appendix  2 Schedule of Assessments (cont.)  
Procedure Screening  Induction Phase 
Cycles 1  to 4 or 6  
(21-Day Cycle) a  Maintenance Phase  
(21-Day Cycle) a  Treatment 
Discontinuation 
Visit Survival Follow-Up  
Days –28 
to –1 Day 1  
(± 3 Days ) b Day 1  
(± 3 Days ) b  ≤ [ADDRESS_743211] Dose of Study 
Treatment  Every 3 Months after 
Disease Progression or 
Loss of Clinical Benefit  
Blood samples for  PD bio markers r x x x x 120 ( ± 30) days after last 
dose of atezolizumab  
Optional blood for DNA extraction  
(RCR only) r, s  x 
Informed consent to continue treatment beyond 
radiographic progression ( Arm A 
atezolizumab-treated patients)   At time of radiographic progression    
Tumor biopsy   At time of radiographic progression t   
Optional tumor biopsy at other timepoints 
(RCR only)   Any time during study treatment or during survival follow -up 
Adverse events u x x x x x 
Concomitant medications  From 
7 days 
before 
screening  x x x  
Patient -reported outcomes v  x v x v  x v 
Survival and anti−cancer  therapy follow -up w     x 
 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
44/Statistical Analysis Plan GO29537  Appendix  2 Schedule of Assessments (cont.)  
ATA  = anti-therapeutic antibody; ECOG  = Eastern Cooperative Oncology Group; EORTC  = European Organization for Research and Treatment of Cancer; 
ePRO  = electronic Patient -Reported Outcome; EQ -5D-3L  = Euro QoL5 Dimensions 3-Level Version; FFPE  = formalin-fixed, paraffin- embedded; HBcAb  = hepatitis 
B core antibody; HBV  = hepatitis B virus; HCV  = hepatitis C virus; IV  = intravenous; LC13  = Lung Cancer module; NSCLC  = non−small cell lung cancer; 
PD  = pharmacodynamic; PGIS  = Patient Global Impression of Severity; PK  = pharmacokinetic; QLQ -C30  = Quality -of-Life Questionnaire Core 30; RCR  = [COMPANY_002] 
Clinical Repository; SILC  = Symptoms in Lung Cancer; TSH  = thyroid -stimulating hormone.  
Notes:  Patients who are randomized to Arm B who receive d erlotinib switch maintenance allowed under Study GO29537 Protocol Versions 1 − 4,or who receive 
pemetrexed switch maintenance,  will continue with cycle visits at the same frequency as those patients randomized to Arm A until disease progression, 
withdraw al of consent, death, or study termination by [CONTACT_1034], whichever occurs first.  
The same treatment -phase schedule of assessments and procedures will apply to the crossover patients, i.e., patients will begin on Cycle 1 (now called Cycle 1A) 
and will follow the same assessments and procedures as outlined in this protocol for this cycle (with the exception of an alternate schedule for PK and 
pharmacodynamic assessments (see  Appendix 3 of Protocol GO29537)  and a biopsy upon progression will not be requested for these patients), as well as for all 
subsequent cycles (i.e., Cycle 2, which will now be called Cycle 2A, etc.).  In addition, patients who entered Study GO29537 under Protocol Versions 1  − [ADDRESS_743212] progression schedule (i.e., SILC monthly for the first 6 months only and EORTC QLQ -C30, QLQ,  
LC13 and EQ-5D-3L at 3 and 6 months  only).  
a Assessments should be performed before study drug infusion unless otherwise noted.  
b Cycle 1, Day 1, must be performed within 5 days after the patient is randomized.  Screening assessments performed ≤ 96 hours before Cycle 1, Day 1 are not 
required to be repeated for Cycle 1, Day 1.  In addition, ECOG performance status, limited physical examination, and local laboratory tests may be performed ≤ 96 hours before Day 1 of each cycle as specified in Section [IP_ADDRESS] of Protocol GO29537.  
c If a representative FFPE tumor specimen in paraffin block (preferred) or 15 ( or more) freshly cut, unstained  sections  on slides from an FFPE tumor specimen 
are not available for PD -L1 testing, contact [CONTACT_565772].  Fine -needle aspi[INVESTIGATOR_1516] 
(defined as a samples that do not preserve tissue architecture and yield cell suspension and/or cell smears), brushing, cell pellets from pleural effusion, and lavage samples are NOT acceptable.  For core-needle biopsy specimens, at least three cores should be submitted for evaluation.  Retrieval of archival tumor sample may occur outside the 28-day screening period prior to enrollment.  See Section 4.1.1 of Protocol GO29537, Inclusion Criteria, and Section 4 .5.7.1 of 
Protocol  GO29537. 
d Vital signs include pulse rate, respi[INVESTIGATOR_697], blood pressures, and temperature.  Vital signs should be recorded as described in Section 4 .5.4 of 
Protocol  GO29537. 
e Symptom -directed physical examinations; see Section 4.5.3 of Protocol  GO29537 for detai ls.  
f ECG recordings will be obtained when clinically indicated.  
g Hematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with differential (neutrophils, lymphocytes, eosinophils, monocytes, 
basophils, and other cells), and platelet count.  Hematology tests must be performed prior to Day 1 infusions and for nab-paclitaxel administration, also prior to 
Day 8 and Day 15 infusions. See Section  [IP_ADDRESS] (Table 11) of Protocol  GO29537  for dose modifications due to hematologic toxiciti es. 
 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
45/Statistical Analysis Plan GO29537  Appendix  2 Schedule of Assessments (cont.)  
h Serum chemistry includes BUN or urea, creatinine, sodium, potassium, magnesium, chloride, bicarbonate or total CO 2, calcium, phosphorus, glucose, 
total bilirubin, ALT, AST, alkaline phosphatase, LDH, total protein, and albumin.  See Section [IP_ADDRESS] of Protocol GO29537 for carboplatin and nab-paclitaxel 
dose modification management due to serum chemistry toxicities.  
 i Serum pregnancy test within 14 days before Cycle  1, Day  1. 
j Urine pregnancy tests; if  a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.  
k Thyroid -function testing (thyroid-stimulating hormone [TSH], free T3, free T4) collected at Cycle 1, Day 1, and every fourth cycle thereafter.  Total T3 will be 
tested only at sites at sites where free T3 testing is not tested.  
l All patients will be tested for HIV prior to the inclusion into the study, and HIV -positive patients will be excluded from the clinical study.  Patients with active 
hepatitis B (chronic or acute; defined as having a positive HBsAg test result at screening) will be excluded from the study.  Patients with past or resolved 
HBV infection (defined as the presence of HBcAb and absence of HBsAg) are eligible only if their HBV DNA test is negative.  Patients with HCV will be 
excluded from the study; patients who test positive for HCV antibody are eligible only if polymerase chain reaction is nega tive for HCV RNA.  
m Urinalysis by [CONTACT_5230] (specific gravity, pH, glucose, protein, ketones, and blood).  
n For atezolizumab, the initial dose will be delivered over 60 ( ± 15) minutes.  If the first infusion is well tolerated, all  subsequent infusions may be delivered over 
30 (± 10) minutes.  For carboplatin + nab-paclitaxel, administer nab- paclitaxel over 30 minutes followed immediately by [CONTACT_565773] 15 − 30 
minutes.  Administer nab-paclitaxel alone on Days 8 and 15.  See Section [IP_ADDRESS] of Protocol GO29537 for details.  Atezolizumab will be delivered as 
monotherapy during the maintenance phase (Arm A only) and for patients who cross over from Arm B (allowed under Study  GO29537 Protocol , 
Versions  1 − 4).  See Section  [IP_ADDRESS] of Protocol GO [ADDRESS_743213] scans (with  oral/IV contrast unless contraindicated) or MRI of the chest and abdomen.  A CT or MRI  scan of the pelvis is required at screening and as 
clinically indicated or as per local standard of care at subsequent response evaluations.  A CT (with contrast) or MRI scan of the head must be done at screening to evaluate CNS metastasis in all patients.  See Section 4.5.5 of Protocol GO29537 for details.  
p Perform every 6 weeks ( ± 7 days ) (approximately every two cycles) for 48 weeks following Cycle 1, Day 1, and then every 9 weeks ( ± 7 days) after the 
completion of the Week 48 tumor assessment, regardless of treatment delays, until radiographic disease progression (loss of clinical benefit for patients assigned to atezolizumab who continue treatment after disease progression according to RECIST v1.1), withdrawal of consent, death, or study termination b y 
the Sponsor, whichever occurs first.  See Section 4.5.[ADDRESS_743214] v1.1 (e.g., toxicity, symptomatic  
deterioration , tumor assessments will continue at the same frequency as would have been followed if the patient had remained on study treatment until 
radiographic disease progression (loss of clinical benefit for patients treated with atezolizumab who continue treatment after disease progression according to 
RECIST  v1.1), withdrawal of consent, death, or study termination by [CONTACT_1034] , whichever occurs first , even if the patient starts another anti -cancer therapy 
after study treatment discontinuat ion. 
r See Appendix  2 of Protocol GO29537 for detailed schedule.  
s The optional RCR whole blood sample requires an additional informed consent  and may be collected at any time during the course of the study  
 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
46/Statistical Analysis Plan GO29537  Appendix  2 Schedule of Assessments (cont.)  
t A mandatory biopsy is required, if clinically feasible, within 40 days of radiographic progression or prior to the start of the next anti -cancer therapy, whichever is 
sooner (see Section [IP_ADDRESS] of Protocol GO29537).  
u All serious adverse events and adverse events of special interest, regardless of relationship to study treatment, will be reported until [ADDRESS_743215] dose 
of study treatment (inclusive of erlotinib [allowed under Study GO29537 Protocol Versions  1−4] or pemetrexed switch maintenance for patients randomized to 
Arm B who receive switch maintenance) or initiation of new systemic anti -cancer therapy.  All other adverse events, regardless of relationship to study 
treatment, will be reported until [ADDRESS_743216] dose of study treatment (inclusive of erlotinib [allowed under Study GO29537 Protocol Versions  1 − 4] or 
pemetrexed switch maintenance for patients randomized to Arm B who receive switch maintenance) or initiation of new non- protocol systemic anti -cancer 
therapy after last dose of study treatment.  After this period,  all deaths will be reported.  In addition, the Sponsor should be notified if the investigator 
becomes aware of any serious adverse event or adverse event of special interest that  is believed to be related to prior exposure to study treatment (see 
Section  5.6 of Protocol GO29537 ). 
v EORTC QLQ -C30, EORTC QLQ -LC13, PGIS, and EQ -5D-3L questionnaires will be completed by [CONTACT_565793] -cycle  
visit during the induction period and then according to the tumor assessment schedule during the treatment maintenance phase prior to administration of study 
drug and prior to any other study assessment(s).  SILC will be completed on an ePRO device at the patient’s home on a weekly basis.  During survival 
follow -up, the EORTC QLQ -C30, EORTC QLQ -LC13, and EQ -5D-3L will be completed at 3 and 6 months following disease progression or loss of clinical 
benefit (for atezolizumab-treated patients).  The SILC will be completed monthly during survival follow -up for [ADDRESS_743217] v1.1 or loss of clinical benefit (for atezolizumab-treated patients who had continued 
treatment  with atezolizumab after radiographic disease progression) as determined by [CONTACT_093] (unless the patient withdraws consent or the Sponsor 
terminates the study).   Study personnel should review all questionnaires for completeness before the patient leaves the investigational site.  Patients whose 
native language is  not available on the ePRO device or who are deemed by [CONTACT_565794].  
w Survival follow -up information will be collected via telephone calls, patient medical records, and/or clinic visits every [ADDRESS_743218].  All patients will be periodically contact[CONTACT_70181] d new anti -
cancer therapy information unless the patient requests to be withdrawn from follow -up (this request must be documented in the source documents and 
signed by [CONTACT_093]).  If the patient withdraws from the study, study staff may use a public  information source (e.g., county records ) when 
permissible, to obtain information about survival status only.  
 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
47/Statistical Analysis Plan GO29537  Appendix  3 Schedule of Pharmacokinetic, Biomarker,  
and Anti -Drug Antibody Assessments  
Study Visit Time  Arm A Arm B 
Screening N/A Biomarkers b Biomarkers b 
Cycle 1,  
Day 1 e Pre-dose (same day 
as treatment 
administration)  Atezolizumab ATA 
Atezolizumab pharmacokinetics  
Carboplatin pharmacokinetics a 
Nab-Paclitaxel  pharmacokinetics a 
Biomarkers d Carboplatin 
pharmacokinetics a 
Nab-Paclitaxel  
pharmacokinetics a 
Biomarkers d 
30 min (± 10 min) 
after end of 
atezolizumab  
infusion  Atezolizumab pharmacokinetics   
5 − 10 min before the 
end of nab-paclitaxel 
infusion a Nab-Paclitaxel  pharmacokinetics a Nab-Paclitaxel  
pharmacokinetics a 
1 hr after end of nab-
paclitaxel infusion a Nab-Paclitaxel  pharmacokinetics a Nab-Paclitaxel  
pharmacokinetics a 
5 − 10 min before the 
end of carboplatin 
infusion a Carboplatin pharmacokinetics a Carboplatin 
pharmacokinetics a 
1 hr after end of 
carboplatin infusion a Carboplatin pharmacokinetics a Carboplatin 
pharmacokinetics a 
Cycle  2,  
Day 1 
(± 3 days)   Pre-dose (same day 
as treatment 
administration)  Atezolizumab ATA 
Atezolizumab pharmacokinetics  
Biomarkers d  Biomarkers d 
 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
48/Statistical Analysis Plan GO29537  Appendix  3 Schedule of Pharmacokinetic, Biomarker,  
and Anti -Drug Antibody Assessments  (cont.)  
Study Visit Time  Arm A Arm B 
Cycle  3,  
Day 1 
(± 3 days)   Pre-dose (same day 
as treatment 
administration)  Atezolizumab ATA 
Atezolizumab pharmacokinetics  
Carboplatin pharmacokinetics a 
Nab-Paclitaxel pharmacokinetics a 
Biomarkers d  Carboplatin 
pharmacokinetics a 
Nab-Paclitaxel 
pharmacokinetics a 
Biomarkers d 
30 min (± 10 min) 
after end of 
atezolizumab  
infusion  Atezolizumab pharmacokinetics   
5 − 10 min before the 
end of nab -paclitaxel 
infusion a Nab-Paclitaxel pharmacokinetics a Nab-Paclitaxel  
pharmacokinetics a 
1 hr after end of nab-
paclitaxel infusion a Nab-Paclitaxel pharmacokinetics a Nab-Paclitaxel  
pharmacokinetics a 
5 − 10 min before the 
end of carboplatin 
infusion a Carboplatin pharmacokinetics a Carboplatin 
pharmacokinetics a 
1 hr after end of 
carboplatin infusion a Carboplatin pharmacokinetics a Carboplatin 
pharmacokinetics a 
Cycles  4, 8, 
and 16,  
Day 1 
(± 3 days)   Pre-dose (same day 
as treatment 
administration)  Atezolizumab  ATA 
Atezolizumab pharmacokinetics  
Biomarkers d  Biomarkers d 
After 
Cycle  16 and 
every eighth 
cycle, Day  1 
(± 3 days)  Pre-dose (same day 
as treatment 
administration)  Atezolizumab ATA 
Atezolizumab pharmacokinetics  
Biomarkers d Biomarkers d 
At time of 
fresh biopsy 
(on-treatment 
or at progression, including during 
follow -up) At visit  Biomarkers 
d Biomarkers d 
 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd 
49/Statistical Analysis Plan GO29537  Appendix  3 Schedule of Pharmacokinetic, Biomarker,  
and Anti -Drug Antibody Assessments  (cont.)  
Study Visit Time  Arm A Arm B 
Treatment 
discontinuation 
visit At visit  Atezolizumab ATA 
Atezolizumab pharmacokinetics  
Biomarkers d Biomarkers d 
120  ± [ADDRESS_743219] dose 
of 
atezolizumab  At visit  Atezolizumab ATA 
Atezolizumab pharmacokinetics  
Biomarkers d  
At any 
timepoint 
during study (RCR  consent  
required)   Optional RCR blood (DNA 
extraction)
 c Optional RCR blood 
(DNA extraction) c 
ATA  = anti-therapeutic antibody; RCR  = [COMPANY_002] Clinical Repository.  
Note:  Serum pharmacokinetic samples for atezolizumab; plasma pharmacokinetic samples for carboplatin, and nab -paclitaxel.  
a At selected centers, 20 patients in each treatment arm will undergo the additional PK 
assessments for carboplatin and nab- paclitaxel. 
b Whole blood for biomarkers.  
c The optional RCR blood sample (for DNA extraction) requires an additional informed consent 
and can be collected at any time during the course of the study.  
d Plasma and serum for biomarkers.  
e Biomarker sampling before Cycle 1, Day [ADDRESS_743220] eroids.  
 